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Abstract 
 
 
Over the last decades, inhalation of compounds has gained new attention since it holds the 
potential to deliver drugs, namely biopharmaceuticals, for both local and systemic action to 
treat a variety of diseases. Despite being extensively studied to formulate hydrophobic drugs, 
polymeric micelles present characteristics poorly exploited towards the systemic 
administration of biopharmaceuticals by inhalation. In particular, polymeric micelles might 
protect proteins against thermal denaturation, or avoid phagocytosis by alveolar 
macrophages due to small size. Thus, this work aims to explore the use of polymeric micelles 
in the development of powders as vehicles for pulmonary delivery of therapeutic peptides and 
proteins, using insulin as a model protein. 
Different amphiphilic polymers (Soluplus®, Pluronic® F68, Pluronic® F108 and Pluronic® F127) 
were used to produce lyophilized nanocomposites for inhalation. The development of 
glucose-sensitive formulations was also attempted with the addition of phenylboronic acid 
(PBA) to the micelles. 
Results showed that size and polydispersity of micelles were dependent on the amphiphilic 
polymer used, being all lower than 300 nm in size, while all the formulations displayed 
spherical shape and surface charge close to neutrality. Association efficiency (AE) and 
loading capacity (LC) ranging from 49.3% to 94.6% and from 5.6% to 8.6%, respectively, 
were obtained. X-ray photoelectron spectroscopy (XPS) analysis confirmed that insulin was 
partially present at the hydrophilic shell of the micelles, while PBA in its hydrophobic inner 
core, as expected taking into account their water solubility. Despite influencing the in vitro 
release of insulin from micelles, PBA did not confer glucose-sensitive properties to 
formulations. 
Upon lyophilization, micelle formulations retained their physical characteristics, further 
providing easily dispersion when in contact to aqueous medium. The native-like conformation 
of insulin was highly maintained after lyophilization as indicated by Fourier transform infrared 
spectroscopy (FTIR) and far-ultraviolet circular dichroism (far-UV CD). Moreover, differential 
scanning calorimetry (DSC) and Raman spectroscopy did not evidence significant 
interactions among the formulation components. 
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Amorphous state formulations showed to be physically stable upon storage up to 6 months 
both at room-temperature (20 ºC) and fridge (4ºC), with only a slight loss (maximum of 15%) 
of the secondary structure of the protein.  
The aerosolization and aerodynamic properties of nanocomposites varied according to the 
formulation, presenting aerodynamic diameters lower than 6.6 µm and fine particle fraction 
(FPF) up to 48 % of the administered dose, predicting good deposition pattern of particles in 
the lungs. 
Solid formulations showed to be compatible with the respiratory tract owing to the absence of 
in vitro toxicity for epithelial respiratory cell lines (A549 and Calu-3) and macrophages (Raw 
264.7). Additionally, some formulations, in particular Pluronic® F127-based formulations, 
enhanced the permeation of insulin through pulmonary epithelial models and underwent 
minimal in vitro internalization by macrophages, as evaluated by confocal microscopy and 
flow cytometry. 
The efficacy and safety of formulations were assessed in vivo using a streptozotocin-induced 
diabetic rat model. Endotracheally instilled powders have shown a faster onset of action than 
subcutaneous administration of insulin at a dose of 10 IU/kg, with pharmacological 
availabilities up to 32.5% of those achieved by subcutaneous route. A significant 
improvement of hypoglycemic effect following inhaled insulin was observed when associated 
to polymeric micelles as compared to its free solution form. In a 14-day sub-acute toxicity 
study, bronchoalveolar lavage screening for cell count, protein content, lactate 
dehydrogenase (LDH), cytokines, and chemokines revealed no signs of lung inflammation 
and cytotoxicity. Histological analysis of lungs, heart and liver showed the absence of tissue 
damage. 
Overall, powder formulations based on polymeric micelles presenting promising 
characteristics for the delivery of therapeutic peptides and proteins by inhalation were 
achieved. Among the polymers tested, Pluronic® F127 produced the more promising carrier 
formulations for systemic delivery of therapeutic proteins. 
 
 
Keywords: Polymeric micelles, Pulmonary administration, Insulin, Nanocomposites, Dry 
powder inhalers 
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Resumo 
 
Ao longo das últimas décadas a inalação de fármacos, incluindo biofármacos, tem sido alvo 
de atenção por parte de investigadores e indústrias farmacêuticas uma vez que permite a 
administração de compostos com ação local e também sistémica, contribuindo assim para o 
tratamento de várias doenças. Apesar de bastante utilizadas na formulação de fármacos 
hidrófobos, as micelas poliméricas possuem características vantajosas pouco exploradas 
para a administração sistémica de biofármacos por via inalatória. Entre essas vantagens 
encontram-se a proteção térmica conferida pelos polímeros presentes na sua constituição e 
a capacidade de evasão à internalização por macrófagos conferida pelos seus reduzidos 
tamanhos. Desta forma, o presente trabalho explora a utilidade das micelas poliméricas no 
desenvolvimento de pós para administração pulmonar de péptidos e proteínas terapêuticas, 
sendo a insulina utilizada como proteína modelo. 
Diferentes polímeros anfifílicos, nomeadamente Soluplus®, Pluronic® F68, Pluronic® F108 e 
Pluronic® F127 foram utilizados para o desenvolvimento de nanocompósitos obtidos por 
liofilização. O desenvolvimento de formulações glucose-sensitivas foi explorado através da 
adição de ácido fenilborónico ao sistema. Os resultados demonstraram a obtenção de 
micelas esféricas com uma carga superficial perto da neutralidade. O tamanho e 
polidispersão mostraram ser dependentes do polímero utilizado, no entanto obtiveram-se 
sempre micelas com diâmetro inferior a 300 nm. Foram também verificadas eficiências de 
associação variando de 49,3% até 94,6% e capacidade de carga variando de 5,6% até 8,6%. 
Ensaios de espectroscopia fotoelectrónica de raio X confirmaram a presença parcial de 
insulina e ausência de ácido fenilborónico na corona hidrófila das micelas, tal como se 
poderia prever tendo em consideração a solubilidade de ambos compostos. Apesar de 
contribuir para libertação in vitro da insulina associada às micelas, o ácido fenilborónico não 
conferiu às formulações as propriedades glucose-sensitivas desejadas.  
O processo de liofilização não alterou significativamente as propriedades físicas das micelas 
que facilmente se dispersam em contacto com meio aquoso. Após liofilização uma elevada 
percentagem de insulina manteve a sua estrutura secundária, como evidenciado pela análise 
de espectroscopia de infravermelho por transformada de Fourier e dicroismo circular no UV-
longínquo. Adicionalmente, a análise por calorimetria diferencial de varrimento e 
espectroscopia de Raman não evidenciaram a existência de interações significativas entre 
os diferentes componentes da formulação. As formulações liofilizadas em estado amorfo 
mostraram ser fisicamente estáveis durante o período de armazenamento de 6 meses à 
xii 
 
temperatura ambiente (20 ºC), bem como refrigeradas (4 ºC), apresentando apenas uma 
reduzida perda da estrutura secundária da proteína (máximo 15%). As propriedades 
aerodinâmicas e a capacidade de aerossolização dos nanocompósitos variam de acordo 
com a formulação, apresentando diâmetros aerodinâmicos inferiores a 6,6 µm e fração de 
partículas finas até 48% da dose administrada, prevendo assim um bom perfil de deposição 
das partículas no sistema respiratório após inalação. 
In vitro, as formulações sólidas mostraram ser compatíveis com o sistema respiratório devido 
à ausência de toxicidade significativa em linhas celulares epiteliais respiratórias (A549 e 
Calu-3) e macrófagos (Raw 264.7). Adicionalmente, algumas formulações, em particular as 
baseadas em Pluronic® F127, promoveram a permeação da insulina através de modelos 
epiteliais in vitro e sofreram reduzida internalização por parte de macrófagos como 
determinado por microscopia de confocal e citometria de fluxo. 
A segurança e a eficácia terapêutica das formulações foram também avaliadas in vivo 
através de um modelo murino de diabetes induzido por estreptozotocina. Os pós 
administrados por instilação endotraqueal demonstraram um início de ação mais rápido do 
que a administração subcutânea de insulina a uma dose de 10 IU/kg, obtendo 
disponibilidades farmacológicas até 32,5% relativamente às observadas para a via 
subcutânea. A associação da insulina às micelas conduziu a um aumento significativo do seu 
efeito hipoglicémico relativamente à insulina livre em solução. 
A toxicidade sub-aguda das formulações foi avaliada após administração múltipla durante um 
período de 14 dias. A análise do fluido de lavagem bronco-alveolar no que diz respeito à 
contagem total de células, teor proteico, e níveis de citoquinas e lactato desidrogenase 
revelou a ausência de sinais de inflamação e toxicidade. Adicionalmente, a análise 
histológica não revelou qualquer dano tecidular em órgãos como pulmões, coração e fígado.  
Em suma, foram conseguidas formulações sólidas baseadas em micelas poliméricas que 
apresentam características promissoras para a administração de proteínas por inalação. 
Entre os polímeros usados, o Pluronic® F127 demonstrou dar origem às formulações com as 
melhores características para administração pulmonar de proteínas terapêuticas com ação 
sistémica. 
 
Palavras-chave: Micelas poliméricas, Administração pulmonar, Insulina, Nanocompósitos, 
Pós para inalação 
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1. Drug delivery systems: innovation and technology 
 
The advent of pharmaceutical industry brought the nececity to control the biodistribution of 
drugs, aiming to enhance their therapeutic efficacy. The concept of drug delivery system 
(DDS) that control the release of the drugs and target them to specific locations in the body 
represents a major clinical breakthrough. This concept is in close agreement with those 
predicted by Paul Ehrlich in the early 20th century; however, we still cannot achieve the 
desired 'magic bullet' (1, 2). The pharmacological properties, clinical use, marketability, and 
competitiveness of drugs are highly dependent on the nature and properties of the DDS used. 
Thus, pharmaceutical companies are continuously seeking for new and improved DDS to 
deliver both new and existing drugs, focusing on its effectiveness, safety and market value. 
Since the success of a DDS relies on several aspects related to the route of administration, 
specific drug properties or disease physiopathology, distinct strategies must be applied during 
its rational development according to the desired application. Ideally, a DDS should possess 
characteristics such as (i) appropriate circulation time in the body to promote a therapeutic or 
diagnostic action, (ii) protect the drug from degradation and from premature clearance, (iii) 
organ/tissue selectivity, (iv) therapeutic concentration of the drug at the target anatomical site, 
(v) release the compound in response to specific stimuli, and (vi) improve the therapeutic 
index of the drug (2-4). Although some studies already refer the development of multi-
functional systems (Figure 1.1), the development of the ideal DDS is still in its infancy. 
 
Figure 1.1 Schematic representation of a multi-functional DDS. 
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Passive or active targeting of drugs to specific organs and tissues, enhancing its therapeutic 
efficacy and decreasing the side effects, can be achieved via different mechanisms. By 
increasing the systemic circulation time of drugs through a reduction of their uptake by the 
reticuloendothelial system (RES) (e.g. by conjugating drugs or coating particles with 
poly(ethylene glycol) (PEG), i.e. PEGylation), drugs are more likely to suffer an enhanced 
permeability and retention effect (EPR effect). Thus, there will be a passive targeting to 
tissues with increased vascular permeability such as solid tumors, being this mechanism 
extensively used by DDS of anticancer drugs. It can also occur at infection or inflammation 
sites. On the other hand, active targeting can be achieved using carriers with stimuli-
sensitiveness once several pathological processes are characterized by changes in pH, 
temperature or redox potential. Thus, an active targeting can be achieved by using carriers 
that release drugs only after exposed to certain conditions (stimulus-sensitive). Other 
potential approach for active targeting might be achieved through the use of specific 
antibodies, molecules recognized by certain cell receptors, or receptors for molecules that are 
overexpressed in certain disease states. These include integrins and vascular endothelial 
growth factor (VEGF) presented in vascular cells of various solid tumors, as well as 
transferrin and folate residues, whose receptors are overexpressed on the surface of various 
tumor cells (4-8). 
The translation of this concept to pulmonary administration leads, for instance, to the 
identification and selection of lung epithelial binding peptides (LEBP), namely LEBP-1, LEBP-
2 and LEBP-3 as peptides that bind selectively to receptors of the alveolar epithelium cells, 
therefore promoting a specific alveolar targeting (9). LEBP-binding DNA complexes 
presented higher in vitro transfection efficiency to lung epithelial cells (L2 cell line) when 
compared to the same formulation without LEBP (10). In another study, Jost and co-workers 
identified a peptide with the amino acid sequence Threonine-Histidine-Alanine-Leucine-
Tryptophan-Histidine-Threonine (THALWHT) that selectively binds to airway epithelial cell 
lines and can be used as targeting moiety for gene delivery (11). Several reports on moieties 
explored to achieve active targeting to lungs like surfactant protein A (SP-A) (12), transferrin 
(13), lectin (14), folate (15) or human immunodeficiency virus-transactivator of transcription 
(HIV-TAT) peptide (16) can be found on the literature. Mannose and its derivatives have been 
also proposed to target the mannose receptor present at the surface of alveolar macrophages 
and improve the treatment of intracellular pathogens like Mycobacterium tuberculosis (17, 
18).   
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In the last decades, several studies have been conducted with the aim of developing 
innovative pharmaceutical forms, arising some of the most promising advances from the 
application of nanotechnology to the production of DDS (19-21). 
 
1.1. Nanotechnology in the development of drug delivery systems 
 
The application of nanotechnology in medicine has been capturing growing interest over 
recent years, having emerged the concept of nanomedicine. This is explained by the nano 
and micrometer scale of cellular and subcellular structures (6). The goal of nanomedicine is 
to allow a more accurate and timely diagnosis and to provide the most effective treatment 
without side effects (22). Currently, the main application areas of nanomedicine are imaging 
and cancer therapy. However, studies in various areas such as peptides and proteins 
delivery, vaccination, gene therapy, tissue engineering or production of devices for the 
administration of drugs are also being carried out (6).  
Both pharmacokinetics and pharmacodynamics of a drug are highly dependent on its physical 
and chemical features, and are influenced by the type of formulation and dosage form used to 
deliver it. NanoDDS like nanoparticles, liposomes or micelles can modulate and improve the 
performance of many drugs to an extent not achievable by conventional formulations. For 
example, nanoDDS can be capitalized to encapsulate drugs and thereby (i) increase their 
solubility, (ii) protect them from degradation, (iii) enhance their epithelial absorption, (iv) 
escape from the in vivo defensive systems, thus increasing their blood circulation time, (v) 
target the drugs to specific cells/tissues/organs, releasing them in a controlled manner as a 
response to a specific stimulus, or (vi) enhance their uptake by cells (19, 23). They also allow 
the reduction of the immunogenicity of proteins, thus decreasing the toxicity of the formulation 
(24). In addition, combined nanoDDS can simultaneously detect and treat a disease by 
encompassing both imaging and therapeutic compounds, an emerging field known as 
theranostics (25). In the near future, nanomedicine could play a key role to achieve the so 
desired personalized medicine.  
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Table 1.1 Examples of nanoDDS with market authorization. AmB is Amphotericin B. 
Type of nanocarrier Drug Tradename 
Polymeric nanoparticles 
and polymer conjugates 
Glatiramer acetate Copaxone 
Pegademase bovine Adagen 
Peginterferon α-2a Pegasys 
Peginterferon α-2b PEG-Intron 
Pegaspargase Onscaspar 
Pegaptanib sodium Macugen 
Pegfilgrastim Neulasta 
Pegvisomant Somavert 
Neocarzinostatin (Smancs) Zinostatin Stimalmer 
PEG -epoetin beta Micera 
Peginesatide Omontys 
Pegloticase Krystexxa 
Certolizumab pegol Cimzia 
Liposomes 
AmB Abelcet 
AmB AmBisome 
Beractant Survanta 
Bovactant Alveofact 
Cisplatin Lipoplatin 
Cytarabine DepoCyt 
Daunorubicin Daunoxome 
Doxorubicin Myocet 
Doxorubicin Doxil/Caelyx 
Inactivated surface Influenza virus 
antigen 
Inflexal V 
Inactivated hepatitis A virus Epaxal 
Mitoxantrone Novantrone 
Morfin DepoDur 
Paclitaxel EndoTAG-1 
Poractant α Curosurf 
Verteporfin Visudyne 
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Over the last decades, the usefulness of nanoDDS design and development to overcome a 
variety of pharmaceutical drawbacks in the diagnosis, prevention, immunization and 
treatment of diseases has been intensively explored by a large number of research groups 
and companies worldwide, generating a high number of patents and scientific papers 
published in international scientific journals. However, and despite the fact that nanomedicine 
began as a discipline almost half century ago, only some nanothechnology-based drug 
delivery system (nanoDDS) paved their way to the market (Table 1.1) (26). This phenomenon 
could be explained by the poor financial profitability, consumer distrust and the lack of 
confidence due to poor information/education, ineffective regulation of new and generic 
Type of nanocarrier Drug Tradename 
Liposomes 
Vincristine Marqibo 
Mifamurtide Mepact 
Factor VIII Octocog alfa 
Octafluoropropane Definity 
Micelles Estradiol Estrasorb 
Nanocrystals 
Megestrol acetate Megace ES 
Aprepitant Emend 
Fenofibrate Tricor 
Sirolimus Rapamune 
Fenofibrate Triglide 
Albumin nanoparticles Paclitaxel Abraxane 
Lipidic coloidal dispersion AmB Amphotec 
Antibody or protein-drug 
conjugate 
Gemtuzumab-ozogamicin Mylotarg 
Tositumomab-iodine I131 Bexxar 
Ibritumomab-tiuxetan Zevalin 
Denileukin-diftitox Ontak 
Brentuximab vedotin Adcetris 
Inorganic particles 
Superparamagnetic iron oxide Feridex 
Superparamagnetic iron oxide Endorem 
Superparamagnetic iron oxide GastroMARK 
Superparamagnetic iron oxide Lumirem 
Superparamagnetic iron oxide Resovist 
Chapter 1 I State-of-art 
___________________________________________________________________________________ 
7 
 
products, and weak patent protection (27). At the moment, regulatory agencies are in process 
of developing specific guidelines and regulations regarding nanotechnology-based products 
in order to develop new tools, standards, and approaches to assess the safety, efficacy, 
quality, and performance of such products (28, 29). Nonetheless, the relatively few marketed 
nanoDDS have been successful in their respective therapeutic areas, especially in cancer 
therapy. According to BCC Research, the global nanomedicine market has been growing 
steadily, reaching a value of $72.8 billion in 2011, being expected to increase at annual 
growth rate of 12.5% until 2016 reaching $130.9 billion (30). 
Currently used technologies at both laboratory and industrial level, including high-pressure 
homogenization, emulsification/solvent evaporation, emulsification/solvent diffusion, 
nanoprecipitation/solvent displacement, salting-out, layer-by-layer synthesis, ionic 
complexation/coacervation, ionotropic gelation, thin-film hydration, supercritical fluids 
technology or microfluidics have been reported as effective methods to produce nanoDDS 
(20, 22, 31, 32). 
 
1.1.1. Lipid-based nanoparticles 
 
Liposomes are spherical vesicles composed of bilayers of phospholipids, cholesterol, and/or 
other lipids (22). Lecithin, phosphatidylglycerol, phosphatidylinositol, 
phosphatidylethanolamine, and phosphatidylserine are the mainly used phospholipids (8). 
They can be classified according to their lamellarity as uni, oligo and multilamellar, or by size 
as small, intermediate and large. Due to its structure, they allow the incorporation of 
hydrophilic drugs in the aqueous core, and lipophilic drugs within the lipid bilayer (Figure 1.2) 
(32). Possessing higher core, unilamellar liposomes are preferred for encapsulation of 
hydrophilic drugs, while multilamellar liposomes are especially used to encapsulate 
hydrophobic drugs due to the higher lipid content (33). Depending on the number and 
composition of the bilayers and the presence of coating, it is possible to obtain systems with 
modified release characteristics (34, 35). Although liposomal-based formulations represent 
the higher number of nanoDDS currently available on the market, they were first 
commercialized for cosmetic purposes (35). Besides the marketed formulations, liposomes 
have been suggested for the administration of several drugs, including peptides and 
therapeutic proteins, as well as for gene therapy (8). 
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Stealth liposomes like Doxil/Caelyx®, Novantrone® or Lipoplatin® are a good example of how 
the previously mentioned PEGylation allows the improvement of blood circulation time and 
the therapeutic efficacy of many drugs through the avoidance of opsonization and escape 
from RES (33).   
 
Figure 1.2 Schematic representation of a liposome. 
 
Nanoemulsions are nanometric scale lipid droplets dispersed in water that were initially 
developed for parental nutrition. They possess the advantage of large-scale production 
through the high-pressure homogenization technique, but lack on controlled release 
properties of drugs (32). More recently, self-emulsifying drug delivery systems (SEDDS) 
composed by mixtures of drugs, oils and surfactants that emulsify with the water present on 
the gastrointestinal tract, have been proposed as nanoDDS. They are easy to produce and 
generally stable, but the high percentage of surfactants on its composition arise toxicity 
concerns (32). 
Lipid nanoparticles generally comprise two types of structures, solid lipid nanoparticles (SLN) 
and nanostructured lipid carriers (NLC) (32, 36). They comprise a solid lipid matrix at both 
room and body temperatures, dispersed in aqueous solution and stabilized with a layer of 
emulsifier agent, usually phospholipids (35). Lipid nanoparticles emerged as an alternative to 
liposomes and pharmaceutical emulsions because of the superior stability in biological fluids. 
They are also less toxic than the inorganic and polymeric particles due to its biocompatibility 
and biodegradability (35). Unlike the SLN, the NLC are composed not only of solid lipids, but 
also by a mixture of solid and liquid lipids, resulting in a solid matrix less rigid and ordered. 
This difference will allow NLC to increase the loading capacity of drugs and the stability 
during storage (Figure 1.3) (32, 36). 
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Figure 1.3 Schematic representation of SLN (S) and NLC (B).  
 
1.1.2. Polymer-based nanoparticles 
 
Polymeric nanocarriers have been adopted as the preferred drug delivery systems mostly by 
the fact that they overcome some of the disadvantages presented by liposomes and lipid 
particles, namely low encapsulation efficiency and stability during storage and rapid release 
of encapsulated compounds. They can be obtained through polymerization of monomers or 
polymer dispersion (Figure 1.4) (31, 35). Among polymeric nanocarriers, those containing 
natural polysaccharides, including chitosan, alginate or hyaluronic acid, receive high 
popularity among drug delivery researchers owing its biocompatible, biodegradable, and non-
toxic properties. Moreover, they possess hydrophilic properties, having in general low cost 
production and many sources in nature (37). Among the synthetic polymers, PEG, poly(D,L-
lactide-co-glycolic acid) (PLGA) or poly(ε-caprolactone) (PCL) are some of the most well 
studied and explored. PLGA is accepted by regulatory authorities and widely used in 
biomedical applications due to its biocompatibility, biodegradation and utility in the production 
of modified release formulations (24, 38). 
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Figure 1.4 Schematic representation of a polymeric nanoparticle. 
 
1.1.3. Polymeric micelles 
 
Micelles are spherical nanosized colloidal dispersions having a hydrophobic core coated by a 
hydrophilic shell (Figure 1.5). Normally, they arise from the self-assembly of amphiphilic 
molecules above the critical micelle concentration (CMC) and critical micellization 
temperature (CMT) (5). The amphiphilic molecules used can be composed by graft and block 
copolymers (generally di- and triblock-copolymers) and/or polymers conjugated with lipids (5, 
22) originating polymeric micelles or phospholipids (22), in the case of conventional micelles. 
Recently, most attention has been paid to polymeric micelles as drug delivery systems, 
especially for poorly water-soluble drugs (39, 40). Due to the higher core hydrophobicity and 
viscosity as well as an highly hydrated shell, polymeric micelles are thermodynamically and 
kinetically more stable then surfactant micelles, presenting slower and delayed disintegration 
and drug release in circulation even upon dilution below the CMC value (41). Therefore, they 
present a promising approach to eliminate the use of excipients such as Cremophor EL® 
which has been associated to hypersensitivity reactions, aggregation of erythrocytes, 
peripheral neuropathy, among others (42). By varying the composition of micelles, namely the 
type and size of the polymers, it is possible to modulate their characteristics such as size, 
encapsulation efficiency and release profile. The most common component of micelle surface 
is PEG but it is possible to use other hydrophilic polymers such as chitosan (43-46), polyvinyl 
alcohol (PVA) (47-49), or polyvinylpyrrolidone (PVP) (50, 51). The hydrophobic core is 
constituted by polymers such lactic acid (52, 53), PCL (44, 54, 55), propylene oxide (56, 57), 
aspartic acid (58), or lipids such as phosphatidylethanolamine (59, 60). 
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Polymeric micelles have been developed to modify several major intrinsic characteristics of 
incorporated drugs, i.e. drug aqueous solubility, in vivo stability, release pattern, 
pharmacokinetics and biodistribution (5, 39). They allow the formulation and administration of 
highly hydrophobic drugs that would be withdrawn from development in the stage of drug 
formulation using conventional formulations (61). Despite being especially used to formulate 
hydrophobic drugs, like liposomes, polymeric micelles allow the encapsulation of drugs with 
different polarities. Hydrophobic drugs are incorporated into the micelle core being the 
solubilization capacity of drugs proportional to the hydrophobicity of the micelle core, while 
water-soluble drugs are adsorbed on the micelle shell and/or surface. Drugs with intermediate 
polarity are distributed along the amphiphilic molecules (62, 63). In addition to the higher 
stability compared to liposomes, micelles present low size and high encapsulation efficiency, 
which, together with the possibility of being sterilized by filtration, make these systems an 
interesting alternative to drug delivery (5, 62, 64).  
 
Figure 1.5 Schematic representation of a micelle. 
 
A few polymeric micelles-based formulations are currently in clinical trials (Table 1.2) (65, 66), 
one of them (Genexol-PM®, Samyang Co.) granted a pre-market authorization in Korea for 
the treatment of breast cancer and non-small cell lung cancer (67-69), while SP1049C 
(Surpatek Pharma, Inc.) granted orphan drug designation by US Food and Drug 
Administration (FDA) for the treatment of gastric cancer (70). Besides the formulations that 
are ongoing on clinical trials, polymeric micelles have successfully enhanced the therapeutic 
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index of various drugs from anticancer and anti-inflammatory drugs (71-75), to genetic 
material (76). They are also been proposed as delivery systems for diagnostic agents (77). 
Due to its small size, generally lower than 200 nm, and hydrophilic surface, micelles are 
poorly recognized by RES and present long circulation times in bloodstream suffering the 
EPR effect at solid tumor sites, reason why have been extensively exploited as drug delivery 
systems for anticancer agents (78-80). Promoting drug selective targeting to specific organs 
and tissues can be also achieved either using stimuli-responsive micelles (63, 79, 81, 82), or 
by modulating their surface with active-targeting ligands (79, 83). By sharing some structural 
and functional features with natural transport systems, e.g. virus and lipoproteins, polymeric 
micelles can be a useful strategy to solve the problem of drug resistance (84). Pluronic®-
based micelles have shown to interfere with the activity of P-glycoprotein and multidrug 
resistance–associated protein (MRP), increasing the therapeutic effectiveness of anticancer 
agents in multidrug resistant cancer cell lines (56, 85-87).    
  
Table 1.2 Examples of polymeric micelles-based formulations that enrolled in clinical trials. 
Formulation Polymer Drug Indication 
Clinical 
phase 
Reference 
SP1049C 
Pluronic
®
 L61 
and F127 
Doxorubicin 
Advanced adenocarcinoma 
of the esophagus, 
gastroesophageal junction 
and stomach 
II/III (70) 
Genexol-PM
®
 PEG-PLA Paclitaxel 
Breast cancer, non-small 
cell lung cancer, advanced 
pancreatic cancer, ovarian 
cancer, and head and neck 
cancer 
I/II/III/IV (68, 88-90) 
NK012 
PEG-PGlu-SN-
38 conjugated 
SN-38 
Breast cancer, colorectal 
cancer and small cell lung 
cancer 
I/II (65, 91, 92) 
NK105 PEG-PAsp Paclitaxel 
Advanced or recurrent 
gastric cancer and breast 
cancer 
I/II/III (66, 93) 
NC-4016 
PEG-DACH- 
platin 
Oxaliplatin 
Advanced solid tumors and 
lymphoma 
I (94) 
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Formulation Polymer Drug Indication 
Clinical 
phase 
Reference 
NC-6004 
(Nanoplatin
®
) 
PEG-PGlu-
cisplatin 
conjugated 
Cisplatin 
Solid tumors, breast 
cancer, pancreatic cancer 
I/II/III (95, 96) 
Paxceed
®
 PEG-PLA Paclitaxel 
Rheumatoid arthritis, 
psoriasis 
II (97, 98) 
CRLX101 
Polymer-
cyclodextrin-
camptothecin 
conjugated 
Camptothe
cin 
Advanced solid tumors, 
ovarian cancer 
I/II  
AquADEK
®
 TPGS 
Vitamins 
and 
antioxidants 
Multivitamin supplement in 
cystic fibrosis 
I/II (99, 100) 
BIND-014 
PEG-PLA and 
PLGA-PEG 
Docetaxel 
Non-small cell lung Cancer 
and prostate cancer 
I/II (101-103) 
PEG-DACH-platin – Poly(ethylene glycol)-dichloro(1,2-diaminocyclohexane)platinum(II); PEG-PAsp – 
Poly(ethylene glycol)-poly(aspartic acid); PEG-PGlu – Poly(ethylene glycol)-poly(L-glutamic acid); 
PEG-PLA – Poly(ethylene glycol)-polylactic acid; PLGA-PEG – Poly(D,L-lactide-co-glycolide)-b-
poly(ethylene glycol); TPGS – D-alpha-tocopheryl-co-PEG 1000 succinate  
 
1.2. The role of amphiphilic polymers in the development of drug delivery systems 
 
Amphiphilic copolymers are heterogeneous compounds composed by both hydrophilic and 
hydrophobic units disposed in sequential blocks (generally di- and triblock-copolymers) or 
grafts. By varying either the type or the chain length of the units, it is possible to modulate the 
polymer properties (41, 104). It is their versatility that makes them suitable for industrial and 
pharmaceutical applications. Regarding the last one, they have been used for a long time in 
different pharmaceutical dosage forms as excipients like emulsifiers, wetting, thickening or 
gel forming agents, and stabilizing agents of suspensions and colloidal dispersions. Still, they 
gained an increased interest in the last decades in the development of new DDS driven by 
the progresses seen in the pharmaceutical sciences and nanomedicine field (41, 105). 
Amphiphilic polymers are used in the development of different types of DDS, such as tablets, 
capsules, gels, microparticles, with emphasis in nanoDDS, namely polymeric micelles. Table 
1.3 presents examples of DDS in development using amphiphilic polymers. 
Self-assembled polymeric micelles as powders for pulmonary administration of insulin 
__________________________________________________________________________ 
14 
 
Table 1.3 Examples of DDS in development using amphiphilic polymers. 
Type of DDS Polymer Drug Reference 
Micelles 
CSO-SA Doxorubicin, paclitaxel and AmB (106-108) 
DSPE-PEG Calcitonin (59) 
HA-C18 Paclitaxel (109) 
mPEG-b-PVL Camptothecin (110) 
PCL-PEG-PCL Rifampicin (111, 112) 
PEG-b-PAA Mitoxantrone and doxorubicin (113) 
PEG-b-(PLL-IM) siRNA (114) 
PEG-b-PBC Paclitaxel (115) 
PEG-b-PCL 
Paclitaxel, indomethacin, 
curcumin, plumbagin and 
etoposide 
(61, 115) 
PEG-Phis Doxorubicin (116, 117) 
PEG-chitosan Methotrexate (118) 
PEG-g-PAE Doxorubicin (119) 
PEG-PAsp Lysozyme, irinotecan (120, 121) 
PEG-PEI DNA (122) 
PEG-PLA Paclitaxel and CsA 
(53, 123, 
124) 
PHEA-g-PDTC Prednisone and tegafur (125) 
PLA-b-PEG-b-Phis Doxorubicin (126) 
PLGA-PEG-PLGA Curcumin, DNA (127, 128) 
Pluronic
®
 F68, F127, L61 
and P85 
DNA 
(76, 128-
130) 
Pluronic
®
 P105 and 
P105/L101 mix and 
Pluronic
®
 P105/PCL mix 
Paclitaxel 
(131, 132) 
(133) 
Poly(sodium N-acryloyl-L-
aminoacidate-co-
alkylacrylamide)s 
Griseofulvin and non-steroidal 
anti-inflammatory drugs 
(134-136) 
PVA-acyl chains Doxorubicin (137) 
Cylindrical 
brushes 
PLLF-g-(PLF-b-PLG) Doxorubicin (138) 
Chapter 1 I State-of-art 
___________________________________________________________________________________ 
15 
 
Type of DDS Polymer Drug Reference 
Microparticles 
PEG-PLA BSA (139) 
Pluronic
®
 F68 BSA (140) 
Nanoparticles 
H40-PCL-PEG 
5-fluorouracil and 
Paclitaxel 
(141) 
HPAE-co-PLA/DPPE Paclitaxel (142) 
HPESO and Pluronic
®
 
F68 
Doxorubicin and mitomycin C (143, 144) 
PDEAEMA-PAEMA siRNA and proteins (145) 
PEG-PBCA Docetaxel (146) 
PEG-PLA Paclitaxel, DNA (147, 148) 
Hydrogels 
MBCP-2 DNA (149) 
P(MAA-g-EG) Insulin, interferon β and calcitonin (150-152) 
PEG-chitosan BSA (153) 
PLGA-PEG-PLGA Dexamethasone and calcitonin (154, 155) 
Pluronic
®
 F127 
Deslorelin, GnRH, Vitamin B12 
and naproxen 
(156-158) 
Patches SIS 
Methyl salicylate, capsaicin, and 
diphenhydramine hydrochloride 
(159) 
Capsules PEG-MOG 
Risperidone, ketoconazole, 
indomethacin, hydrocortisone 
and CsA 
(160) 
Solid solutions 
(Extrudates) 
Soluplus
®
 
Danazol, fenofibrate and 
itraconazole 
(161) 
Tablets 
Soluplus
®
, Pluronic
®
 and 
Vitamin E-TPGS
®
 
Amine drugs like donepezil, 
olanzapine or tamsulosin 
(162) 
AmB - Amphotericin B; BSA – Bovine serum albumin; CsA – Cyclosporin A; CSO-SA – Chitosan 
oligosaccharide-stearic acid; DSPE-PEG – 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-
methoxy(poly(ethylene glycol); GnRH – Gonadotropin-releasing hormone; H40-PCL-PEG – 
Hyperbranched aliphatic polyester Boltorn H40-poly(ε-caprolactone)-poly(ethylene glycol); HA-C18 – 
Hyaluronic acid-g-octadecyl; HPAE-co-PLA/DPPE – Poly[(amine-ester)-co-(D,L-lactide)]/1,2-
dipalmitoyl-sn-glycero-3-phosphoethanolamine; HPESO – Hydrolyzed polymers of epoxidized soybean 
oil; MBCP-2 – Pluronic P104-b-di(ethylene glycol) divinyl ether; mPEG-b-PVL – Methoxy poly(ethylene 
glycol)-b-poly(valerolactone); P(MAA-g-EG) – Poly(methacrylic acid-grafted-poly(ethylene glycol)); PCL 
– Poly(ε-caprolactone); PCL-PEG-PCL – Poly(ε-caprolactone)-b-poly(ethylene glycol)-b-poly(ε-
caprolactone); PDEAEMA-PAEMA – Poly(diethylaminoethyl methacrylate)-poly(aminoethyl 
methacrylate); PEG-b-(PLL-IM) – Iminothiolane-modified poly(ethylene glycol)-b-poly(L-lysine); PEG-b-
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PAA – Poly(ethylene glycol)-b-polyacrylic acid; PEG-b-PBC – Poly(ethylene glycol)-b-poly(α-benzyl 
carboxylate- ε-caprolactone); PEG-b-PCL – Poly(ethylene glycol)-b-poly(ε-caprolactone); PEG-
chitosan - Poly(ethylene glycol)-chitosan; PEG-g-PAE – Poly(ethylene glycol)-g-poly(b-amino ester); 
PEG-MOG – Poly(ethylene glycol)-monooleylglyceride; PEG-PAsp – Poly(ethylene glycol)-
poly(aspartic acid); PEG-PBCA – Poly(ethylene glycol)-poly(n-butylcyano acrylate); PEG-PEI – 
Poly(ethylene glycol)-poly(ethylene imine); PEG-PHis – Poly(ethylene glycol)-poly(L-histidine); PEG-
PLA – Poly(ethylene glycol)–polylactic acid; PHEA-g-PDTC – Poly-a,b-[N-(2-hydroxyethyl)-L-
aspartamide]-g-poly(2,2-dimethyltrimethylene carbonate); PLA-b-PEG-b-PHis – Poly(L-lactic acid)-b-
poly(ethylene glycol)-b-poly(L-histidine); PLGA-PEG-PLGA – Poly(D,L-lactide-co-glycolide)-b-
poly(ethylene glycol)-b-poly(D,L-lactide-co-glycolide); PLLF-g-(PLF-b-PLG) – Poly(l-lysine-co-l-
phenylalanine)-g-poly(l-phenylalanine)-b-poly(l-glutamic acid); PVA-acyl chains – Polyvinyl alcohol-
modified with acyl chains; SIS – Styrene-isoprene-styrene. 
 
Among the different structures available, the most extensively explored for the production of 
DDS are composed of PEG as hydrophilic block and (i) polypropylene oxide (PPO); (ii) 
poly(ester)s like PCL or PLGA; (iii) poly(amino acid)s such as poly(L-aspartic acid) and 
poly(L-glutamic acid); or (iv) lipids like phosphatidylethanolamine (PE) as hydrophobic block 
(5). Particular interest has been given to poly(ethylene glycol)-b-polypropylene oxide-b-
poly(ethylene glycol) (PEG-PPO-PEG) block copolymers (poloxamers and poloxamines) 
(163, 164), mainly due to their commercial accessibility in a wide range of compositions and 
molecular weight (MW) (Pluronic®/Lutrol®/Kolliphor P® and Tetronic®).  
  
1.2.1. Synthesis of copolymers 
 
Due to environmental concerns, the synthesis of these polymers has evolved in the last 
decades, in order to achieve a cleaner production, in the scope of the ''green-chemistry''. 
Among the different methods, reversible addition-fragmentation chain transfer (RAFT) 
polymerization and ring-opening polymerization (ROP) of lactones, lactides and cyclic 
anhydrides are extensively used, mainly due to its ability to prepare both homo- and 
copolymers of different MW and architectures with well-defined structures or end-groups 
(165-167). Enzyme-catalyzed ROP has also been used to eliminate the use of organometallic 
catalysts, but only low MW polymers can be obtained using this method (168, 169). The ROP 
can be performed either as a bulk polymerization, in solution, emulsion or dispersion (166), 
while RAFT is commonly performed in emulsions (167). Copolymers can be produced by the 
sequential addition of monomers or by the conjugation of the preformed homopolymers, e.g. 
by reactive extrusion using transesterifcation at high temperature (166). For example, 
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poloxamers are synthesized using anionic polymerization in the presence of an alkaline 
catalyst, generally sodium or potassium hydroxide. The PPO central unit is formed by the 
polymerization of propylene oxide monomers followed by the addition of ethylene glycol to the 
PPO end-groups (105). 
 
1.2.2. Characteristics of copolymers and copolymer-based structures 
 
1.2.2.1. Stimuli-responsiveness 
 
These polymers present some characteristics that make them suitable for human 
administration, namely their water-solubility, biodegradability, biocompatibility and low 
immunogenicity. Among all characteristics presented by some amphiphilic polymers for the 
development of advanced controlled nanoDDS, one of the most interesting is the stimuli-
responsiveness (170, 171). Stimuli-responsive polymers are a class of “smart” polymers that 
undergo physical or chemical changes as response to a specific stimulus, e.g. temperature, 
pH, redox potential, magnetic field or light (172, 173). Monomers of N-alkyl substituted 
acrylamides and acrylate/methacrylate derivatives are commonly used in the development of 
thermo-responsive and pH-responsive copolymers, respectively (171, 174). pH-responsive 
hydrogels were able to protect proteins from the harsh gastric environment, promoting their 
release only at distal parts of intestine. At acidic pH the existence of intermolecular polymer 
complexes lead to the formation of compact gels that swells just at basic pH (150, 152). Due 
to their properties, the hydrogels enhanced the in vivo intestinal absorption and hypoglycemic 
effects of oral insulin (152).  
 
1.2.2.2. Self-assembly: the crucial phenomenon  
 
Amphiphilic copolymers are able to form nanoscopic structures with different morphologies, 
e.g. polymersomes, nanocapsules, nanospheres, nanogels or dendrimers, although 
polymeric micelles are the most commonly used and studied (105, 175, 176). Polymeric 
micelles are supramolecular structures formed by self-assembly of amphiphilic copolymers 
into spherical nanosized particles with a hydrophilic corona and hydrophobic core. The self-
assembly or micellization occurs at or above a threshold level of concentration (CMC) and 
temperature (CMT), which are specific for the polymer (Figure 1.6) (5).  
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Figure 1.6 Schematic representation of micellization. 
 
In water, this process is driven by an increase in entropy of the solvent molecules in contact 
to the hydrophobic units and a consequent decrease of free energy in the system as the 
hydrophobic components are withdrawn from the aqueous media to form the micelle core (39, 
177). Two forces are involved in the micelle formation, an attractive force that leads to the 
association of molecules and a repulsive force that prevents unlimited growth of the micelles 
(178). The free energy of the micellization process, Δ°Gm, is given by the follow Equation 1.1. 
 
∆°𝐺𝑚 = 𝑅𝑇 ln 𝐶𝑀𝐶                                                                                                  Equation 1.1 
 
where R is the gas constant and T is the temperature of the system. 
 
MW, molecular architecture, temperature, solvent-polymer interactions or salt concentration 
are parameters that influence the self-assembly of polymers. Increasing temperature of the 
system, the solvency of hydrophilic unit as well as the CMC value will decrease, promoting 
the micellization. Similarly, this phenomena is favored when the attractive hydrophobic 
interactions increases as a result of a gain in the MW of the hydrophobic domain (179). For 
example, poly(ethylene glycol)-b-poly(3-hydroxyoctanoate-co-3-hydroxyhexanoate) (PEG-b-
PHOHH) copolymers present a CMC value of 5.50 and 0.93 mg/L for poly(3-
hydroxyoctanoate-co-3-hydroxyhexanoate) (PHOHH) segments with 1500 and 7700 g/mol, 
respectively (180). During the development of amphiphilic copolymers for DDS is imperative 
to determine the CMC value, which is generally estimated by a steady-state fluorescence 
method using pyrene as a probe. In Table 1.4 are presented estimated CMC values of some 
amphiphilic copolymers. 
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Table 1.4 Estimated critical micelle concentration (CMC) values for some amphiphilic copolymers. 
CopolymerMw (g/mol) or mol% CMC (mg/L or mM) Reference 
CSO-SA 140 (106) 
HA-C18* 10-37.3 (109) 
HPESO4866 0.075-0.080 (181) 
HPSO3800 0.055 (181) 
mPEG-b-PVL2000-10000 0.01-0.1 (110) 
PAGE-b-PLA 60-160 (182) 
PCL1050-7850-PEG6000-20000-
PCL1050-7850 
2.2.10
-3
-39.10
-3
 (111) 
PEG5000-b-PHOHH1500-7700 5.50-0.93 (180) 
PEG-MOG5-10 300-4000 (160) 
PEG-PPS 0.0076-0.027 (183) 
PEG-PPS-PEG 0.0015-0.015 (183) 
PLGA-PEG-PLGA 5 (128) 
Pluronic
®
 F108 3.08 (184) 
Pluronic
®
 F127 0.56 (184) 
Pluronic
®
 P103 0.14 (184) 
Pluronic
®
 P105 0.46 (184) 
Pluronic
®
 P123 0.05 (184) 
PPEGMEA-g-PMOMMA 1.63 (185) 
PVP-b-PDLLA27 or 38 4.3 and 2.6 (186) 
SAGly-DA16 2.9 (134) 
SALeu-DA16 0.4 (134) 
SAPhe-DA16 1.5 (134) 
SAVal-DA9 or 16 0.9 and 4.5 (187) 
SAVal-OA16 22 (136) 
CSO-SA – Chitosan oligosaccharide-stearic acid; HA-C18 – Hyaluronic acid-g-octadecyl (* Octadecyl 
moiety with various substitution degrees); HPESO – Hydrolyzed polymers of epoxidized soybean oil; 
HPSO – Hydrolyzed polymers of soybean oil; mPEG-b-PVL – Methoxy poly(ethylene glycol)-b-
poly(valerolactone); PAGE-b-PLA – Poly(allyl glycidyl ether)-b-polylactide; PCL-PEG-PCL – Poly(ε-
caprolactone)-b-poly(ethylene glycol)-b-poly(ε-caprolactone); PEG-b-PHOHH – Poly(ethylene glycol)-
b-poly(3-hydroxyoctanoate-co-3-hydroxyhexanoate); PEG-MOG – Poly(ethylene glycol)-
monooleylglyceride; PEG-PPS – Poly(ethylene glycol)-b-poly(propylene sulfide); PEG-PPS-PEG – 
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Poly(ethylene glycol)-b-poly(propylene sulfide)-b-poly(ethylene glycol); PLGA-PEG-PLGA – Poly(D,L-
lactide-co-glycolide)-b-poly(ethylene glycol)-b-poly(D,L-lactide-co-glycolide); PPEGMEA-g-PMOMMA – 
Poly[poly(ethylene glycol) methyl ether acrylate]-g-poly(methacrylate acid); PVP-b-PDLLA – Poly(N-
vinyl-2-pyrrolidone)-b-poly(D,L-lactide); SAGly-DA – Poly[(sodium N-acryloyl-L- glycinate)-co-(N-
dodecylacrylamide)]; SALeu-DA – Poly[(sodium N-acryloyl-L- leucinate)-co-(N-dodecylacrylamide)]; 
SAPhe-DA – Poly[(sodium N-acryloyl-L- phenylalaninate)-co-(N-dodecylacrylamide)]; SAVal-DA – 
Poly[(sodium N-acryloyl-L-valinate)-co-(N-dodecylacrylamide)]; SAVal-OA – Poly[(sodium N-acryloyl-L-
valinate)-co-(N-octylacrylamide)]. 
 
1.2.2.3. Hydrophilic surface: stability and functional role 
 
While the hydrophobic core of micelles, in addition to the solubilization and protection of 
drugs, provides appropriate mechanical properties for the desired application, hydrophilic 
shell masks the particle from the biological environment, reducing the protein absorption and 
cellular adhesion, thereby enhancing the particle stability (188, 189). 
Opsonin proteins present in the blood serum promptly bind to particles, allowing their 
recognition by macrophages that will quickly remove the encapsulated drugs from 
bloodstream (190). The presence of hydrophilic layer on the surface of particles (stealth 
particles) will reduce or delay the opsonization via steric repulsion forces, thus increasing the 
plasma circulation time of particles and the half-life time (t1/2) of drugs (190, 191). PEG and 
poloxamers are generally used as hydrophilic polymers to cover the surface of many 
nanoDDS (146). Although PEGylation presents advantages, may not always be necessary. 
Indeed, unnecessary or excessive PEGylation could lead to a non-desirable increase in the 
particle size. Additionally, an increase in the cost of the final product could also be noticed. 
Thus, the quantification of hydrophilic groups at the surface of particles must be performed 
using techniques like XPS or secondary ion mass spectroscopy (SIMS) (192, 193) in order to 
assess the convenience of PEGylation (or other method to increase hydrophilicity) and to 
predict the nanoDDS behavior in vivo.   
From the technological point of view, the importance of the hydrophilic surface on nanoDDS 
relies not only in the stealth properties but also in their functionalization potential by chemical 
modification or bioconjugation. The functionalization is mainly used to bind targeting moieties 
to the particles surface that allows the biodistribution control of nanoDDS (194) and different 
ligands can be used accordingly to the required application (195), as referred before. The 
conjugation of folate at the surface of hyperbranched aliphatic polyester Boltorn H40-poly(ε-
caprolactone)-poly(ethylene glycol) (H40-PCL-PEG) nanoparticles enhances the in vitro drug 
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uptake and therapeutic efficacy of anticancer agents in Hela and A549 cells. The presence of 
acid folic in the media reduces the particles uptake by receptor saturation, proving the 
effectiveness of folate in the targeting of tumor cells (141). Similarly, Arginine-Glycine-
Aspartic acid (RGD) peptide and transferrin improved the cytotoxicity of paclitaxel-loaded 
micelles against αvβ3 integrin and transferrin over-expressed human cells, respectively (115, 
142). 
 
1.3. Safety of nanocarriers 
 
The growing development of nanotechnology in the last decades is intensifying the use of 
materials whose security profile is not completely clarified. Although some of the materials 
possess toxicological data, their chemical, physical and biological properties can suffer 
changes when at the nanometric scale. Some studies suggest the development of side 
effects to health derivate from the occupational or environmental exposure to nanomaterials 
(196, 197). Despite the advantages presented by nanocarriers, their small size provides high 
surface area and possible higher reactivity with celular components. In vitro and in vivo 
studies showed induction of inflamatory responses and damage to the pulmonary epitelium, 
as well as extrapulmonary effects like increase in the blood coagulation and oxidative stress 
derived from the translocation of inhaled nanoparticles to the circulation and accumulation in 
other organs (197-200). These could result in alterations of respiratory, cardiovascular and 
immune systems. However, such studies are based on high doses of nanoparticles, not 
corresponding to the normal doses of exposition (198), yet the possibility of deleterious 
effects for health due to inhalation of nanocarriers should not be overlooked, requiring further 
detailed studies. Also, some researchers mention the urgent need for the development of 
standardized procedures for the analysis of biological samples of people exposed to 
nanoparticles, with a view to characterizing their safety profile (197). 
Regardless of all the potential of nanotechnology in various areas of health, the euphoria 
observed must give way to conscious and carefull decisions regarding its safety based in 
evidence. During the development of new nanomaterials the health side effects and the 
environmental impact resultant from secondary production and disposal might be considered 
(196, 201). Thus, a risk assessment should be carried out before the marketing of such 
materials, as well as a review and monitoring of long-term effects of whose already on the 
market. 
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2. Therapeutic peptides and proteins 
 
2.1. Properties 
 
Biopharmaceuticals, including therapeutic peptides and proteins have emerged as useful and 
promising drugs in the treatment of various diseases such as diabetes, cancer or 
autoimmune diseases (202). The first biotechnologically derived product approved for market 
was recombinant human insulin (Humulin®, Eli Lilly) in 1982 (203) and since then, many 
efforts and investment have been located to the research of biopharmaceuticals. In 2013, 
around 900 biopharmaceuticals targeting more than 100 diseases were under development 
by American’s research companies (204). This is explained by the overall improvement in 
quality of life and reduced burden of complex and challenging diseases achieved by these 
specific and selective medicines in an extent sometimes not reached by conventional drugs 
(205). Consequently, many biopharmaceutical products have granted market authorization 
over the years (206) and gain an increased share in global pharmaceutical market year-by-
year (207). For example, peptides, proteins, enzymes and monoclonal antibodies together 
account for 26% of the total approved medicines by FDA between 2009 and 2011 (208). This 
is due to the development of molecular biology that allowed the understanding of the role of 
biopharmaceuticals in pathophysiological processes as well as the growing development of 
biotechnology, bioengineering and recombinant DNA technology, which allowed their large-
scale production. Despite the tendency to classify peptides and proteins as new therapeutic 
agents, insulin extracted from animal’s pancreas was produced at industrial level for the first 
time in 1923 by the company E. Lilly (209). 
Sequences with fewer than 50 amino acids (< 5 kDa) are considered to originate peptides, 
while proteins are composed by bigger amino acid sequences (> 5 kDa). By that, both 
peptides and proteins by far exceed the 500 Da of MW cutoff of molecules generally 
assumed to be orally absorbed (210). Thus, and 
regardless of all the therapeutic potential associated with peptides and proteins, they have 
physicochemical characteristics that limit their therapeutic applications. Due to their high MW 
and general hydrophilicity, peptides and proteins have limited ability to cross biological 
membranes and consequently reduced permeability and bioavailability (211). Also, they 
complex structure makes difficult its formulation and administration in the active conformation 
as discussed below. 
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2.2. Stability and formulation challenges 
 
Due to its complex structure, peptides and proteins have limited chemical stability in vivo, 
undergoing aggregation, degradation and proteolytic cleavage, being further removed from 
the bloodstream, thus presenting reduced systemic t1/2. Apart from the above characteristics 
that determine its pharmacokinetics and pharmacodynamics, they also present in vitro 
barriers to their stability during the pharmaceutical development. The reactivity of some 
aminoacids results in degradation reactions such as deamination, racemization, oxidation or 
hydrolysis, that are dependent of production and storage condition such as pH, temperature, 
agitation, ionic strength, shear stress, light exposure, presence of metal ions, surfactants or 
solvents. This could lead to changes in the primary, secondary and tertiary structure of the 
molecules, originating a loss of their activity. When unstable, they tend to undergo 
aggregation with possible precipitation, adsorption and denaturation, which will limit its 
concentration and therapeutic levels after administration, and could present safety problems 
(209, 211, 212). 
The problems of in vitro and in vivo instability of proteins can be solved with the addition of 
excipients that act as stabilizers by different mechanisms. Examples are sugars and salts that 
increase the thermal stability of proteins, the non-ionic surfactants that reduce its 
aggregation, metal chelators and enzyme inhibitors that reduce the ability of various 
proteolytic enzymes (211, 213). Attention should be paid to the addition of sugars, since 
glycation of the peptides and proteins could occasionally occur by reaction of the sugars with 
the amino groups of the amino acids (214). In addition to the referred excipients, the drying of 
the final product using techniques like lyophilization and spray-freeze-drying reduce the 
instability mechanisms occurring in liquid medium. Also, chemical modification of proteins 
such as conjugation with PEG or Fc fusion protein, glycosylation or acylation has shown to 
decrease the immunogenicity of peptides and proteins, and improve their stability and the t1/2 
by increasing their resistance to proteolysis by conformational restriction in vivo (211, 213).   
 
2.3. Administration routes of therapeutic peptides and proteins  
 
Parenteral administration can overcome the problem of reduced bioavailability of peptides 
and proteins through biological membranes, being its usual route of administration. However, 
it does not eliminate the instability in the bloodstream (211). Moreover, this is an invasive 
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route, which can lead to a reduced acceptance by patients and, consequently, increased 
costs of therapy, especially when it required a prolonged or chronic treatment. Besides, there 
is a need for sterilization and cold chain transport and storage of various formulations of 
peptide drugs, as well as the need for specialized personnel for its administration (215, 216).  
The problems associated with parenteral administration boosted industrial and academic 
researchers to seek for needle-free and user-friendly formulations for non-invasive 
administration of peptides and proteins. Among the different non-invasive routes of 
administration appears oral, buccal, pulmonary, nasal, transdermal, ocular, rectal or vaginal 
(211). Oral administration is considered the most attractive route for drug administration and 
the preferred/accepted by patients due of its ease and convenience of administration. 
However, the harsh gastric environment (acidic pH and proteolysis) and the intestinal 
epithelia arise as strong barriers to efficient delivery of macromolecules (217). The 
bioavailability of proteins and peptides after oral administration is very low due to its instability 
in the gastrointestinal tract and low permeability through the intestinal mucosa (218, 219). 
Actually several studies are focused on oral administration of proteins, many of them using 
nanotechnology to increase their bioavailability. 
Parallel to the oral, inhalation is seen as an effective way to deliver peptides and proteins and 
appears as an alternative route to parenteral administration, as demonstrated by the several 
experimental and clinical assays proposed so far (213, 220) and mentioned in the section 4 of 
the present chapter. 
 
3. Pulmonary administration as non-invasive route for systemic delivery of 
therapeutic peptides and proteins 
 
3.1. Brief history of inhalation 
 
Inhalation of compounds as a means to treat diseases is used since ancient times. The oldest 
reports came from China and India around 2000 BC and are related to the inhalation of 
smoke from burned herbal preparations based on Ephedra sinica, Atropa belladonna or 
Datura stramonium to treat throat and chest diseases like asthma (221-224). Pedanus 
Discorides (40-90 AD) the Greek physician, surgeon, pharmacologist, botanist and author of 
De Materia Medica (considered the first pharmacopeia) as well as Aelius Galenus (129-
199/217 AD) prescribed inhaled sulfur vapors to their patients (225). Although the word 
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“inhaler” was used for the first time by the English physician John Mudge in 1778 to describe 
his invention, the first therapeutic inhalation device is attributed to Hippocrates (460–377 BC) 
(221, 222). Through the years, many compounds and mixtures were proposed and used to 
treat distinct diseases using various methods for inhalation, from ceramic inhalers, to 
combustible powders, burning papers and liquid atomizers. A very curious and popular way to 
inhale compounds in the 19th and 20th centuries was based on the use of asthma cigarettes, 
which were withdrawn from the market in 1992 (221, 225). The inhalation of vapor from 
solutions of picric acid, tar, iodine or sulfuric acid was very popular in the 20th century to treat 
tuberculosis and other infections, especially in spa’s (225). The first mentions regarding 
inhalation of antibiotics such as penicillin by nebulization to treat pulmonary infections were 
published in the 1940s (225-229). Nowadays, inhaled drugs are preferentially administered 
via dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI), being also used 
nebulizers in hospitals.  
Despite inhalation started as a route to treat diseases confined to the respiratory tract, with 
the observed scientific and technology advances, a change in paradigm took place over the 
years, and inhalation has been evaluated and used to treat both local and systemic diseases 
(230) such as asthma (231), tuberculosis (232), other bacterial infections (233), influenza 
virus infection (234), fungal infections (235), cystic fibrosis (236), chronic obstructive 
pulmonary disease (237), diabetes (238) or cancer (239, 240). Moreover, inhalation has been 
also tested as a non-invasive vaccination platform (241-243). 
 
3.2. Anatomo-physiological characteristics of lungs and airways 
 
Over the past 20 years, the research focus on inhalation shifted from the almost exclusive 
local treatment to include drugs with systemic action. However, the understanding and 
characterization of pulmonary administration of drugs is a complex task that involves not only 
the release of the drug from inhalation devices, but also the mechanisms of drug deposition 
and absorption, which are related to the physiology of the respiratory system (244). 
The respiratory system consists in the upper and lower airways and lungs. The upper airways 
consist on the nose, mouth, pharynx and larynx. The trachea follows the larynx and branch 
into two bronchi. The bronchi divide consecutively in bronchioles which branch into alveolar 
ducts and terminate in alveolar sacs (245). The gas exchange with blood occurs through 
approximately 300 million alveoli (246), occupying a surface area of 75-150 m2 (245, 247), 
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which corresponds to approximately 98% of the adult lungs (248). These begin to emerge in 
smaller bronchioles, which are called respiratory bronchioles. The lower airways are divided 
into conduction zone and the respiratory zone. The respiratory zone is comprised by the 
respiratory bronchioles and the alveolar ducts and sacs (246). 
 
Figure 1.7 Schematic representation of the bronchial epithelium. 
 
The airways, with the exception of the alveoli, possess a pseudostratified epithelium 
composed of ciliated cells, basal cells and mucus-producing cells (goblet cells and Clara 
cells) (246) (Figure 1.7). The alveolar wall consists of three tissue components: epithelium 
(around 0.3 µm of thickness), supporting tissue/basement membrane (around 1.2 µm of 
thickness) and blood capillaries (endothelium with around 0.4 µm of thickness) (249). The 
epithelium is composed of two types of cells called pneumocytes (Figure 1.8). The alveolar 
type I pneumocytes occupy most of the alveolar surface and have the function of barrier while 
type II pneumocytes, interspersed with type I, are responsible for secreting surfactant. This 
consists of phospholipids (90%) and protein (10%), forming a 0.1-0.2 µm thick film that is 
responsible for the decrease in surface tension existing in the alveoli, thereby preventing its 
collapse. In several areas of the alveolar wall, the tissue support is absent allowing the fusion 
of the basement membrane with the alveolar capillary endothelium of the extensive blood 
capillaries plexus surrounding alveoli. Thus, a very low thickness barrier separates the 
alveolar air from the bloodstream (245, 246, 250). 
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The epithelium of the respiratory system has also lymphoid tissue called mucosa-associated 
lymphoid tissue (MALT) that is responsible for its immunological activity. The lymphoid 
follicles present in the airways (nasal-associated lymphoid tissue (NALT) and bronchus-
associated lymphoid tissue (BALT)) have many immune cells such as dendritic cells and T 
and B lymphocytes. The epithelium covering the lymphoid follicles called follicle associated 
epithelium (FAE) possesses M cells that are involved in uptake, transport and presentation of 
antigens in the respiratory lumen (216). 
 
Figure 1.8 Schematic representation of the alveolar epithelium. 
 
Taking into account the physiological characteristics of the respiratory system, it becomes 
clear that this route provides a non-invasive alternative presenting a large surface area, a thin 
epithelial barrier, extensive blood supply (flow 5 L/min), and lower enzymatic activity and 
efflux systems compared to other organs and tissues (e.g., gastrointestinal tract). Moreover, 
the reduced volume of fluid allows high concentrations of drug near the bloodstream, and the 
first-pass metabolism is avoided by pulmonary administration, which is especially useful for 
drugs that suffer high hepatic metabolism (251). These features are the reason for the higher 
bioavailability of inhaled peptides and proteins (10-200 times higher) compared with other 
non-invasive routes (84, 252).  
 
3.3. Pulmonary biodistribution of inhaled peptides and proteins 
 
After inhalation, particles will undergo lung deposition and be subjected to the existing 
clearance mechanisms of the respiratory system. Being the place of gas exchange and 
constant contact with the exterior ambient, respiratory system developed complex and not 
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fully clarified defense mechanisms working as barrier for foreign particles that could impair 
the efficient delivery of drugs (248). The complex geometry and humidity of the airways 
hampers the passage of the larger particles to the deep lung, and the movement of the 
bronchial cilia, known as mucociliary escalator, transports the particles trapped in the mucus 
layer to the gastrointestinal tract. Particles/compounds capable of evade the mentioned 
barriers and reach the deep lung have to face other defense mechanisms like phagocytosis 
by alveolar macrophages, alveolar lining fluid, intra- and extra-cellular catabolism, and the 
epithelium to attain the bloodstream (253, 254). Phagocytized compounds can be transported 
through the alveolar surface, undergo translocation to the lymphatic system or degradation by 
the intracellular enzymatic lysosomal system (69). 
In some studies, the rate of protein clearance did not significantly change in the presence or 
absence of an endotracheal tube, suggesting a reduced role of mucociliary escalator in the 
lung’s protein clearance (255). Also, demonstrate that only small amounts of proteins are 
found in macrophages (255). Despite the higher phagocytic capacity of macrophages 
compared to the endocytic capacity of pneumocytes, the first ones do not play an important 
role in clearance of proteins before 48 hours after exposure (254, 255). In addition, several 
large-sized proteins reach the circulation in intact form after instillation, suggesting a lower 
impact of catabolism in lung protein clearance (248, 254). However, degradation by 
proteolysis is relevant for proteins with small MW (< 3 kDa) (256). The use of enzyme 
inhibitors such as bacitracin, chymostatin, leupeptin or nafmostato mesylate reduces 
proteolysis and, thereby, increase the bioavailability of proteins prone to suffer high 
catabolism (8).  
In addition to the mechanisms/barriers described above and able to influence the permeability 
of compounds from the respiratory tract to the bloodstream and their bioavailability, the 
alveolar and airway epithelium arise as a major barrier to absorption of drugs. The absorption 
of macromolecules through the respiratory tract is a complex and enigmatic process that 
involves various mechanisms that are not yet well characterized, being apparently dependent 
on the hydrophilicity and the size of macromolecules (257-259). Different studies suggest that 
the rate of absorption is inversely proportional to the MW of the macromolecule. This 
influence not only the percentage of drug absorbed, but also the time necessary to the 
absorption occurs. For example, the t1/2 of the alveolar absorption of macromolecules 
increases with their MW (inulin with MW: 5250 Da and t1/2: 225 min; dextran with MW: 20000 
Da and t1/2: 688 min; dextran with MW: 75000 Da and t1/2: 1670 min) (260).  
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Two major mechanisms were proposed to characterize pulmonary absorption of proteins: 
paracellular diffusion and transcytosis (Figure 1.9). Transcytosis may further be classified into 
vesicular endocytosis or pinocytosis, and receptor dependent transcytosis. Proteins with 
small MW are apparently absorbed by the paracellular route, diffusing through the tight 
junctions, while molecules with higher MW seem to suffer endocytosis (248). Peptides can be 
absorbed by receptor mediated transcytosis using the high-affinity peptide transporter 2 
(247), while immunoglobulins are absorbed by a conjugation of pinocytosis with receptor 
mediated transcytosis. After suffer endocytosis, immunoglobulins bind with the fragment 
crystallizable (Fc) receptors that prevent the fusion with lysosomes and are release in the 
basolateral side of epithelial cells (261). This immunoglobulin transport pathway is used to 
deliver proteins by conjugation of the therapeutic macromolecule with Fc regions of 
immunoglobulins (261, 262). Other strategy proposed to enhance the pulmonary absorption 
of proteins is their coupling with specific peptidic sequences that not alter the biologic activity 
but promote their translocation through the epithelium probably by receptor mediated 
transport (263).  
 
Figure 1.9 Schematic representation of absorption routes. 
 
3.4. Formulation requirements for pulmonary delivery of drugs 
 
Different aspects related to the formulation, inhalation device, and patient influence the 
aerosolization and deposition of drugs and, consequently, their therapeutic efficacy. The 
airways geometry, respiratory capacity (tidal volume, inspiratory flow rate and breathing 
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frequency), inhaler handling, smoking, and pathologies affecting the lungs will be responsible 
for therapeutic inter-individual variations.  
Formulation plays an important role in the inhaled drugs performance, in terms of stability, 
deposition and absorption. It should maintain the drug in the active state and deliver it to a 
specific site of action to be absorbed or released for systemic or local action, respectively. 
Additionally, the formulation must be stable upon storage. Since proteins are labile drugs, 
suitable to lose their activity through physical and chemical instability, maintenance of the 
active conformation is a challenge and a series of considerations should be taken into 
account during their production and storage. Temperature, pH, agitation, ionic strength or 
presence of surfactants needs to be controlled in order to avoid aggregation, degradation or 
conformation lost (264, 265). The stability of proteins and their therapeutic performance can 
be improved through the incorporation of some excipients to the formulation as detailed in the 
section 3.4.2. 
 
3.4.1. Aerodynamic properties of particles 
 
Among the different formulation characteristics, aerodynamic diameter (dae) plays a key role 
in the deposition pattern and therapeutic efficiency of the aerosolized particles. Aerodynamic 
diameter is the diameter of a unit density sphere that has the same terminal settling velocity 
in still air as the particle in consideration (266) and is defined by the following Equation 1.2. 
 
d𝑎𝑒 = d𝑒𝑞√
ρ𝑝
ρ𝑜𝜒
                                                                                                       Equation 1.2  
 
where deq is the geometric diameter of an equivalent volume sphere of unit density, ρp and 
ρo are particle and unit densities, respectively, and χ is the dynamic shape factor. 
When determined based on the mass size of particles through methods like aerosolization 
using impactors, dae receives the denomination of mass median aerodynamic diameter 
(MMAD). 
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Figure 1.10 Deposition profile of particles on the different areas of the respiratory system according to 
their aerodynamic diameter. 
 
After inhalation, depending on dae or MMAD, particles will move through the airways and 
deposit in different parts of the respiratory track or be exhaled. For deposition at the lower 
regions of lungs, particles in the range of 1–100 nm and 0.5–5 µm are required. Particles 
larger than 5 µm will impact in the throat and be swallowed, while the middle sized particles 
will be essentially exhaled (Figure 1.10) (198, 267). Different forces, namely inertial 
impaction, sedimentation, diffusion and interception, will govern the particles fate and are 
related to the aerodynamic and hydrophilic properties of particles and shape of airways (253, 
268, 269). By manipulating the particle size, is possible to target specific regions of the 
respiratory tract (more than 50% of deposition). For systemic delivery, alveolar deposition is 
needed, while for local action, delivery at bronchial level is preferred. As referred before, 
although alveolar macrophages are part of the respiratory defense system, they are 
sometimes the therapeutic target, for example in the treatment of tuberculosis. Targeting of 
alveolar macrophages could be achieved by surface-decoration with ligands of the lectin-like 
receptors present at the membrane of macrophages (17), or by deliver particles with a size 
that promote their phagocytosis (270, 271). 
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Formulations based on peptides and proteins loaded into nano- or microparticles have been 
widely proposed in the last years as strategies to overcome the limitations of conventional 
formulations. Since a wide range of the developed nanoparticles falls within the particle’s size 
range liable to suffer exhalation, the agglomeration of nanoparticles into micron-sized 
particles (nanocomposites) with proper aerodynamic characteristics that disaggregate after 
deposition have been exploited (34, 272). One possible advantage of use agglomerates of 
nanoparticles instead of microparticles relies on the capacity of nanoparticles to easily evade 
mucociliary clearance and phagocytosis by alveolar macrophages. Some studies show that 
smaller particles are internalized at a lower extent than particles higher in size (273, 274). 
 
3.4.2. Excipients used in the development of inhalatory formulations 
 
Besides drugs, pharmaceutical excipients constitute an integral part of pharmaceutical 
formulations. They provide physical, chemical or microbiological stability, bulk properties that 
improve handling and metering, while controlling the mechanical and pharmaceutical 
properties of formulations such as release and permeation (267, 275). At the moment, only a 
small number of excipients are authorized for pulmonary delivery, but a variety of new 
excipients is under evaluation. Since lungs have limited buffer capacity, only compounds that 
are biocompatible or endogenous to the lung and that are easily metabolized or cleared can 
be used in inhaled formulations (275). 
Since formulations for nebulization are liquid solutions or suspensions, the common 
excipients used are salts (e.g., NaCl) to adjust the osmolarity (300 mosmol/L), HCl, NaOH, 
phosphates to adjust the pH to neutrality, and surfactants such as polysorbates, sorbitan 
monostearate, oleic acid, and soya lecithin to facilitate the formation of liquid droplets. 
Ethanol can be used as co-solvent and permeation enhancer only in small concentration due 
to its irritation potential. Preservatives such as parabens and benzalkonium chloride, 
antioxidants like ascorbic acid or chelating agents such as ethylenediaminetetraacetic acid 
(EDTA) can also be used to enhance stability (267). 
The excipients used in pMDI are similar to those found in preparations for nebulization 
excepting the gas propellants. The most widely excipient used as propellant in pMDI is 
hydrofluoroalkane, a non-toxic, non-flammable, and chemically stable gas without 
carcinogenic or mutagenic effects. Due to the absence of ozone-depleting properties, 
hydrofluoroalkane have been replacing chlorofluorocarbon-based propellants (276). DPI were 
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developed as a response to the limitations regarding stability and environmental aspects of 
pMDI and nebulizers (275). 
DPI are considered the most advantageous devices for inhalation regarding long-term 
stability of formulation, absence of gas propellants and patient convenience since are breath-
actuated and easy to use without the need of hand-lung inhalation co-ordination (277, 278). 
However, the development of particles with a narrow particle-size distribution and good 
flowability, suitable for aerosolization and lung deposition of peptides and proteins in the 
active state is challenging and depends on the appropriate use of powder technology and 
particle engineering. Techniques like microcrystallization, micronization by jet- or ball-milling, 
lyophilization, spray-drying, spray-freeze-drying or supercritical fluid technology can be used 
to produce solid particles (267, 279). All the methods present advantages and disadvantages, 
and should be chosen according to the effect on the stability of the proteins, the 
characteristics of particles required to a specific formulation, scale-up, cost-effectiveness and 
safety issues (279). As stated before, the capacity to produce an aerosol with a narrow 
particle-size distribution will influence the deposition pattern of the drugs. Taking this in 
consideration, it is crucial to produce powders with good dispersibility. Solid particles are 
subject to cohesive and adhesive interactions with the surrounding environment, that need to 
be break during the aerosolization. Different forces are involved in particle’s interactions and 
include electrostatic and van der Waals forces, capillary forces from to the presence of 
residual water at the surface of particles, and mechanical interlocking due to surface 
roughness (275). Distinct aerosolization properties could be obtained playing with these 
forces by specific particle engineering. For example, an efficient drying of the particles needs 
to be provided by the production method to reduce moisture and capillary forces, but extra 
drying should be avoided due to the formation of charges at the surface of particles that 
promote electrostatic interactions. One of the main factors affecting the particle’s interactions 
is their surface area. The larger surface area, the greater will be the interactions between 
particles, and lower will be the flowability. Surface area is dependent on size, shape and 
morphology of particles (269, 275). Particles in the size range suitable for inhalation possess 
high surface areas and are generally mixed with larger coarse carrier particles of excipients to 
improve their flow properties. In DPI, the coarse carrier particle is the major component of the 
formulation (>95%, w/w). It provides bulk properties and reduces the cohesion forces 
between drug particles, facilitating the aerosol dispersion and defining deposition pattern 
(280). Lactose is the main excipient used as coarse and larger carrier particles and, to a 
lower extent, as cryoprotectant when particles are prepared using lyophilization (281). There 
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are commercially available a variety of inhalation grade lactose with different characteristics 
and narrow particle size distribution (Flowlac®, Granulac®, Respitose®, Lactohale®, Inhalac®, 
etc.) that should be carefully selected during the development of the formulation (282, 283). 
Other sugars such as glucose, trehalose and mannitol are also used as cryoprotectants and 
coarse carriers (267). Magnesium stearate is approved for inhalation to protect drug from 
moisture and to reduce the cohesion and adhesion between particles (284). The 
characteristics of the carriers and the adhesive forces between carrier and drug particles 
influence the performance of the formulation and need to be assessed and optimized. 
Blending of drugs with coarse carriers is a critical point during the development of a DPI and 
also object of optimization (285-289).       
Regarding inhaled nanoDDS, most of the components are generally not approved for 
inhalation. In this case, new excipients proposed for inhalatory formulations need to pass 
through the entire process of safety evaluation, including complete in vitro toxicological 
evaluation and in vivo assessment of non-clinical and clinical safety prior to licensing. 
Unfortunately, there is a lack of specific regulatory guidance regarding the toxicological 
assessment of excipients for inhalation (290-292). Excipients generally recognized as safe 
(GRAS) or those approved for other routes of administration need a more limited number of 
experiments for safety evaluation, being its acceptance by regulatory agencies usually easier. 
This is the case of phosphatidylcholine (PC), a lipid surfactant and one of the constituents of 
lung surfactant that is commonly used in the production of liposomes. Studies show that PC-
based liposomes do not affect or slightly decrease the viability of human A549 alveolar cells 
after 24h of exposure. The effects on cell viability are dependent on the PC derivate and the 
concentration used (293). Other compounds used in the development of nanoDDS such as 
dextran, alginate, carrageenan or gelatin also possess GRAS status. It should be mentioned 
that those regulations apply not only to the material itself but also to its source. For example, 
contrary to what happen with shrimp-derived chitosan, chitosan obtained from Aspergillus 
niger is in the process to obtain GRAS status (294). Chitosan does not present significant 
toxicity to pulmonary tissue and cell lines after inhalation (295, 296). In fact, some studies 
showed some protective effect against oxidative stress (295). PLGA is another biodegradable 
polymer extensively used in the production of nanoDDS and present in various approved 
medicines including Trelstar® Depot (Pfizer), Risperidal® Consta (Johnson & Johnson), 
Sandostatin LAR® Depot (Novartis), Suprecur® MP (Aventis) or Lupron Depot® (TAP). The 
cytotoxicity of PLGA nanoparticles with different coatings and surface charges was assessed. 
Results showed that the cytotoxicity of the nanoparticles to human bronchial Calu-3 cells was 
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very limited, with the absence of inflammatory response (297). Cyclodextrins have been 
tested as complexing agent and excipient of inhalatory formulations. Various approved 
formulations containing cyclodextrins such as Voltaren® (Novartis), Clorocil® (Laboratório 
Edol), Brexin® (Chiesi Farmaceutici) or Vfend® (Pfizer), are daily used in the clinical practice 
for administration routes other than inhalation (298).  
Recently, carrier-free formulations that presented good aerosolization properties and 
deposition patterns have been developed and proposed as promising inhalatory formulations 
(299, 300). This “carrierless” strategy prevented the need of long and expensive safety 
studies, facilitating the authorization by regulatory agencies. Some engineered drug particles 
alone fulfill the requirements for inhalation, which is possible by the development of large 
porous/hollow particles (301-303). Due to its small density, particles with high geometric size 
and, consequently, reduced cohesive forces, present appropriate aerodynamic diameters. 
For example, salbutamol particles prepared by thermal ink-jet spray-freeze-drying with mean 
geometric diameter of 35 µm and mean aerodynamic diameter lower than 8.7 µm, present a 
percentage of FPF comparable to a salbutamol commercial formulation (302). At the moment, 
there are commercially available carrier-free DPI composed by agglomerates of pure 
terbutalin and budesonide particles, namely Bricanyl Turbohaler® (AstraZeneca) and 
Pulmicort Turbohaler ® (AstraZeneca), respectively. 
 
3.4.3. Inhalation devices 
 
Apart from the characteristics of particles, pulmonary administration demands an inhaler 
device that produces an appropriate aerosol. There are numerous devices available with 
distinct properties and specifications that are more appropriate for each type of formulation – 
nebulizer for liquids, pMDI for liquids and powders, and DPI for powders (280, 304, 305). 
Since the device greatly influences the particle aerosolization and deposition pattern, the 
choice of the right inhaler for a specific formulation is one of the most time-consuming and 
challenging stages during the development of inhalable medicines, and it is imperative to 
ensure the appropriate drug efficacy (280, 306). For example, Alexander and co-workers 
tested the aerosolization efficacy of Ambisome® (Gilead Sciences) using different nebulizers 
and they found differences among all of them (307). The ideal inhaler should generate an 
aerosol with a FPF and reproducible drug dosage, guaranty protection and stability of the 
product during storage, be accurate, small, easy to handle, discrete, and user friendly in order 
to be accepted. One of the claimed reasons for the market failure of Exubera® (Pfizer) was 
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the low patient compliance partially due to the complex inhaler device (308). Owing to the 
great therapeutic potential of this alternative administration route, the last decades witnessed 
the development of devices with greater FPF and lung deposition patterns of approximately 
40–50% of the nominal dose as compared with the low levels between 10 and 15% verified in 
the past (276).  
However, it is worth mentioning that this is a growing and dynamic field and innovative 
technologies are emerging. For example, power-assisted devices activated by vibration (309, 
310) or pneumatic technology (311), called active inhalers, have been developed for the 
delivery of systemically proteins and active drugs that have narrow therapeutic windows as 
well as for inhalatory nanoDDS (275). Examples of such devices are the AERx® from 
Aradigm, Respimat® from Boehringer or AeroDose® from Aerogen Inc (8). Also, the 
development of adjusted inhalers that present specific inhalation patterns that are useful for 
the treatment of certain pulmonary diseases can be faced (276). It is also important to 
consider the cost relative to the production of the device and its impact on the final product 
price. A balanced price/therapeutic efficacy relationship is a crucial factor that can limit the 
clinical application of a certain product. 
 
3.5. Limitations of pulmonary administration 
 
The main limitation faced by pulmonary administration of drugs relates to the reproducibility of 
the dose. From the delivery device until be absorbed in the lungs, the drug undergoes 
consecutive losses during aerosolization and deposition. Thus, the absorbed dose is usually 
lower than the dose present in the delivery device. 
As stated before, the deposition of particles at the lower respiratory tract is a complex 
phenomenon and its efficiency depends on several factors like the type of formulation, 
delivery device used and their capacity to produce the aerosol (250, 277, 312, 313). 
Unfortunately, there is no inhaler device producing only particles within the size limits 
appropriate to the lung deposition which results in a very low rate of dose emitted (277). 
Another issue of relevance arises from the fact that more than 50% of patients improperly 
uses the delivery device, leading to non-reproducibility (312). Thus, an intensive education of 
patients by health care professionals is required to an increase the effectiveness of the 
treatment (277). 
The respiratory capacity of patients also plays an important role on the delivery efficiency of 
particles, being reduced in patients with lower respiratory capacity like children, elderly 
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persons or adults with certain disease conditions that compromises the lungs functions, 
resulting in non-reproducible pharmacokinetics and pharmacodynamic responses (314). 
 
4. State-of-art on therapeutic peptides and proteins for inhalation 
 
In 1993 the FDA approved the first protein administered via inhalation, a highly purified 
solution of recombinant human desoxyribonuclease I (rhDNase), also known as dornase 
alpha (Pulmozyme® from Genentech), for treatment of cystic fibrosis (315). Despite the 
promise and advantages presented by pulmonary delivery, only Pulmozyme® and, more 
recently, Afrezza® (insulin DPI from MannKind) granted market authorization. This could be 
attributed to the formulation and delivery challenges of inhalable drugs referred previously. 
However, the rational design of particles with appropriate characteristics for inhalation 
enabled the development of many formulations some of which already entered in clinical 
evaluation. 
Insulin has branded the history of the development of inhaled protein therapeutics with cycles 
of hope and disappointment. Attempts to develop an inhaled insulin formulation to substitute 
the current treatment of diabetes by subcutaneous injection have been made by dozens of 
researchers and companies all over the world during decades. The apogee of inhaled insulin 
was reached in 2006 when FDA and European Medicines Agency (EMA) granted market 
authorization to Exubera® (Pfizer/Nektar), a spray-dried mixture of insulin, sodium citrate 
(dihydrate), sodium hydroxide, mannitol and glycine (308, 316). During clinical trials, patients 
treated with Exubera® presented similar postprandial glycemic control and values of glycated 
hemoglobin (HbA1c), faster onset of action, lower weight gain, lower incidence and severity 
of hypoglycaemia and greater satisfaction (higher comfort and convenience) compared with 
patients receiving subcutaneous injection of regular insulin (238, 317-319). However, less 
than two years later, the product was withdrawn without achieving the excepted market 
success (308). This decision had as casualty the development’s interruption of AERx iDMS® 
(Novo Nordisk/Aradigm) and AIR® (Eli Lilly/Alkermes) both at phase III clinical trials, few 
months after Pfizer decision (320). Because of its short-term action, there was the necessity 
to inject a long-acting insulin for overnight glycemic control (24, 321). Moreover, Exubera® 
showed a bioavailability of only 10-20% compared to subcutaneous injection. The big size of 
the inhaler device and its complex handling also contribute to the low acceptance of the 
product by both patients and clinicians (215, 322). Although Pfizer argued that the decision 
was due to a commercial failure related to limitations of the formulation and the inhaler device 
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hampering the acceptance of the product; the development of serum insulin autoantibodies 
and the emergence of lung cancer cases in patients treated with Exubera® raised questions 
regarding the immunological effects and safety of inhaled proteins (238, 319, 323). Pfizer 
stated that patients that developed lung cancer had a history of smoking. It could be related 
to vasodilator and growth promoting capacities of insulin (238). However, due to the low 
number of cases was not possible to establish a causal relationship between the emergence 
of lung cancer and the use of Exubera®. Nonetheless, some companies continued the 
development of their products with different and improved technologies, hoping to succeed 
were Exubera® failed.  
Afrezza® (MannKind), a DPI based on Technosphere® technology (324) using a next-
generation inhaler device (Dreamboat®) recently granted FDA approval. The change of the 
inhaler device from MedTone® to Dreamboat® over of the clinical studies raised concerns by 
FDA about the equivalence of the two devices, which delayed the product approval. 
Technosphere® technology is based on fumaryl diketopiperazine large porous particles with a 
MMAD of 2-2.5 µm, suitable for delivery at deep lung, where small proteins can be absorbed 
onto the surface. Pharmacodynamic and pharmacokinetic analysis of Afrezza® showed a 
rapid absorption (time of maximum concentration observed (tmax) = 12–14 min), short onset of 
action (20–30 min) and action duration time (2–3 hours) that mimic the physiological insulin 
requirements to cover prandial glucose absorption in type 2 diabetic patients (325). In a pilot 
study an optimal dose of inhaled insulin was able to control the postprandial glycemic levels 
of type 2 diabetes patients regardless the meal carbohydrate content (326). In addition, the 
absorption and pharmacokinetics of insulin after inhalation was not significantly altered in 
patients with mild-to-moderate chronic obstructive pulmonary disease (COPD) (maximum 
concentration observed (Cmax) = 34.7 µU/mL and area under the curve (AUC) = 
2037 µU/mL·min) compared to healthy patients (Cmax = 39.5 µU/mL and AUC = 
2279 µU/mL·min) (327). Concerning safety, in a 2-years study, Afrezza® showed to be well 
tolerated, promoting slightly changes in lung function, comparable to the usual treatment and 
mild, transient cough after inhalation (328). However, the results of the study should be 
analyzed carefully, since a high percentage of treatment discontinuation owing to adverse 
events was higher in the Afrezza® treated group. 
Other inhalable insulin products are under clinical stage such as Aerodose (phase II), Abbott 
Labs’ inhaled insulin (phase II), QDose (phase I), Alveair® (phase I), BioAir® (phase I) or 
ProMaxx® (phase I) (320). Insulin is commonly used as drug model in the development of 
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formulations for delivery of proteins, which explains the high number of studies at preclinical 
stage published (34, 322, 329-337). 
Besides Afrezza®, MannKind is also developing a glucagon-like peptide 1 (GLP-1)-based 
product to treat type 2 diabetes by inhalation based on the same Technosphere® system. The 
product (MKC253) is currently at phase I stage and, so far, proved to be able to stimulate the 
insulin secretion and, consequently, reduce the postprandial glycemic levels. Also, the 
gastrointestinal adverse effects usually observed with the subcutaneous or oral administration 
of GLP-1 and its analogs used in clinical practice are absent with this inhaled formulation 
(338). 
Aerovance is a biopharmaceutical company that is also exploiting the potential of 
biopharmaceuticals’ inhalation to treat local diseases. Presently, two DPI are at phase II 
clinical studies for the treatment of asthma (pitrakinra) and cystic fibrosis and COPD 
(bikunin). Pitrakinra is a recombinant human interleukin 4(IL-4) variant that efficiently inhibits 
both IL-4 and interleukin 13 (IL-13) activity, reducing the inflammation in asthma and eczema 
(339, 340). At the first studies both liquid and powder formulations were tested, but the last 
news available are related to a DPI (Aerovant®) formulation to treat exacerbations in patients 
with eosinophilic asthma. Bikunin is a truncated human SPINT2 serine protease inhibitor that 
presents the capacity to reduce the airway epithelial sodium ion channels activity, thereby 
reducing sodium hyper absorption in cystic fibrosis patients and COPD (341). Is currently 
under development with the name Aerolytic® and Pulmolytic®.  
Inhalable proteins to treat viral infections have also been proposed. DAS181 is a recombinant 
sialidase fusion protein that inactivates viral receptors on the cells of the human respiratory 
tract, thus preventing and treating infection by various influenza virus subtypes, including 
H5N1, and parainfluenza (342-344). In a phase II clinical trial, DAS181 was able to reduce 
the lung viral load in patients infected with influenza B, H3N2 and H1N1 without significant 
side effects (342). DAS181 was formulated using TOSAP® technology into dry powder 
microspheres for pulmonary delivery (Fludase®).  
In Table 1.5 are presented examples of formulations and products proposed for inhalation of 
therapeutic peptides and proteins that are currently in clinical trials. 
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Table 1.5 Formulations for pulmonary administration of therapeutic peptides and proteins ongoing 
clinical trials. 
 
Peptide/protein 
Therapeutic 
indication 
Name/System 
Inhalation 
mode 
Clinical 
phase 
Reference 
Bikunin 
Cystic fibrosis 
and COPD 
Aerolytic and Pulmolytic 
Nebulizer 
and DPI 
phase II (345) 
CsA 
Lung 
transplant 
rejection 
Liquid solution Nebulizer phase III (346) 
CsA 
Lung 
transplant 
rejection 
Sugar-based particles DPI phase 0 (347) 
DAS181 
Influenza virus 
infection 
Fludase/TOSAP DPI phase II (342) 
GLP-1 
Diabetes 
mellitus 
MKC253/Technosphere DPI phase I (338) 
INF-γ 
Cystic fibrosis, 
lung infection 
Liquid solution Nebulizer phase II (348, 349) 
Insulin 
Diabetes 
mellitus 
Aerodose/liquid solution Nebulizer phase II (350, 351) 
Insulin 
Diabetes 
mellitus 
Dry crystals pMDI phase II (352) 
Insulin 
Diabetes 
mellitus 
QDose DPI phase I (353) 
Insulin 
Diabetes 
mellitus 
Alveair/liquid solution Nebulizer phase I (238) 
Insulin 
Diabetes 
mellitus 
BioAir/pegylated calcium 
phosphate nanoparticles 
DPI phase I (354) 
Insulin 
Diabetes 
mellitus 
ProMaxx/microspheres DPI phase I (355) 
IL-2 
Metastatic or 
unresectable 
solid tumors 
Liquid solution Nebulizer phase I (356) 
Pitrakinra Asthma Aerovant DPI phase II (340) 
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Peptide/protein 
Therapeutic 
indication 
Name/System 
Inhalation 
mode 
Clinical 
phase 
Reference 
Sargramostin 
Metastatic 
cancer, 
sarcoma 
Liquid solution Nebulizer phase II (357) 
α1-antitrypsin Cystic fibrosis Liquid solution Nebulizer phase I (358) 
COPD – Chronic obstructive pulmonary disease; CsA – Cyclosporin A; DPI – Dry powder inhaler; GLP-
1 – Glucagon-like peptide 1; INF- γ – Interferon-γ; IL-2 – Interleukin 2; pMDI – Pressurized metered-
dose inhaler. 
 
 
A variety of formulations for inhalation of therapeutic peptides and proteins have been 
developed at preclinical stage. Some examples include calcitonin (359-361), parathyroid 
hormone (362), detirelix (363, 364), erythropoietin (262), interferon-α (INF-α) (365), follicle-
stimulating hormone (366), glucagon (367), among others. 
 
4.1. The new era of pulmonary administration: nanomedicine-based formulations 
 
Driven by the progresses in the nanomedicine field, many researchers have consolidated the 
concept of pulmonary delivery of drugs using nanoDDS by developing innovative formulations 
with improved biopharmaceutical features (23, 368). For example, mucoadhesive (369) and 
mucus-penetrating particulates (370, 371) showed to increase the residence time of drugs 
into the lungs and improve their absorption and/or therapeutic efficacy. The last approach 
could have great impact in the pulmonary delivery of drugs to treat diseases with high mucus 
production like cystic fibrosis (372, 373). Preliminary results are promising and it is expected 
that the clinical relevance of such products could be proven in clinical trials (19, 84, 240). In 
this context, a new door has been opened in the field of inhalation therapy and new advances 
could be expected in the near future. Still, several issues such as large scale production, 
batch-to-batch reproducibility, variable lung deposition pattern, or cost- effectiveness balance 
of the treatment need to be addressed and optimized in order to ensure the bench-to-bedside 
translation of inhalatory nanoDDS. 
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4.1.1. Lipid-based formulations 
 
From the lipid-based nanoDDS for inhalation, liposomes appear as the preference of 
researchers owing to its interaction with endogenous surfactant phospholipids, promoting an 
increased retention of drugs in the lungs. Furthermore, the use of phospholipids similar to the 
surfactant promotes the absorption of the incorporated drugs, although the mechanism 
underlying the permeation enhancing is not yet clear (34). 
As discussed above, insulin is the most studied protein for pulmonary delivery. Several 
formulations containing nanocarriers have been developed for pulmonary delivery of insulin in 
order to overcome the problems associated with conventional formulations (238, 319). Huang 
and co-workers produced liposomes using the membrane destabilization/dialysis method with 
an average diameter of 200 nm and encapsulation efficiency of 52% (335). In vivo studies 
demonstrate a homogeneous deposition of liposomes in alveoli with reduction of systemic 
levels of glucose and absence of immunoreaction of lung tissue (335). In another study, the 
liposomes obtained using the reverse phase evaporation technique possessing an average 
diameter of 295 nm and an encapsulation efficiency of 43%, were subjected to spray 
congealing before solvent evaporation (336). The formulation proved to be stable after three 
months of storage, promoting a decrease in systemic levels of glucose for 12 hours when 
compared with solutions for pulmonary administration of insulin and subcutaneous injection 
(336). Chono and co-workers produced liposomes containing different derivatives of 
phosphatidylcholine by hydration of lipid film technique (337). In vivo studies using rats as an 
animal model showed a greater reduction of serum glucose after intratracheal administration 
of insulin encapsulated in liposomes as compared to insulin solution. However, this reduction 
was only significant for liposomes containing the derivative dipalmitoylphosphatidylcholine. In 
this study it was also assessed the influence of the size of liposomes in the absorption of 
insulin. There was a greater reduction in levels of plasma glucose and increased serum 
insulin after administration of liposomes with an average diameter of 100 nm. In the case of 
liposomes of 1000 nm, it was observed an increased retention by macrophages. In vitro tests 
performed in cell cultures of Calu-3 showed the existence of an absorption promoting effect of 
liposomes, possibly by opening of tight junctions (337). 
Leuprolide, also called leuprorrelin, is a highly hydrophilic luteinizing-hormone-releasing 
hormone (LHRH) agonist peptide with a MW of 1.2 kDa, used in treatment of prostate cancer, 
endometriosis, and precocious puberty (374). In order to develop a DPI for pulmonary 
administration of leuprolide, Shahiwala and co-workers produced liposomes by reverse phase 
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evaporation technique followed by lyophilization (374). The diameter of the aggregates of 
liposomes obtained lies within the limits compatible with alveolar deposition of particles from 
3.5 to 4.3 µm possessing high encapsulation efficiency (66-72%). After intratracheal 
instillation in rats, liposomes promoted higher serum luteinizing hormone levels than the 
solution of leuprolide and an increased t1/2 when compared to solutions for pulmonary and 
subcutaneous administration. However, the bioavailability of liposomes was only 50% 
compared with subcutaneous injection and it is necessary to change the formulation in order 
to increase the bioavailability of leuprolide (374). 
Liposomal inhaled cyclosporin A (CsA) to treat rejection of lung transplants was also 
proposed.. Pulmonary administration to dogs resulted in higher concentration of CsA in the 
lungs instead of the liver, kidneys, spleen, heart and blood compartment. However, three 
hours after administration, there was some accumulation of CsA in the kidney and spleen, so 
the effects on the kidney should be studied (375). In another study, pulmonary delivery of 
liposome-encapsulated CsA promoted an accumulation of CsA in the lungs. The formulation 
was stable after nebulization and maintains the immunosuppressive activity of CsA after 
encapsulation (376). Gilbert and co-workers administered liposomal CsA by inhalation to 
healthy humans and found a preferential deposition of the particles in the alveolar region 
(70% of inhaled dose) (377). When the formulation was administered via a mouth-only face 
mask for 45 minutes, no changes were observed in pulmonary function. In contrast, the 
administration using a nebulizer mouthpiece has proved troublesome, leading to coughing 
and throat irritation and a slight decrease in lung function. This may be due to the fact of 
particles, when administered by a nebulizer mouthpiece suffer greater impaction in the throat. 
The observed differences do not appear to be due to the formulation, because in both cases 
were used the same formula, with the same particle size at the same dose (377).  
In an in vivo study conducted by Khanna and co-workers in healthy dogs, the pulmonary 
administration of interleukin 2 (IL-2)-loaded liposomes led to an activation of the immune 
response by a significant increase in leukocyte levels in the lung and serum mononuclear 
cells (378). This response was more efficient compared to inhaled free IL-2. The observed 
differences may be due to increased cellular uptake or decreased clearance of liposomal IL-
2. In vitro studies showed that activation of pulmonary leukocytes leads to inhibition of 
proliferation of tumor cells (378). Another study of the same researchers conducted in dogs 
with primary lung carcinoma or lung metastasis of other carcinomas, has shown that there is 
no significant toxicity associated with pulmonary administration of liposomal IL-2 (379). It was 
also found that liposomal Il-2 stimulates the immune system after inhalation. Moreover, in 
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some animals it was observed the complete regression of metastasis and the non-
progression of primary lung carcinoma in another animal. Most significantly results were 
observed in treating pulmonary metastasis from osteosarcoma (379). In a phase I clinical 
trial, the pulmonary delivery of liposomes containing IL-2 to patients with various carcinomas 
affecting the lungs (pulmonary sarcoma, renal cell carcinoma, melanoma and metastatic 
osteosarcoma) was well tolerated and there was no significant toxicity observed at doses that 
may possess therapeutic effect (380). However, in this study it was not determined the 
clinical efficacy of the formulation. In another phase I clinical trial was studied the utility of 
inhaled lipossomal IL-2 in patients with common variable immunodeficiency (381). IL-2 
retained its biological activity after encapsulation. No changes were observed in pulmonary 
function or significant side effects during treatment. Although the patients treated with IL-2 
liposome declare sense of improving their condition was not detected alterations of the 
immune response within the blood compartment. Such lack of response evidence may be 
due to low specificity of the markers used in the study (381). 
Superoxide dismutase (SOD) is an antioxidant enzyme, kidnapper of free radicals, ubiquitous 
in mammalian cells. It causes a decrease of reactive oxygen species responsible for oxidative 
stress, involved in phenomena such as carcinogenesis, inflammation and neurodegeneration 
(382). Studies demonstrate the success of the use of SOD in the treatment of rheumatoid 
arthritis and ischemia-reperfusion injury. However, after intravenous and oral administration, 
the SOD has a reduced circulation t1/2 and a high-level gastrointestinal degradation, 
respectively. With the aim of developing a non-invasive formulation that promotes an 
increased t1/2 of SOD, Kaipel and co-workers produced liposomes for pulmonary 
administration (382). In vivo studies conducted in pigs showed a prolonged release of SOD 
into the systemic circulation and an increase in its t1/2. There were no side effects such as 
irritation or inflammation in the lung, as well as changes in pH and plasmatic O2 and CO2 
pressure (382). 
Different liposomal formulations were developed for aerosol delivery of a cationic α-helical 
peptide called CM3 with antimicrobial and antiendotoxin activity (383). The pulmonary 
delivery of CM3 allows the treatment of local infections and reduction of systemic effects. Of 
the several formulations developed, the best results in terms of the encapsulation and 
nebulization efficiencies and maintenance of liposomal integrity during nebulization were 
achieved with the combination of dimyristoyl phosphatidylcholine and dimyristoyl 
phosphatidylglycerol with a 3:1 molar ratio. With this formulation liposomes with diameter of 
262 nm were obtained, presenting an encapsulation efficiency of 73%. Using a mathematical 
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model it was possible to predict the deposition profile and distribution in lungs of liposomes in 
adults and children of different ages. Data showed a pulmonary deposition in the all lungs, 
particularly in the tracheobronchial region. In this region, the minimum inhibitory levels of 
CM3 can be reached in the adult model, and can be exceeded in pediatric model subjects 
(383). 
SLN have been proposed for pulmonary administration of insulin. Examples are the 
nanoparticles of lecithin obtained by emulsification method with an average diameter of 300 
nm, and alveolar deposition of 45% (w/w) of the dose delivered after lyophilization. It was 
confirmed the retention of the primary, secondary and tertiary structure of insulin after 
processing (322). In another study, Liu and co-workers produced SLN containing micelles 
inside by double emulsion with an average diameter 115 nm and an encapsulation efficiency 
of 98% (329). In vitro studies showed prolonged release of insulin. It was also demonstrated 
to retain the integrity of insulin after encapsulation and stability of the formulation after 6 
months of preparation at 4 °C (329). 
  
4.1.2. Polymeric nanoparticles 
 
A variety of polymeric nanocarriers have been explored for the pulmonary administration of 
proteins. A study compared six different types of nanocarriers composed by gelatin, chitosan, 
alginate, PLGA, poly(D,L-lactide-co-glycolic acid)-chitosan (PLGA-chitosan), and Poly(D,L-
lactide-co-glycolide)-b-poly(ethylene glycol) (PLGA-PEG), as DDS for inhalation of proteins 
using bovine serum albumin (BSA) and erythropoietin as model proteins (384). Excepting 
those of PLGA-PEG and alginate, particles presented a mean diameter lower than 300 nm. 
Gelatin and PLGA nanoparticles presented the best in vitro cytocompatibility and uptake by 
human type I alveolar epithelial cells. Additional in vivo studies in rats, showed that inhalation 
of these systems led to the release and retention of the proteins in lung tissue up to 10 days 
(384). Thus, these systems could be explored for the pulmonary administration of proteins 
with local therapeutic activity. In another study, powders for inhalation based on poly(glycerol 
adipate-co-ω-pentadecalactone) (PGA-co-PDL) nanoparticles co-spray with L-leucine were 
assessed (385). Powder presenting high FPF (> 75%) and a MMAD compatible to deep lung 
deposition (1.21 ± 0.67 μm) had shown to be compatible with pulmonary cell lines (A549 and 
16HBE14o-). Also, the primary and secondary structure of the encapsulated BSA was 
maintained (385). The same research group developed a similar system based on 
poly(ethylene glycol)-co-poly(glycerol adipate-co-ω-pentadecalactone) (PEG-co-(PGA-co-
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PDL)) for pulmonary administration of α-chymotrypsin and DNase I. The obtained powders 
maintain the activity of both enzymes and presented characteristics compatible with good 
lung deposition after inhalation (386).        
Inhalation of insulin encapsulated in polymeric nanoDDS has also been proposed. Huang and 
co-workers have developed nanoparticles of low MW chitosan using the 
emulsification/solvent evaporation technique (330). The resulting particles have a spherical 
shape with average diameter of approximately 400 nm, zeta potential of about +42 mV and 
encapsulation efficiency of 96%. The release profile of insulin was characterized by a burst 
effect followed by prolonged release for 24 hours. When administered to diabetic rats, the 
formulation has demonstrated a hypoglycemic effect similar to subcutaneous administration 
of insulin solution but prolonged in time (330). In a series of studies, Grenha and co-workers 
produced chitosan nanoparticles with and without lipid coating obtained by ionic gelation and 
then spray-dried to obtain nanocomposites. The nanoparticles obtained had an average 
diameter between 380 and 450 nm and encapsulation efficiency between 65 and 81%, while 
the spray-dried powder particles a dae of 2.5 – 2.8 µm (34, 272, 333). In vitro studies 
demonstrate a rapid release of insulin in the case of lipid nanoparticles without coating and a 
prolonged release in formulation containing lipid coating (34, 333). Additionally, formulations 
showed to be compatible with the epithelial respiratory A549 and Calu-3 cell lines (296). In 
vivo studies in rats show that after intratracheal administration, uncoated lipid nanoparticles 
reach the alveolar region and promote a greater reduction of systemic levels of glucose, 
compared to insulin solution (272, 387). Kawashima and co-workers obtained PLGA 
nanoparticles with average diameter of 400 nm, and alveolar deposition of 75% (w/w) using 
the modified emulsification/solvent evaporation method (332). In vitro dissolution tests 
showed an insulin release profile characterized by an initial burst effect followed by extended 
release. In vivo studies show a significant reduction in systemic levels of glucose which lasts 
for a period exceeding 48 hours, compared with an aqueous solution of insulin for inhalation 
(332). This biphasic release of insulin can mimic the marketed injectable insulin mixtures of 
short and long duration of action. In another study, PLGA nanoparticles were produced using 
the emulsification/solvent evaporation technique followed by granulation (331). In vitro and in 
vivo showed an alveolar deposition of approximately 45% (w/w) of emitted dose and 
pharmacological effect of prolonged over 12 hours when compared with solutions of insulin 
administered intratracheally and intravenously (331). Poly(n-butyl cyanoacrylate) 
(PBCA)/dextran nanoparticles obtained by Zhang and co-workers using the in situ 
polymerization method have a diameter of 255 nm and an encapsulation efficiency of 79% 
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(334). In vitro assays demonstrate an insulin release profile characterized by an initial burst 
effect followed by prolonged release. In vivo studies are characterized by a prolonged 
therapeutic effect over time when compared to insulin solution administered intratracheally 
and a bioavailability of 57% compared with subcutaneous administration (334). 
PLGA nanoparticles coated with chitosan obtained by the emulsion and solvent diffusion 
technique have been proposed to administer calcitonin by pulmonary route (388). Due to the 
mucoadhesion promoted by chitosan, coated nanoparticles were eliminated more slowly from 
the lung compared to those not coated. Moreover, the opening of tight junctions also 
promoted by chitosan led to an increased absorption of calcitonin and a decreased in in vivo 
systemic levels of calcium (388). The pharmacological effect was prolonged for 24 hours after 
inhalation. The particles with a diameter of 650 nm and were nebulized with success and the 
release profile of calcitonin is characterized by a burst effect followed by prolonged release 
over time (388). Based in the previous study and to enjoy the advantages of solid calcitonin 
formulations for inhalation over the liquid ones (389), chitosan-modified PLGA 
nanocomposites were produced by spray drying fluidized bed granulation (Agglomaster®) and 
dry powder coating technique (Mechanofusion®) (390). Powders obtained with the 
Agglomaster® showed improved redispersibility of powders in liquid media and higher in vivo 
lung retention and hypocalcemic effect, which could be explained by the lower strong 
aggregation of particles using the spray drying fluidized bed granulation technique (390). 
Chitosan nanoparticles co-sprayed with mannitol as powders for inhalation of calcitonin were 
also proposed by other research group, presenting appropriate aerodynamic properties and 
good absorption to the systemic circulation after pulmonary administration to rats (391). 
 
5. State-of-art of micelles as drug delivery systems by inhalation 
 
In the last two decades, pulmonary administration of nanoDDS has been a growing topic of 
interest among researchers (278, 384, 392). However, micelles as platforms for inhalation of 
drugs have been poorly explored. Numerous examples of liposomes intended for inhalation 
have been proposed over the years presenting good results (393, 394), with at least two 
formulations enrolling clinical trials Arikace® (Insmed at phase I/II) (395) and Pulmaquin® 
(Aradigm at phase III) (396). Since polymeric micelles presented advantages over liposomes, 
like higher stability and high capacity of solubilization of hydrophobic drugs, as described 
before, they possess the potential for pulmonary delivery of drugs. Additionally, the capacity 
demonstrated by some micelles to overcome multidrug resistance (56, 397) and enhance the 
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transfection of genetic material to cells (130), make them promising vehicles for local delivery 
of anticancer drugs to treat lung cancer, and genetic material to target cells. Also, the small 
size of micelles confers them the opportunity to escape easily from phagocytosis by alveolar 
macrophages and allow the delivery and absorption of drugs with systemic action through an 
epithelium with high surface area and reduced enzymatic activity. Thus, the feasibility of 
micelles as DDS for pulmonary administration of drugs has been explored in the last years 
with some studies reviewed in this section. Taking into account the results so far, is expected 
an increase in the upcoming years of the studies using formulations based on polymeric 
micelles as inhaled DDS. As referred before, a careful and detailed assessment of the safety 
of such formulations should be performed, especially in the case of the ones expected to be 
chronically administered. 
 
5.1. Lipid-polymer micelles 
 
As referred previously, lipid-polymer micelles are composed by polymers conjugated with 
phospholipids or long-chain fatty acids. Several combinations of polymers and 
lipids/phospholipids have been tested for the preparation and application of micelles. 
Chitosan oligosaccharide-stearic acid (CSO-SA) micelles were developed by Gilani and co-
workers, for the pulmonary administration of amphotericin B (AmB) to treat invasive 
pulmonary fungal infections in some patients receiving immune suppressive treatments (108). 
Local administration avoids the systemic side effects of AmB and improves their 
bioavailability (398). After encapsulation into micelles, AmB presented the same antifungal 
activity of Fungizone® but lower toxicity (108), a phenomenon intimately related to its 
aggregation state (399). The micelles possessed positive charges with mean diameters 
between 100-250 nm, and were efficiently nebulized using an Air-jet nebulizer to particles 
with FPF up to 52%, making them suitable for pulmonary delivery of AmB (108). The same 
research group developed chitosan-stearic acid micelles encapsulating itraconazole for 
pulmonary delivery (400). Positively charged micelles with mean diameters inferior to 200 nm 
were efficiently and stably nebulized presenting FPF up to 48%. The antifungal activity of 
itraconazole against C. albicans, A. fumegatus, and A. niger was maintained after its 
encapsulation into micelles (400). Thus, the solubilization of hydrophobic itraconazole into 
polymeric micelles could be an effective approach to deliver the drugs by inhalation in order 
to treat pulmonary fungal infections.     
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Different research groups have been studying the administration of drugs to treat tuberculosis 
using polymeric micelles. Stearic acid-branched polyethyleneimine (SA-BPEI) micelles 
encapsulating rifampicin were spray-dried and powders with a drug content of 48%, a MMAD 
lower than 2.5 µm, and FPF of 67% obtained. Moreover, micelles showed in vitro 
biocompatibility up to 75 μg/mL concentration and taken up by THP-1 cells differentiated to 
macrophages (401). Thus this system could be explored to target alveolar macrophages, the 
reservoir of Mycobacterium tuberculosis. Methoxy poly(ethylene oxide)-b-distearoyl 
phosphatidyl-ethanolamine (mPEG–DSPE) micelles where also proposed as carriers for 
rifampicin, although its therapeutic efficacy was not assessed (60). Rifampicin was entrapped 
with high encapsulation efficiency into these micelles that sustained its release over 3 days in 
vitro. Formulations presented a fraction of fine particles of approximately 40% after 
nebulization (60). 
The potential of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy(poly(ethylene 
glycol)) (DSPE-PEG) as pulmonary DDS was evaluated. Paclitaxel was successfully 
encapsulated in DSPE-PEG micelles with an encapsulation efficiency of 95% and was slowly 
released in simulated surfactant lung fluid, reaching 90% of drug release after 8 hours. 
Additionally, micelles showed to be stable in water during 3 months of storage. After 
intratracheal administration of paclitaxel-loaded micelles in rats, the lung concentration of 
paclitaxel was significantly higher as compared to intravenous administration of micelles and 
intratracheal administration of Taxol®. While paclitaxel is mainly accumulated in organs such 
liver and spleen and rapidly cleared from lungs after intravenous administration of micelles 
and intratracheal administration of Taxol®, respectively, around 50% of the paclitaxel 
concentration remains in lungs 12 hours after intratracheal administration of paclitaxel-loaded 
micelles. These results show that pulmonary administration of paclitaxel leave to low 
systemic exposure, resulting in localized chemotherapy to the lungs and avoiding the 
unwanted side effects to other tissues (402). In another study, inhaled DSPE-PEG micelles of 
16 nm in size encapsulating doxorubicin showed higher accumulation in the lungs and lower 
distribution in non-target organs compared to its intravenous administration (403). These 
results reinforce the usefulness of local administration of anticancer drugs through inhalation 
to treat lung cancer. In addition, micelles showed a strongest tendency to be accumulated 
to the lungs for the longer periods of time compared to mesoporous silica nanoparticles, 
dendrimers, and quantum dots (403), demonstrating the feasibility of micelles as nanoDDS 
for inhalations of drugs. 
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DSPE-PEG micelles have also been proposed for pulmonary delivery of anti-inflammatory 
drugs like beclomethasone dipropionate (404, 405) or budesonide (406). Gaber and co-
workers developed micelles of 22 nm diameter and a high encapsulation efficiency (> 96%) 
presenting a sustained release profile and a FPF suitable for pulmonary delivery, with lower 
deposition of particles in the throat (404). In another study DSPE-PEG was conjugated with 
α,β-poly(N-2-hydroxyethyl)-DL-aspartamide (PHEA) in order to further improve the pulmonary 
delivery of corticosteroids to treat bronchial inflammatory diseases (407). Beclomethasone 
dipropionate was efficiently encapsulated in 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-methoxy(poly(ethylene glycol))-α,β-poly(N-2-hydroxyethyl)-DL-
aspartamide (DSPE-PEG-PHEA) micelles presenting a sustained release in vitro with less 
than 30% of the drug being released after 48 hours. The obtained micelles showed to be 
biocompatible with human bronchial epithelial cells (16HBE14o-) and enhanced the drug 
uptake by the same cell line after 48 hours of incubation (407).  
Due to its cationic nature, chitosan can be complexed with negatively charged DNA and be 
used as non-viral vector for gene therapy. Hu and co-workers synthesized CSO-SA in order 
to produce polymeric micelles to delivery pEGFP-C1 (408). The CSO-SA/DNA micelles 
efficiently protected the condensed DNA from enzymatic degradation by DNase I, presented 
lower cytotoxicity and comparable transfection efficiency in A549 cells compared to 
Lipofectamine® 2000 (408), making these micelles a promising gene delivery system in the 
treatment of pulmonary diseases. The same research group developed CSO-SA micelles for 
the delivery of drugs like paclitaxel (107) or doxorubicin (106, 409). The encapsulation of 
doxorubicin in CSO-SA micelles resulted in higher uptake and accumulation by A549 cells 
and a decreasing in the half maximal inhibitory concentration (IC50) value (45). Although the 
promising results, the feasibility of such formulations as inhaled or intravenous delivery 
systems needs to be confirmed with in vivo studies. 
 
5.2. Copolymer-based micelles 
 
As referred previously, besides the use of lipids as hydrophobic segment of polymeric 
micelles, is possible to produce this kind of micelles with amphiphilic copolymers composed 
by segments with different water affinity nature, being ones hydrophilic and others 
hydrophobic. 
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Laouini and co-workers developed different systems, namely polymeric micelles, liposomes, 
SLN and nano-emulsions, intended for pulmonary administration of vitamin E and assess 
their aerodynamic properties using different techniques (410). PEG-b-PCL micelles of 154 nm 
in size, low PdI (0.09) and high AE (87.4%) (411), presented a dae of 5.8 µm and a FPF of 
29% as determined by laser diffraction analysis of the nebulized micelles dispersion (410). 
On the other hand, a MMAD of 3.2 µm and a FPF of 78% were obtained when the 
formulations were assessed by cascade impaction. Additionally, an in silico prediction of the 
aerodynamic behavior of nebulized micelles using the multiple-path particle dosimetry, 
resulted in ~52% of lung deposition (410). These results evidence the importance of multiple 
technique assessment of the aerodynamic properties of inhaled formulations, in order to 
better predict its in vivo behavior. The incorporation of a hydrazone bond between the PEG 
and PCL blocks allowed the development of pH-sensitive micelles (411), that could be 
explored for the targeting of drugs to cancer or inflammation tissues.   
As referred previously, polymeric micelles have been proposed as platforms for the inhalation 
of antitubercular drugs. Wu and co-workers synthesized and characterized polylactide-
chitosan (PLA-chitosan) copolymers with different molar ratios for delivery of rifampicin (412). 
As polylactide (PLA) molar ratio increased, the micelle size and drug-loading content 
increased with a decreasing in rifampicin release rate (412). In another study, enantiomeric 
poly(ethylene glycol)–polylactic acid (PEG-PLA) stereocomplex micelles composed by a 
equimolar mixture of enantiomeric poly(ethylene glycol)–poly(l-lactide) (PEG-PLLA) and 
poly(ethylene glycol)–poly(d-lactide) (PEG-PDLA) were developed to sustained release of 
rifampicin (413). The stereocomplex micelles presented lower CMC and mean diameter, 
higher stability in water and encapsulation efficiency than those observed with the single 
enantiomeric micelles. In vitro drug delivery release was characterized by an initial burst 
release followed by a sustained release until 48 hours (413). Silva and co-workers evaluated 
the feasibility of poly(ethylene glycol)-poly(aspartic acid) (PEG-Pasp) micelles as delivery 
system for tuberculostatic agents. The conjugation of isoniazid and pyrazinamide with PEG-
Pasp improved the activity against Mycobacterium tuberculosis by reducing the minimal 
inhibitory concentration (MIC) of the drug (58, 414). Poly(ε-caprolactone)-b-poly(ethylene 
glycol)-b-poly(ε-caprolactone) (PCL-PEG-PCL) micelles surface modified with chitosan and 
galatomannan were also proposed as nanoDDS for delivery of rifampicin. The presence of 
galatomannan increased the uptake by macrophages, being these micelles proposed for 
improved therapy of tuberculosis by targeting alveolar macrophages (18). 
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For the treatment of fungal infections, in a 12 days study in mice, the inhalation of 
itraconazole:polysorbate 80:F127 nanostructured aggregates triggered higher lung 
concentrations and lung-to-serum ratios of itraconazole, improved survival of infected animals 
while decreasing toxicity compared with orally administered itraconazole formulations (415-
418). No signs of lung inflammation or changes in pulmonary histology were detected (419). It 
is worth stressing that a lower drug dose was required to achieve lung and serum therapeutic 
levels using inhaled formulation comparing to oral administration (416). 
Liu and co-workers developed an tri-block copolymer consisting of Poly(epsilon-
caprolactone)-b-chitooligosaccharide-b-poly(ethylene glycol) (PCL-b-COS-b-PEG) for 
delivery of doxorubicin (420). The obtained polymer presents the capacity to form micelles 
with encapsulation efficiency of doxorubicin close to 50%. Genipin post-crosslinking did not 
affect the macroscopic characteristics of the micelles but delayed the in vitro release of 
doxorubicin from the micellar reservoir (420). Similar results were obtained by Chen and co-
workers using chitosan-poly(ε-caprolactone)-poly(ethylene glycol) to encapsulate paclitaxel 
and rutin with glutaraldehyde post-crosslinking (44). In another study, Kontoyianni and co-
workers synthesized a new type of amphiphilic polymer based on the PEGylation of a 
hyperbranched aliphatic polyester (BH40-PEG polymer) (421). The polymer produces 
micelles presenting 20 nm of mean diameter that could encapsulate paclitaxel. Paclitaxel 
water solubility significantly increased after encapsulation into micelles, and the polymer 
showed to be non-toxic to A549 cells up to a concentration of 1.75 mg/mL, while the median 
lethal dose (LD50) was 3.5 mg/mL (421). The obtained results make these systems promising 
for administration of anticancer agents, however, further studies are required in order to 
assess their feasibility as inhaled drug delivery systems. 
Besides the conventional chemotherapy, it is possible resort to photodynamic therapy (PDT) 
to treat lung cancer. PDT consists in the administration of photosensitizer agents that 
generate reactive oxygen species after activation of the system by light exposure at the 
targeted tissues. Pluronic L122 was used by Yang and co-workers to encapsulate 
hematoporphyrin for pulmonary delivery. Micelles with 98% of encapsulation efficiency 
exhibited higher cellular uptake and cytotoxicity against A549 cells as compared to the free 
drug. In addition, micelles were efficiently incorporated into lactose microparticles with ~2 μm 
by spray-drying, making the system a suitable DPI for pulmonary administration (422). 
Gene therapy aiming to treat pulmonary pathologies was also explored. An amphiphilic 
polyethylenimine (PEI) derivative was synthesized by Roesler and co-workers (423). 
Although PEI is one of the most effective polycations for gene delivery due to is high-density 
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charge, it presents short t1/2 and systemic cytotoxicity due to adherence to cell membranes 
and aggregation with blood components. PEGylation of PEI reduces their cytotoxicity and 
improves their stability. In addition, the micelles produced efficiently condensed the DNA and 
presented higher transfection efficiency of PEI/DNA complexes after intratracheally instillation 
in mice (423). Chao and co-workers study the feasibility of PEG-PPO-PEG micelles as 
inhaled gene delivery systems (424). DNA was efficiently encapsulated into micelles and their 
degradation by DNase I was delayed. Significant gene expression in mice lungs was detected 
48 hours after the inhalation of DNA-micelles co-formulated with 10% ethanol as permeation 
enhancer. After 6 doses, gene expression was also detected in other tissues such trachea, 
stomach and duodenum (424). 
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Chapter 2 
 
Aims and Goals 
 
 
Recent advances in biotechnology and genetic engineering have resulted in the promotion of 
peptides and proteins as an important class of therapeutic agents. Despite the emergence of 
several peptides and proteins with therapeutic potential, their administration in the active 
conformation has been shown to be an enormous challenge for the pharmaceutical industry. 
There are several limitations that are imposed as low bioavailability, physical or chemical 
instability and side effects (425). Currently, due to instability and reduced permeability of 
proteins through biomembranes, the parenteral route is the most used for the administration 
of such drugs. However, this is an invasive route, which can lead to a reduced acceptance by 
patients and, consequently, increased costs of therapy, especially when is required a 
prolonged or chronic treatment (215, 216). Alternative routes for administration of proteins 
have been the focus of many research groups, being respiratory system receiving special 
attention due to its physiological characteristics (19). Several formulations for inhalation of 
peptides and proteins are currently under development and in clinical trials. Some of them 
showed positive results. However, conventional formulations have some limitations, namely 
reduced bioavailability (215, 322).  
Polymers such as gums, cellulose derivatives, acrylates or PVP have been used from 
decades in the development of conventional DDS, in order to control the release pattern of 
drugs from the polymeric matrix (170, 426). With the advent of new technologies applied to 
health, namely nanomedicine, and the progresses seen in chemical and surface engineering, 
new and improved polymers have been produced and the older ones have gained new 
functionalities (7). Controlling the size and molecular architecture of polymers is possible to 
obtain formulations with distinct properties. The incorporation or conjugation of therapeutic or 
imaging agents with polymers modifies their pharmacokinetics and pharmacodynamics (127, 
426, 427). Characteristics of drugs such as hydrophilicity, release and degradation profile, 
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stability, transport across biological membranes, plasma circulation time, and biodistribution 
can be tailored to specific needs (428, 429). In addition, recent DDS have been designed as 
responsive and recognitive systems that can target drugs to specific sites and deliver them in 
response to a stimulus (35, 430). Among polymers, those possessing amphiphilic properties 
have been rediscovered in the last years and used in the development of intelligent and 
advanced systems in the field of nanomedicine (79, 431). 
 
 
Figure 2.1 General structure of Soluplus
®
 (A) and Pluronic
®
 (B). 
 
In this thesis we explore the utility of amphiphilic polymers in the development of solid 
formulations for pulmonary administration of proteins, using insulin as model drug. The 
system comprised polymeric micelles composed by polyvinyl caprolactam-polyvinyl acetate-
poly(ethylene glycol) graft copolymer (Soluplus® (SOL), Figure 2.1) or PEG-PPO-PEG 
(Pluronic® F68 (F68), Pluronic® F108 (F108), and Pluronic® F127 (F127)) (Figure 2.1 and 
Table 2.1) in which insulin was encapsulated. 
 
Table 2.1 Poly(ethylene glycol) (a) and polypropylene oxide (b) units of the different Pluronic
®
 used 
(according to the manufacturer). 
Type of Pluronic® a b 
F68 80 27 
F108 141 44 
F127 101 56 
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The main objectives undertaken on the present thesis were: 
 
i) Develop polymeric micelles as delivery systems for insulin, as model therapeutic 
protein. Different polymers, production conditions and polymer:protein ratio were 
tested; 
ii) Explore the possibility of develop stimuli-sensitive formulations. For that, PBA was 
added to the system, since boronic acid derivatives have been proposed as 
excipients to control the release of insulin from formulations as response to 
glucose concentration; 
iii) Develop solid formulations presenting appropriate characteristics for inhalation. 
Lyophilization was used as technique for the production of nanocomposites based 
on polymeric micelles and its effect on the conformation of insulin evaluated; 
iv) Assess the biological efficiency and biocompatibility of formulations. Pulmonary 
cell lines and macrophages were used to study the toxicity, pulmonary 
permeability and phagocytosis of formulations; 
v) Evaluate the in vivo efficacy and safety of the insulin-loaded polymeric micelles. 
Thereunto, powders were administered by intratracheal instillation to diabetic 
murine models.   
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Chapter 3 
 
Design and characterization of self-assembled 
micelles for insulin delivery 
 
 
 
 
The information presented in this chapter was partially published in the following publication: 
 
Fernanda Andrade, Pedro Fonte, Mireia Oliva, Mafalda Videira, Domingos Ferreira, Bruno 
Sarmento, Solid state formulations composed by amphiphilic polymers for delivery of 
proteins: characterization and stability, International Journal of Pharmaceutics, 2015, 
486:195-206 
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1. Introduction 
 
In the last decades, the use of polymers in the development of drug delivery systems has 
gained a new breath as consequence of the progresses seen in the fields of polymer 
engineering and nanotechnology applied to health. Among them, amphiphilic polymers have 
emerged as platforms for advanced delivery of a variety of drugs (41). A multitude of 
monomers and polymers can be conjugated in order to obtain amphiphilic polymers with 
modulated characteristics (136). The most commonly used are poloxamers, triblock 
copolymers of polyoxyethylene and polyoxypropylene, commercially known as Pluronic® 
(164). However, PLGA-PEG, poly(ethylene glycol)-b-poly(ε-caprolactone) (PEG-b-PCL) as 
well as their derivatives (18, 127) are also commonly used. 
Nanotechnology-based delivery systems have been explored to solve the drawbacks of 
conventional formulations such as instability and degradation, reduced permeation through 
biomembranes and bioavailability (25, 428). Polymeric micelles are spherical shape nano-
sized structures composed by amphiphilic polymers or polymers conjugated with lipids that 
are suitable as drug delivery systems. The inner core of micelles presents the capacity to 
encapsulate hydrophobic drugs, while the shell can associate the hydrophilic ones (79). Due 
to its small size, micelles generally escape from the reticulo-endothelial system, presenting 
higher bloodstream circulation time (40). Also, some studies suggest the capacity of 
polymeric micelles to inhibit the drug efflux mechanisms and consequently multidrug 
resistance (113, 397). In addition, as liposomes, the surface of polymeric micelles can be 
easily tailored with specific ligands for targeted delivery (141). Nevertheless, micelles present 
the advantage of being more stable than liposomes (63). The versatility of micelles explains 
why they have been proposed as vehicles for solubilization and delivery of a variety of drugs 
like doxorubicin (119), paclitaxel (66, 68), rifampicin (18), calcitonin (59), CsA (124) among 
others, being some formulations in clinical trials (66, 68). 
Due to the development noted in the biotechnology field, biopharmaceuticals have emerged 
as an alternative to conventional drugs in the treatment of many diseases. Since the 
commercialization of insulin obtained by biotechnology processes in 1982, 
biopharmaceuticals have gained an increased share in the global pharmaceutical market 
(207). Despite their well-known therapeutic efficacy, the major drawback of biopharmaceutical 
drugs is the difficulty of administration via non-invasive routes in their active conformation. 
Among the different non-invasive routes of administration, inhalation appears as a promise 
one due to the physiological characteristics of lungs and airways resulting in higher 
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bioavailability than for other non-invasive routes (213). In addition, inhalation of insulin 
presented better therapeutic results when compared to the oral administration. As a result, an 
insulin-based formulation (Exubera®) achieved market authorization from FDA and EMA. 
However, the product was withdrawn due to commercial and financial reasons, being also 
reported cases of adverse effects and lung cancer after the use of this product (238). More 
recently, FDA approved a new and improved powder formulation for insulin inhalation 
(Afrezza®). 
In this chapter the production of micelles with characteristics appropriated to pulmonary 
delivery and the association of insulin to the system was explored.     
 
2. Experimental 
  
2.1. Materials 
 
SOL, F68, F108 and F127 were kindly provided by BASF (Ludwigshafen, Germany). 
Lyophilized human insulin, PBA and phosphate buffer saline pH 7.4 (PBS) were purchased 
from Sigma-Aldrich (St. Louis, MO, USA). The other reagents used were methanol and 
ethanol absolute from analytical grade; acetonitrile and trifluoroacetic acid (TFA) from high-
performance liquid chromatography (HPLC) grade (Merck, Germany) and Type 1 ultrapure 
water (18.2 MΩ.cm at 25 ºC, Milli-Q®, Billerica, MA, USA). 
 
2.2. Production of micelles 
 
Micelles were prepared using the thin-film hydration technique. Briefly, each polymer was 
individually weight and dissolved in methanol or a mixture of methanol:ethanol (1:1). Then, 
the solvent was removed under vacuum and the film was left to dry overnight at room-
temperature to eliminate any remained solvent. The film was then hydrated with Type I 
ultrapure water or PBS at 37 ºC in order to obtain a 1 % (w/v) solution and vortexed for 5 min. 
The obtained dispersion was filtered through a 0.22 µm syringe filter to remove possible dust 
and aggregates. PBA containing micelles were prepared by dissolving PBA with the polymers 
in the solvents prior to the production of the film at a ratio of 10:1 (polymer:PBA). Insulin 
formulations were prepared by adding different amounts of insulin in the form of solution in 
PBS during the film hydration, to obtain polymer:insulin ratios ranging from 10:0.1 to 10:1 
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(w/w). The other steps were the same as for plain formulations. After preparation, the pH of 
all formulations was measured, ranging between 6.1 and 7.1. 
 
2.3. Determination of size, zeta potential, association efficiency, and osmolality 
of formulations  
 
Particle mean hydrodynamic diameter and polydispersity index (PdI) were measured without 
previous sample dilution by dynamic light scattering (DLS) at both 25 °C and 37 °C using a 
detection angle of 173° and zeta potential by laser doppler micro-electrophoresis using a 
NanoZS (Malvern Instruments, UK). For each type of formulation were produced and 
analyzed at least three replicates. The osmolality of formulations was determined at room 
temperature using a Micro-Osmometer M3320 (Advanced Instruments, Inc., MA, USA). 
Triplicates of each formulation were analyzed. 
AE, i.e. the amount of insulin associated with the micelles, and the LC, i.e. the mass 
percentage of insulin of the total mass of the particles was calculated according to the 
Equation 3.1 and 3.2, respectively. The free insulin in filtrate was recovered after filtration of 
the formulations by centrifugation for 10 min at 10,000 rpm at 37 ºC, using a 30k pore filter 
(Nanosep® Centrifugal Devices, Pall Corporation, Spain). A previously validated HPLC 
method was used to quantify the insulin (432). Briefly, the mobile phase consists of 
acetonitrile:0.1% (v/v) TFA aqueous solution initially set to a ratio of 30:70 (v/v), which was 
linearly changed to 40:60 (v/v) over 5 min. From 5 to 10 min the ratio was kept constant at 
40:60 (v/v). The mobile phase was pumped at a constant flow rate of 1 ml/min, the injection 
volume was 20 µl and the detection wavelength used was 214 nm. The HPLC (UltiMate® 
3000 UHPLC+ focused, Dionex, USA) system was equipped with a Purospher® STAR RP-
18e (5µm) LiChroCART® 250-4.6 (Merck, Germany) and a LiChrospher® 100 RP-18 (5 µm) 
LiChroCART® 4-4 guard column (Merck, Germany). All experiments were performed at 20 ºC 
and the total area of the peak was used to quantify insulin. For each type of formulation were 
analyzed at least three replicates. 
 
AE= 
total amount of insulin – free insulin in filtrate
total amount of insulin
 × 100                                                        Equation 3.1     
 
LC= 
total amount of insulin – free insulin in filtrate
total weight of micelles
 × 100                                                         Equation 3.2 
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2.4. Morphological characterization of micelles 
 
Different microscopic techniques, namely atomic force microscopy (AFM), field emission 
scanning electron microscopy (FE-SEM) and transmission electron microscopy (TEM), were 
used to characterize the morphology of the micelles. 
AFM imaging was performed using a MultiMode VIII microscope (Bruker AXS Inc., Madison, 
WI, USA) with a NanoScope V controller (Veeco Instruments Inc., Plainview, NY, USA). One 
drop of formulation was placed on top of freshly cleaved highly oriented pyrolytic graphite and 
left for 15 min before being removed and replaced with PBS, with no drying step in between. 
Analysis was conducted under fluid tapping mode using sharp silicon tips on nitride levers 
(model SLN-10 A, Bruker AFM Probes) with pyramidal shape and nominal tip radius of 2 nm 
and nominal spring constant 0.35 N.m-1. 
For FE-SEM performed in a Hitachi H-4100FE (Hitachi Ltd., Tokyo, Japan), a drop of 
formulation was placed on top of freshly cleaved highly oriented pyrolytic graphite and dried 
in a desiccator overnight prior to carbon coating. 
Regarding TEM, samples were placed on a grid, treated with uranil acetate and then 
observed in a JEM-1400 Transmission Electron Microscope (JEOL Ltd., Tokyo, Japan). 
 
2.5. Statistical analysis 
 
One-way ANOVA was used to investigate the differences between formulations. Post hoc 
comparisons were performed according to Tukey’s HSD test (p0.05 was accepted as 
significant different) using Prism 6.02 software (GraphPad Software, Inc., CA, USA). 
 
3. Results 
 
3.1. Size, surface charge and association efficiency of micelles 
 
For the production of micelles, a first screening with different combinations of polymers (SOL, 
F68, F108 and F127) evaporation solvents, namely methanol and a mixture of methanol and 
ethanol (1:1), and hydration solvent (H2O or PBS) were tested and the characteristics of the 
micelles are presented in Table 3.1. No significant differences were observed in respect to 
the evaporation and hydration solvents used. Thus, in order to control the pH of formulations 
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and reduce the percentage of methanol used, the combination of methanol:ethanol (1:1) and 
PBS was chosen for further studies. Also, a filtration step after the hydration of the polymeric 
film was added to the production protocol to eliminate the aggregates observed for Pluronic®-
based micelles. 
 
Table 3.1 Mean hydrodynamic diameter, polydispersity index (PdI) and zeta potential of micelles 
produced with different evaporation and hydration solvents. Samples were analyzed at 25 ºC. The 
results are expressed as mean values ± SD, n≥3. 
Polymer 
Evaporation 
Solvent 
Hydration 
Solvent 
Hydrodynamic 
Diameter (nm) 
PdI 
Zeta Potential 
(mV) 
SOL 
Methanol 
H2O 53.6±11.4 0.031±0.007 -4.9±15.1 
PBS 43.0±1.9 0.063±0.042 -7.8±8.3 
Methanol: 
Ethanol 
H2O 50.4±2.5 0.022±0.001 -2.7±1.0 
PBS 50.9±6.6 0.038±0.015 -8.9±11.3 
F68 
Methanol 
H2O 56.4±20.8 0.566±0.161 -5.7±7.4 
PBS 337.9±219.5 0.364±0.060 -9.2±2.1 
Methanol: 
Ethanol 
H2O 148.3±39.1 0.203±0.036 -20.1±4.7 
PBS 87.0±21.6 0.294±0.122 -4.3±4.8 
F108 
Methanol 
H2O 417.1±98.3 0.279±0.387 -22.5±22.9 
PBS 400.8±312.2 0.680±0.267 -2.3±2.3 
Methanol: 
Ethanol 
H2O 550.6±268.0 0.406±0.029 -16.9±30.9 
PBS 455.6±105.3 0.345±0.148 0.2±3.6 
F127 
Methanol 
H2O 283.6±112.7 0.144±0.081 -2.6±2.5 
PBS 165.1±118.2 0.360±0.100 -4.2±3.4 
Methanol: 
Ethanol 
H2O 268.4±159.1 0.254±0.308 -9.1±22.0 
PBS 131.6±76.3 0.356±0.070 -1.9±6.2 
 
The results regarding the characterization of the selected micelles in terms of size and 
surface charge are presented in Figure 3.1. Empty micelles of SOL presented a mean 
hydrodynamic diameter of 55.10 ± 7.72 nm and 288.80 ± 37.35 nm, and a PdI of 0.026 ± 
0.015 and 0.298 ±0.115 at 25 ºC and 37 ºC, respectively, showing a clear temperature 
dependence behavior (p<0.05). The incorporation of insulin at different ratios up to 10:1 
reduced the size of micelles although no statistical differences were observed (p>0.05). In the 
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same way, the incorporation of PBA to micelles did not produce significant differences 
compared to the plain micelles (p>0.05). All micelles presented higher mean diameters and 
PdI at 37 ºC compared to 25 ºC (p<0.05). Regarding the surface charge, particles showed 
negative zeta potential values near zero without significant differences among formulations 
(p>0.05). 
 
 
Figure 3.1 Mean hydrodynamic diameter, polydispersity index (PdI) and zeta potential of SOL (black 
bars and squares) (A), F68 (grey bars and triangles) (A), F108 (black bars and squares) (B) and F127 
(grey bars and triangles) (B) empty micelles, containing just PBA micelles (empty:PBA), insulin-loaded 
micelles with different polymer:insulin ratio (10:0.1, 10:0.2, 10:0.3, 10:0.4, 10:0.5, 10:0.75 and 10:1) 
and insulin-loaded containing PBA micelles with 10:1 polymer:insulin ratio (10:1:PBA) after production 
(mean ± SD, n≥3). 
 
Pluronic®-based micelles presented different results depending of the polymer used. The 
mean diameter and PdI of empty micelles at 25 ºC was 92.47 ± 21.46 nm and 0.233 ± 0.087 
for F68; 53.19 ± 29.91 nm and 0.575 ± 0.176 for F108; and 29.54 ± 10.09 nm and 0.202 ± 
0.060 for F127. At 37 ºC the micelles were somewhat larger in size, presenting higher 
polydispersity, being the differences not significant (p>0.05) for the majority of formulations. 
The incorporation of insulin up to 10:1 increased the diameter of micelles prepared by F68 
(p<0.05), and did not promote significant changes in micelles prepared by F108 and F127 
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(p>0.05). On the other hand, the incorporation of PBA did not significantly alter the 
characteristics of F68, F108 and F127 micelles (p>0.05). Pluronic®-based micelles also 
presented a surface charge slightly negative and close to neutrality without significant 
differences among the formulations (p>0.05).  
Micelles composed by 10:1 polymer:insulin ratio were chosen to proceed with the production 
and characterization, since they showed to possess similar values of size, PdI and surface 
charge of the ones containing lower insulin payloads.   
The AE and LC were determined for micelles with a polymer:insulin ratio of 10:1. As seen in 
Table 3.2, excepting for F68, all the formulations presented an AE higher than 80% and LC of 
at least 7%. The presence of PBA didn´t affect the values of AE and LC (p>0.05). 
 
Table 3.2 Association efficiency (AE), loading capacity (LC) and osmolality of the different insulin-
loaded formulations. Results are presented as mean values ± SD (n≥3). 
Sample AE (%) LC (%) 
Osmolality 
(mOsm/Kg) 
SOL:Ins 94.63±3.24 8.60±0.29 397±15 
SOL:Ins:PBA 84.03±5.14 7.31±0.45 402±6 
F68:Ins 76.22±14.56 6.93±1.32 325±12 
F68:Ins:PBA 49.31±36.80 5.60±3.13 314±9 
F108:Ins 87.28±11.57 7.93±1.05 316±10 
F108:Ins:PBA 87.63±3.63 7.62±0.32 330±14 
F127:Ins 80.90±14.92 7.35±1.36 325±18 
F127:Ins:PBA 83.15±10.05 7.23±0.87 322±10 
 
The osmolality of formulations was superior to 300 mOsm/Kg, being SOL-based samples 
similar between them (p>0.05) and different from the Pluronic®-based micelles (p<0.05). No 
differences were observed between the different Pluronic®-based formulations (p>0.05). 
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3.2. Morphological characterization 
 
The morphology of micelles was analyzed with different microscopy techniques. FE-SEM 
images are presented in Figure 3.2, while TEM images presented in Figure 3.3 and 3.4, and 
AFM images depicted in Figure 3.5 and 3.6. All the microscopy techniques used showed that 
the micelles of the different polymers are mainly spherical in shape. 
 
 
Figure 3.2 FE-SEM micrographs of SOL (A), F68 (B), F108 (C) and F127 (D) insulin-loaded micelles. 
 
It also revealed the presence of some aggregates of smaller particles. FE-SEM analysis 
revealed a higher degree of aggregation compared to TEM and AFM due to the dried state of 
samples during the analysis. No visible differences between empty, insulin-loaded micelles 
and micelles containing PBA were observed. 
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Figure 3.3 TEM images of SOL (A-C) and F68 (B-D) empty micelles (A-B) and insulin-loaded micelles 
(C-D). 
 
Figure 3.4 TEM images of F108 (A-C) and F127 (B-D) empty micelles (A-B) and insulin-loaded 
micelles (C-D). 
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Figure 3.5 AFM images of SOL (A-B) and F68 (C-D) insulin-loaded micelles (A-C) and insulin-loaded 
micelles containing PBA (B-D). 
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Figure 3.6 AFM images of F108 (A-B) and F127 (C-D) insulin-loaded micelles (A-C) and insulin-loaded 
micelles containing PBA (B-D). 
 
4. Discussion 
 
This study aimed to develop nanoformulations for the pulmonary administration of insulin, 
based on polymeric micelles. Different polymers with amphiphilic nature were tested namely 
SOL, F68, F08 and F127. The MW and CMC values of the polymers are summarized in 
Table 3.3. Although SOL possesses higher MW, is the one that present lower CMC value, 
which could be explained by the lower percentage of hydrophilic content: 13% of PEG against 
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the ~70% in F127, and ~80% in F68 and F108. For Pluronic® copolymers, F127 possess the 
higher number PPO units and lower percentage of PEG and, consequently, lower CMC and 
hydrophilic-lipophilic balance (HLB), whereas F68 presents the smaller number of PPO units 
and higher CMC. 
 
Table 3.3 Molecular weight (MW) and critical micelle concentration (CMC) values of the polymers used 
(according to the manufacturer). 
Type of polymer 
Average MW of the polymer 
(g/mol) 
CMC (M) 
Approximate MW of 
PEG chains (g/mol) 
Pluronic
®
 F68 7,680 – 9,510 4.8x10
-4
 4000 
Pluronic
®
 F108 12,700 – 17,400 2.2x10
-5
 7000 
Pluronic
®
 F127 9,840 – 14,600 2.8x10
-6
 5000 
Soluplus
®
 90,000 – 140,000 6.4x10
-8
 6000 
 
In these work, PBA was added to micelles to provide them with glucose-sensitive properties. 
Boronic acid derivatives have been proposed as excipients to control the release of drugs, 
including insulin, from formulations as response to glucose concentration (433-436). Neutral 
boronic moieties convert to anionic boronate esters upon reaction with the diol group of 
sugars, increasing the hydrophilicity of the system. Many hydrogels containing boronic acid 
derivatives have been shown to swallow and release insulin as response to the increase in 
the hydrophilicity (433). At pH of 7.4, PBA (pKa ~9) will present predominantly neutral 
moieties to react with glucose and is expected that the differences in hydrophilicity of the 
micelles as a response to the glucose concentration, may control the release of insulin.  
Micelles were produced using the thin-film hydration technique, previously described for the 
production of both liposomes and micelles (164, 437). The organic solvents generally used to 
prepare the films are chloroform and dichloromethane. However, according to the guideline 
from International Conference on Harmonization (ICH) “Impurities: Guideline for Residual 
Solvents Q3C (R5)”, the use of these solvents (class 2) in the production of pharmaceutical 
products should be limited due to its toxicity. The permitted daily exposure (PDE) and 
residual concentration limit are 0.6 mg/day and 60 ppm for chloroform and 6.0 mg/day and 
600 ppm for dichloromethane, respectively (438). In order to substitute these solvents, 
ethanol was proposed since it is a class 3 solvent, with low toxic potential. Unfortunately, the 
polymers showed to be insoluble in pure ethanol, but soluble in ethanol:methanol (1:1) 
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mixture and methanol alone. By that methanol, a class 2 solvent with higher PDE (30 mg/day) 
and residual concentration limits (3000 ppm) compared to chloroform and dichloromethane 
(438) was used to prepare the films in pure form or as a mixture with ethanol. 
Since particles produced using methanol presented similar mean hydrodynamic diameter and 
PdI values of those prepared using the methanol:ethanol mixture (Table 3.1), the mixture of 
solvents was selected. This decision was related to the objective of reduce the amount of 
class 2 solvents used in the production of particles. Also, similar results were obtained when 
water (Table 3.1) or PBS were used to produce empty micelles. For this reason, and in order 
to have a higher control in the pH of formulations, PBS was used to produce the insulin-
loaded micelles. 
Micellization of amphiphilic polymers in aqueous solution occurs at concentrations higher 
than the CMC, and since is an entropic process, namely for Pluronic®, is favored at 
temperatures higher than the CMT at a fixed concentration. As the CMT values of 1 wt. % 
solutions of F68, F108 and F127 are 54-56.21 ºC, 30-34.55 ºC (439) and 24 ºC (440), 
respectively, it was decided to hydrate the films with solutions at 37 ºC. This body 
temperature, although lower than the CMT of F68, is expected to favor the micellization of the 
polymers without promote significant loss of insulin conformation.       
Two different temperatures, 25 and 37 ºC, were selected for the determination of the 
hydrodynamic diameter of particles, with the objective of study the influence of temperature in 
the characteristics of micelles and also to determine its size at body temperature. The 
obtained micelles presented different hydrodynamic diameters and PdI, according to the 
polymer used (Figure 3.1). The size of micelles composed by Pluronic® seems to be directly 
related to the CMC and CMT values of the copolymer used, since F127 presented the lower 
CMC and CMT values and the smaller micelles, whereas F68 presented the higher CMC and 
CMT values and micelles bigger in size. As the temperature increase above the CMT, 
Pluronic® copolymers tend to present a reduced surface tension and be more hydrophobic, 
aggregating with the consequent formation of micelles. Both 25 ºC and 37 ºC are above the 
CMT of F127, explaining its small size of micelles. Also, the small changes observed when 
the temperature increase from 25 ºC to 37 ºC can be explained by the effect of small 
concentrations of NaCl (presented in the PBS at 0.14 M) in reducing the influence of 
temperature in the size of F127 micelles (441). In the case of F108, is possible to observe a 
slightly increase in mean hydrodynamic diameter and reduction in PdI from 25 ºC to 37 ºC, as 
a consequence of the aggregation of unimers with small size and the formation of higher 
amount of micelles or aggregates as the temperature goes above the CMT. For F68, since 
Chapter 3 I Design and characterization of self-assembled micelles for insulin delivery 
___________________________________________________________________________________ 
73 
 
both 25 ºC and 37 ºC are below its CMT value and is the polymer that presents higher 
surface tension and lower viscosity when in solution, the system will be composed by 
unimers, aggregates and some micelles less hydrophobic, and consequently, less compact 
than the ones obtained by the other two copolymers used, resulting in micelles of higher size 
and PdI. Although the presence of salts such NaCl is known to reduce the CMT values of 
many Pluronic® copolymers, the effect of the NaCl concentration used is not enough to 
decrease the CMT values of F68 below 37 ºC, since a reduction of 20 ºC in CMT is observed 
only for NaCl concentrations of 1 M (442). The mean hydrodynamic diameters obtained for 
F108 and F127-based micelles were in agreement of those described by others (10-100 nm) 
(178, 443). The high PdI values observed are related to the fact that above CMC and CMT 
both unimers and micelles co-exist at different percentages since both values are the mean of 
a range of values, due to the copolymer polydispersity and the existence of some diblocks 
copolymers in the composition of the final product (441, 444). 
SOL is a recently commercial available polymer that has been proposed as enhancer of the 
aqueous solubility of hydrophobic drugs in solid dispersions (161). Due to its amphiphilic 
nature it was studied its usefulness in the development of micelles to deliver proteins. To our 
knowledge these is the first work regarding the use of SOL as vehicle for biopharmaceutical 
drugs. SOL produces micelles of small and uniform size at 25 ºC, as seen by the low PdI 
values (Figure 3.1). At 37 ºC is possible to observe an increase in the opacity of formulations 
accompanied by an increase in the size and polydispersity of micelles, which is due to a 
reduction in the viscosity of the polymer with the temperature increase. However, the PdI 
values still remain lower than the ones observed for Pluronic®-based micelles, which is 
explained by the low CMC and high glass transition temperature of SOL (around 70 ºC as 
determined by DSC, Figure 4.2, Chapter 4), resulting in more compact and stable particles 
even at body temperature. 
The different polymers produced micelles with surface charge close to neutrality. The near 
neutral charge is expected since is well documented by many authors that PEG confers 
hydrophilic and neutral charge to particles when at its surface (190, 445). Also, the polymers 
used do not present major ionic species at the work pH, as estimated in silico using the 
Marvin Suite software (ChemAxon, Hungary). The hydrophilic surface of particles confers 
them stealth properties, predicting that they should not suffer significant uptake by alveolar 
macrophages after inhalation (190). In addition, PEGylation of particles was reported to 
increase the retention and bioavailability of inhaled drugs in lungs by promoting their uptake 
by alveolar type II cells and increasing its penetration through surfactant and mucus layer 
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(371, 446). The high observed standard deviation of zeta potential values could be 
consequence of the difficulty on the equipment in determines neutral charges with precision. 
Excepting for F68-based micelles, all the formulations presented high AE values (>80%) 
(Table 3.1). The smaller MW of F68 and the less compact micelles can be the reason to its 
lower capacity to load the protein between the PEG chains. In addition the protein presented 
at the surface of the micelles, as evidenced by XPS (Table 4.2, Chapter 4), can be easily 
released during the filtration by centrifugation step used to determine both AE and LC. Some 
anionic moieties of PBA could be competing with insulin for the spaces in the PEG shell, 
resulting in a reduced protein association and loading capacity in PBA-containing 
formulations. 
The osmolality values of formulations were slightly hyper-osmolal with blood plasma, 
although within the range of tolerable values for inhaled formulations (447), thus, no changes 
on the osmolality of lung fluids derived from inhalation of these formulations are expected. 
Microscopic imaging of micelles (Figure 3.2 – 3.6) showed general spherical shape and 
demonstrated that, mainly for Pluronic®-based formulations, some bigger particles are, in fact, 
aggregates of smaller ones, which can results is values of mean hydrodynamic diameters 
determined by DLS bigger than the reality. Also, this aggregation, in addition to the co-
existence of unimers and micelles already referred, explains the high PdI values observed. 
Micelles composed by SOL presented a uniform size and lower polydispersity, which is in 
accordance with the values of PdI from DLS measurements. FE-SEM images showed higher 
aggregation of particles owing to the drying overnight step used in the preparation of samples 
prior to analysis (Figure 3.2). Since TEM and AFM images were taken using liquid samples, 
they are more appropriate to conclude about the aggregation of micelles.  
 
5. Conclusions 
 
Polymeric micelles containing insulin composed with different amphiphilic polymers were 
prepared using thin film hydration technique. The incorporation of PBA and insulin up to a 
polymer:protein ratio of 10:1 didn’t affect the size of micelles. Neutral charged and spherical 
micelles with sizes in general smaller than 200 nm were obtained. In addition, high 
association of insulin to the system and osmolalities compatible with pulmonary 
administration were achieved. These interesting characteristics triggered further development 
and characterization of formulations for insulin inhalation. 
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1. Introduction 
 
Inhalation of compounds has been performed since ancient cultures to treat diseases mainly 
affecting the respiratory system like asthma. However, a change in the paradigm is occurring 
and pulmonary administration of drugs with systemic action has been proposed (84, 448). 
Recently, a large extent of research has been performed regarding the development of 
formulations for inhalation and improved delivery devices, especially dry powder inhalers, due 
to their advantages over liquid formulations, namely long-term stability and patients 
convenience (449). The efficacy of an inhaled drug is dependent on its deposition pattern in 
the respiratory system, which is affected by several factors related to the properties of the 
formulation and the inhaler device, as well as physiologic characteristics of patients. Particles 
with a MMAD lower than 5 μm are assumed to deposit in the lungs and reach the alveoli if 
MMAD is below 3 μm, therefore becoming available to either exert a local effect or to undergo 
systemic absorption (275, 277, 449, 450). It was already demonstrated that the in vitro 
particle size and aerosolization profiles correlate in an acceptable way with in vivo lung 
deposition pattern (451), reason why the regulatory agencies require in vitro data regarding 
particle size distribution and aerosolization properties of the inhalable formulations before 
approval. Accordingly, FPF (particles < 5 µm), defined as the percentage of particles from the 
total emitted dose that are able to reach and deposit in the airways and deep lung, is used as 
an indicator for formulation efficiency. Compendial devices like the eight-stage Andersen non-
viable Cascade Impactor are commonly used to assess the deposition profile of inhaled 
formulations. 
In this chapter it is described the development and characterization of powders through the 
lyophilization of the insulin-loaded micelles described in the Chapter 3.  
 
2. Experimental 
 
2.1. Materials 
 
SOL, F68, F108 and F127 were kindly provided by BASF (Ludwigshafen, Germany). 
Lyophilized human insulin, PBA, PBS, and D-glucose were purchased from Sigma-Aldrich 
(St. Louis, MO, USA). The other reagents used were acetonitrile and TFA from HPLC grade 
(Merck, Germany) and Type 1 ultrapure water (18.2 MΩ.cm at 25 ºC, Milli-Q®, Billerica, MA, 
USA). 
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2.2. Production of micelles and lyophilization 
 
Micelles were prepared using the thin-film hydration technique. Briefly, each polymer was 
individually weight and dissolved in a mixture of methanol:ethanol (1:1). Then, the solvent 
was removed under vacuum and the film was left to dry overnight at room-temperature to 
eliminate any remained solvent. The film was then hydrated with PBS at 37 ºC in order to 
obtain a 1 % (w/v) solution and vortexed for 5 min. The obtained dispersion was filtered 
through a 0.22 µm syringe filter to remove possible dust and aggregates. 
PBA containing micelles were prepared by dissolving PBA with the polymers in the solvents 
prior to the production of the film at a ratio of 10:1 (w/w) (polymer:PBA). Insulin-loaded 
micelles were prepared by hydrating the polymeric films with an insulin solution in PBS to 
obtain polymer:insulin ratios of 10:1 (w/w). The other steps were the same as for plain 
formulations. 
After production micelles were lyophilized in an AdVantage 2.0 BenchTop Freeze Dryer (SP 
Scientific, Warminster, PA, USA). The cycle used was the follow: the samples were frozen at 
-30 ˚C and the temperature maintained for 60 min, the primary drying was set at 20 ˚C for 480 
min at 150 mTorr and the secondary drying for another 480 min at 30 ˚C and 100 mTorr. 
 
2.3. Determination of size and zeta potential of formulations  
 
Particle mean hydrodynamic diameter and PdI was measured without dilution of the samples 
by DLS at both 25 °C and 37 °C using a detection angle of 173° and zeta potential by laser 
doppler micro-electrophoresis using a NanoZS (Malvern Instruments, UK). For each type of 
formulation were produced and analyzed at least three replicates. 
 
2.4. Thermal analysis 
 
The thermal behavior of the pure compounds, physical mixtures (1:1) and lyophilized 
formulations was assessed by DSC. Thermograms were obtained using a Shimadzu DSC-60 
system (Shimadzu, Kyoto, Japan). 5 mg of each powder sample in an aluminum crimp was 
exposed to a controlled thermal treatment, specifically heated from 30 to 300ºC at a rate of 
10ºC/min under constant purging of nitrogen at 40 mL/min, and the heat flow measured. 
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2.5. X-ray diffraction (XRD) experiments 
 
Crystallization properties of powder samples were analyzed by XRD. Spectra were acquired 
using X’Pert PRO MPD / powder diffractometer of 240 mm of radius (PANalytical B.V., 
Almelo, Netherlands) in a configuration of convergent beam with a focalizing mirror and a 
transmission geometry. Samples were sandwiched between films of polyester of 3.6 µm of 
thickness and scanned at 45 kV, 40 mA using Cu Kα1 radiation (λ = 1.5418 Å) at the range 
2/ scans from 2 to 60 º2 with a step size of 0.026 º2 and a measuring time of 400 s per 
step. 
 
2.6. Raman spectroscopy 
 
The micro-Raman spectra of powder formulations were acquired using dispersive high 
resolution micro Raman spectrometer (Jobin-Yvon LabRam HR 800) coupled with an optic 
microscope (Olympus BXFM) with a 50X objective. A laser of 532 nm wavelength and 2.5 
mW of potency and a charge coupled device detector cooled at -70 ºC were used. The 
spectra were acquired and analyzed with the software LabSpec 5 (Horiba, Kyoto, Japan). 
 
2.7. Surface analysis 
 
The elemental composition of the surface of particles in powder state was analyzed by XPS. 
XPS experiments were performed in a PHI 5500 Multitechnique System (Physical 
Electronics, MN, USA) equipped with a monochromatic X-ray source (Aluminium Kalfa line of 
1486.6 eV energy and 350 W), placed perpendicular to the analyzer axis and calibrated using 
the 3d5/2 line of Ag with a full width at half maximum of 0.8 eV. The analyzed area was a 
circle of 0.8 mm diameter, and the selected resolution for the survey spectra was 187.85 eV 
of pass energy and 0.8 eV/step. A low energy electron gun (less than 10 eV) was used in 
order to discharge the surface when necessary. All measurements were made in an ultra-
high vacuum chamber with a pressure between 5x10-9 and 2x10-8 torr. The spectra were 
acquired, analyzed, and the atomic concentration of the elements quantified using the 
MultiPak 6 software (Physical Electronics, MN, USA). 
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2.8. Assessment of insulin conformation 
 
FTIR and far-UV CD were used to analyze the conformation of insulin in the formulations in 
order to assess its stability after lyophilization. 
Infrared spectroscopy analysis was conducted in a FTIR spectrometer ABB MB3000 (ABB, 
Switzerland) equipped with a deuterated triglycine sulphate detector and using a MIRacle 
single reflection horizontal attenuated total reflectance accessory (PIKE Technologies, USA) 
with a diamond/Se crystal plate. All spectra were acquired with 256 scans and 4 cm−1 
resolution in the region of 4000–600 cm−1 using a triplicate set of samples and the related 
blank sample (raw polymer) after a background, and insulin spectra were obtained by a 
double subtraction procedure (452). After subtraction, spectra were derived using a 15 points 
Savitzky–Golay second-derivative and the amide I region (1590–1710 cm−1) was selected. 
The spectra were baseline corrected using a 3–4 point adjustment and area-normalized. All 
spectra treatment was executed using the Horizon MB FTIR software (ABB, Switzerland). 
Quantitative comparison of the overall similarity of the FTIR spectra between native insulin 
and insulin-loaded micelles was assessed by using spectral correlation coefficient (SCC) and 
area of overlap (AO) algorithms (Origin software, OriginLab Corporation, MA, USA) (453). 
The far-UV CD spectra were acquired using a Jasco J-815 spectropolarimeter (JASCO 
International Co., Ltd., Japan) at 20 ºC. In the far-UV region the spectra were recorded in a 1 
cm cell from 250 to 190 nm, using a step size of 0.5 nm, a bandwidth of 1.5 nm and a speed 
of 50 nm/min with the lamp housing purged with nitrogen flow at 10 mL/min to remove 
oxygen. For all spectra and average of 5 scans was obtained. Appropriate references were 
used to subtract the signal of the polymers from the spectra of the protein-loaded. The mean 
residue ellipticity [θ] for insulin was calculated as the CD signal (θ) × mean residual weight 
(MRW) (116 Da for each insulin residue)/[10 × cell pathlength (cm) × insulin concentration 
(g/ml)] (454). 
 
2.9. Scanning electron microscopy 
 
The shape and morphology of lyophilized formulations was observed by scanning electron 
microscopy (SEM) on a FEI ESEM Quanta 200 (FEI, Hillsboro, USA). Samples were 
mounted onto metal stubs and coated with a carbon layer prior to observation.  
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2.10. Powder’s particle size distribution and aerodynamic diameter 
 
The geometrical particle size distribution of the 20 mg samples of lyophilized formulations 
was determined by laser diffraction using a Malvern Mastersizer 2000® laser diffractometer 
equipped with a dry sampling system (Scirocco® 2000, Malvern Instruments, UK) The 
powders were passed through a 840 µm sieve prior to analysis to eliminate possible 
aggregates.  
The volume particle size distribution was characterized by D0.1 (10% of the particles volume 
has a diameter below that value), D0.5 also known as mass median diameter (50% of the 
particles volume has a diameter below that value), and D0.9 (90% of the particles volume has 
a diameter below that value). Values presented are the average of at least three replicates. 
The theoretical dae, Carr’s index, and Hausner ratio were estimated from the geometrical 
particle size and tapped density (ρ, determined by tap density measurements) data according 
to Equation 4.1, 4.2, and 4.3, respectively. 
 
dae = 𝐷0.5√
𝜌
𝜌𝑜𝜒
                                                                                                      Equation 4.1 
 
where D0.5 is assumed as geometrical mean diameter, ρ0 is the reference density of a 1 g/cm
3 
sphere, and χ is the dynamic shape factor. 
 
Carr′s index =  
tap density−bulk density
tap density
 × 100                                                             Equation 4.2 
 
 
Hausner ratio =  
tap density
bulk density
                                                                                     Equation 4.3 
 
2.11. In vitro aerosolization and deposition properties 
 
An eight-stage Andersen non-viable Cascade Impactor (ACI, Copley Scientific, UK) was used 
to determine the aerosolization and deposition properties of formulations in vitro. Hard gelatin 
nº 4 capsules were manually filled with the powder formulations sieved through a 300 µm 
sieve, and individually loaded into a Rotahaler® (GlaxoSmithKline, RTP, NC) inhaler device. 
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The experiments were performed at a flow rate of 28.3 L/min and four liters of air passed 
through the system, as recommended by European Pharmacopoeia (2.9.18. Preparations for 
inhalation: aerodynamic assessment of fine particles) (455). The stages were individually 
weighted and the FDF calculated as the amount of the particles deposited in stage 3 or lower 
in the cascade impactor (particles < 4.7 μm) as a percentage of the initial amount of particles. 
MMAD and geometrical standard deviation (GSD) were estimated through the cumulative 
masses of powder deposited in the impactor using a mathematic software (MMADcalculator) 
developed by Dr. Jay Holt (456). Each experiment was run in triplicate. 
 
2.12. Insulin in vitro release study 
 
Insulin-loaded micelles were dispersed in 10.0 mL of PBS with and without D-glucose (1.2 
mmol/L) and incubated at 37°C under magnetic stirring. Samples of 0.5 mL were taken at 
predetermined time intervals of 15, 30, 45 min, 1, 2, 4, 6, 8 and 24 hours and replaced with 
fresh medium maintained at the same temperature. The collected samples were centrifuged 
for 10 min at 10,000 rpm and 37 ºC, using 100k pore filters (Nanosep® Centrifugal Devices, 
Pall Corporation, Spain) and insulin quantified by the HPLC methodology described in 
Chapter 3. All samples were run in triplicate. 
The similarity factor (f2) used for comparison of the different formulations was calculated 
according to the Equation 4.4. 
 
𝑓2 = 50 × log {[1 +  (
1
𝑛
) ∑ (𝑅𝑡 − 𝑇𝑡)𝑛𝑡=1 ]
−0.5
× 100}                                               Equation 4.4 
 
where n is the number of time-points considered, and Rt and Tt are the percentage of insulin 
released at each time-point (t) for reference and test  
formulations, respectively. Insulin release profiles with values of f2 between 50 and 100 were 
assumed to be similar (457). 
 
2.13. Stability studies 
 
In order to assess the stability of formulations, samples were stored in closed vials and in the 
dark at both 20 ºC and 4 ºC after production and lyophilization. At predetermined times (1, 3 
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and 6 months), formulations were characterized regarding mean hydrodynamic diameter and 
zeta potential after redispersion in liquid, and the insulin structure assessed by FTIR and far-
UV CD as described previously. 
 
2.14. Statistical analysis 
 
One-way ANOVA was used to investigate the differences between the formulations and 
controls. Post hoc comparisons were performed according to Tukey’s HSD test (p0.05 was 
accepted as significant different) using Prism 6.02 software (GraphPad Software, Inc., CA, 
USA). 
 
Figure 4.1 Mean hydrodynamic diameter, polydispersity index (PdI) and zeta potential of SOL (black 
bars and squares), F68 (dark grey bars and triangles), F108 (medium grey bars and squares) and 
F127 (light grey bars and triangles) based empty, containing just PBA (empty:PBA), insulin-loaded 
(Mic:Ins) and insulin-loaded containing PBA (Mic:Ins:PBA) lyophilized micelles after dispersion in water 
(mean ± SD, n≥3). * p<0.05 compared to the liquid micelles. 
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3. Results 
 
3.1. Determination of size and zeta potential of formulations 
 
Nanocomposites were dispersed in water and the size and surface charge of redispersed 
micelles analyzed to study the effect of lyophilization on their characteristics. Results 
expressed in Figure 4.1 showed an increase in the size of micelles, being this increase not 
significant for the majority of formulations. Also, no changes on the surface charge of micelles 
were observed (p>0.05).     
 
3.2. Thermal analysis 
 
DSC thermograms of insulin, polymers, PBA, physical mixtures and micelles with a 
polymer:insulin ratio of 10:1 are presented in Figure 4.2. Insulin thermogram showed a board 
endothermic peak at 94.16 ºC corresponding to the glass transition and denaturation of 
insulin and, at some extent, water lost (218). After 230 ºC a group of peaks can be detected, 
as a result of the degradation of the protein. PBA presented a sharp endothermic peak at 
221.26 ºC, as a result of its melting. SOL presented a board endothermic peak at 69.2 ºC 
corresponding to the glass transition of the polymer. Thermograms of F68, F108 and F127 
presented melting endothermic peaks at 46.89 ºC, 58.33 ºC and 50.84 ºC, respectively. In 
both physical mixtures and micelles the peaks corresponding to insulin glass transition and 
denaturation and melting of PBA are not detected, while the peaks of Pluronic® copolymers 
shifted to 51.43 ºC, 52.38 ºC and 47.62 ºC for F68, 57.3 ºC, 57.12 ºC and 51.77 ºC for F108, 
and 51.51 ºC, 57.62 ºC and 49.23 ºC for F127, in physical mixtures, insulin-loaded micelles 
and insulin-loaded micelles containing PBA, respectively. 
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Figure 4.2 DSC thermograms of raw materials, polymer insulin physical mixture, insulin-loaded 
(polymer:Ins) and insulin-loaded lyophilized micelles containing PBA (polymer:Ins:PBA) of SOL (A), 
F68 (B), F108 (C), and F127 (D). 
 
3.3. XRD analysis  
 
The X-ray diffractograms of the pure compounds and lyophilized micelles with a 
polymer:insulin ratio of 10:1 are depicted in Figure 4.3. All samples presented two small 
peaks at around 2θ of 16.30º and 42.90º derivate from the polystyrene films. The crystalline 
nature of PBA was confirmed by the numerous sharp peaks between 2θ of 10º and 30º. Two 
main peaks at 2θ of 19.13º and 23.27-23.32º also indicated that Pluronic® copolymers 
possess a crystalline nature. On the other hand, the absence of distinct peaks in SOL spectra 
indicates its amorphous nature. Insulin presented few small peaks between 2θ 2-10º 
indicating a low degree of crystallization. Regarding micelles, distinct peaks at 2θ of 27.4º, 
31.7º, 45.54º, 53.9º and 56.5º deriving from the NaCl existent in the PBS used to produce the 
formulations, can be detected. On the contrary, the peaks of PBA as well as the ones 
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respecting insulin disappeared, while the distinct peaks of Pluronic® copolymers presented a 
reduction in intensity compared to the pure polymers. 
 
Figure 4.3 XRD patterns of insulin-loaded lyophilized micelles (Mic:Ins) and insulin-loaded containing 
PBA (Mic:Ins:PBA) lyophilized micelles of SOL (A), F68 (B), F108 (C), and F127 (D). 
 
3.4. Raman spectroscopy 
 
Raman spectroscopy was used to study possible interactions between the components of the 
formulations. The spectra of insulin, PBA, polymers and lyophilized micelles (10:1 
polymer:insulin ratio) are presented in Figure 4.4 and the major peak assignments detailed in 
Table 4.1. In the spectrum of insulin, characteristic peaks related to amide I (1659 and 1673 
cm-1) and the aromatic rings of phenylalanine (1005 and 1606-1612 cm-1) and tyrosine (832 
cm-1) can be identified. The B-O assymetrical stretch (1313-1368 cm-1) and the vibration (994 
cm-1) and stretch (1602 cm-1) of the aromatic ring are characteristic peaks of PBA. The 
characteristic peaks regarding ester C-O stretch (1029-1267 cm-1), C=O stretch of the tertiary 
amide (1631 cm-1) and ester carbonyl stretch (1732 cm-1) can be identified in the SOL 
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spectra. In Pluronic® spectra are presented the characteristic peaks of C-O and C-C stretch 
(1127-1144 cm-1) and CH2 twist (1234-1280 cm-1).    
For frequencies above 2000 cm-1, board and large peaks related to CH, CH2 and CH3 
aliphatic stretching, as well as water molecules can be detected (data not shown). 
The characteristic peaks of insulin are not present in the spectra of insulin-loaded 
formulations, while small peaks related to PBA (1000 and 1602 cm-1) can be detected in the 
spectra of insulin-loaded PBA containing micelles. Neither the appearance of new peaks nor 
the significant shift of the existing peaks is perceived in the spectra of micelles. 
 
Figure 4.4 Raman spectra of insulin-loaded (Mic:Ins) and insulin-loaded containing PBA (Mic:Ins:PBA) 
lyophilized micelles of SOL (A), F68 (B), F108 (C), and F127 (D). 
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Table 4.1 Major peak assignments in the Raman spectra of the insulin, polymers and micelles. 
Frequencies (cm-1) 
Assignments Native 
insulin 
PBA SOL 
SOL: 
Ins 
SOL:Ins
:PBA 
F68 
F68: 
Ins 
F68:Ins
:PBA 
F108 
F108: 
Ins 
F108:Ins 
:PBA 
F127 
F127: 
Ins 
F127:Ins 
:PBA 
832 
             
Tyr 
  
799-
848 
799-
848 
799-848 845 845 845 845 845 845 845 845 845 C-O-C stretch 
1005 994 
  
1000 
  
1000 
  
1000 
  
1000 
Aromatic ring vibration 
(Phe in insulin) 
  
1029-
1264 
1029-
1267 
1029-
1264          
Ester C-O stretch 
     
1127-
1144 
1127-
1141 
1125-
1141 
1125-
1141 
1127-
1144 
1127-
1144 
1125-
1141 
1127-
1144 
1127-
1144 
C-O and C-C stretch 
 
1160-
1180 
 
           
CH3 and CH2 assymetrical 
deformation 
     
1234-
1280 
1231-
1280 
1234-
1280 
1231-
1280 
1234-
1280 
1234-
1280 
1231-
1280 
1234-
1280 
1234-
1280 
CH2 twist 
 
1313-
1368 
 
           
B-O assymetrical stretch 
1450 
 
1449 1447 1449 1482 1482 1479 1482 1482 1482 1482 1482 1482 
O-CH3 and/or CH2 
deformation 
1606-
1612 
1602 
  
1602 
  
1602 
  
1602 
  
1602 
Aromatic ring quadrant 
strech (Phe in insulin) 
  
1631 1634 1632 
         
C=O stretching (tertiary 
amide) 
1657 
             
Amide I - α helix 
1673 
             
Amide I - β sheet 
  
1732 1735 1735 
         
Ester carbonyl stretch 
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3.5. Surface analysis 
 
XPS was used to determine the elemental surface composition of the lyophilized 
formulations from the survey spectra. The atomic concentration of each sample as well as 
the raw materials is presented in Table 4.2. For raw materials, the elements identified are 
in good agreement with its molecular formula, although the atomic concentration can vary 
slightly from the theoretical values due to polymer polydispersion and the presence of 
dimers/conjugates in the case of insulin and PBA.  
 
Table 4.2 Atomic concentration of the powders’ surface.  
Sample C O N Cl Na S B 
Insulin 66.40 18.89 13.68 
  
1.02 
 
PBA 75.27 12.86 
    
11.87 
SOL raw 72.96 20.77 6.27 
    
SOL mic 62.42 22.72 5.24 4.17 5.45 
  
SOL:Ins 63.50 22.76 5.71 3.74 4.30 
  
SOL:PBA 68.56 22.22 3.76 2.64 2.81 
  
SOL:Ins:PBA 69.00 21.41 5.28 1.67 2.65 
  
F68 raw 68.63 31.37 
     
F68 mic 66.67 32.33 
 
0.42 0.58 
  
F68:Ins 67.09 30.95 0.67 0.61 0.69 
  
F68:PBA 67.11 31.18 
 
0.79 0.91 
  
F68:Ins:PBA 68.28 29.52 0.96 0.73 0.52 
  
F108 raw 67.34 32.66 
     
F108 mic 66.06 31.20 
 
1.66 1.07 
  
F108:Ins 70.22 27.91 
 
1.23 0.64 
  
F108:PBA 68.95 28.83 
 
1.18 1.04 
  
F108:Ins:PBA 70.29 28.42 
 
0.70 0.59 
  
F127 raw 69.15 30.85 
     
F127 mic 67.83 29.49 
 
1.59 1.09 
  
F127:Ins 67.70 29.56 0.64 1.36 0.74 
  
F127:PBA 70.42 27.93 
 
0.96 0.69 
  
F127:Ins:PBA 69.41 28.96 0.09 1.07 0.47 
  
The results are expressed as a percentage of the total amount of atoms detected in each sample. 
B – boron; C – carbon; Cl – chlorine; Ins – insulin; mic – empty lyophilized micelles; N – nitrogen; 
Na – sodium; O – oxygen; PBA – phenylboronic acid; raw – raw polymers without processing; S – 
sulphur. 
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Variations in the elemental composition of loaded micelles compared to empty micelles 
and from the last ones to raw materials can be observed. In all formulations is possible to 
identify the presence of chlorine and sodium derived from the PBS used during its 
production. Excepting for F108, all the formulations containing insulin showed the 
presence of nitrogen at the surface. 
 
3.6. Protein conformation 
 
FTIR spectra of the area-normalized second-derivative amide I region of native insulin in 
solution, lyophilized insulin, and lyophilized insulin-loaded micelles are presented in Figure 
4.5. The spectrum of native insulin is dominated by a peak at 1655 cm-1 related to the 
major α-helix content of the protein.  
 
Figure 4.5 Area-normalized second-derivative amide I spectra of insulin solution 30 mg/mL, 
insulin-loaded (polymer:Ins), and insulin-loaded containing PBA (polymer:Ins:PBA) lyophilized 
micelles of SOL (A), F68 (B), F108 (C), and F127 (D). 
 
β-sheet assignments from high-frequency at 1685 cm-1 and low-frequency at 1616 cm-1 
and β-turn (1632 cm-1) minor components are also present (453). Visual comparison of 
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the spectra of Pluronic®-based micelles had showed a narrow and a slight shift of the 
peaks. For SOL-based micelles is possible to observe a shift of the peak of α-helix to 
1637 cm-1, corresponding to a random coil, and the disappearance of the peaks related to 
β-sheet and β-turn. The incorporation of PBA into the micelles did not affect the 
secondary structure of insulin. 
In order to facilitate the comparison of the spectra of native insulin and formulations, AO 
and SCC (indicators of the maintenance of the secondary structure of insulin) were 
calculated and the results obtained are expressed in Table 4.3. SOL-based micelles 
presented AO and SCC values lower than the lyophilized insulin and Pluronic®-based 
micelles (p<0.05). The presence of PBA increased the AO in a significant manner 
(p<0.05), but not the SCC (p>0.05). The differences observed between the AO values of 
Pluronic®-based micelles and lyophilized insulin, and between the three polymers are just 
statistical significant in the absence of PBA (p<0.05). Regarding SCC values, F127 
insulin-loaded micelles differ from lyophilized insulin, F68 and F108 insulin-loaded 
micelles and F127 insulin-loaded micelles containing PBA (p<0.05). For PBA containing 
micelles no differences are observed (p>0.05). 
 
Table 4.3 Area of overlap (AO) and spectral correlation coefficient (SCC) of lyophilized insulin, 
insulin-loaded (polymer:Ins) and insulin-loaded containing PBA (polymer:Ins:PBA) lyophilized 
micelles. Values are expressed as mean values ± SD, n=3. 
Formulation AO SCC 
SOL:Ins 50.09±0.88 49.73±0.90 
F68:Ins 85.16±0.32 96.81±0.11 
F108:Ins 83.01±1.60 95.32±0.49 
F127:Ins 78.77±0.76 93.03±0.35 
SOL:Ins:PBA 53.50±0.13 51.49±0.47 
F68:Ins:PBA 87.39±1.38 97.05±0.49 
F108:Ins:PBA 86.29±0.53 96.51±0.13 
F127:Ins:PBA 86.89±1.53 96.82±0.47 
Lyophilized 
insulin 
87.26±0.28 97.61±0.12 
 
The far-UV CD spectra of standard insulin solution, lyophilized insulin and lyophilized 
formulations showed two minima peaks around 208-209 and 220-222 nm and a maximum 
at 193-195 nm, related to the α-helix and β-sheet, respectively (Figure 4.6). Both 
lyophilized insulin and insulin-loaded micelles present less intense negative and positive 
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peaks and a shift in the positive peak, indicating a slight loss in the secondary structure of 
the protein. 
 
Figure 4.6 far-UV CD spectra of insulin-loaded (polymer:Ins) and insulin-loaded containing PBA 
(polymer:Ins:PBA) lyophilized micelles of SOL (A), F68 (B), F108 (C), and F127 (D). 
 
3.7. Morphology and particle size distribution of powders 
 
The shape and morphology of lyophilized formulations was analyzed by SEM. 
Micrographs of formulations are presented in Figure 4.7, evidencing the presence of a 
mixture of needle-shape and plate-shape structures resembling parts of an incomplete 
polymeric network. The incorporation of PBA to the systems did not affect the morphology 
and structure of powders. It can be noted the presence of pores and spherical 
nanocomposites smaller than 5 µm attached to the surface of bigger structures. SOL-
based formulations presented smaller and more needle-shape structures, while F68 
seemed to produce more compact and bigger particles, explaining the differences 
observed in the particle size distribution of powders (Table 4.3).  
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Figure 4.7 SEM micrographs of insulin-loaded formulations composed of SOL (A), F68 (B), F108 
(C), and F127 (D), without (top panel) or with (bottom panel) PBA. Scale bar: 400 µm in 
formulations without PBA and 100 µm in formulations with PBA. 
 
As seen in Table 4.4, all the formulations presented dae smaller than the geometric 
diameter due to their low densities (p < 0.22 g/cm3, data not shown). SOL led to the 
formation of powder particles with lower D0.5 and dae, while F68 and F108-based 
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formulations showed higher amount of larger particles/aggregates (D0.9). Both F68 and 
F108 formulations present higher CMC and size of micelles at 25ºC before lyophilization, 
which could be influencing the final particle size and percentage of aggregates of 
powders. On the other hand, SOL and F127 could be originating more compact and stable 
micelles that suffer lower degree of aggregation during lyophilization. Nevertheless, no 
significant differences were observed between different samples (p>0.05). With the 
exception of F68-based particles, all the formulations presented D0.5 values lower than 
25µm and dae values lower than 6 µm.  
All formulations presented high Carr’s index (≥ 26) and Hausner ratio values (≥ 1.35), 
predicting poor flowability of powders according to European Pharmacopoeia (2.9.36. 
Powder flow) (455). 
 
Table 4.4 Particle size distribution over the volume, aerodynamic diameter, Carr’s index, and 
Hausner ratio of the different insulin-based formulations. Results are presented as mean values ± 
SD (n=3). 
Sample D0.1 (µm) D0.5 (µm) D0.9 (µm) dae (µm) Carr's index 
Hausner 
ratio 
SOL:Ins 4.5±0.6 15.3±0.1 44.3±1.9 3.1±0.2 49.2±11.3 2.03±0.45 
SOL:Ins:PBA 4.6±0.9 16.0±2.6 42.8±6.9 2.9±0.4 51.1±1.9 2.05±0.08 
F68:Ins 9.5±2.3 39.1±11.3 328.9±127.8 13.8±4.6 44.4±19.3 2.00±0.87 
F68:Ins:PBA 8.7±0.3 29.7±0.1 410.9±314.1 8.1±0.3 50.0±7.1 2.03±0.29 
F108:Ins 6.5±0.5 23.4±2.8 358.3±304.5 5.8±0.2 55.7±5.2 2.28±0.25 
F108:Ins:PBA 6.9±0.3 23.3±1.3 235.9±153.0 5.4±0.8 49.2±8.0 2.00±0.29 
F127:Ins 6.7±1.1 21.6±3.6 81.9±31.0 5.6±0.8 51.9±3.2 2.08±0.14 
F127:Ins:PBA 7.4±0.3 24.2±1.3 68.3±7.2 5.5±0.1 47.7±9.3 1.95±0.33 
 
3.8. Deposition profile of formulations 
 
The aerosolization properties of formulations were assessed in vitro following 
pharmacopeial instructions using an ACI impactor and a Rotahaler® as inhaler device and 
are presented in Table 4.5. Powders composed by SOL and F127 presented the higher 
FPF (around 48% and 44%, respectively) while F68 and F108 showed lower FPF (around 
27% and 26%, respectively). Expecting for F108-based powders, the presence of PBA did 
not affect the FPF of powders (p>0.05). All the formulations showed a MMDA lower than 
6.6 µm and GSD under 2.1 µm. 
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Table 4.5 Deposition profile of formulation powders after aerosolization into an Andersen Cascade Impactor via a Rotahaler
®
 and estimation of mass median 
aerodynamic diameter (MMDA) and geometrical standard deviation (GSD). The results of aerosolization profile and fine particle fraction (FPF) are expressed 
as the amount of particles deposited in each stage as a percentage of the initial amount of particles, and the results of MMAD expressed as size in 
micrometers (mean ± SD, n=3). T+C+D is composed by throat, capsule and inhaler device. 
Stage Size (µm) SOL:Ins SOL:Ins: PBA F68: Ins F68:Ins: PBA F108: Ins F108:Ins: PBA F127: Ins F127:Ins: PBA 
T+C+D > 10 6.2±10.7 10.8±9.4 12.7±20.6 8.4±8.2 20.6±6.9 0.6±1.0 1.0±1.0 8.0±7.7 
0 9.0-10.0 23.5±8.4 19.6±4.8 29.7±7.9 25.3±5.6 21.7±7.6 20.0±8.4 20.2±3.8 30.9±6.9 
1 5.8-9.0 8.4±1.4 11.5±2.0 13.6±2.4 18.4±0.6 20.5±2.4 21.0±3.0 22.0±3.9 20.3±4.3 
2 4.7-5.8 18.0±2.8 20.8±5.4 16.9±4.7 14.7±1.8 11.3±1.7 19.8±1.7 14.6±2.1 11.0±7.1 
3 3.3-4.7 18.7±5.0 19.4±3.1 17.0±3.1 15.3±4.5 10.9±0.5 17.7±3.5 14.1±1.8 13.3±1.8 
4 2.1-3.3 3.9±2.1 1.3±2.2 4.1±3.7 5.5±2.5 3.4±1.5 3.8±0.2 4.6±2.3 1.2±1.1 
5 1.1-2.1 7.2±6.4 5.3±3.2 3.0±5.2 8.3±8.0 4.6±2.7 7.7±2.2 8.1±5.4 6.8±4.2 
6 0.65-1.1 7.8±5.2 6.1±9.0 1.2±2.1 4.7±3.1 2.2±2.0 9.5±1.6 10.4±4.1 2.8±1.1 
7 0.43-0.65 10.2±2.5 8.6±8.2 1.7±1.7 1.5±2.6 4.7±5.4 5.1±1.0 6.9±2.9 7.0±1.3 
FPF <4.7 47.8±15.8 40.6±16.6 27.1±12.0 35.3±7.8 25.8±1.3 43.9±3.1 44.0±10.3 31.2±6.5 
MMAD  4.8±0.7 4.9±0.5 5.8±0.2 5.6±0.2 6.1±0.3 5.1±0.3 5.1±0.6 6.6±1.1 
GSD  1.8±0.2 1.7±0.7 1.9±0.5 1.7±0.3 1.9±0.3 1.5±0.0 2.1±0.2 2.1±0.5 
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The presence of PBA did not affect the MMAD and GSD values of formulations (p>0.05). 
No differences (p>0.05) in the MMAD and GSD values were observed between the 
different powders. 
  
3.9. Determination of the insulin release pattern from micelles 
 
Release studies of insulin from micelles were performed at physiological pH and 
temperature (pH 7.4 and 37 °C) in the absence or presence of glucose (1.2 mM). Results 
of in vitro release studies are reported in Figure 4.8 as percentage of protein released 
over time. Insulin release presented a biphasic pattern, with notorious burst release in the 
first 15 minutes followed by a sustained release of the protein over the following 24 hours. 
Both F68:Ins and F68:PBA:Ins formulations released around 85-95 % of insulin in the 
absence of glucose (Figure 4.8A), presenting similar release profiles (f2>50, Table 4.5). 
SOL:Ins and SOL:PBA:Ins released 40-55 % and 50-65 % of the total insulin, 
respectively. The high difference in the percentage of insulin released between SOL and 
F68-based formulations could be related to the MW of polymers and the structure of 
micelles. Having higher MW and lower CMC, SOL could present more compacted 
micelles which difficult the release of insulin. The presence of PBA seemed to affect 
specially F108 and F127-based formulations since, in both cases, the totality of insulin 
was released from PBA containing micelles (f2>50), whereas only 80 % and 60 % of the 
protein was release after 24 hours from F108:Ins and F127:Ins formulations, respectively. 
Despite the different percentage of total insulin release, F108:Ins and F127:Ins also 
presented similar release profiles (f2>50).  
 
Figure 4.8 In vitro release profiles of insulin from different formulations in PBS (pH 7.4) without 
glucose (A) and with 1.2 mM glucose (B). Results are presented as mean ± SD (n=3).
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The presence of glucose did not affect the release of insulin (f2>50) from formulations 
(Figure 4.8B and Table 4.6), excepting for SOL:Ins formulations (f2<50). Although the 
presence of PBA did not confer glucose-sensing properties to the formulations, it seemed 
to increase the release of insulin for the majority of formulations by a mechanism 
independent of glucose concentration. 
 
Table 4.6 Similarity factor (f2) values between insulin release profiles of the different formulations in 
PBS (pH 7.4) without glucose (white columns) and with 1.2 mM glucose (grey columns). 
 
SOL: 
Ins 
SOL:Ins: 
PBA 
F68: 
Ins 
F68:Ins: 
PBA 
F108: 
Ins 
F108:Ins:
PBA 
F127: 
Ins 
F127:Ins:
PBA 
SOL:Ins --- 44.1 31.1 29.5 42.1 24.2 48.4 21.2 
SOL:Ins: 
PBA 
48.0 --- 22.0 20.9 62.6 17.1 62.6 14.9 
F68:Ins 20.0 25.3 --- 72.9 21.1 48.3 23.8 42.2 
F68:Ins 
:PBA 
19.1 24.3 68.7 --- 20.1 54.1 22.7 45.8 
F108:Ins 35.6 44.2 24.6 23.9 --- 16.6 58.0 14.4 
F108:Ins: 
PBA 
13.3 17.2 41.7 43.9 17.4 --- 18.6 58.4 
F127:Ins 45.9 60.8 25.3 24.3 52.6 17.3 --- 16.4 
F127:Ins: 
PBA 
12.6 16.2 38.9 40.7 16.4 71.9 16.4 --- 
 
3.10. Stability of formulations upon storage 
 
In order to assess the stability of the lyophilized formulations upon storage, samples of 
each formulation were produced and stored at two different temperatures, namely 20 ºC 
and 4 ºC, and characterized after 1, 3 and 6 months. Results regarding mean 
hydrodynamic diameter and surface charge of micelles after the dispersion of powders in 
water are presented in Figure 4.9 and 4.10. The results of the majority of samples stored 
for 1 month were similar to the ones obtained for redispersed powders after lyophilization 
(p>0.05), excepting for F68-based insulin-loaded micelles containing PBA and F108-
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based micelles that presented higher micelles size when stored at 20 ºC and analyzed at 
25 ºC (p<0.05).  
 
 
Figure 4.9 Mean hydrodynamic diameter, polydispersity index (PdI) and zeta potential of SOL (A) 
and F68 (B)-based lyophilized insulin-loaded (Mic:Ins) and insulin-loaded containing PBA 
(Mic:Ins:PBA) micelles stored for 1 month (black bars and squares), 3 months (medium grey bars 
and squares), and 6 months (light grey bars and squares) at 4 ºC and 20 ºC after redispersion in 
water (mean ± SD, n=3). * p<0.05 compared to the formulations after lyophilization, ** p<0.05 
between different months of storage, *** p<0.05 between 20 ºC and 4 ºC. 
 
Neither time nor temperature of storage affected in a high extension the characteristics of 
SOL and F127-based micelles (p>0.05, for almost all formulations). On the other hand, 
F68 and F108-based micelles stored at 20 ºC seems to be more sensitive to the time and 
temperature of storage, since some formulations stored at 4 ºC presented smaller mean 
hydrodynamic diameter (p<0.05), and had variable size upon storage. The zeta potential 
of the formulations remained slightly negative as at liquid state and recently lyophilized 
samples. 
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Figure 4.10 Mean hydrodynamic diameter, polydispersity index (PdI) and zeta potential of F108 (A) 
and F127 (B)-based lyophilized insulin-loaded (Mic:Ins) and insulin-loaded containing PBA 
(Mic:Ins:PBA) micelles stored for 1 month (black bars and squares), 3 months (medium grey bars 
and squares), and 6 months (light grey bars and squares) at 4 ºC and 20 ºC after redispersion in 
water (mean ± SD, n=3). * p<0.05 compared to the formulations after lyophilization, ** p<0.05 
between different months of storage, *** p<0.05 between 20 ºC and 4 ºC. 
 
 
Regarding the protein conformation, FTIR spectra of the area-normalized second-
derivative amide I region of native insulin without storage and lyophilized insulin-loaded 
micelles and insulin-loaded micelles containing PBA stored up to 6 months at both 4 ºC 
and 20 ºC are presented in Figure 4.11 and 4.12, respectively.  
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Figure 4.11 Area-normalized second-derivative amide I spectra of insulin solution 30 mg/mL and 
insulin-loaded micelles (polymer:ins) after lyophilization (t0) and upon 1 month (t1), 3 months (t3) 
and 6 months (t6) of storage at 4 ºC and 20 ºC. 
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AO and SCC values depicted in Table 4.7 show that, similarly to micelles after production 
and lyophilization, SOL-based micelles presented the lower percentage of native-like 
insulin conformation. After 6 months of storage, both AO and SCC values were lower 
(p<0.05) than the ones obtained after production and lyophilization, expecting for F127 
insulin-loaded micelles stored at both temperatures as well as F108 insulin-loaded 
micelles, and SOL and F127 insulin-loaded micelles containing PBA stored at 4 ºC 
(p>0.05). The storage temperature did not seemed to affect extensively the secondary 
conformation of insulin, since differences (p<0.05) in AO values were only observed for 
F68 and F127 insulin-loaded micelles containing PBA, while for SCC values were 
observed for F127 insulin-loaded micelles containing PBA. In addition, the presence of 
PBA only affected the AO values of SOL and F68 insulin-loaded micelles stored at 4 and 
20 ºC, respectively; the SCC values of SOL and F108 insulin-loaded micelles stored at 4 
ºC and the SCC values of F68 insulin-loaded micelles stored at 20 ºC. In Table 4.8 are 
presented the values related to the percentage of reduction in the AO and SCC values of 
freeze-dried micelles after 6 months of storage. It is possible to notice that SOL-based 
micelles suffered the higher reduction in the conformation of insulin upon storage with a 
decrease of 15.0 and 22.7% in the AO and SCC values, respectively. 
Regarding the spectra it was noticed that, for SOL insulin-loaded micelles, at 4 ºC insulin 
structure changed from a random coil organization at t0 to a dominant low-frequency β-
sheet assignment at 1616 cm-1 after 1 month of storage, while at 20 ºC this modification 
was just observed after 6 months. For SOL insulin-loaded micelles containing PBA a 
similar pattern of insulin structural modifications was observed. At 4 ºC the modification of 
random coil structure into a low-frequency assignment after 1 month was observed, but 
after 3 and 6 months was observed a tendency to an organization of both random coil and 
β-sheet. At 20 ºC this latter structural organization of a random coil and β-sheet bands 
was observed since 1 month until 6 months of storage. Considering the Pluronic® 
formulations, just a few changes were observed in the α-helix band intensity, which 
seemed to increase during time up to 6 months of storage, both for 4ºC and 20ºC storage 
conditions. However, a band peak at 1600 cm-1 appeared after 1 month of storage in all 
the Pluronic®-based micelles containing PBA. 
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Figure 4.12 Area-normalized second-derivative amide I spectra of insulin solution 30 mg/mL and 
insulin-loaded micelles containing PBA (polymer:ins:PBA) after lyophilization (t0) and upon 1 month 
(t1), 3 months (t3) and 6 months (t6) of storage at 4 ºC and 20 ºC. 
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Table 4.7 Area of overlap (AO) and spectral correlation coefficient (SCC) of insulin-loaded freeze-
dried micelles after storage at 4 ºC and 20 ºC. Values are expressed as mean ± SD, n=3. 
Formulation 
Temperature 
of storage 
1 month 3 months 6 months 
AO SCC AO SCC AO SCC 
Sol:Ins 4 ºC 44.5±0.9 37.9±1.4 46.2±1.4 40.6±2.2 42.6±0.2 38.5±1.2 
F68:Ins 4 ºC 78.7±4.1 93.1±1.9 76.4±0.8 91.0±0.5 79.9±0.0 93.2±0.0 
F108:Ins 4 ºC 83.4±1.0 95.6±0.5 86.5±2.2 97.2±1.0 80.1±1.2 93.7±0.7 
F127:Ins 4 ºC 84.4±1.2 95.7±0.5 84.1±2.6 95.9±0.9 79.2±0.5 92.4±0.3 
Sol:Ins:PBA 4 ºC 45.6±1.5 39.8±0.9 49.6±1.0 44.6±1.8 50.2±0.6 45.9±1.1 
F68:Ins:PBA 4 ºC 70.8±2.0 83.1±2.3 66.5±1.5 77.9±2.4 77.6±1.3 90.1±1.4 
F108:Ins:PBA 4 ºC 73.5±0.3 87.2±0.4 77.6±1.2 89.9±1.7 76.3±1.4 87.9±1.1 
F127:Ins:PBA 4 ºC 71.9±2.3 84.8±2.0 86.8±0.4 97.1±0.2 83.6±0.1 94.3±0.2 
Sol:Ins 20 ºC 48.3±0.5 45.8±1.0 45.6±0.8 43.3±1.3 43.8±1.1 42.2±3.8 
F68:Ins 20 ºC 86.4±2.9 96.8±1.1 82.9±1.3 95.4±1.0 80.2±4.1 93.2±2.1 
F108:Ins 20 ºC 81.5±1.8 94.6±1.2 83.8±2.0 96.0±1.3 78.4±0.3 91.5±0.3 
F127:Ins 20 ºC 83.4±0.5 95.1±0.2 82.8±2.0 95.6±0.9 79.9±0.8 93.7±0.4 
Sol:Ins:PBA 20 ºC 50.5±0.8 46.8±1.1 49.3±1.9 44.7±2.8 47.7±0.9 44.4±1.7 
F68:Ins:PBA 20 ºC 69.3±2.5 82.2±2.7 74.1±1.7 87.2±1.3 71.8±3.8 85.2±3.2 
F108:Ins:PBA 20 ºC 70.9±3.2 83.2±3.6 72.8±2.1 85.7±2.1 76.6±0.5 90.6±1.3 
F127:Ins:PBA 20 ºC 77.8±4.6 89.9±3.8 86.2±0.6 96.6±0.4 77.2±2.6 89.1±2.0 
 
Table 4.8 Percentage of reduction in the area of overlap (AO) and spectral correlation coefficient 
(SCC) of insulin-loaded freeze-dried micelles after 6 months of storage at 4 ºC and 20 ºC when 
compared to micelles after production. Values are expressed as mean ± SD, n=3. 
Formulation Temp (ºC) AO SCC Temp (ºC) AO SCC 
SOL:Ins 
4 
15.0±0.2 22.7±1.1 
20 
12.5±2.2 15.2±7.6 
F68:Ins 6.2±0.0 3.7±0.0 5.8±4.7 3.7±2.2 
F108:Ins 3.5±1.2 1.7±0.7 5.5±0.4 4.0±0.4 
F127:Ins -0.5±0.5 0.7±0.3 -1.4±1.0 -0.7±0.4 
SOL:Ins:PBA 6.2±0.6 10.8±1.0 10.8±1.7 13.7±3.2 
F68:Ins:PBA 11.2±1.3 7.2±1.4 17.9±4.4 12.2±3.3 
F108:Ins:PBA 11.6±1.4 8.9±1.1 11.2±0.5 6.1±1.3 
F127:Ins:PBA 3.8±0.1 2.6±0.2 11.2±2.9 8.0±2.1 
 
Regarding far-UV CD, the pattern of spectra of formulations after 6 months of storage 
were similar to the ones obtained after lyophilization (Figure 4.13). 
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Figure 4.13 far-UV CD spectra of insulin-loaded lyophilized micelles (polymer:Ins) and insulin-
loaded lyophilized micelles containing PBA (polymer:Ins:PBA) of SOL and F68 (A and C) and F108 
and F127 (B and D) stored for 6 months at 20 ºC (A and B) and 4 ºC (C and D). 
 
4. Discussion 
 
As a consequence of the lack of evident surface charge, after some weeks of storage in 
liquid state micelles tend to aggregate and suffer deposition (data not shown). In order to 
improve the storage stability of formulations and to produce powders for inhalation the 
samples were lyophilized and nanocomposites obtained. Although spray-drying is 
considered the technique of excellence for the production of inhaled powders, 
formulations like Afrezza® (insulin dry powder formulation with market authorization) were 
successfully produced by lyophilization (458).  
Nanocomposites of 3-5 µm in diameter can be easily administered by inhalation, reaching 
the deep lungs and deliver the nanoparticles when in contact to the lung fluids (333, 459). 
The nanocomposites obtained were easily dispersed in water, producing micelles with 
mean hydrodynamic diameters and PdI slightly, but not significantly, higher than the fresh 
samples (Figure 4.1), as consequence of the aggregation promoted by lyophilization. 
However, excepting for micelles of F68, all the insulin-loaded micelles presented mean 
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hydrodynamic diameters smaller than 200 nm at both 25 and 37 ºC, being in the desired 
range of sizes to expect low uptake by alveolar macrophages (460). A slight increase of 
particle size of Pluronic®-based micelles after lyophilization and redispersion was 
previously reported by other research groups (461). The produced micelles showed to be 
easily redispersed without the addition of cryoprotectants. This good redispersion 
behavior can be related to the capacity of Pluronic® copolymers to protect particles from 
aggregation during lyophilization when present in the system at high concentrations, 
working as themselves as cryoprotectants, possibly due to the presence of PEG chains 
(462). SOL seems to behave the same way as Pluronic® copolymers, since also present 
PEG in its structure.   
Insulin thermogram showed a board endothermic peak that corresponds to the glass 
transition and denaturation of insulin (Figure 4.2). Contrary to other reports, was not 
possible to detect the two distinct endothermic peaks corresponding to the biphasic 
denaturation of insulin (218). PBA showed a sharp endothermic peak that corresponds to 
its melting point, indicating a high crystallinity degree of the compound. Contrary to SOL, 
that showed to be amorphous with a glass transition temperature close to 70 ºC (463, 
464), Pluronic® copolymers presented a crystalline solid state with melting temperature 
around 45-60 ºC (465). In both physical mixtures and insulin-loaded micelles the peaks 
corresponding to insulin glass transition and denaturation and the melting of PBA 
disappeared, indicating that they are molecularly dispersed in the polymers and in its 
amorphous state (466). Also, the melting peaks of Pluronic® copolymers suffered a shift 
when in physical mixtures and micelles, indicating a possible change in its crystallinity.  
The results of DSC were corroborated with XRD studies, where is possible to see a 
disappearance of characteristic peaks of insulin and PBA, indicating a change in its state 
from crystal to amorphous when formulated into micelles (Figure 4.3). Also, Pluronic® 
copolymers suffered a reduction in the crystallinity after formulation and lyophilization, 
revealed by the reduction in the peaks intensity, indicating a successful lyophilization 
process. The amorphous state of raw SOL was also confirmed by XRD. The 
diffractograms of the polymers were in good agreement to the ones reported by others 
(464, 465). Raman spectroscopy was used to study possible interactions between the 
different components of formulations. The spectra obtained (Figure 4.4) were in close 
agreement with others already reported (464, 467-469). No visual changes were observed 
in the Raman spectra of micelles containing insulin compared to the polymers, indicating 
the absence of significant physical interactions between the protein and the components 
of the formulation. In addition, the major characteristic peaks of insulin disappeared and 
small peaks related to the vibration and stretching of the aromatic ring of PBA can be 
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detected in PBA containing formulations. These results reinforce the association/loading 
of the protein into the micelles and the amorphous state of both PBA and insulin. 
In order to assess the loading and presence of insulin at the surface of particles, both raw 
materials and formulations were analyzed by XPS (Table 4.2). The photoelectrons binding 
energy is used to identify and quantify the elements (excepting hydrogen and helium) 
occurring on the outermost surface layer to a few nm depth (around 7 nm) of powder 
samples. Nitrogen is one key element used in the identification of proteins in the samples 
(469). As referred, although the elemental composition of raw material is in agreement 
with the elements presented in its molecular formula, the differences in the atomic 
concentrations from the theoretical expected can be explained by the polydispersity of the 
polymers and by the presence of dimers of PBA and insulin. The absence of boron in the 
spectra of formulations containing PBA indicates that it is present in the more interior 
layers of the micelles, probably due to its neutral, and consequently more hydrophobic, 
conformation at the pH of the micelles at liquid state after formulation. Regarding insulin is 
possible to detect it in the outermost layer in all formulations, excepting for the 
formulations composed by F108. Since insulin is hydrophilic in nature, it is expected that 
remains between the PEG chains in the outer shell of micelles, being detected by the 
laser at the surface and in few nm depth. As F108 presents the PEG chains with higher 
number of monomers, and consequently the higher MW (Table 3.3), insulin was possibly 
entrapped deeper in the PEG chains, not being available to be excited by the laser and 
detected.   
Secondary structure of insulin was assessed using FTIR spectroscopy and far-UV CD. In 
FTIR studies the amide I region is considered the most representative target in protein 
spectra and spectral variations can be used for comparison after second-derivative and 
area-normalization treatment (453). Usually, the lyophilization process is responsible for a 
decrease in the α-helix and an increase in β-sheet content. This decrease is motivated by 
protein-protein interactions, leading to the formation of intermolecular β-sheets during 
water removal. Therefore, the α-helix band is a better indicator of protein structural 
maintenance (470). Two different spectral similarity approaches, namely the calculation of 
AO and SCC, were used in this study as indicators of the maintenance of the 
conformation of the protein. Since SCC values are related to the differences in band 
positions and not in relative peak width or height, they give an overestimated idea of 
conformation maintenance. Nevertheless, SCC can be used as complementary indicator 
of similarity non-intensity related (453). As showed in Figure 4.5, the spectra of native 
insulin and formulations are not completely overlapped, being the biggest difference 
observed for SOL micelles. These visual differences are corroborated with the values of 
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AO and SCC (Table 4.3). After production and lyophilization, insulin loses some of the 
secondary structure. Still, the secondary structure of protein was maintained at least 50 % 
after formulation. As referred above, SOL-based formulations presented the higher insulin 
structural changes and it was noticed a clear modification of its α-helix band into a random 
coil at 1637 cm-1. These structural modifications seem to be related with some physical 
interaction between insulin and SOL, leading to a great loss of insulin native structure. 
Regarding the other tested formulations, just a slight shift on the α-helix band position was 
noticed; however it remained in the 1660-1655 cm-1 characteristic α-helix range of insulin 
band. These results showed that Pluronic®-based formulations were able to encapsulate 
and protect insulin structure from lyophilization stresses. The maintenance of the structure 
of the protein can be partially due to the cryoprotection properties of the PEG chains 
(471). In addition, it was noticed that for all the polymer formulations the addition of PBA 
seemed not to affect insulin secondary structure after micelles production, since similar 
levels of protein structural maintenance were noticed for both containing and not 
containing PBA formulations. However, precaution should be taken in the analysis of the 
results regarding SOL micelles, since SOL presents a peak regarding the tertiary amide 
close to the region of the amide I and some interference of the polymer spectrum during 
the subtraction can occur. To confirm the results obtained by FTIR, far-UV CD was also 
used to assess the secondary structure of the protein. As seen in Figure 4.6, the spectrum 
of standard insulin solution is in accordance with the typical spectra of α+β proteins with 
the dominance of α-helical secondary structure already reported by others (472-474). It is 
possible to observe a slight decrease in the intensity of the peaks of both lyophilized 
insulin and formulations compared to the standard insulin solution, which can indicate 
change in the ratio of α-helix and β-sheet components or a reduction in the α-helix content 
and the native conformation as a consequence of the process of lyophilization. In the 
same way, the shift and noise observed in the positive peak can be due to the presence of 
the chloride ions in the solution that absorb below 200 nm or interference from the 
polymers that cannot be completely eliminated during subtraction of empty micelles 
spectra (454). It should be noted that the spectra of formulations are similar to the spectra 
of lyophilized insulin, which is in accordance to the results obtained by FTIR for Pluronic®-
based micelles but differs in the case of SOL-based micelles. 
Regarding the morphology of powders, SEM images (Figure 4.7) showed a polymeric 
network-like structure typical from hydrogels and solid dispersions obtained with higher 
percentages of polymers (475, 476). Although micelles were prepared using low 
concentrated polymer solutions (1% w/v), it seems that during the freeze and drying steps 
of lyophilization an increase in polymer concentration and/or aggregation of micelles lead 
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to the formation of the observed structures. Similar network-like structure was observed 
for freeze-dried PCL–PEG–PCL micelles (< 6% w/v) (112). 
Size, density and shape of particles are the main characteristics affecting the 
aerosolization and deposition properties of particles (449, 477). The theoretical 
aerodynamic diameter (dae) of powder particles was calculated using a dynamic shape 
factor of 1.6 as the mean value described by Hassan and Lau (2009) (477) for needle-
shape (χ=1.7) and plate-shape (χ=1.5) particles (Table 4.3). For many years it was 
assumed that aerosolized dry particles should present a size ranging 1-5 µm for efficient 
lung deposition. Nowadays is accepted that large porous particles presenting small 
particle mass density (p < 0.4 g/cm3) and geometric size above 5 µm can be properly 
released from inhalers and reach the deep lung (449). Despite presenting the same 
aerodynamic diameter, large porous particles have a lower surface-to-volume ratio 
compared to small nonporous particles, thus aggregating less and behaving more as 
single entities during aerosolization. Additionally due to its high geometric size they could 
avoid more easily phagocytosis by macrophages (301). For example, insulin-
encapsulated PLGA/cyclodextrin microspheres presenting geometrical diameter similar to 
our particles (D0.5 of 26 µm) were able to reach the deep lung and promote a significant 
hypoglycemic effect when tested in vivo in rodents (24). 
Due to its shape and elevated Carr’s index (≥ 26) and Hausner ratio (≥ 1.35) values, 
formulations could present some limitations regarding flowability and by that, lung 
deposition. Despite being extensively used to predict the quality of powders regarding 
flowability and deposition; precaution must be taken during the analysis of Carr’s index 
and Hausner ratio, since for some powders a direct correlation between lower Carr’s index 
and Hausner ratio values and higher FPF was not observed (477, 478). Additionally, non-
spherical particles, especially fibers, could present some dispersion limitations due to the 
attractive forces existent between adjacent particles (269).  
Nevertheless, in this study good aerosolization properties were obtained as observed by 
the low MMAD and high FPF fractions, in spite of the low theoretical flowability. SOL and 
F127 presented the higher FPF and best aerosolization properties (Table 4.5) correlating 
to the particle size distribution determined by laser diffraction, were both formulations 
presented the smallest mean diameter values and absence of large size aggregates. The 
lower CMC values of SOL and F127 originated more compact, smaller micelles that could 
lead to small powder particles. The FPF of insulin dry powders varies according to the 
formulation, the technique and the parameters used to assess it, which turns the 
comparison between formulations a rather intricate task. A formulation of freeze-dried 
insulin with lactose as coarse carrier showed a FPF of ~52% at a flow rate of 60 L/min 
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(479), while spore like particles showed FPF >69% (480), and Exubera® a FPF of 33-45% 
(481). Unlike many authors that take stage 2 (corresponds to the pharynx with a cutoff 
diameter of 5.8 µm) and lower into account for the calculation of FPF (482-484), in this 
work only particles that are able to deposit in the trachea (stage 3 with cutoff diameter of 
4.7 µm) or lower airways and alveoli were considered. The pharmacological efficacy and 
clinical outcome of aerosol formulations is related to its deposition profile in the lungs 
(449), thus higher amounts of insulin are expected to reach the lungs and become 
available to be absorbed in SOL and F127-based formulations. Future improvements in 
the efficiency of the formulations could be explored by screening an inhaler device that 
best fits the characteristics of the developed powders, since the inhaler device has shown 
to influence the performance of the formulations (280). Additionally, the incorporation of 
an appropriate coarse carrier to the formulation could improve the deposition of particles 
in the deep lung by reducing the particle to particle interaction and aggregation of 
nanocomposites, as well as their electrostatic interaction with the capsule and the inhaler 
device (283, 485).  
Release studies of insulin from micelles were performed in the absence or presence of 1.2 
mM glucose. The concentration of glucose used was based on determinations of lung 
glucose levels performed in diabetic patients without lung disease (486). Insulin release 
profiles followed a biphasic pattern (Figure 4.8) as reported by others (333). F68 and F108 
showed the faster and higher release of insulin, while SOL and F127 presented a more 
sustained release of insulin over time, which is related to the higher stability upon dilution 
of micelles composed of polymers with lower CMC. Therefore, the former could be 
explored as formulations of rapid-acting insulin, while the latter ones as long-acting insulin 
powders. Furthermore, with a proper mixture of different micelles a formulation with both 
post-prandial and long-acting effects could be achieved, which holds an advantage over 
formulations that only present fast-acting or prolonged released of insulin (334, 481, 487). 
PBA did not confer glucose-sensitive properties to formulations but promoted a faster in 
vitro release of insulin from the micelles. At pH 7.4, PBA presents mainly neutral 
hydrophobic moieties (433) (~96 % estimated by in silico simulation using the Marvin 
Suite software from ChemAxon, Hungary), thus potentially being present in the inner core 
of the micelles as confirmed by XPS analysis, not being able to react with the glucose 
present in liquid media. Nevertheless, the small percentage of ionic species might 
increase the hydrophilicity of micelles, promoting some destabilization and a faster 
release of insulin when compared to the formulations without PBA, even in the absence of 
glucose. Grafting PBA to the hydrophilic segments of the polymers could ensure the 
presence PBA at the surface of micelles and provide them with the desired glucose-
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sensitive properties (436). Also, a covalent modification of insulin as recently performed 
by Chou and co-workers (488) prior to its encapsulation into the micelles is other possible 
approach. Regarding SOL-based formulations, further studies are required to analyze 
deeply the effect of glucose concentration of the release properties of SOL and study the 
possible stimuli-responsive properties of the polymer in future applications.  
Lyophilized formulations were stored at two different temperatures and characterized in 
terms of size, surface charge and insulin conformation after 1, 3 and 6 months of storage 
(Figure 4.9 and 4.10). Excepting for some F68 and F108-based micelles for which time 
and storage temperature induced some degree of particle aggregation, formulations 
presented similar particle sizes after dispersion in water compared to recently lyophilized 
formulations. In addition, no changes in the surface charge of micelles were observed. 
Redispersed micelles presented particle size lower than 600 nm and neutral surface 
charge in all formulations. SOL and F127-based micelles presented the best results 
during the storage period studied. Regarding protein stability, storage seemed to induce, 
to a small extension, loss on insulin conformation in all formulations as seen by a 
decrease of AO and SCC values in stored samples (Table 4.7). The higher percentages of 
conformational loss were observed for insulin-loaded SOL micelles stored at 4ºC, with a 
reduction of 15.04±0.20% and 22.65±1.15% in AO and SCC values, respectively. The 
storage temperature did not show to influence to a high extent the secondary structure of 
insulin. In SOL-based micelles insulin structure was dominated by a random coil and low-
frequency β-sheet organization. Considering the Pluronic® formulations it was observed 
that no significant changes in insulin structure band positions was observed. Indeed, the 
α-helix band of insulin in all those formulations was maintained in its characteristic band 
range, maintaining also happened to its high and low β-sheets assignments. The FTIR 
spectra results for these formulations, justify in fact the high AO and SCC values obtained, 
since minor band position changes were observed. Pluronic® copolymers showed to 
enhance the conformational stability of different proteins against different processing 
methods and thermal stress, including salmon calcitonin (489), interleukin-1 (IL-1) 
receptor antagonist (490), which can be due to the PEG chains as already mentioned. 
Nevertheless, for PBA containing formulations although the α-helix and β-sheets high-
frequency assignments did not drastically change over the 6 months of storage at both 4 
ºC and 20 ºC, the appearance of a band peak at 1600 cm-1 suggested that PBA may 
affect insulin stability during storage. These results regarding PBA containing formulations 
were not corroborated with the far-UV CD experiments performed to the samples stored 
during 6 months (Figure 4.13), since no significant differences were observed between 
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micelles with and without PBA. However, a close attention to the effect of PBA on insulin 
structure should be paid. 
Taking into account the results, lyophilization of insulin-loaded micelles may improve the 
storage shelf-life of the final product, since the acquisition of amorphous powders will 
improve the physical and chemical stability of formulations. As referred previously, in 
liquid state micelles tend to aggregate creating particles on micron size range. Also, 
powders for pulmonary administration are considered advantageous over liquid 
formulations for many reasons including higher stability. Regarding the protein, solutions 
of insulin shown to be more prone to instability due to hydrolytic activity of water, namely 
with the earlier loss of conformation upon storage (453). In addition, in lyophilized 
formulations insulin shown to be at amorphous state, which may improve its stability, 
since contrary to what happens with many proteins, insulin presents greater stability in 
amorphous state (491). This assumption is supported by the maintenance of high 
percentages of native-like conformation of insulin in lyophilized formulations upon storage 
compared to recently formulated samples, as well as taking into consideration the 
example of Exubera®, a spray-dried insulin formulation in amorphous state that shown to 
be stable when stored at room-temperature (481). 
 
5. Conclusions 
 
Lyophilization of micelles allowed the production of powder nanocomposites that were 
easily redispersed when in contact to liquid media, originating micelles smaller than 300 
nm and neutral charge at body temperature. This behavior can contribute for an increase 
in the bioavailability of insulin as micelles should prevent partially the clearance of 
micelles by alveolar macrophages. Insulin shown to be at amorphous state as evidenced 
by DSC, XRD and Raman spectroscopy and partially at the surface of micelles as 
evidenced by XPS. In addition, these formulations can be recovered by dispersion, in a 
manner of preserving the structure and potentially maintaining the activity of insulin. 
Lyophilized low-density powders composed by large-porous particles presented, in 
general, aerodynamic diameters compatible with good lung deposition patterns. Analysis 
of powder morphology shown that they are formed by a non-homogenous population of 
needle-shape particles mixed with a kind of plate-shape structures which could result in 
limited flowability of powders, as predicted by Carr’s index and Hausner ratio. However, 
the in vitro deposition profiles observed presumes interesting in vivo performance of some 
formulations. 
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PBA did not significantly affect the characteristics of formulations but promote a faster in 
vitro release of insulin from the micelles. However, it did not confer the formulations with 
glucose-sensitive properties. 
Formulations showed to be physically stable upon storage with minimal loss of the 
insulin’s native-like structure. Pluronic®-based formulations presented the best results 
regarding the maintenance of protein conformation analyzed by FTIR, however, far-UV 
CD studies showed that SOL-based micelles can also maintain a good amount the native-
like structure. 
In conclusion, powders formulations have shown promising results as delivery systems of 
inhaled proteins justifying further in vitro and in vivo assessment. 
 
 
 
 
 
 
 
Self-assembled polymeric micelles as powders for pulmonary administration of insulin 
_______________________________________________________________________ 
112 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5 I In vitro biological assessment of powder formulations for inhalation of insulin 
________________________________________________________________________________ 
113 
 
 
Chapter 5 
 
In vitro biological assessment of powder 
formulations for inhalation of insulin 
 
 
 
 
The information presented in this chapter was partially published in the following 
publication: 
 
Fernanda Andrade, José das Neves, Petra Gener, Simó Schwartz Jr, Domingos Ferreira, 
Mireia Oliva, Bruno Sarmento, Biological assessment of self-assembled polymeric 
micelles for pulmonary administration of proteins, submitted for publication 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Self-assembled polymeric micelles as powders for pulmonary administration of insulin 
_______________________________________________________________________ 
114 
 
1. Introduction 
 
Biopharmaceuticals hold the potential for the treatment of numerous diseases, for many of 
which there is no current available cure provided by small molecule drugs (492). This 
explains the high demand for research and development of formulations based on 
biopharmaceuticals and the exponential increase in the approval and market share of 
these formulations that has been witnessed over the past few years. Since 
biopharmaceuticals are generally administered by injection, a variety of approaches to 
develop systems for non-invasive administration of such drugs have been proposed 
recently. For example, oral and pulmonary administration of insulin is being pursued by 
many researchers, and positive advances in the field have been achieved (326, 493-495). 
Inhalation appears as a promising non-invasive route for systemic delivery of 
biopharmaceuticals, reasoned by characteristics of the respiratory system, such as the 
high area of absorption and blood supply, and the absence of hepatic first-pass 
metabolism, thus allowing high bioavailability values compared to other non-invasive 
routes (213, 492). Additionally, reduced costs associated to the production, transport and 
administration, as well as higher stability and patient compliance are expected for solid 
formulations for inhalation as compared to parental administration (492). However, the 
complexity of inhalation and respiratory system (geometry, humidity, defense 
mechanisms) allied to the challenges posed by the development of biopharmaceuticals-
based inhaled formulations, are underneath the fact that only a very restricted number of 
these products has reached the market so far (213). Thus, several research groups have 
developed new and improved formulations based on advances observed in molecular 
biology and particle engineering technology. Nanocarriers, including polymeric micelles, 
have been proposed as advanced inhaled drug delivery systems with optimized 
pharmacokinetics and pharmacodynamics. Among other things, nanocarriers could 
increase the permeation of compounds through the epithelium, reduce the clearance by 
mucociliary escalator through the penetration of particles in the mucus as well as reduce 
the recognition of particles by alveolar macrophages (496). 
In this chapter, the suitability of powders developed in Chapter 4 as delivery systems for 
inhalation of proteins was assessed in vitro using pulmonary epithelial cell lines and 
macrophages. 
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2. Experimental 
 
2.1. Materials 
 
SOL, F68, F108, and F127 were kindly provided by BASF (Ludwigshafen, Germany). 
Lyophilized human insulin (potency ≥ 27.5 units per mg), PBA, PBS, 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), Triton X-100, β-
mercaptoethanol, phorbol 12-myristate 13-acetate (PMA), and 5-([4,6-dichlorotriazin-2-yl]
amino)fluorescein hydrochloride (5-DTAF) were purchase from Sigma-Aldrich (St. Louis, 
MO, USA), while sodium bicarbonate and dimethyl sulfoxide (DMSO) from Merck KGaA 
(Darmstadt, Germany). The other reagents used were methanol, ethanol and acetic acid 
from analytical grade; acetonitrile and TFA of HPLC grade (Merck, Germany) and Type 1 
ultrapure water (18.2 MΩ.cm at 25 ºC, Milli-Q®, Billerica, MA, USA). 
Dulbecco’s modified eagle medium (DMEM) supplemented with L-glutamine (DMEM-
GlutaMAX®), fetal bovine serum (FBS), non-essential amino acids, 10000 U/mL penicillin 
and 10000 µg/mL streptomycin, 0.25% Trypsin-EDTA were purchased from Gibco (Life 
Technologies Ltd., Paisley, UK). CellMask® DeepRed Plasma membrane Stain, 4′,6-
diamidino-2-phenylindole (DAPI) and ProLong® Gold Antifade Mountant were purchased 
from Molecular Probes (Life Technologies Ltd., Paisley, UK). RPMI-1640 was purchased 
from Lonza (Basel, Switzerland). 
 
2.2. Production of micelles and lyophilization 
 
Micelles were prepared using the thin-film hydration technique. Briefly, each polymer was 
individually weight and dissolved in a mixture of methanol:ethanol (1:1). Then, the solvent 
was removed under vacuum and the film was left to dry overnight at room-temperature to 
eliminate any remained solvent. The film was then hydrated with PBS at 37 ºC in order to 
obtain a 1 % (w/v) solution and vortexed for 5 min. The obtained dispersion was filtered 
through a 0.22 µm syringe filter to remove possible dust and aggregates. 
PBA containing micelles were prepared by dissolving PBA with the polymers in the 
solvents prior to the production of the film at a ratio of 10:1 (w/w) (polymer:PBA). Insulin-
loaded micelles were prepared by hydrating the polymeric films with an insulin solution in 
PBS to obtain polymer:insulin ratios of 10:1 (w/w). The other steps were the same as for 
plain formulations. 
After production micelles were lyophilized in an AdVantage 2.0 BenchTop Freeze Dryer 
(SP Scientific, Warminster, PA, USA). The cycle used was the follow: the samples were 
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frozen at -30 ˚C and the temperature maintained for 60 min, the primary drying was set at 
20 ˚C for 480 min at 150 mTorr and the secondary drying for another 480 min at 30 ˚C 
and 100 mTorr. 
 
2.3. Conjugation of polymers with 5-DTAF 
 
Polymers were fluorescently conjugated with 5-DTAF in an aqueous medium via 
nucleophilic aromatic substitution by an addition-elimination pathway as previously 
described (497). Briefly, a stock solution of 20 g/L 5-DTAF in DMSO was diluted in 0.1M 
sodium bicarbonate (pH 9.3) and added to a 6 % (w/v) polymer solution in 0.1M sodium 
bicarbonate (pH 9.3) to a final molar ratio of 1:2 (polymer:5-DTAF). The reaction 
proceeded overnight in the dark at room-temperature. The labelled polymer was purified 
from the excess of unreacted 5-DTAF by dialysis (12,000-14,000 MWCO Spectra/Por® 
membrane from Spectrum Europe BV, The Netherlands) against Type I ultrapure water. 
The dialyzed polymer solutions were lyophilized as described in the manuscript and 
stored in closed containers protected from light. A schematic representation of 
fluorescent-labeled polymers preparation is depicted in Figure 5.1. 
 
 
Figure 5.1 Reaction schematic for the conjugation of the polymers with 5-DTAF via nucleophilic 
aromatic substitution by an addition-elimination mechanism. At basic pH, the terminal hydroxyl 
group of PEG blocks presented in the polymers, attack the reactive moiety (2-amino-4,6-dichloro-s-
triazine) on the 5-DTAF molecule, promoted by strong electron-withdrawing groups (N) of the s-
triazine ring. 
 
2.4. Production and characterization of fluorescent micelles 
 
Fluorescent-micelles were produced and lyophilized like empty micelles substituting 
polymers by 5-DTAF-conjugated polymers. Particle mean hydrodynamic diameter and PdI 
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was measured without dilution of the samples by DLS at 37 °C using a detection angle of 
173° and zeta potential by laser doppler micro-electrophoresis using a NanoZS (Malvern 
Instruments, UK). For each type of formulation were produced and analyzed at least three 
replicates. 
 
2.5. Cell lines and culture conditions  
 
Calu-3 (ATCC number HTB-55), A549 (ATCC number CCL-185), RAW 264.7 (ATCC 
number TIB-71), THP-1 (ATCC number TIB-202) and U937 (ATCC number CRL-1593.2) 
cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, 
VA, USA). Calu-3, A549 and RAW 264.7 adherent cells were grown separately in flasks in 
DMEM-GlutaMAX® while THP-1 and U937 cells were grown separately in suspension in 
flasks in RPMI-1640 at 37ºC under 5% CO2 water saturated atmosphere. Both media 
were supplemented with 10% (v/v) FBS, 1% (v/v) non-essential amino acids and 100 
U/mL penicillin and streptomycin. For THP-1 cells, β-mercaptoethanol to a final 
concentration of 0.05 mM was further added to the medium. The medium was changed 
every other day and, upon confluence, cells were harvested from flasks with trypsin-EDTA 
(Calu-3 and A549) or a cell scraper (RAW 264.7) and passed or just passed (THP-1 and 
U937) to other flasks to continue expansion, be frozen or used in in vitro studies. 
 
2.6. Assessment of cytotoxicity 
 
The effect of formulations on cellular viability and membrane integrity of Calu-3, A549 and 
Raw 246.7 cell after 24h incubation was assessed using the MTT conversion assay and a 
LDH leakage assay (LDH Cytotoxicity Detection Kit, Takara Bio Inc., Shiga, Japan), 
respectively. 
For MTT assay, cells were seeded separately in 96-well microplates at 5x103 cells/well in 
200 µl of complete medium and incubated for 24 hours at 37 ºC in 5% CO2 environment. 
The medium was removed and the cells washed with 200 µl of PBS. Then, test solutions, 
positive control (complete medium) and negative control (2% (w/v) Triton X-100) were 
added to cells for 24 hours, after which 20 µl of 5mg/ml of MTT solution was added to 
each well and incubated for 4 hours at 37 ºC. After dissolution of the formed formazan 
crystals with 200 µl of DMSO, the absorbance was determined at 590 nm with 630 nm 
background deduction. Each treatment was tested at least in five individual wells. 
Regarding LDH release assay, cells were seeded in 96-well microplates at 5x103 
cells/well and incubated for 24 hours at 37 ºC in 5% CO2 environment. The medium was 
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removed and cells washed with 200 µl of PBS. Test solution, negative control (medium) 
and positive control (2% (m/v) Triton X-100) in serum free medium were added in at least 
five wells each and cells incubated for 24 hours. After that, the plates were centrifuged for 
10 min at 250xg to remove detached cells and the LDH-content of 100 μl supernatant was 
measured at 490 nm (and 630 nm for background deduction) in a plate reader using a 
commercial test kit after incubation for 30 min at room temperature in the dark. The 
apparent cytotoxicity was calculated according to Equation 5.1. 
 
Cytotocxicity % =  
Experimental value − Negative control
Positive Control−Negative Control
 × 100                                Equation 5.1 
 
The results of MTT and LDH release assay were used for the determination of half 
maximal cytotoxic concentration (CC50) index by nonlinear regression of concentration-
effect curve fit using Prism 6.02 software (GraphPad Software, Inc., CA, USA). 
 
2.7. Permeability of insulin through pulmonary epithelium 
 
The permeability of free and formulated insulin through alveolar and bronchial epithelium 
was assessed using A549 and Calu-3 cell monolayers, respectively. Cells were seeded at 
a density of 8x105 cells/cm2 onto the apical surface of Transwell® permeable supports 
(0.33 cm2 polyester, 0.4 mm pore size, from Costar®, Corning Life Sciences, France) in 
0.2 mL complete medium with 0.5 mL medium added to the basolateral chamber. The 
development of cell monolayers was monitored by measuring the transepithelial electrical 
resistance (TEER) using chopstick electrodes (STX-2) and an EVOM voltohmmeter from 
World Precision Instruments (Stevenage, UK). TEER was calculated by subtracting the 
resistance of a cell-free culture insert and correcting for the surface area of the Transwell® 
cell culture support. Cell monolayers were used after TEER values reached stable 
maximum values at 14-15 days in culture. TEER was also measured during experiments 
as an index of cell viability and monolayer integrity. For all permeability studies, the culture 
medium was removed and the cell monolayers were washed with 37 ºC PBS. After 
washing, 0.2 mL of insulin solution or insulin-loaded micelles dispersed in PBS heated at 
37 °C and at an initial concentration of 1000 μg/mL was added to the apical (donor) side, 
while 0.6 mL of PBS at 37 °C was added to the basolateral (receptor) side. At different 
times (0.25, 0.5, 0.45, 1, 2, 4, 6, 8 hours), 0.2 mL of basolateral samples were collected 
and replaced by equal volumes of PBS pre-heated at 37 °C, and insulin determined by 
HPLC as described in Chapter 3. 
Chapter 5 I In vitro biological assessment of powder formulations for inhalation of insulin 
________________________________________________________________________________ 
119 
 
Apparent permeability coefficient (Papp) values (cm/s) were calculated from the 
measurement of the flow rate of insulin from the donor to the acceptor chambers using 
Equation 5.2. 
 
Papp =
dQ
dt
(A × C0)                                                                                            Equation 5.2 
 
where dQ is the total amount of permeated insulin (μg), A is the diffusion area 
(cm2), C0 is the initial concentration of insulin (μg/mL), and dt is the time of 
experiment (s). The coefficient dQ/dt represents the steady-state flux of insulin 
across the monolayer. The permeability enhancement ratio (PER), expressed as 
the ratio between the Papp of insulin associated with micelles and the Papp of 
insulin in solution, was also calculated. 
 
2.8. Interaction of micelles with macrophages 
 
The uptake of the 5-DTAF-labelled micelles by PMA-stimulated THP-1 and U937 
macrophages was assessed qualitatively by confocal microscopy using a Spectral 
Confocal Microscope MFV1000 (Olympus Corporation, Japan) and quantitatively by flow 
cytometry (fluorescence-activated cell sorting (FACS) analysis) in a cytometer Fortessa 
(BD Biosciences, USA). THP-1 and U937 cells at a density of 5x105 cells/well were 
seeded separately in 24-well plates in complete medium supplemented with 25 ng/mL of 
PMA to induce the monocytic differentiation into adherent macrophages. 48 hours after 
seeding, the medium and non-adherent cells were removed by washing twice with PBS. 
Particle suspensions in complete medium (1 and 2 mg/mL) were incubated for 4h at 37 ºC 
and non-internalized fluorescent micelles removed by washing twice with PBS. Cells were 
detach with trypsin:EDTA (U937 cells) or using a cell scraper (THP-1 cells) and 
redispersed in PBS, supplemented with 10% FBS. Cells were then analyzed in a 
cytometer Fortessa (BD Biosciences, USA). Green fluorescence from micelles was 
detected through the EYG-A channel. The viability of the cells was assessed using DAPI 
and the cells derbies and doublets of cells were removed by forward and side scatter 
gating. The analysis of the obtained data was performed with FACS Express 4 software. 
For each sample, at least 10,000 individual cells were collected and the mean 
fluorescence intensity was evaluated.   
For microscopy studies, 0.1% gelatin-coated coverslips were inserted into the wells prior 
to cells addition. After 48h of differentiation, the medium containing PMA was removed 
Self-assembled polymeric micelles as powders for pulmonary administration of insulin 
_______________________________________________________________________ 
120 
 
and the cells washed twice with PBS to remove non-adherent cells and fluorescent 
micelles suspension (1 mg/mL) was added to each well. After 4h incubation at 37 ºC, the 
cells were washed twice with PBS and the membrane stained with CellMask® DeepRed (5 
µg/mL) for 5 min at 37 ºC. After washing with PBS (2x), cells were fixed with a mixture of 
methanol:acetic acid (3:1) for 20 min at room-temperature. Cells were further washed with 
PBS and the nucleus stained with DAPI (0.2 mg/mL) for 5 min at room-temperature. 
Before mounting the coverslips into glass slides with ProLong® Gold Antifade Mountant 
and allowing them to dry, the cells were washed with Type I ultrapure water to remove salt 
traces. Image analysis of xy planes and z-series scanning was performed using a Spectral 
Confocal Microscope MFV1000 (Olympus Corporation, Japan). The 561 nm excitation 
wavelength of the green laser (10mW) was used for selective detection of the red 
fluorochrome (CellMask® DeepRed). The 488 nm excitation wavelength of Argon multiline 
laser: 458nm, 488nm and 515nm (40 mW) was used for selective detection of the green 
fluorochrome (5-DTAF). The nuclear staining DAPI was excited at 405 nm with a violet 
laser (6 mW). For detecting 3 PMT, detectors for fluorescence (2 plus 1 spectral detection 
with conventional filters) plus 1 per detector interdifferential contrast were used. Images 
were acquired with the FluoView FV10-ASW software (Olympus Corporation, Japan), and 
processed in conjugation with the orthogonals projections using the ImageJ 1.48v 
software (National Institutes of Health, MD, USA). 
 
2.9. Statistical analysis 
 
One-way ANOVA was used to investigate the differences between the formulations and 
controls. Post hoc comparisons were performed according to Tukey’s HSD test (p<0.05 
was accepted as denoting significance) using Prism 6.02 software (GraphPad Software, 
Inc., CA, USA). 
 
3. Results 
 
3.1. In vitro assessment of the effect of formulations on cell membrane 
toxicity and viability 
 
The effect of formulations on cell viability and membrane integrity of pulmonary bronchial 
(Calu-3) and alveolar (A549) epithelial cell lines, as well as in macrophages (Raw 264.7) 
after 24h of incubation is presented in Figure 5.2 and 5.3, respectively. 
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Figure 5.2 Formulations’ toxicity profile regarding cell viability of Raw 246.7, Calu.3 and A549 cell lines. Results are expressed as mean ± SEM (n=5). * 
Denotes a significant (p<0.05) lower percentage of viability when compared to lower concentrations of the formulation. 
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Figure 5.3 Formulations’ toxicity profile regarding membrane integrity of Raw 246.7, Calu.3 and A549 cell lines. Results are expressed as mean ± SEM (n=5). 
* Denotes a significant (p<0.05) higher percentage of cytotoxicity when compared to lower concentrations of the formulation. 
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Additionally, CC50 values are expressed in Table 5.1.  
 
Table 5.1 Half maximal cytotoxic concentration (CC50) values (in mg/mL) of insulin-loaded micelles 
as determined by lactate dehydrogenase (LDH) leakage and 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay in different cell lines. The values presented were 
obtained through a nonlinear regression of the mean percentage toxicity values versus 
concentration of formulation using 5 replicates.  
Sample 
LDH MTT 
Raw 264.7 A549 Calu-3 Raw 264.7 A549 Calu-3 
SOL:Ins >10 >10 >10 4.9 1.0 >10 
SOL:Ins:PBA >10 >10 >10 >10 >10 >10 
F68:Ins 6.2 >10 >10 >10 7.5 >10 
F68:Ins:PBA 8.3 >10 >10 >10 >10 >10 
F108:Ins >10 >10 >10 >10 1.8 1.2 
F108:Ins:PBA 8.2 >10 >10 >10 >10 >10 
F127:Ins >10 9.0 >10 >10 1.2 1.2 
F127:Ins:PBA 6.0 >10 >10 6.1 3.4 >10 
 
At high concentrations, formulations seemed to exert higher negative effects on the 
viability of A549 cells (MTT assay), while Raw 264.7 cells seemed to be more prone to 
suffer membrane damage (LDH leakage assay). The CC50 values of all formulations are 
superior to their concentrations expected in the lungs after administration. 
 
3.2. Determination of the apparent permeability coefficient of insulin through 
pulmonary epithelium   
 
Permeability of insulin through pulmonary epithelium was assessed using monolayers of 
A549 or Calu-3 cells. Results as the cumulative percentage of insulin presented in the 
basolateral chamber of Transwell® systems over time are presented in Figure 5.4 (A and 
C). Also, values of Papp and PER in both monolayers are presented in Table 5.2. In both 
models, insulin levels rapidly increased in the first 60 min and continued to be transported 
at least up to 8h. The total amount of insulin in solution that crossed the cell barrier after 
8h was around 5 % and 7 % of the initial concentration in Calu-3 and A549 monolayers, 
respectively. 
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Figure 5.4 Permeability of insulin through A549 (A) and Calu-3 (C) cell monolayers, expressed as 
the percentage of insulin added to the apical chamber of Transwell
®
 system; and transepithelial 
electrical resistance (TEER) values as percentage of the of the values prior to experiment during 
permeability studies across A549 (B) and Calu-3 (D) cell monolayers. Results are presented as 
mean values ± SD (n=3). * Removal of samples after the 8h of experiment and addition of complete 
medium. 
 
Some formulations were able to increase the epithelial permeability of insulin, especially 
through Calu-3 monolayers, as compared to the insulin in solution as evidenced by the 
PER values. However, only F127-based formulations were able to increase significantly 
the permeability of insulin through Calu-3 monolayers (p<0.05).  
Contrasting to insulin solution, the presence of formulations affected the TEER values of 
cell monolayers (Figure 5.4 B and D). However the decrease in the resistance of the 
monolayers was reversible, since it recovered to initial values after the substitution of 
formulations for complete medium. The initial values of TEER remained until at least 24 
hours after the beginning of the experiment, indicating integrity of the monolayer after the 
incubation with the formulations, and that the effects of formulations on tight junctions, if 
any, were fully reversible. 
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Table 5.2 Apparent permeability coefficient (Papp) and permeability enhancement ratio (PER) of 
insulin across A549 and Calu-3 cell monolayers. Results are presented as mean values ± SD 
(n=3). * Denotes a significant difference (p<0.05) when compared to the insulin solution.  
Sample 
A549 Calu-3 
Papp (cm/s 10
-6
) PER Papp (cm/s 10
-6
) PER 
Insulin solution 1.29±0.06 
 
0.89±0.03 
 
SOL:Ins 0.94±0.08 0.73 0.82±0.07 0.93 
SOL:Ins:PBA 1.76±0.10 1.36 1.41±0.12 1.58 
F68:Ins 1.15±0.05 0.89 0.97±0.16 1.08 
F68:Ins:PBA 1.29±0.04 1.00 0.79±0.04 0.88 
F108:Ins 1.17±0.07 0.91 1.15±0.04 1.29 
F108:Ins:PBA 1.21±0.11 0.94 1.09±0.09 1.22 
F127:Ins 1.45±0.12 1.13 2.15±0.31* 2.40 
F127:Ins:PBA 1.32±0.06 1.02 1.88±0.24* 2.10 
 
3.3. Characterization of fluorescent micelles  
 
Fluorescent-labelled micelles were produced and lyophilized to be used in macrophage 
uptake experiments. The characteristics of redispersed micelles at 37 ºC are resumed in 
Table 5.3. The conjugation of polymers with the fluorescent probe did not affect strongly 
the characteristics of micelles. Only F68 and F108-based micelles showed some 
differences (p<0.05) compared to the non-fluorescent insulin-loaded micelles at the same 
temperature. 
 
Table 5.3 Mean hydrodynamic diameter, polydispersity index (PdI) and zeta potential of 
redispersed lyophilized fluorescent-labelled micelles at 37 ºC. Results are presented as mean 
values ± SD (n=3). * Denotes a significant difference (p<0.05) when compared to the insulin-loaded 
redispersed lyophilized micelles of the same polymer analyzed at 37 ºC. 
Sample Hydrodynamic diameter (nm) PdI Zeta potential (mV) 
SOL 235.8±12.5 0.19±0.01 0.1±0.11 
F68 211.2±7.9* 0.55±0.02 -0.1±0.05 
F108 224.9±41.7* 0.40±0.05 -0.3±0.06 
F127 39.4±4.5 0.37±0.03 0.1±0.03 
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3.4. Uptake of micelles by human macrophages 
 
PMA-stimulated THP-1 and U937 cells were used as models to study the uptake of 
micelles by macrophages. 
 
 
Figure 5.5 Confocal microscopy micrographs of SOL (A), F68 (B), F108 (C) and F127 (D) micelle’s 
internalization by PMA-stimulated THP-1 and U937 macrophages. Each image provides a xy plane 
through a cell layer, and the cross-sectional view of the same section of the cell layer in the x–y 
and y–z orientation. Blue, green, and red fluorescence are from DAPI (nucleus), 5-DTAF-polymer 
(micelles) and CellMask
®
 Deep Red (membrane), respectively.  
 
All the formulations were internalized by the cells after 4h of incubation. Micelles 
attachment to the surface of cells was not apparent (Figure 5.5). 
 
Table 5.4 FACS quantification of micelles uptake by PMA-stimulated THP-1 and U937 
macrophages. The values are expressed as the percentage of cells emitting green fluorescence 
after 4h incubation with micelles at concentrations of 1 mg/mL and 2 mg/mL. 
Sample 
THP-1 U937 
1 mg/mL 2 mg/mL 1 mg/mL 2 mg/mL 
SOL 22.47 35.65 36.47 61.63 
F68 25.99 45.1 14.92 37.47 
F108 75.78 91.83 88.55 98.56 
F127 12.08 34.56 13.4 38.86 
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As seen in Figure 5.6, Figure 5.7, and Table 5.4, the uptake of the micelles by 
macrophages varied according to the polymer used and was shown to be concentration 
dependent. An increase in the percentage of cells presenting fluorescence was observed 
when the concentration of micelles increased from 1 to 2 mg/mL.  
 
Figure 5.6 FACS quantification of micelles uptake by PMA-stimulated THP-1 and U937 
macrophages. The values are expressed as the percentage of cells emitting green fluorescence 
after 4h incubation with micelles at a concentration of 1 mg/mL. 
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Figure 5.7 FACS quantification of micelles uptake by PMA-stimulated THP-1 and U937 
macrophages. The values are expressed as the percentage of cells emitting green fluorescence 
after 4h incubation with micelles at a concentration of 2 mg/mL. 
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F127-micelles showed minimal uptake by both PMA-stimulated THP-1 and U937 
macrophages while the other formulations underwent higher uptake. F108-micelles 
suffered the higher uptake by macrophages. 
 
4. Discussion 
 
Pluronic® are considered biocompatible and biodegradable polymers used in many 
biomedical applications including cell’s encapsulation (498, 499). Thus, as expected, no 
significant signs of toxicity to both pulmonary cell lines and macrophages were observed 
in the in vitro experimental setting used as determined by MTT and LDH leakage assays 
(Table 5.1). This results are in accordance to other reports where F68 shown a CC50 
higher than 10 mg/mL in Calu-3 cells (297), and F127 shown negligible toxicity against 
A549 cell up to 1 mg/mL (56). Some Pluronic® were shown to interact with cell 
membranes and intracellular organelles such as the mitochondria where it can interfere 
with metabolic processes (500). Demina and co-workers (2005) reported that Pluronic® 
presenting higher degree of hydrophobicity are more able to interfere with the membrane 
(501), which could be somehow related to the lower CC50 obtained with F108 and F127 
formulations. Still, al the CC50 values are superior to 0.84 mg/mL, the concentration of 
formulation expected in the lungs taking into account basal requirements of insulin. These 
concentrations were calculated assuming 10 mL as volume of lung epithelial lining fluid 
(vary from 10 to 40 mL (502, 503)) and 21 IU as daily mean basal requirement for a 70 kg 
patient according to American Diabetes Association (504). Consequently, no significant 
pulmonary toxic effects of the formulations should be expected. However, in vitro/in vivo 
extrapolations should be done with caution, and in vivo studies are required to assess the 
pulmonary biocompatibility of formulations in animal models. 
Monolayers of A549 or Calu-3 cells were selected as models to assess the permeability of 
insulin through pulmonary epithelium. Both cell lines have been extensively reported and 
used for study the drug transport across pulmonary epithelium (505, 506), being in vitro 
models considered a reliable method to predict the permeation behavior and 
bioavailability of drugs (507, 508). Due to its hydrophilic nature, insulin is expected to 
permeate monolayers manly via the paracellular route by passive diffusion; however, 
basolateral to apical transport of insulin have shown higher Papp values from those 
described to the apical to basolateral direction (508, 509), which could explain partially the 
low insulin permeability observed in this study and reported by others (510, 511). 
Nevertheless, both paracellular and transcellular pathways were described for insulin 
across pulmonary cell monolayers (Calu-3 and 16HBE14o-) (512). The values of Papp 
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obtained in this study differed from those reported by other groups, which could be 
explained by differences in the methodology used between studies (e.g. area available for 
permeation, concentration of protein, number of cells) (506, 513). Amphiphilic polymers, 
including Pluronic®, have been proposed as excipients for improved delivery of many 
drugs. Although not completely understood, it seems that this characteristic is related to 
its capacity to interact with cell membranes and interfere with its structure and 
microviscosity/fluidity (85, 501). This mechanism is also thought to interfere with the 
function of P-glycoprotein, explaining the inhibition of this efflux system observed with 
these polymers (85, 500). Pluronic® with HLB values and number of hydrophobic parts 
closer to those of F127 (HLB=18-23), reduced the cell membrane microviscosity and 
increased the fluidity, contrasting to polymers with higher HLB values like F68 and F108 
(HLB>24) (85). The increased fluidity of the membrane could increase the transcytosis of 
insulin through the cells, thus explaining the higher permeation observed with F127 (Table 
5.2). Macrogol-15-hydroxystearate (Solutol® HS15) micelles have shown to increase the 
transepithelial permeation of insulin through Calu-3 cell monolayers by a mechanism 
dependent on partitioning and changes on cellular membrane structure/fluidity (514). The 
same polymer also enhanced the nasal permeation of human growth hormone in rats 
(515). The variation in the TEER vs time profile of cell monolayers exposed to micelles 
(Figure 5.4) compared to insulin solution could be a consequence of the rearrangement of 
F-actin cellular distribution owing to a change in the membrane lipid environment (516), 
and not so dependent on effects in zonula occludens-1 (ZO-1) protein, as happens with 
other permeation enhancers like chitosan (517). Although, since ZO-1 binds directly to F-
actin (518), changes in the F-actin could lead at some extent to distortions in ZO-1, 
contributing to the paracellular transport of insulin. Indeed, Solutol® HS15 micelles have 
shown to promote a redistribution of F-actin and slight changes in ZO-1 (514), being 
expected a similar pattern with our formulations. 
As expected F127-micelles showed a lower uptake (Table 5.4) by macrophages which is 
possibly correlated to the small size of redispersed lyophilized micelles at 37 ºC (273, 
519), while the other polymers presented larger particles and, consequently, underwent 
higher uptake. Also, the lower percentage of PEG in the constitution of SOL (13% of the 
polymer) could be contributing to the higher percentage of uptake when compared to 
F127-based micelles (70% of PEG), since the density of PEGylation seems to influence 
the phagocytosis (52, 520). Differences observed between F68 and F127 could also be 
related to the small MW of the PEG chains presented in F68 (approximately 4000 g/mol 
for F68 and 5000 g/mol for F127). In other studies, F68-coated particles showed higher 
uptake by macrophages when compared to F127-coated particles (521, 522). Regarding 
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F108 micelles, size appears to be the main responsible for the higher uptake compared to 
F127 micelles. However, there were no apparent differences in size and surface charge of 
micelles that could explain the high values of uptake observed with F108-micelles. 
Additionally, confocal microscopy analysis did not reveal a so marked difference between 
samples. Since the uptake of particles by macrophages is not restricted to phagocytosis 
(523, 524), and the experiment was run in a static model, it is possible that a percentage 
of the observed uptake occurred via nonphagocytic. In fact, the experiment was 
performed in medium supplemented with 10% FBS heat inactivated, which lacks on 
immunoglobulins and components of the complement system, the main serum opsonins; 
although presenting serum proteins that could also work as opsonins; which could lead to 
a reduced activation of the phagocytic pathway (190). However, the alveolar and airway 
area of lungs contains low levels of complement components, reason why alveolar 
macrophages seem to primarily execute phagocytosis via opsonin-independent 
mechanisms (525). SP-A and surfactant protein D (SP-D), member of collectin (collagen-
lectin) family that also includes mannose-binding protein and some bovine serum proteins, 
act as opsonins in lungs (526, 527). SP-A, the most prevalent protein of surfactant, binds 
preferentially to lipophilic surfaces (528), thus we can speculate that low opsonization 
derived from SP-A adsorption and consequent low phagocytosis should be expected for 
small size PEGylated-hydrophilic shell micelles, which are in accordance to the results 
obtained. For example, Patel and co-workers (2012) showed that the conjugation of PEG 
to PLGA nanoparticles reduced their internalization by rat alveolar macrophages (529). 
Nevertheless, since differentiated monocytic cell lines and human macrophages take up 
particles via different mechanisms (524), and the concentrations tested are above the 
expected therapeutic concentration requested, the extrapolation of the in vitro results to 
the in vivo situation becomes difficulty. Being an in vitro model with advantages and 
drawbacks, this experiment serves as preliminary assessment with a predictive value that 
needs to be confirmed with further in vivo experiments. 
 
5. Conclusions 
 
No significant signs of toxicity on both pulmonary cell lines and macrophages were 
observed in the in vitro experiment setting used as determined by MTT and LDH leakage 
assays. Additionally, some formulations, namely F108 and F127-based micelles, were 
able to increase the permeation of insulin across bronchial and alveolar cell monolayers, 
without damage the membrane integrity. All the formulations were taken up by 
macrophages, being the degree of internalization dependent on the polymer used. Above 
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all the polymers, F127 have shown to work as permeability enhancer of insulin and avoid 
more efficiently to be taken up by macrophages. 
Taking into account the results, were managed to achieve formulations with interesting 
and promising characteristics for pulmonary administration of proteins justifying further in 
vivo studies. 
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1. Introduction 
 
Despite the interest in systemic delivery of therapeutic peptides and proteins via 
inhalation, the accurate assessment of formulation’s behavior is a challenging 
experimental task. Different in vitro, ex vivo and in vivo models have been proposed and 
used over the years (530). From the works developed in animal models by Schanker and 
coworkers during the 70´s and 80´s (531-533) up to now, new devices and techniques 
have been developed and proposed to study drug disposition within and absorption from 
lungs, their pharmacokinetics, pharmacological efficacy and toxicological profile after 
pulmonary administration (59, 336, 534-537). 
Many methodological variables like animal used, method of anesthesia, administration 
technique, aerosol generator device, delivery site and animal posture could influence the 
results, explaining the high intra and inter-laboratory variability observed in inhalation 
studies (530). For preliminary experiments on pulmonary administration rodents like mice, 
rats and guinea pigs are employed, being rats and guinea pigs preferred over mice due to 
easier access to trachea and multiple blood dosing (538). Among the administration 
techniques used, direct tracheal access by endotracheal instillation using tracheotomy or 
orotracheal intubation is mainly used due to higher accuracy and reproducibility. Animals 
are anesthetized and placed in a supine position, then trachea is accessed up to the 
carina (tracheal bifurcation) and the formulations aerosolized (539, 540). Streptozotocin is 
an antibiotic that can cause pancreatic β-cell destruction, being capable of inducing type 1 
diabetes mellitus (541). Streptozotocin-induced diabetic mice and rats are generally 
employed as animal models to study the mechanisms of diabetes, screening for potential 
therapies, and assess the behavior of insulin-based formulations (24, 541-543).  
In this chapter it is presented the in vivo pharmacological and toxicological assessment of 
formulations after endotracheal instillation to a streptozotocin-induced murine diabetic 
model. 
 
2. Experimental 
 
2.1. Materials 
 
SOL, F68, F108, and F127 were kindly provided by BASF (Ludwigshafen, Germany). 
Lyophilized human insulin (potency ≥ 27.5 IU/mg), PBS, PBA, streptozotocin, LDH, rat 
cytokine-induced neutrophil chemoattractant 3 (CINC-3) enzyme-linked immunosorbent 
assay (ELISA) kit, and Eukitt® quick-hardening mounting medium were purchase from 
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Sigma-Aldrich (St. Louis, MO, USA). Rat tumor necrosis factor alpha (TNF-α) and rat 
interleukin 6 (IL-6) ELISA kits were purchased from BioLegend (London, UK) while human 
insulin and insulin autoantibodies (IAA) ELISA kits were purchased from ALPCO 
Diagnostics (Salem, NH, USA). Pierce® biocinchoninic acid (BCA) Protein Assay and 
Clear-Rite® 3 were purchased from Thermo Fisher Scientific (Rockford, lL, USA). LDH 
Cytotoxicity Detection Kit was purchased from Takara Bio Europe/Clontech (France). 
Ketamine (Clorketam 1000®) was kindly provided by Vétoquinol (Barcarena, Portugal), 
xylazine (Seton 2 %®) was purchased from Laboratorios Calier (Sintra, Portugal), and 
isoflurane (Isoflo®) was purchased from Esteve Veterinária (Carnaxide, Portugal). The 
other reagents used were methanol, ethanol absolute, Turk’s solution, sodium citrate, 
citric acid, paraformaldehyde, paraffin for histology, Gill’s hematoxylin II solution, and 
eosin alcoholic solution (Merck, Germany) and Type 1 ultrapure water (18.2 MΩ.cm at 25 
ºC, Milli-Q®, Billerica, MA, USA).  
 
2.2. Production of powder formulations 
 
Micelles were prepared using the thin-film hydration technique. Briefly, each polymer was 
individually weight and dissolved in a mixture of methanol:ethanol (1:1). Then, the solvent 
was removed under vacuum and the film was left to dry overnight at room-temperature to 
eliminate any remained solvent. The film was then hydrated with PBS at 37 ºC in order to 
obtain a 1 % (w/v) solution and vortexed for 5 min. The obtained dispersion was filtered 
through a 0.22 µm syringe filter to remove possible dust and aggregates. 
PBA containing micelles were prepared by dissolving PBA with the polymers in the 
solvents prior to the production of the film at a ratio of 10:1 (w/w) (polymer:PBA). Insulin-
loaded micelles were prepared by hydrating the polymeric films with an insulin solution in 
PBS to obtain polymer:insulin ratios of 10:1 (w/w). The other steps were the same as for 
plain formulations. After production micelles were lyophilized in an AdVantage 2.0 
BenchTop Freeze Dryer (SP Scientific, Warminster, PA, USA). The cycle used was the 
follow: the samples were frozen at -30 ˚C and the temperature maintained for 60 min, the 
primary drying was set at 20 ˚C for 480 min at 150 mTorr and the secondary drying for 
another 480 min at 30 ˚C and 100 mTorr. 
 
2.3. Animals 
 
Animals were maintained in accordance with Federation of Laboratory Animal Science 
Associations (FELASA) recommendations and the European Union legislation (European 
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Parliament and Council Directive 2010/63/EU). Male Wistar Han rats (150-174g) from 
Harlan, Spain were kept for seven days after reception for behavioral, physiologic and 
nutritional stabilization. Animals were provided with food (Diet Standard, Mucedola s.r.l., 
Italy) and water ad libitum. Cages floor were covered with corn cob bedding (Corn Cob 
ULTRA12, Ultragene, Portugal) and enriched with nesting material. Animals were 
maintained at 22°C ± 2°C, 55% ± 10% room humidity, and 12h/12h light cycle, and 
submitted to daily inspection. After quarantine, diabetes was induced in all animals by 
intraperitoneal injection of streptozocin (10 mg/mL in pH 4.5 citrate buffer) at 60 mg/kg. 
After one week, animals with fasted blood glucose levels above 250 mg/dL were randomly 
grouped (n = 6) and used in the experiments. 
 
2.4. In vivo pharmacological activity of insulin 
 
Animals were divided into ten groups (n = 6) and fasted 12 hours before and 24 hours 
during the experiment, but were allowed water ad libitum. Prior to the endotracheal 
administration procedure, rats were anesthetized by inhalation of isoflurane (dose of 5 % 
for induction) followed by intraperitoneal injection of 100 mg/kg body weight (bw) of 
ketamine and 10 mg/kg bw of xylazine (for maintenance). Powder formulations (containing 
around 10 IU/kg bw) were administered endotracheally using a Dry Powder Insufflator® - 
Model DP-4 (Penn-Century. Inc. Wyndmoor, PA, USA). The delivery tube was introduced 
into the rat trachea just before the carina and the powder was released after activation of 
the device with 2 ml of air, which corresponds to the tidal volume of rats. Endotracheal 
instillation (MicroSprayer® Aerosolizer - Model IA-1B, Penn-Century. Inc. Wyndmoor, PA, 
USA) and subcutaneous injection of an insulin solution in PBS (10 IU/kg bw) were used as 
control groups. Blood samples were collected from the tail vein at different time points (15, 
30, 45 min, 1, 2, 4, 8 and 24h) and the plasma glucose levels determined using a 
Precision Xtra blood glucose meter and test strips (Abbot Laboratories, Portugal, range 
20-500 mg/dL). Serum insulin levels were determined at 4 and 24h after administration by 
an ELISA kit according to manufactures’ instructions. Serum was obtained after 
centrifugation (10000 rpm for 20 min) of whole blood and stored at -80 °C until analysis. At 
the end of the assay, animals were euthanized by exsanguination after intraperitoneal 
injection of 300 mg/kg bw of ketamine and 30 mg/kg bw of xylazine. 
Plasma glucose levels as the percentage of the values prior administration of insulin were 
plotted against time to evaluate the cumulative hypoglycemic effect over time, quantified 
by the area above the curve, determined using the trapezoidal method (Prism 6.02, 
GraphPad Software, Inc., CA, USA). Pharmacological availability (PA) of inhaled insulin-
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containing powders and solution as the relative cumulative hypoglycemic effect of inhaled 
insulin compared to a 100% availability of the control insulin administered subcutaneously 
was determined according to Equation 6.1. 
 
 𝑃𝐴 =  
𝐴𝐴𝐶 𝑡𝑒𝑠𝑡
𝐷𝑜𝑠𝑒 𝑡𝑒𝑠𝑡
𝐴𝐴𝐶 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
𝐷𝑜𝑠𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
 × 100                                                                                    Equation 6.1 
 
where AAC test and AAC control are the area above curve values of inhaled insulin 
groups and subcutaneous control group, respectively; and Dose test and Dose control is 
the insulin dose (IU/kg bw) administered in inhaled insulin groups and subcutaneous 
control group, respectively.  
 
2.5. Sub-acute toxicity of insulin-loaded polymeric micelles 
 
Rats were divided into ten groups (5 animals per group) and administered endotracheally 
with insulin-loaded formulations (containing around 10 IU/kg bw) as described for the 
pharmacological activity study. Rats administered endotracheally with insulin solution in 
PBS (10 IU/kg bw) and PBS alone were used as controls. Before insufflation animals were 
anesthetized by intraperitoneal injection of 100 mg/kg bw of ketamine and 10 mg/kg bw of 
xylazine. In order to avoid the daily exposure of rats to the anesthesia and reduce the 
development of tolerance or side effects, the procedure was performed every two days for 
a period of 14 days. One day after the last administration, the animals were euthanized by 
exsanguination after intraperitoneal injection of 300 mg/kg bw of ketamine and 30 mg/kg 
bw of xylazine. Blood samples were collected, the trachea exposed for bronchoalveolar 
lavage (3 x 5 mL of PBS) and bronchoalveolar lavage fluid (BALF) collected and stored at 
-80ºC until analysis. BALF was screened for total number of nucleated cells (Turk’s 
solution staining), protein content (BCA assay), relevant inflammatory cytokines and 
chemokines (TNF-α, IL-6, CINC-3 ELISA kits) and lactate dehydrogenase. Serum 
samples were screened for the development of insulin autoantibodies using an ELISA kit 
according to the manufactures’ instructions. Serum was obtained after centrifugation 
(10000 rpm for 20 min) of whole blood and stored at -80 °C until analysis.  
 
2.6. Histological analysis 
 
After euthanasia samples of the lungs, liver and heart were collected and processed for 
hematoxylin and eosin (H&E) staining and light microscopy histological assessment. 
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Briefly, the tissues were fixed with 4% paraformaldehyde for 24 hours and processed 
automatically in a Spin Tissue Processor STP120 (Thermo Scientific, Germany) 
consisting in graded dehydrations steps in ethanol for 10 minutes each, followed by a 
diaphanization step using Clear-Rite® 3 for 10 minutes twice. Processing was finished by 
placing the tissues in liquid paraffin for 2 hours. Tissues were orientated according the 
plane of cut and, after paraffin solidification, sectioned with a thickness between 5-10 μm 
using a Leica RM2255 microtome (Leica Biosystems, Germany). The glass slides with the 
sections were allowed to dry overnight at 37°C before H&E staining.  
For the H&E staining, sections were dewaxed in Clear-Rite® 3 for 10 minutes and 
hydrated through graded alcohols to water for 2 minutes each. After the staining with Gill’s 
hematoxylin II solution for 5 minutes, sections were abundantly washed in tap water for 2 
minutes, and dehydration through graded alcohols for 2 minutes each. Then, sections 
were stained with eosin alcoholic solution for 3 minutes and dipped quickly three times in 
absolute alcohol. At last, sections were dipped in xylene three times and mount in Eukitt® 
quick-hardening mounting medium. 
 
2.7. Statistical analysis 
 
One-way ANOVA was used to investigate the differences between the formulations and 
controls. Post hoc comparisons were performed according to Tukey’s HSD test (p<0.05 
was accepted as significant different) using Prism 6.02 software (GraphPad Software, 
Inc., CA, USA). 
 
3. Results 
 
3.1. Pharmacological activity of insulin-loaded polymeric micelles 
 
The hypoglycemic effect of powder formulations and insulin solutions administered to 
fasted diabetic rats was assessed up to 24h. The plasma glucose levels versus time after 
endotracheal instillation of powders, insulin solution and subcutaneous administration of 
insulin solution are depicted in Figure 6.1, and the PA values expressed in Figure 6.2. The 
mean plasma glucose level at time 0 (baseline value) was taken as 100%. Between 8 
hours and 24 hours, a drop on the plasma glucose levels was observed for the majority of 
formulations, which could be related to the fasting state of animals. 
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Figure 6.1 Plasma glucose levels as the percentage of the plasma glucose levels at time 0 after 
subcutaneous administration of insulin solution (10 IU/kg), endotracheal instillation of insulin 
solution (10 IU/kg) and SOL, F68-based powders (10 IU/kg) (A), F108, F127-based powders (10 
IU/kg) (B), and powders without PBA (10 IU/kg) (C). Results are expressed as mean ± SD (n=6). * 
denotes significant differences of subcutaneous administration compared to endotracheal 
administration of insulin. 
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Endotracheal instillation of insulin (10 IU/kg bw) promoted a lower hypoglycemic effect, 
with an initial reduction at 0.5-1 hours for F68 and F127-based powders, followed by a 
continuous slow decrease of plasma glucose levels. Insulin solution SOL and F108-based 
powders didn’t promote a significant reduction of glucose levels effect over time. 
Subcutaneous administration of 10 IU/kg insulin promoted a decrease of plasma glucose 
levels reaching a minimum decrease to 17.6% of its initial value 6 hours after 
administration. 
 
Figure 6.2 Pharmacological availability (PA) values of insulin after subcutaneous administration of 
insulin solution (10 IU/kg), and endotracheal instillation of insulin solution (10 IU/kg), SOL, F68, 
F108, and F127-based powders (10 IU/kg). Results are expressed as mean ± SD (n=6). 
 
Excepting for F68-based powders, the presence of PBA significantly increased the PA 
values, thus increasing the hypoglycemic effects of formulations. Inhaled insulin solution 
showed the lowest hypoglycemic effect as observed by the plasma glucose profile and the 
low PA value (5.6%). 
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Figure 6.3 Serum insulin levels 4 hours and 24 hours after subcutaneous administration of insulin 
solution (10 IU/kg) and endotracheal instillation of insulin solution (10 IU/kg) and SOL, F68, F108, 
F127-based powders (10 IU/kg). Results are expressed as mean ± SD (n=6). a denotes significant 
differences of subcutaneous administration compared to subcutaneous administration of insulin, 
and b denotes significant differences of subcutaneous administration compared to endotracheal 
administration of insulin. 
 
Serum insulin levels of formulations at 4 and 24 hours presented in Figure 6.3 showed 
small differences that could be related to differences in deposition, release and absorption 
of insulin, although without statistical significance. 
 
3.2. Sub-acute toxicity 
 
The sub-acute toxicity of formulations was assessed after 14-days of exposure. In 
general, no differences in cell count, protein content, LDH and TNF-α levels in BALF of 
animals treated with formulations was observed compared to control animals (Figure 6.4). 
Additionally, CINC-3 and IL-6 were not detected in the BALF of both treated and control 
animals.  
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Figure 6.4 Levels of pulmonary toxicity markers in bronchoalveolar lavage fluid (BALF) after 14-
days administration of insulin solution (10 IU/kg), insulin-containing SOL, F68, F108, F127-based 
powders (10 IU/kg), and PBS as negative control: Total nucleated cells (A), total protein content 
(B), LDH levels (C), and TNF-α levels (D). Results are expressed as mean ± SD (n=5). * denotes 
significant differences (p<0.05) compared to endotracheal administration of PBS. 
 
Also, no changes in the bw of animals was registered during the experimental period 
(Figure 6.5). 
Blood samples were also screened for the development of antibodies against insulin and 
the results are displayed in Table 6.1. According to the ELISA kit used, all the samples 
showed to be negative for the presence of IAA (negative <0.95, borderline 0.95-1.05, and 
positive >1.05). 
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Figure 6.5 Body weight fluctuation of animals during 14 days administration of PBS, insulin 
solution (10 IU/kg), insulin-containing SOL, F68, F108, and F127-based powders (10 IU/kg). 
Results are expressed as mean ± SD (n=5). 
 
 
Table 6.1 Insulin autoantibodies (IAA) ratio value of PBS, insulin solution (10 IU/kg), insulin-
containing SOL, F68, F108, and F127-based powders (10 IU/kg) after 14-days administration. 
Results are expressed as mean ± SD (n=5). 
Formulation IAA ratio value (U/mL) 
PBS 0.061±0.004 
Insulin solution 0.061±0.007 
SOL:Ins 0.065±0.004 
SOL:Ins:PBA 0.062±0.006 
F68:Ins 0.058±0.005 
F68:Ins:PBA 0.061±0.006 
F108:Ins 0.055±0.006 
F108:Ins:PBA 0.061±0.010 
F127:Ins 0.062±0.007 
F127:Ins:PBA 0.063±0.010 
 
After euthanasia of animals, selected organs were collected and processed for histological 
analysis. The histological sections of lungs, liver and heart are displayed in Figure 6.6, 6.7 
and 6.8, respectively. No significant histological changes were observed in animals 
treated with insulin solution and formulations compared to PBS. 
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Figure 6.6 Photomicrographs of lung tissue from animals 24 hours after the last administration. Animals treated with PBS (A), insulin solution (B), insulin-
loaded SOL (C), SOL:PBA (D), F68 (E), F68:PBA (F) F108 (G), F108:PBA (H), F127 (I), and F127:PBA (J)-based powders. H & E staining with a 
magnification of 40X. Scale bars are 20 µm. 
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Figure 6.7 Photomicrographs of liver tissue from animals 24 hours after the last administration. Animals treated with PBS (A), insulin solution (B), insulin-
loaded SOL (C), SOL:PBA (D), F68 (E), F68:PBA (F) F108 (G), F108:PBA (H), F127 (I), and F127:PBA (J)-based powders. H & E staining with a 
magnification of 40X. Scale bars are 20 µm. 
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Figure 6.8 Photomicrographs of heart tissue from animals 24 hours after the last administration. Animals treated with PBS (A), insulin solution (B), insulin-
loaded SOL (C), SOL:PBA (D), F68 (E), F68:PBA (F) F108 (G), F108:PBA (H), F127 (I), and F127:PBA (J)-based powders. H & E staining with a 
magnification of 40X. Scale bars are 20 µm. 
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4. Discussion 
 
The therapeutic effect of inhaled formulations for systemic delivery of proteins is a 
complex balance between deposition profile of particles in the respiratory system, release 
from the formulation, degradation, uptake by macrophages and elimination by other 
defense mechanisms, and absorption to the bloodstream. Encapsulation of proteins for 
inhalation has been described to increase its bioavailability by protecting from degradation 
and increasing the transepithelial transport, explaining the higher PA values of powder 
formulations compared to insulin solution (Figure 6.2). Formulations presented different 
pharmacological profiles, which are related to its characteristics. The higher PA value of 
F127-based formulations (28.9%) could be explained by the high FPF (Table 4.4, Chapter 
4), the low uptake by macrophages (Table 5.4, Chapter 5), and the enhanced permeation 
through pulmonary cell lines (Table 5.2, Chapter 5) observed for this formulation. Despite 
the lower FPF of F68-based powders, the release of >85% of insulin in the first 15 min 
could be related to the PA values (18.6-32.5%) of these formulations (Figure 4.8, Chapter 
4). On the other hand, the controlled release of insulin from SOL-based powders (<55% in 
24 hours), the low permeation through pulmonary cell monolayers, and the apparent lower 
maintenance of insulin conformation after lyophilization (Table 4.2, Chapter 4), could lead 
to the low PA value (6.9%) observed, while PBA containing micelles, due to the higher 
permeation present higher pharmacological activity (PA of 18.9%). Regarding F108-based 
powders, the PA value of 13.2% could be a result of the lower FPF and a higher uptake by 
macrophages. The higher release of insulin observed for PBA containing micelles of SOL, 
F108 and F127, explaining the higher PA values observed when compared to micelles 
without PBA (18.9%, 23.3% and 38.4%, respectively). On the other hand, the lower 
permeation of F68 micelles containing PBA could be responsible for its lower PA value. 
As referred in Chapter 5, Pluronic® polymers have shown to interfere with the cellular 
membrane and alter its microsviscosity/fluidity (85), influencing the epithelial permeability. 
It has been demonstrated that the polymers with intermediate length of PEG blocks and 
lipophilicity interfere at a higher extent with the membrane (85), which could also 
contribute to the higher permeation and pharmacological availability exhibited by F68 and 
F127. 
Besides alveolar macrophages, the mucus presented in the airways represents an 
important mechanism of defense that prevents particles from reaching the mucosa by 
hindering its movement (544). The shell of micelles of both SOL and Pluronic® is 
composed by PEG, which was shown to provide particles with stealth and mucus 
penetrating properties when at its surface. Thus, the developed powders could present 
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some mucus penetrating properties, enabling insulin to be absorbed at bronchial level in 
addition to the alveolar area. The capacity to avoid interactions with mucins and penetrate 
through its chain network is dependent on the MW of PEG and the surface coating 
density, being the mobility inversely proportional to the PEG MW and directly proportional 
to the PEG surface density (545). F68, F127, SOL and F108 possess PEG chains with 
approximate 4000, 5000, 6000 and 7000 g/mol, respectively. Additionally, SOL is 
composed by 13 % of PEG, while Pluronic® possesses a PEG density of 70-80 %. Hence, 
F68 and F127 should present the highest bronchial absorption, whereas SOL the lowest, 
in correlation with the observed PA values. 
The quicker reduction of plasma glucose levels observed for F68 and F127-based 
powders indicates that inhaled insulin could be absorbed more rapidly than subcutaneous 
insulin, and correlates with the serum insulin levels at 4 hours (Figure 6.3). Other inhaled 
formulations, including Afrezza® and Exubera®, showed faster absorption and onset of 
action of inhaled insulin over subcutaneous administration (325, 495, 511) that is related 
to physiologic characteristics of lungs like large surface area, thin epithelial barrier, 
extensive blood supply, and lower enzymatic activity and efflux systems (224), making 
them a good place for absorption of compounds, including proteins. 
Despite the possible quicker absorption, the lower hypoglycemic effect of inhaled insulin 
compared to subcutaneous insulin could be explained by the amount of insulin 
administered and available to be absorbed. Since FPF do not correspond to the total of 
the aerosolized formulation, the amount of insulin deposited in the peripheral lung and 
available to be absorbed is far from the theoretical 10 IU/kg administered. Also, after 
endocytosis by alveolar cells, insulin is partially degraded in the lysosomes by proteolytic 
enzymes (546). Additionally, the mixture of anesthetics used in this study has been shown 
to induce glucose intolerance with an increase of plasma glucose levels in rats up to 5 
hours after intraperitoneal injection (547). That phenomenon could be behind the 
observations reported for the animals administered with inhaled insulin, since in that case 
the administration was performed under anesthesia, unlike in the subcutaneous insulin 
group. 
A variety of formulations intended for pulmonary administration of insulin have been 
developed and proposed in the last decade, including Exubera® and Afrezza® (392). For 
example, insulin-loaded PLGA microcapsules promoted a sustained release of insulin and 
a prolonged hypoglycemic effect compared to subcutaneous administration of 4 IU per 
animal (495), a higher dose than that tested in this study (2-2.5 IU per animal). The 
complexity of inhalation, in addition to the differences inherent to each formulation, and 
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the in vivo study design render an adequate comparison of the different formulations very 
difficult. 
The sub-acute toxicity of formulations was assessed after 14 days of exposure. The 
intraperitoneal injection of the combination of anesthetics at the dose used in this study 
showed to promote localized tissue damage with muscle necrosis, and a transient 
increase in serum aspartate transaminase, alanine transaminase, and creatine kinase 
levels (548). Furthermore, neurotoxicity of ketamine has also been reported (549). For this 
reason, and since diabetic animals have impaired wound healing, it was decided that the 
administration of formulations would be performed every two days rather than daily. One 
day after the last administration, bronchoalveolar lavage was performed and BALF 
collected for pulmonary toxicity markers screening, namely total nucleated cells, protein 
content, and LDH, TNF-α, IL-6 and CINC-3 levels. Additionally, blood samples were 
analyzed for the presence of IAA. F127-based formulations produced an increase of the 
total protein on BALF compared to PBS, which could be related to the enhanced alveolar-
capillary permeability observed in vitro. However, no differences on membrane damage 
(LDH content) and inflammatory induction and response (TNF-α, IL-6, CINC-3, and 
nucleated cell counts) (Figure 6.4), nor weight loss (Figure 6.5) were observed among 
controls and experimental groups, indicating the absence of significant toxicity of 
formulations.  
Additional histological evaluations were performed in lung (Figure 6.6), liver (Figure 6.7) 
and heart (Figure 6.8) tissues. No histopathological changes in lungs as acute infiltration 
of neutrophils, edema in alveolar sacs or significant alveolar septal thickening, typically 
observed in acute pulmonary irritation and inflammation (495), were observed in this 
study. Alterations on liver and heart of treated were also absent. Overall, no signs of 
tissue damage in important organs were observed in animals treated with inhaled insulin 
formulations, compared to the negative control (PBS). 
Alongside with the low bioavailability of insulin presented by Exubera® or the development 
of cough and difficulties in managing the inhaler device, the development of antibodies 
against insulin (319) opened the debate regarding the long-term efficacy and safety of the 
product (550). In this study, the serum of both treated and control animals was negative 
for the presence of IAA (Table 6.1), as determined by ELISA for qualitative determination 
of IgG antibodies to insulin. Although some studies have failed to establish a correlation 
between increased levels of IAA and clinically relevant alterations in respiratory or 
metabolic parameters of patients treated with inhaled insulin (551, 552), the development 
of low levels of antibodies against insulin or their absence could be beneficial parameter in 
the development of new and improved inhaled formulations. 
Self-assembled polymeric micelles as powders for pulmonary administration of insulin 
_______________________________________________________________________ 
150 
 
5. Conclusions 
 
The association of insulin to polymeric micelles improved the efficiency of the protein by 
increasing its hypoglycemic effect and bioavailability as compared to its free solution form. 
The higher release of insulin from micelles observed in vitro could be related to the higher 
pharmacological activity presented by PBA-containing formulations. No inflammation 
induction or cytotoxicity was promoted by pulmonary administration after 14-days of 
exposure. In addition no weight loss or tissue damage were observed, indicating the 
absence of significant sub-acute toxicity of the formulations. The presence of PBA did not 
alter the toxicity profile of micelles. Also, was not observed the development of antibodies 
against insulin, indicating the absence of significant immunogenicity of insulin when 
associated to micelles. 
In this work, we have achieved formulations with promising pharmacological and 
toxicological features for inhalation of insulin, especially the ones based on F127, as 
predicted by in vitro assessment. Polymeric micelles have shown to be feasible delivery 
systems for pulmonary delivery of insulin. These systems could serve as a platform for 
future development of improved dry powder inhalers of other proteins and 
biopharmaceuticals. 
 
 
 
Chapter 7 I General conclusions and future perspectives 
________________________________________________________________________________ 
151 
 
 
Chapter 7 
 
General conclusions and future perspectives 
 
 
 
The importance of inhalation as a route for both local and systemic administration of 
drugs, including therapeutic peptides and proteins, gained a new breath in the last 
decades. This is a result of the important advances observed in the field of molecular 
biology and particle engineering technology, which in turn, have allowed the development 
of new and improved formulations. Also, new insights on the understanding of aerosol 
mechanics boosted the development of innovative inhalation devices with improved 
aerosolization properties and adapted for the challenges imposed by the new 
formulations. Still, the development of efficient and safe formulations for pulmonary 
delivery of drugs imposes numerous challenges. 
In these work it was pursued to achieve a formulation for pulmonary administration of 
insulin based on nanotechnology. Polymeric micelles prepared by thin film hydration 
technique were chosen owing to its easy production, small size, versatility to encapsulate 
both hydrophobic and hydrophilic compounds, and higher stability compared to liposomes. 
Insulin, used as model protein, was associated to polymeric micelles composed by 
different polymers, namely SOL, F68, F108 and F127 up to a polymer:insulin ratio of 10:1. 
PBA was added to the system to provide them with glucose sensitive properties. From the 
different conditions tested, the combination of ethanol and methanol mixed in equal 
proportions as evaporation solvent, and PBS as hydration solvent was selected to 
produce micelles of small size (≤ 200 nm for the majority of formulations), neutral surface 
charge, spherical shape and high protein association.  
In order to increase the formulations stability and to produce solid systems for inhalation 
based on nanocomposites, micelles were lyophilized. Lyophilization promoted a slight 
aggregation of particles, although, due to the inherent lyoprotectant properties of PEG 
present in the polymers used, this effect was not significant for the majority of 
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formulations. By that, no additional cryoprotectans were required, which simplifies the 
formulation and could impact in their stability and safety profile. Dispersed 
nanocomposites originate neutral charged micelles generally lower than 300 nm, 
foreseeing a possible increase in the bioavailability of insulin by a reduction in the 
recognition of micelles by alveolar macrophages. Importantly, the lyophilized systems 
preserved the native-like secondary structure of insulin to a good extent, potentially 
maintaining its activity as assessed by FTIR and far-UV CD.  
XPS analysis confirmed the expected core localization of PBA and the shell localization of 
insulin into micelles, owing to its mainly hydrophobic and hydrophilic nature at neutral pH, 
respectively. Insulin was also partially detected at the surface of micelles, excepting for 
F108 micelles, due to the higher MW of PEG portions of the polymer. Also, no significant 
interactions between the different components of the systems were detected by DSC and 
micro-Raman spectroscopy. 
Nanocomposites of low density and high mean geometrical diameter, presented 
theoretical aerodynamic diameters compatible with good deposition profiles in the 
respiratory tract. However, morphological analysis and determination of Carr’s index and 
Hausner ratio predict flowability limitations. Nevertheless, in vitro determination of FPF 
and MMAD evidenced good aerosolization properties. 
Insulin release from the formulations depends on the polymer used, being fast for F68 and 
controlled for SOL-based systems. Thus, both fast and long-acting insulin formulations 
were achieved. Despite promote the faster in vitro release of insulin from the micelles, 
PBA did not modify the release profile of insulin in the presence of glucose. Since PBA 
was mainly in the core of micelles, it was not available to react with the glucose present in 
the media. 
Regarding the stability of formulations, the lyophilized powders were stored at 4 and 20 ºC 
for 6 months and the size, surface charge and insulin conformation analyzed over time. 
No significant differences on the characteristics of micelles were observed up to six 
months. Additionally, the native-like structure of insulin was maintained, which could be 
attributed to the amorphous state of the protein in the lyophilized systems as evidenced by 
XRD, DSC, and micro-Raman spectroscopy. 
After production and physical and chemical characterization, biological assessment of 
formulations was performed resorting pulmonary epithelial cells lines and macrophages. 
No significant signs of cytotoxicity were observed as determined by MTT and LDH 
leakage assays, thus, no substantial toxicity is expected at therapeutic doses. 
Furthermore, some formulations, especially F127-based systems, were able to increase 
the permeation of insulin across bronchial and alveolar epithelium, without damage the 
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membrane integrity. All the formulations were partially taken up by macrophages, being 
the percentage internalization lower to F127-based powders.  
Lastly, in vivo pharmacological activity and sub-acute toxicity of formulations were 
assessed through endotracheal instillation to a streptozotocin-induced diabetic murine 
model. The association of insulin to polymeric micelles improved its therapeutic activity by 
increasing its hypoglycemic effect and bioavailability as compared to its free solution form. 
The addition of PBA to micelles, in general increased the PA of formulations, which could 
be related to the higher release of insulin from the micelles when PBA is present. Sub-
acute toxicity of formulations was assessed by quantification of inflammation and toxicity 
markers present on BALF and histological analysis of selected organs after multiple 
administrations during 14 days. No signs of inflammation induction, cytotoxicity or tissue 
damage were observed after 14 days of exposure. Additionally, no weight loss neither the 
development of antibodies against insulin was detected, indicating the absence of 
significant sub-acute toxicity of the formulations. The presence of PBA did not affect the 
toxicity profile of formulations. 
In conclusion, solid formulations based on amphiphilic polymers with appropriate 
characteristics for pulmonary delivery of insulin and good storage stability were achieved. 
Additionally, they present promising in vitro and in vivo pharmacological and toxicological 
features for inhalation of proteins. Above all the polymers, F127 showed to originate 
powders that redisperse into micelles of small size, present good aerosolization 
properties, work as permeability enhancer of insulin and efficiently avoid the particles to 
be taken up by macrophages. These formulations serve as a platform for future 
development of improved dry powder inhalers of therapeutic peptides and proteins. 
Future improvements in the aerodynamic properties of formulations such as addition of a 
coarse carrier or the use of different inhaler device should be explored. Also a different 
technique for powder production, namely spray-drying, should be tested to produce 
spherical solid particles with better aerodynamic properties.  
Regarding glucose sensitive properties, grafting PBA to the hydrophilic segments of the 
polymers could be a possible approach to ensure the presence PBA more at the surface 
of the micelles. Conjugation of insulin to PBA before association to micelles is also a 
possibility. 
Following the evolution that has been observed in this field during the recent years, is 
expected in the near future an increase in the development of formulations based on 
nanocarriers to improve the properties of several drugs. Due to the well-known 
advantages presented by these systems would not be surprising to see an exponential 
increase of marketing authorization and commercialization of nanotechnology products, 
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with particular emphasis for administration of therapeutic peptides and proteins by other 
routes than the parental one, including the promising inhalation route. 
 
References 
________________________________________________________________________________ 
155 
 
References 
 
 
1. Kayser O, Lemke A, Hernández-Trejo N. The impact of nanobiotechnology on the 
development of new drug delivery systems. Curr Pharm Biotechnol 2005; 6(1):3-5. 
2. Jain KK. Drug delivery systems - an overview. Methods Mol Biol 2008; 437:1-50. 
3. Torchilin V. Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. Eur 
J Pharm Biopharm 2009; 71(3):431-44. 
4. Lammers T, Hennink WE, Storm G. Tumour-targeted nanomedicines: principles 
and practice. Br J Cancer 2008; 99(3):392-7. 
5. Torchilin V. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res 2007; 
24(1):1-16. 
6. Hartig S, Greene R, DasGupta J, Carlesso G, Dikov M, Prokop A, et al. 
Multifunctional nanoparticulate polyelectrolyte complexes. Pharm Res 2007; 24(12):2353-
69. 
7. Hoffman A. The origins and evolution of "controlled" drug delivery systems. J 
Control Release 2008; 132(3):153-63. 
8. Cryan S. Carrier-based strategies for targeting protein and peptide drugs to the 
lungs. AAPS J 2005; 7(1):E20-41. 
9. Wu M, Pasula R, Smith PA, Martin WJ. Mapping alveolar binding sites in vivo 
using phage peptide libraries. Gene Ther 2003; 10(17):1429-36. 
10. Kim HA, Park JH, Cho SH, Lee M. Lung epithelial binding peptide-linked high 
mobility group box-1 A box for lung epithelial cell-specific delivery of DNA. J Drug Target 
2011; 19(7):589-96. 
11. Jost PJ, Harbottle RP, Knight A, Miller AD, Coutelle C, Schneider H. A novel 
peptide, THALWHT, for the targeting of human airway epithelia. FEBS Lett 2001; 489(2-
3):263-9. 
12. Ross GF, Morris RE, Ciraolo G, Huelsman K, Bruno M, Whitsett JA, et al. 
Surfactant protein A-polylysine conjugates for delivery of DNA to airway cells in culture. 
Hum Gene Ther 1995; 6(1):31-40. 
13. Rudolph C, Schillinger U, Plank C, Gessner A, Nicklaus P, Müller R, et al. Nonviral 
gene delivery to the lung with copolymer-protected and transferrin-modified 
polyethylenimine. Biochim Biophys Acta 2002; 1573(1):75-83. 
14. Fajac I, Thévenot G, Bédouet L, Danel C, Riquet M, Merten M, et al. Uptake of 
plasmid/glycosylated polymer complexes and gene transfer efficiency in differentiated 
airway epithelial cells. J Gene Med 2003; 5(1):38-48. 
15. Goren D, Horowitz AT, Tzemach D, Tarshish M, Zalipsky S, Gabizon A. Nuclear 
delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance 
efflux pump. Clin Cancer Res 2000; 6(5):1949-57. 
16. Torchilin VP. Tat peptide-mediated intracellular delivery of pharmaceutical 
nanocarriers. Adv Drug Deliv Rev 2008; 60(4-5):548-58. 
17. Chono S, Tanino T, Seki T, Morimoto K. Efficient drug targeting to rat alveolar 
macrophages by pulmonary administration of ciprofloxacin incorporated into 
mannosylated liposomes for treatment of respiratory intracellular parasitic infections. J 
Control Release 2008; 127(1):50-8. 
Self-assembled polymeric micelles as powders for pulmonary administration of insulin 
_______________________________________________________________________ 
156 
 
18. Moretton MA, Chiappetta DA, Andrade F, das Neves J, Ferreira D, Sarmento B, et 
al. Hydrolyzed galactomannan-modified nanoparticles and flower-like polymeric micelles 
for the active targeting of rifampicin to macrophages. J Biomed Nanotechnol 2013; 
9(6):1076-87. 
19. Bailey M, Berkland C. Nanoparticle formulations in pulmonary drug delivery. Med 
Res Rev 2009; 29(1):196-212. 
20. Zhang Y, Chan HF, Leong KW. Advanced materials and processing for drug 
delivery: the past and the future. Adv Drug Deliv Rev 2013; 65(1):104-20. 
21. Yan L, Yang Y, Zhang W, Chen X. Advanced materials and nanotechnology for 
drug delivery. Adv Mater 2014; 26(31):5533-40. 
22. Mishra B, Patel B, Tiwari S. Colloidal nanocarriers: a review on formulation 
technology, types and applications toward targeted drug delivery. Nanomedicine 2010; 
6(1):9-24. 
23. Mansour HM, Rhee YS, Wu X. Nanomedicine in pulmonary delivery. Int J 
Nanomedicine 2009; 4:299-319. 
24. Ungaro F, d'Emmanuele di Villa Bianca R, Giovino C, Miro A, Sorrentino R, 
Quaglia F, et al. Insulin-loaded PLGA/cyclodextrin large porous particles with improved 
aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat 
lungs. J Control Release 2009; 135(1):25-34. 
25. Bawarski WE, Chidlowsky E, Bharali DJ, Mousa SA. Emerging 
nanopharmaceuticals. Nanomedicine 2008; 4(4):273-82. 
26. Duncan R, Gaspar R. Nanomedicine(s) under the microscope. Mol Pharm 2011; 
8(6):2101-41. 
27. Bosetti R, Vereeck L. Future of nanomedicine: obstacles and remedies. 
Nanomedicine (Lond) 2011; 6(4):747-55. 
28. Hamburg M. FDA's Approach to Regulation of Products of Nanotechnology. 
Science 2012; 336(6079):299-300. 
29. U.S. Department of Health and Human Services, Food and Drug 
Administration. Guidance for Industry:Considering Whether an FDA-Regulated Product 
Involves the Application of Nanotechnology. 2014. 
30. BCC Research, Nanotechnology in Medical Applications: The Global Market 
(HLC069B). 2012. 
31. Soppimath K, Aminabhavi T, Kulkarni A, Rudzinski W. Biodegradable polymeric 
nanoparticles as drug delivery devices. J Control Release 2001; 70(1-2):1-20. 
32. Martins S, Sarmento B, Ferreira D, Souto E. Lipid-based colloidal carriers for 
peptide and protein delivery-liposomes versus lipid nanoparticles. Int J Nanomedicine 
2007; 2(4):595-607. 
33. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, 
rationale, and clinical applications, existing and potential. Int J Nanomedicine 2006; 
1(3):297-315. 
34. Grenha A, Remuñán-López C, Carvalho E, Seijo B. Microspheres containing 
lipid/chitosan nanoparticles complexes for pulmonary delivery of therapeutic proteins. Eur 
J Pharm Biopharm 2008; 69(1):83-93. 
35. Faraji A, Wipf P. Nanoparticles in cellular drug delivery. Bioorg Med Chem 2009; 
17(8):2950-62. 
36. Müller R, Petersen R, Hommoss A, Pardeike J. Nanostructured lipid carriers (NLC) 
in cosmetic dermal products. Adv Drug Deliv Rev 2007; 59(6):522-30. 
References 
________________________________________________________________________________ 
157 
 
37. Liu Z, Jiao Y, Wang Y, Zhou C, Zhang Z. Polysaccharides-based nanoparticles as 
drug delivery systems. Adv Drug Deliv Rev 2008; 60(15):1650-62. 
38. Yang Y, Bajaj N, Xu P, Ohn K, Tsifansky M, Yeo Y. Development of highly porous 
large PLGA microparticles for pulmonary drug delivery. Biomaterials 2009; 30(10):1947-
53. 
39. Lu Y, Park K. Polymeric micelles and alternative nanonized delivery vehicles for 
poorly soluble drugs. Int J Pharm 2013; 453(1):198-214. 
40. Cabral H, Kataoka K. Progress of drug-loaded polymeric micelles into clinical 
studies. J Control Release 2014; 190:465-76. 
41. Adams ML, Lavasanifar A, Kwon GS. Amphiphilic block copolymers for drug 
delivery. J Pharm Sci 2003; 92(7):1343-55. 
42. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks 
and advantages of vehicle selection for drug formulation. Eur J Cancer 2001; 
37(13):1590-8. 
43. Xiao Y, Lin ZT, Chen Y, Wang H, Deng YL, Le DE, et al. High molecular weight 
chitosan derivative polymeric micelles encapsulating superparamagnetic iron oxide for 
tumor-targeted magnetic resonance imaging. Int J Nanomedicine 2015; 10:1155-72. 
44. Chen C, Cai G, Zhang H, Jiang H, Wang L. Chitosan-poly(ε-caprolactone)-
poly(ethylene glycol) graft copolymers: synthesis, self-assembly, and drug release 
behavior. J Biomed Mater Res A 2011; 96(1):116-24. 
45. Ye YQ, Chen FY, Wu QA, Hu FQ, Du YZ, Yuan H, et al. Enhanced cytotoxicity of 
core modified chitosan based polymeric micelles for doxorubicin delivery. J Pharm Sci 
2009; 98(2):704-12. 
46. Bei YY, Yuan ZQ, Zhang L, Zhou XF, Chen WL, Xia P, et al. Novel self-assembled 
micelles based on palmitoyl-trimethyl-chitosan for efficient delivery of harmine to liver 
cancer. Expert Opin Drug Deliv 2014; 11(6):843-54. 
47. Luppi B, Orienti I, Bigucci F, Cerchiara T, Zuccari G, Fazzi S, et al. 
Poly(vinylalcohol-co-vinyloleate) for the preparation of micelles enhancing retinyl palmitate 
transcutaneous permeation. Drug Deliv 2002; 9(3):147-52. 
48. Luppi B, Bigucci F, Cerchiara T, Andrisano V, Pucci V, Mandrioli R, et al. Micelles 
based on polyvinyl alcohol substituted with oleic acid for targeting of lipophilic drugs. Drug 
Deliv 2005; 12(1):21-6. 
49. Zuccari G, Bergamante V, Carosio R, Gotti R, Montaldo PG, Orienti I. Micellar 
complexes of all-trans retinoic acid with polyvinylalcohol-nicotinoyl esters as new 
parenteral formulations in neuroblastoma. Drug Deliv 2009; 16(4):189-95. 
50. Hu Y, Jiang Z, Chen R, Wu W, Jiang X. Degradation and degradation-induced re-
assembly of PVP-PCL micelles. Biomacromolecules 2010; 11(2):481-8. 
51. Yuan J, Luo Y, Gao Q. Self-assembled polyion complex micelles for sustained 
release of hydrophilic drug. J Microencapsul 2011; 28(2):93-8. 
52. Essa S, Rabanel JM, Hildgen P. Characterization of rhodamine loaded PEG-g-PLA 
nanoparticles (NPs): effect of poly(ethylene glycol) grafting density. Int J Pharm 2011; 
411(1-2):178-87. 
53. Zhan C, Gu B, Xie C, Li J, Liu Y, Lu W. Cyclic RGD conjugated poly(ethylene 
glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect. J Control 
Release 2010; 143(1):136-42. 
Self-assembled polymeric micelles as powders for pulmonary administration of insulin 
_______________________________________________________________________ 
158 
 
54. Gong CY, Wang YJ, Wang XH, Wei XW, Wu QJ, Wang BL, et al. Biodegradable 
self-assembled PEG-PCL-PEG micelles for hydrophobic drug delivery, part 2: in vitro and 
in vivo toxicity evaluation. J Nanopart Res 2011; 13:721–31. 
55. Ma M, Li F, Liu XH, Yuan ZF, Chen FJ, Zhuo RX. Self-assembled micellar 
aggregates based monomethoxyl poly(ethylene glycol)-b-poly(ε-caprolactone)-b-
poly(aminoethyl methacrylate) triblock copolymers as efficient gene delivery vectors. J 
Mater Sci Mater Med 2010; 21(10):2817-25. 
56. Chen L, Sha X, Jiang X, Chen Y, Ren Q, Fang X. Pluronic P105/F127 mixed 
micelles for the delivery of docetaxel against Taxol-resistant non-small cell lung cancer: 
optimization and in vitro, in vivo evaluation. Int J Nanomedicine 2013; 8:73-84. 
57. Wei Z, Hao J, Yuan S, Li Y, Juan W, Sha X, et al. Paclitaxel-loaded Pluronic 
P123/F127 mixed polymeric micelles: formulation, optimization and in vitro 
characterization. Int J Pharm 2009; 376(1-2):176-85. 
58. Silva M, Ricelli N, El Seoud O, Valentim C, Ferreira A, Sato D, et al. Potential 
tuberculostatic agent: micelle-forming pyrazinamide prodrug. Archiv Der Pharmazie 2006; 
339(6):283-90. 
59. Baginski L, Gobbo OL, Tewes F, Salomon JJ, Healy AM, Bakowsky U, et al. In 
vitro and In vivo characterisation of PEG-lipid-based micellar complexes of salmon 
calcitonin for pulmonary delivery. Pharm Res 2012; 29(6):1425-34. 
60. Abdulla JM, Tan YT, Darwis Y. Rehydrated lyophilized rifampicin-loaded mPEG-
DSPE formulations for nebulization. AAPS PharmSciTech 2010; 11(2):663-71. 
61. Letchford K, Liggins R, Burt H. Solubilization of hydrophobic drugs by methoxy 
poly(ethylene glycol)-block-polycaprolactone diblock copolymer micelles: theoretical and 
experimental data and correlations. J Pharm Sci 2008; 97(3):1179-90. 
62. Kwon G, Okano T. Polymeric micelles as new drug carriers. Adv Drug Deliv Rev 
1996; 21(2):107-16. 
63. Zhang Y, Huang Y, Li S. Polymeric micelles: nanocarriers for cancer-targeted drug 
delivery. AAPS PharmSciTech 2014; 15(4):862-71. 
64. Ohuchi M, Harada M, Amano Y, Kato Y, Physiologically active polypeptide- or 
protein-encapsulating polymer micelles, and method for production of the same. 
US2009/02911302009. 
65. Matsumura Y. Preclinical and clinical studies of NK012, an SN-38-incorporating 
polymeric micelles, which is designed based on EPR effect. Adv Drug Deliv Rev 2011; 
63(3):184-92. 
66. Kato K, Chin K, Yoshikawa T, Yamaguchi K, Tsuji Y, Esaki T, et al. Phase II study 
of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced 
or recurrent gastric cancer. Invest New Drugs 2012; 30(4):1621-7. 
67. Kim DW, Kim SY, Kim HK, Kim SW, Shin SW, Kim JS, et al. Multicenter phase II 
trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, 
with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 2007; 
18(12):2009-14. 
68. Lee KS, Chung HC, Im SA, Park YH, Kim CS, Kim SB, et al. Multicenter phase II 
trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in 
patients with metastatic breast cancer. Breast Cancer Res Treat 2008; 108(2):241-50. 
69. Saif MW, Rubin MS, Figueroa JA, Kerr RO. Multicenter phase II trial of Genexol-
PM (GPM), a novel Cremophor-free, polymeric micelle formulation of paclitaxel in patients 
References 
________________________________________________________________________________ 
159 
 
with advanced pancreatic cancer (APC): Final results. Gastrointestinal Cancers 
Symposium, Orlando; 2008. 
70. Valle JW, Armstrong A, Newman C, Alakhov V, Pietrzynski G, Brewer J, et al. A 
phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients 
with advanced adenocarcinoma of the esophagus and gastroesophageal junction. Invest 
New Drugs 2011; 29(5):1029-37. 
71. Exner AA, Krupka TM, Scherrer K, Teets JM. Enhancement of carboplatin toxicity 
by Pluronic block copolymers. J Control Release 2005; 106(1-2):188-97. 
72. Aliabadi HM, Mahmud A, Sharifabadi AD, Lavasanifar A. Micelles of methoxy 
poly(ethylene oxide)-b-poly(epsilon-caprolactone) as vehicles for the solubilization and 
controlled delivery of cyclosporine A. J Control Release 2005; 104(2):301-11. 
73. Wang J, Mongayt D, Torchilin VP. Polymeric micelles for delivery of poorly soluble 
drugs: preparation and anticancer activity in vitro of paclitaxel incorporated into mixed 
micelles based on poly(ethylene glycol)-lipid conjugate and positively charged lipids. J 
Drug Target 2005; 13(1):73-80. 
74. Benahmed A, Ranger M, Leroux JC. Novel polymeric micelles based on the 
amphiphilic diblock copolymer poly(N-vinyl-2-pyrrolidone)-block-poly(D,L-lactide). Pharm 
Res 2001; 18(3):323-8. 
75. Watanabe M, Kawano K, Yokoyama M, Opanasopit P, Okano T, Maitani Y. 
Preparation of camptothecin-loaded polymeric micelles and evaluation of their 
incorporation and circulation stability. Int J Pharm 2006; 308(1-2):183-9. 
76. Liaw J, Chang SF, Hsiao FC. In vivo gene delivery into ocular tissues by eye drops 
of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-PEO) 
polymeric micelles. Gene Ther 2001; 8(13):999-1004. 
77. Torchilin VP. PEG-based micelles as carriers of contrast agents for different 
imaging modalities. Adv Drug Deliv Rev 2002; 54(2):235-52. 
78. Opanasopit P, Yokoyama M, Watanabe M, Kawano K, Maitani Y, Okano T. Block 
copolymer design for camptothecin incorporation into polymeric micelles for passive tumor 
targeting. Pharm Res 2004; 21(11):2001-8. 
79. Kedar U, Phutane P, Shidhaye S, Kadam V. Advances in polymeric micelles for 
drug delivery and tumor targeting. Nanomedicine 2010; 6(6):714-29. 
80. Le Garrec D, Ranger M, Leroux J-C. Micelles in anticancer drug delivery. Am J 
Drug Deliv 2004; 2(1):15-42. 
81. Rapoport N. Physical stimuli-responsive polymeric micelles for anti-cancer drug 
delivery. Progress in Polymer Science 2007; 32:962-90. 
82. Yuan Q, Venkatasubramanian R, Hein S, Misra RD. A stimulus-responsive 
magnetic nanoparticle drug carrier: magnetite encapsulated by chitosan-grafted-
copolymer. Acta Biomater 2008; 4(4):1024-37. 
83. Bae Y, Jang WD, Nishiyama N, Fukushima S, Kataoka K. Multifunctional polymeric 
micelles with folate-mediated cancer cell targeting and pH-triggered drug releasing 
properties for active intracellular drug delivery. Mol Biosyst 2005; 1(3):242-50. 
84. Smola M, Vandamme T, Sokolowski A. Nanocarriers as pulmonary drug delivery 
systems to treat and to diagnose respiratory and non respiratory diseases. Int J 
Nanomedicine 2008; 3(1):1-19. 
85. Batrakova EV, Li S, Alakhov VY, Miller DW, Kabanov AV. Optimal structure 
requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux 
Self-assembled polymeric micelles as powders for pulmonary administration of insulin 
_______________________________________________________________________ 
160 
 
transporter activity in bovine brain microvessel endothelial cells. J Pharmacol Exp Ther 
2003; 304(2):845-54. 
86. Batrakova EV, Kelly DL, Li S, Li Y, Yang Z, Xiao L, et al. Alteration of genomic 
responses to doxorubicin and prevention of MDR in breast cancer cells by a polymer 
excipient: pluronic P85. Mol Pharm 2006; 3(2):113-23. 
87. Miller DW, Batrakova EV, Kabanov AV. Inhibition of multidrug resistance-
associated protein (MRP) functional activity with pluronic block copolymers. Pharm Res 
1999; 16(3):396-401. 
88. Seoul National University Hospital. A phase II study of Genexol-PM and cisplatin 
as induction chemotherapy in unresectable, locally advanced head and neck squamous 
cell carcinoma (HNSCC). NCT01689194: https://clinicaltrials.gov [accessed on April 
2015]. 
89. Samyang Biopharmaceuticals Corporation. Open-label, multicenter, phase I trial to 
evaluate efficacy and safety of the combination therapy of Genexol®-PM plus carboplatin 
as a firstline treatment in subjects with advanced ovarian cancer. NCT00877253: 
https://clinicaltrials.gov [accessed on April 2015].  
90. Korean Breast Cancer Study Group. A clinical trial of paclitaxel loaded polymeric 
micelle (Genexol-PM®) in patients with taxane-pretreated recurrent breast 
cancer.NCT00912639: https://clinicaltrials.gov [accessed on April 2015]. 
91. Nippon Kayaku Co. A phase I dose-escalation study of NK012 administered 
intravenously as a single dose every three weeks in patients with refractory solid tumors. 
NCT00542958: https://clinicaltrials.gov [accessed on April 2015]. 
92. Nippon Kayaku Co. A phase II study of NK012 in sensitive relapsed and refractory 
relapsed small-cell lung cancer (SCLC). NCT00951613: https://clinicaltrials.gov [accessed 
on April 2015]. 
93. Nippon Kayaku Co. A multi-national phase III clinical study comparing NK105 
versus paclitaxel in patients with metastatic or recurrent breast cancer. NCT01644890: 
https://clinicaltrials.gov [accessed on April 2015]. 
94. M.D. Anderson Cancer Center. A phase 1 dose-escalation and pharmacokinetic 
study of NC-4016 in patients with advanced solid tumors or lymphoma.NCT01999491: 
https://clinicaltrials.gov [accessed on April 2015]. 
95. Orient Europharma Co. A phase III, open-label, randomized study of the 
combination therapy with NC-6004 and gemcitabine versus gemcitabine alone in patients 
with locally advanced or metastatic pancreatic cancer. NCT02043288: 
https://clinicaltrials.gov [accessed on April 2015]. 
96. Nanocarrier Co. A phase 1b/2 dose escalation and expansion trial of NC-6004 
(nanoparticle cisplatin) plus gemcitabine in patients with advanced solid tumors or non-
small cell lung cancer. NCT02240238: https://clinicaltrials.gov [accessed on April 2015]. 
97. National Cancer Institute. A pilot open-label single-dose study using intravenous 
micellar paclitaxel for patients with severe psoriasis. NCT00006276: 
https://clinicaltrials.gov [accessed on April 2015]. 
98. Angiotech Pharmaceuticals. A phase 2 open-label clinical study using intravenous 
Paxceed™ to treat patients with rheumatoid arthritis. NCT00055133: 
https://clinicaltrials.gov [accessed on April 2015]. 
99. University of Colorado. Safety and efficacy of a novel antioxidant-rich multivitamin 
supplement for persons with cystic fibrosis. NCT01018303: https://clinicaltrials.gov 
[accessed on April 2015]. 
References 
________________________________________________________________________________ 
161 
 
100. University of Colorado. A multi-center, randomized, controlled, double-blind study 
of the effects of an antioxidant-enriched multivitamin supplement on inflammation and 
oxidative stress in cystic fibrosis patients. NCT01859390: https://clinicaltrials.gov 
[accessed on April 2015]. 
101. BIND Therapeutics. An open label, multicenter, Phase 2 study to determine the 
safety and efficacy of BIND-014 (docetaxel nanoparticles for injectable suspension) as a 
second-line therapy for patients with KRAS mutation positive or squamous cell non-small 
cell lung cancer. NCT02283320: https://clinicaltrials.gov [accessed on April 2015]. 
102. BIND Therapeutics. A phase 1 open label, safety, pharmacokinetic and 
pharmacodynamic dose escalation study of BIND-014 (docetaxel nanoparticles for 
injectable suspension), given by intravenous infusion to patients with advanced or 
metastatic cancer. NCT01300533: https://clinicaltrials.gov [accessed on April 2015]. 
103. BIND Therapeutics. An open label, multicenter, phase 2 study to determine the 
safety and efficacy of BIND-014 (docetaxel nanoparticles for injectable suspension), 
administered to patients with metastatic castration-resistant prostate cancer. 
NCT01812746: https://clinicaltrials.gov [accessed on April 2015]. 
104. Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: 
design, characterization and biological significance. Adv Drug Deliv Rev 2001; 47(1):113-
31. 
105. Xiong XB, Binkhathlan Z, Molavi O, Lavasanifar A. Amphiphilic block co-polymers: 
Preparation and application in nanodrug and gene delivery. Acta Biomater 2012; 
8(6):2017-33. 
106. Hu FQ, Liu LN, Du YZ, Yuan H. Synthesis and antitumor activity of doxorubicin 
conjugated stearic acid-g-chitosan oligosaccharide polymeric micelles. Biomaterials 2009; 
30(36):6955-63. 
107. Hu FQ, Ren GF, Yuan H, Du YZ, Zeng S. Shell cross-linked stearic acid grafted 
chitosan oligosaccharide self-aggregated micelles for controlled release of paclitaxel. 
Colloids Surf B 2006; 50(2):97-103. 
108. Gilani K, Moazeni E, Ramezanli T, Amini M, Fazeli MR, Jamalifar H. Development 
of respirable nanomicelle carriers for delivery of amphotericin B by jet nebulization. J 
Pharm Sci 2011; 100(1):252-9. 
109. Liu Y, Sun J, Cao W, Yang J, Lian H, Li X, et al. Dual targeting folate-conjugated 
hyaluronic acid polymeric micelles for paclitaxel delivery. Int J Pharm 2011; 421(1):160-9. 
110. Chang Y-C, Chu I-M. Methoxy poly(ethylene glycol)-b-poly(valerolactone) diblock 
polymeric micelles for enhanced encapsulation and protection of camptothecin. Eur Polym 
J 2008; 44:3922–30. 
111. Moretton MA, Glisoni RJ, Chiappetta DA, Sosnik A. Molecular implications in the 
nanoencapsulation of the anti-tuberculosis drug rifampicin within flower-like polymeric 
micelles. Colloids Surf B 2010; 79(2):467-79. 
112. Moretton MA, Chiappetta DA, Sosnik A. Cryoprotection-lyophilization and physical 
stabilization of rifampicin-loaded flower-like polymeric micelles. J R Soc Interface 2012; 
9(68):487-502. 
113. Ramasamy T, Kim J, Choi HG, Yong CS, Kim JO. Novel dual drug-loaded block 
ionomer complex micelles for enhancing the efficacy of chemotherapy treatments. J 
Biomed Nanotechnol 2014; 10(7):1304-12. 
Self-assembled polymeric micelles as powders for pulmonary administration of insulin 
_______________________________________________________________________ 
162 
 
114. Matsumoto S, Christie RJ, Nishiyama N, Miyata K, Ishii A, Oba M, et al. 
Environment-responsive block copolymer micelles with a disulfide cross-linked core for 
enhanced siRNA delivery. Biomacromolecules 2009; 10(1):119-27. 
115. Shahin M, Ahmed S, Kaur K, Lavasanifar A. Decoration of polymeric micelles with 
cancer-specific peptide ligands for active targeting of paclitaxel. Biomaterials 2011; 
32(22):5123-33. 
116. Gao ZG, Lee DH, Kim DI, Bae YH. Doxorubicin loaded pH-sensitive micelle 
targeting acidic extracellular pH of human ovarian A2780 tumor in mice. J Drug Target 
2005; 13(7):391-7. 
117. Lee ES, Na K, Bae YH. Doxorubicin loaded pH-sensitive polymeric micelles for 
reversal of resistant MCF-7 tumor. J Control Release 2005; 103(2):405-18. 
118. Seo D, Jeong Y, Kim D, Jang M, Jang M, Nah J. Methotrexate-incorporated 
polymeric nanoparticles of methoxy poly(ethylene glycol)-grafted chitosan. Colloids Surf B 
2009; 69(2):157-63. 
119. Chen J, Zehtabi F, Ouyang J, Kong J, Zhong W, Xing MMQ. Reducible self-
assembled micelles for enhanced intracellular delivery of doxorubicin. J Mater Chem 
2012; 22:7121-29. 
120. Harada A, Kataoka K. Pronounced activity of enzymes through the incorporation 
into the core of polyion complex micelles made from charged block copolymers. J Control 
Release 2001; 72(1-3):85-91. 
121. Ramasamy T, Choi JY, Cho HJ, Umadevi SK, Shin BS, Choi HG, et al. 
Polypeptide-based micelles for delivery of irinotecan: physicochemical and in vivo 
characterization. Pharm Res 2014; in press. 
122. Zhan C, Qian J, Feng L, Zhong G, Zhu J, Lu W. Cyclic RGD-poly(ethylene glycol)-
polyethyleneimine is more suitable for glioblastoma targeting gene transfer in vivo. J Drug 
Target 2011; 19(7):573-81. 
123. Mondon K, Zeisser-Labouèbe M, Gurny R, Möller M. Novel cyclosporin A 
formulations using MPEG-hexyl-substituted polylactide micelles: a suitability study. Eur J 
Pharm Biopharm 2011; 77(1):56-65. 
124. Di Tommaso C, Bourges JL, Valamanesh F, Trubitsyn G, Torriglia A, Jeanny JC, 
et al. Novel micelle carriers for cyclosporin A topical ocular delivery: In vivo cornea 
penetration, ocular distribution and efficacy studies. Eur J Pharm Biopharm 2012; 
81(2):257-64. 
125. Peng T, Su J, Cheng SX, Zhuo RX. Degradation and drug release properties of 
poly-alpha,beta-[N-(2-hydroxyethyl)-L-aspartamide]-g-poly(2,2-dimethyltrimethylene 
carbonate). J Mater Sci Mater Med 2007; 18(9):1765-9. 
126. Lee ES, Gao Z, Kim D, Park K, Kwon IC, Bae YH. Super pH-sensitive 
multifunctional polymeric micelle for tumor pH(e) specific TAT exposure and multidrug 
resistance. J Control Release 2008; 129(3):228-36. 
127. Song Z, Feng R, Sun M, Guo C, Gao Y, Li L, et al. Curcumin-loaded PLGA-PEG-
PLGA triblock copolymeric micelles: Preparation, pharmacokinetics and distribution in 
vivo. J Colloid Interface Sci 2011; 354(1):116-23. 
128. Jeong JH, Kim SW, Park TG. Biodegradable triblock copolymer of PLGA-PEG-
PLGA enhances gene transfection efficiency. Pharm Res 2004; 21(1):50-4. 
129. Chang SF, Chang HY, Tong YC, Chen SH, Hsaio FC, Lu SC, et al. Nonionic 
polymeric micelles for oral gene delivery in vivo. Hum Gene Ther 2004; 15(5):481-93. 
References 
________________________________________________________________________________ 
163 
 
130. Chen YC, Jiang LP, Liu NX, Ding L, Liu XL, Wang ZH, et al. Enhanced gene 
transduction into skeletal muscle of mice in vivo with pluronic block copolymers and 
ultrasound exposure. Cell Biochem Biophys 2011; 60(3):267-73. 
131. Wang Y, Yu L, Han L, Sha X, Fang X. Difunctional Pluronic copolymer micelles for 
paclitaxel delivery: synergistic effect of folate-mediated targeting and Pluronic-mediated 
overcoming multidrug resistance in tumor cell lines. Int J Pharm 2007; 337(1-2):63-73. 
132. Wang Y, Li Y, Wang Q, Wu J, Fang X. Pharmacokinetics and biodistribution of 
paclitaxel-loaded pluronic P105/L101 mixed polymeric micelles. Yakugaku Zasshi 2008; 
128(6):941-50. 
133. Wang Y, Li Y, Wang Q, Fang X. Pharmacokinetics and biodistribution of polymeric 
micelles of paclitaxel with pluronic P105/poly(caprolactone) copolymers. Pharmazie 2008; 
63(6):446-52. 
134. Dutta P, Dey J. Drug solubilization by amino acid based polymeric nanoparticles: 
characterization and biocompatibility studies. Int J Pharm 2011; 421(2):353-63. 
135. Dutta P, Dey J, Perumal V, Mandal M. Amino acid based amphiphilic copolymer 
micelles as carriers of non-steroidal anti-inflammatory drugs: solubilization, in vitro release 
and biological evaluation. Int J Pharm 2011; 407(1-2):207-16. 
136. Dutta P, Shrivastava S, Dey J. Amphiphilic polymer nanoparticles: characterization 
and assessment as new drug carriers. Macromol Biosci 2009; 9(11):1116-26. 
137. Orienti I, Zuccari G, Fini A, Rabasco AM, Carosio R, Raffaghello L, et al. Modified 
doxorubicin for improved encapsulation in PVA polymeric micelles. Drug Deliv 2005; 
12(1):15-20. 
138. Zeng X, Li J, Zheng J, Pan Y, Wang J, Zhang L, et al. Amphiphilic cylindrical 
copolypeptide brushes as potential nanocarriers for the simultaneous encapsulation of 
hydrophobic and cationic drugs. Colloids Surf B 2012; 94:324-32. 
139. Wei Y, Wang Y, Wang L, Hao D, Ma G. Fabrication strategy for amphiphilic 
microcapsules with narrow size distribution by premix membrane emulsification. Colloids 
Surf B 2011; 87(2):399-408. 
140. Morita T, Horikiri Y, Suzuki T, Yoshino H. Applicability of various amphiphilic 
polymers to the modification of protein release kinetics from biodegradable reservoir-type 
microspheres. Eur J Pharm Biopharm 2001; 51(1):45-53. 
141. Chen S, Zhang XZ, Cheng SX, Zhuo RX, Gu ZW. Functionalized amphiphilic 
hyperbranched polymers for targeted drug delivery. Biomacromolecules 2008; 9(10):2578-
85. 
142. Xu Q, Liu Y, Su S, Li W, Chen C, Wu Y. Anti-tumor activity of paclitaxel through 
dual-targeting carrier of cyclic RGD and transferrin conjugated hyperbranched copolymer 
nanoparticles. Biomaterials 2012; 33(5):1627-39. 
143. Wong HL, Bendayan R, Rauth AM, Xue HY, Babakhanian K, Wu XY. A 
mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant 
breast cancer cells using a polymer-lipid hybrid nanoparticle system. J Pharmacol Exp 
Ther 2006; 317(3):1372-81. 
144. Shuhendler AJ, Cheung RY, Manias J, Connor A, Rauth AM, Wu XY. A novel 
doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer 
synergy in multidrug resistant human breast cancer cells. Breast Cancer Res Treat 2010; 
119(2):255-69. 
Self-assembled polymeric micelles as powders for pulmonary administration of insulin 
_______________________________________________________________________ 
164 
 
145. Hu Y, Atukorale PU, Lu JJ, Moon JJ, Um SH, Cho EC, et al. Cytosolic delivery 
mediated via electrostatic surface binding of protein, virus, or siRNA cargos to pH-
responsive core-shell gel particles. Biomacromolecules 2009; 10(4):756-65. 
146. Chaudhari KR, Ukawala M, Manjappa AS, Kumar A, Mundada PK, Mishra AK, et 
al. Opsonization, biodistribution, cellular uptake and apoptosis study of PEGylated PBCA 
nanoparticle as potential drug delivery carrier. Pharm Res 2012; 29(1):53-68. 
147. Song N, Liu W, Tu Q, Liu R, Zhang Y, Wang J. Preparation and in vitro properties 
of redox-responsive polymeric nanoparticles for paclitaxel delivery. Colloids Surf B 2011; 
87(2):454-63. 
148. Chen J, Tian B, Yin X, Zhang Y, Hu D, Hu Z, et al. Preparation, characterization 
and transfection efficiency of cationic PEGylated PLA nanoparticles as gene delivery 
systems. J Biotechnol 2007; 130(2):107-13. 
149. Kwon JS, Park IK, Cho AS, Shin SM, Hong MH, Jeong SY, et al. Enhanced 
angiogenesis mediated by vascular endothelial growth factor plasmid-loaded thermo-
responsive amphiphilic polymer in a rat myocardial infarction model. J Control Release 
2009; 138(2):168-76. 
150. Kamei N, Morishita M, Chiba H, Kavimandan NJ, Peppas NA, Takayama K. 
Complexation hydrogels for intestinal delivery of interferon beta and calcitonin. J Control 
Release 2009; 134(2):98-102. 
151. Nakamura K, Murray RJ, Joseph JI, Peppas NA, Morishita M, Lowman AM. Oral 
insulin delivery using P(MAA-g-EG) hydrogels: effects of network morphology on insulin 
delivery characteristics. J Control Release 2004; 95(3):589-99. 
152. Morishita M, Goto T, Nakamura K, Lowman AM, Takayama K, Peppas NA. Novel 
oral insulin delivery systems based on complexation polymer hydrogels: single and 
multiple administration studies in type 1 and 2 diabetic rats. J Control Release 2006; 
110(3):587-94. 
153. Bhattarai N, Ramay HR, Gunn J, Matsen FA, Zhang M. PEG-grafted chitosan as 
an injectable thermosensitive hydrogel for sustained protein release. J Control Release 
2005; 103(3):609-24. 
154. Gao Y, Sun Y, Ren F, Gao S. PLGA-PEG-PLGA hydrogel for ocular drug delivery 
of dexamethasone acetate. Drug Dev Ind Pharm 2010; 36(10):1131-8. 
155. Ghahremankhani AA, Dorkoosh F, Dinarvand R. PLGA-PEG-PLGA tri-block 
copolymers as in situ gel-forming peptide delivery system: effect of formulation properties 
on peptide release. Pharm Dev Technol 2008; 13(1):49-55. 
156. Wenzel J, Balaji K, Koushik K, Navarre C, Duran S, Rahe C, et al. Pluronic F127 
gel formulations of deslorelin and GnRH reduce drug degradation and sustain drug 
release and effect in cattle. J Control Release 2002; 85(1-3):51-9. 
157. Pisal S, Paradkar A, Mahadik K, Kadam S. Pluronic gels for nasal delivery of 
vitamin B-12. Part I: preformulation study. Int J Pharm 2004; 270(1-2):37-45. 
158. Escobar-Chavez J, Quintanar-Guerrero D, Ganem-Quintanar A. In vivo skin 
permeation of sodium naproxen formulated in pluronic F-127 gels: Effect of Azone and 
Transcutol. Drug Dev Ind Pharm 2005; 31(4-5):447-54. 
159. Wang C, Han W, Tang X, Zhang H. Evaluation of drug release profile from patches 
based on styrene-isoprene-styrene block copolymer: the effect of block structure and 
plasticizer. AAPS PharmSciTech 2012; 13(2):556-67. 
References 
________________________________________________________________________________ 
165 
 
160. Rouxhet L, Dinguizli M, Latere Dwan'isa JP, Ould-Ouali L, Twaddle P, Nathan A, et 
al. Monoglyceride-based self-assembling copolymers as carriers for poorly water-soluble 
drugs. Int J Pharm 2009; 382(1-2):244-53. 
161. Linn M, Collnot EM, Djuric D, Hempel K, Fabian E, Kolter K, et al. Soluplus® as an 
effective absorption enhancer of poorly soluble drugs in vitro and in vivo. Eur J Pharm Sci 
2012; 45(3):336-43. 
162. Zu Y, Gorukanti S, Ahmed SU, inventors; Abon Pharmaceuticals, LLC, assignee. 
Extended-release oral dosage forms for poorly soluble amine drugs. US20120087979 A1 
2012. 
163. Moghimi SM, Hunter AC. Poloxamers and poloxamines in nanoparticle 
engineering and experimental medicine. Trends Biotechnol 2000; 18(10):412-20. 
164. Kabanov AV, Batrakova EV, Alakhov VY. Pluronic block copolymers as novel 
polymer therapeutics for drug and gene delivery. J Control Release 2002; 82(2-3):189-
212. 
165. Stridsberg K, Ryner M, Albertsson A. Controlled ring-opening polymerization: 
polymers with designed macromolecular architecture. In: Albertsson A, editor. Degradable 
Aliphatic Polyesters: Advances in Polymer Science. Springer-Verlag Berlin Heidelberg; 
2002. p. 41-65. 
166. Albertsson A, Varma I. Recent developments in ring opening polymerization of 
lactones for biomedical applications. Biomacromolecules 2003; 4(6):1466-86. 
167. O’Donnell JM. Reversible addition-fragmentation chain transfer polymerization in 
microemulsion. Chem Soc Rev 2012; 41:3061–76. 
168. Srivastava R, Albertsson A. Enzyme-catalyzed ring-opening polymerization of 
seven-membered ring lactones leading to terminal-functionalized and triblock polyesters. 
Macromolecules 2006; 39(1):46-54. 
169. Albertsson A, Srivastava R. Recent developments in enzyme-catalyzed ring-
opening polymerization. Adv Drug Deliv Rev 2008; 60(9):1077-93. 
170. Kumar M, Kumar N, Domb A, Arora M. Pharmaceutical polymeric controlled drug 
delivery systems. In: Filled Elastomers Drug Delivery Systems: Advances in Polymer 
Science. Springer-Verlag Berlin Heidelberg; 2002. p. 45-117. 
171. Smith A, Xu X, McCormick C. Stimuli-responsive amphiphilic (co)polymers via 
RAFT polymerization. Prog Polym Sci 2010; 35(1-2):45-93. 
172. Ward MA, Georgiou TK. Thermoresponsive polymers for biomedical applications. 
Polymers 2011; 3:1215-42. 
173. Motornov M, Roiter Y, Tokarev I, Minko S. Stimuli-responsive nanoparticles, 
nanogels and capsules for integrated multifunctional intelligent systems. Prog Polym Sci 
2010; 35(1-2):174-211. 
174. Hu Y, Litwin T, Nagaraja AR, Kwong B, Katz J, Watson N, et al. Cytosolic delivery 
of membrane-impermeable molecules in dendritic cells using pH-responsive core-shell 
nanoparticles. Nano Lett 2007; 7(10):3056-64. 
175. Urbani CN, Bell CA, Lonsdale D, Whittaker MR, Monteiro MJ. Self-assembly of 
amphiphilic polymeric dendrimers synthesized with selective degradable 
linkages. Macromolecules 2008; 41:76-86. 
176. Letchford K, Burt H. A review of the formation and classification of amphiphilic 
block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and 
polymersomes. Eur J Pharm Biopharm 2007; 65(3):259-69. 
Self-assembled polymeric micelles as powders for pulmonary administration of insulin 
_______________________________________________________________________ 
166 
 
177. Myers D. Surfactant science and technology. 3rd ed. USA: Wiley-Interscience; 
2006. 
178. Jones M, Leroux J. Polymeric micelles - a new generation of colloidal drug 
carriers. Eur J Pharma Biopharm. 1999; 48:101-11. 
179. Malmsten M. Surfactants and polymers in drug delivery. CRC Press; 2002. 
180. Babinot J, Guigner JM, Renard E, Langlois V. A micellization study of medium 
chain length poly(3-hydroxyalkanoate)-based amphiphilic diblock copolymers. J Colloid 
Interface Sci 2012; 375(1):88-93. 
181. Abdekhodaie MJ, Liu Z, Erhan SZ, Wu XY. Characterization of novel soybean-oil-
based thermosensitive amphiphilic polymers for drug delivery applications. Polym Int 
2012; 61(9):1477-84. 
182. Hu Z, Fan X, Wang H, Wang J. Synthesis and characterization of biodegradable 
and biocompatible amphiphilic block copolymers bearing pendant amino acid residues. 
Polymer 2009; 50(17):4175–81. 
183. Cerritelli S, O'Neil CP, Velluto D, Fontana A, Adrian M, Dubochet J, et al. 
Aggregation behavior of poly(ethylene glycol-bl-propylene sulfide) di- and triblock 
copolymers in aqueous solution. Langmuir 2009; 25(19):11328-35. 
184. Alexandridis P, Holzwarthf JF, Hatton TA. Micellization of poly(ethylene oxide)-
poly(propylene oxide)-poly(ethylene oxide) triblock copolymers in aqueous solutions: 
thermodynamics of copolymer association. Macromolecules 1994; 27:2414-25. 
185. Gu L, Shen Z, Feng C, Li Y, Lu G, Huang X. Synthesis of double hydrophilic graft 
copolymer containing poly(ethylene glycol) and poly(methacrylic acid) side chains via 
successive ATRP. J Polym Sci Pol Chem 2008; 46:4056–69. 
186. Fournier E, Dufresne MH, Smith DC, Ranger M, Leroux JC. A novel one-step drug-
loading procedure for water-soluble amphiphilic nanocarriers. Pharm Res 2004; 
21(6):962-8. 
187. Dutta P, Dey J, Ghosh G, Nayak RR. Self-association and microenvironment of 
random amphiphilic copolymers of sodium N-acryloyl-L-valinate and N-dodecylacrylamide 
in aqueous solution. Polymer 2009; 50:1516–25. 
188. Ho K, Li W, Wong C, Li P. Amphiphilic polymeric particles with core-shell 
nanostructures: emulsion-based syntheses and potential applications. Colloid Polym Sci 
2010; 288(16-17):1503-23. 
189. Kwon GS. Amphiphilic block copolymer micelles for nanoscale drug delivery. Drug 
Develop Res 2006; 67(1):15-22. 
190. Owens DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of 
polymeric nanoparticles. Int J Pharm 2006; 307(1):93-102. 
191. Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: 
critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid 
Res 2003; 42(6):463-78. 
192. Merrett K, Cornelius RM, McClung WG, Unsworth LD, Sheardown H. Surface 
analysis methods for characterizing polymeric biomaterials. J Biomater Sci Polym Ed 
2002; 13(6):593-621. 
193. Morales ME, Ruiz MA, Oliva I, Oliva M, Gallardo V. Chemical characterization with 
XPS of the surface of polymer microparticles loaded with morphine. Int J Pharm 2007; 
333(1-2):162-6. 
194. Rösler A, Vandermeulen GW, Klok HA. Advanced drug delivery devices via self-
assembly of amphiphilic block copolymers. Adv Drug Deliv Rev 2001; 53(1):95-108. 
References 
________________________________________________________________________________ 
167 
 
195. Kamaly N, Xiao Z, Valencia PM, Radovic-Moreno AF, Farokhzad OC. Targeted 
polymeric therapeutic nanoparticles: design, development and clinical translation. Chem 
Soc Rev 2012; 41(7):2971-3010. 
196. Linkov I, Satterstrom F, Corey L. Nanotoxicology and nanomedicine: making hard 
decisions. Nanomedicine 2008; 4(2):167-71. 
197. Rinaldo M, Andujar P, Lacourt A, Martinon L, Canal Raffin M, Dumortier P, et al. 
Perspectives in biological monitoring of inhaled nanosized particles. Ann Occup Hyg 
2015; in press. 
198. Oberdörster G, Oberdörster E, Oberdörster J. Nanotoxicology: an emerging 
discipline evolving from studies of ultrafine particles. Environ Health Perspect 2005; 
113(7):823-39. 
199. Möller W, Felten K, Sommerer K, Scheuch G, Meyer G, Meyer P, et al. Deposition, 
retention, and translocation of ultrafine particles from the central airways and lung 
periphery. Am J Respir Crit Care Med 2008; 177(4):426-32. 
200. Renwick L, Brown D, Clouter A, Donaldson K. Increased inflammation and altered 
macrophage chemotactic responses caused by two ultrafine particle types. Occup Environ 
Med 2004; 61(5):442-7. 
201. Pickup J, Zhi Z, Khan F, Saxl T, Birch D. Nanomedicine and its potential in 
diabetes research and practice. Diabetes Metab Res Rev 2008; 24(8):604-10. 
202. Tauzin B. Biotechnology Medicines in Development. Washington DC: 
Pharmaceutical Research and Manufacturers Association, 2008. 
203. Tang L, Meibohm B. Pharmacokinetics of peptides and proteins. In: Meibohm B, 
editor. Pharmacokinetics and pharmacodynamics of biotech drugs - principles and case 
studies in drug development. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA; 2006. p. 
17-43. 
204. PhRMA. 2013 Overview: medicines in development - biologics: 
http://www.phrma.org [accessed on December 2014]. 
205. Morishita M, Peppas N. Is the oral route possible for peptide and protein drug 
delivery? Drug Discov Today 2006; 11(19-20):905-10. 
206. Rader RA. FDA biopharmaceutical product approvals and trends in 2012. 
BioProcess Int 2013; 11(3):18-27. 
207. EvaluatePharma. World Preview 2018: http://www.evaluatepharma.com [accessed 
on June 2014]. 
208. Albericio F, Kruger HG. Therapeutic peptides. Future Med Chem 2012; 
4(12):1527-31. 
209. Hillery A. Drug delivery: the basic concepts. In: Hillery A, Lloyd A, Swarbrick J, 
editors. Drug delivery and targeting for pharmacists and pharmaceutical scientists. First 
ed. London and New York: Taylor & Francis; 2001. p. 1-48. 
210. Craik DJ, Fairlie DP, Liras S, Price D. The future of peptide-based drugs. Chem 
Biol Drug Des 2013; 81(1):136-47. 
211. Antosova Z, Mackova M, Kral V, Macek T. Therapeutic application of peptides and 
proteins: parenteral forever? Trends Biotechnol 2009; 27(11):628-35. 
212. Sharma AR, Kundu SK, Nam JS, Sharma G, Priya Doss CG, Lee SS, et al. Next 
generation delivery system for proteins and genes of therapeutic purpose: why and how? 
Biomed Res Int 2014; 2014:327950. 
213. Depreter F, Pilcer G, Amighi K. Inhaled proteins: challenges and perspectives. Int 
J Pharm 2013; 447(1-2):251-80. 
Self-assembled polymeric micelles as powders for pulmonary administration of insulin 
_______________________________________________________________________ 
168 
 
214. Quan C, Alcala E, Petkovska I, Matthews D, Canova-Davis E, Taticek R, et al. A 
study in glycation of a therapeutic recombinant humanized monoclonal antibody: where it 
is, how it got there, and how it affects charge-based behavior. Anal Biochem 2008; 
373(2):179-91. 
215. Klingler C, Müller B, Steckel H. Insulin-micro- and nanoparticles for pulmonary 
delivery. Int J Pharm 2009; 377(1-2):173-9. 
216. Amidi M, Mastrobattista E, Jiskoot W, Hennink W. Chitosan-based delivery 
systems for protein therapeutics and antigens. Adv Drug Deliv Rev 2010; 62(1):59-82. 
217. Pinto Reis C, Silva C, Martinho N, Rosado C. Drug carriers for oral delivery of 
peptides and proteins: accomplishments and future perspectives. Ther Deliv 2013; 
4(2):251-65. 
218. Sarmento B, Ribeiro A, Veiga F, Ferreira D. Development and characterization of 
new insulin containing polysaccharide nanoparticles. Colloids Surf B 2006; 53(2):193-202. 
219. Bayat A, Dorkoosh F, Dehpour A, Moezi L, Larijani B, Junginger H, et al. 
Nanoparticles of quaternized chitosan derivatives as a carrier for colon delivery of insulin: 
ex vivo and in vivo studies. Int J Pharm 2008; 356(1-2):259-66. 
220. Kane C, O'Neil K, Conk M, Picha K. Inhalation delivery of protein therapeutics. 
Inflamm Allergy Drug Targets 2013; 12(2):81-7. 
221. Anderson PJ. History of aerosol therapy: liquid nebulization to MDIs to DPIs. 
Respir Care 2005; 50(9):1139-50. 
222. Sanders M. Inhalation therapy: an historical review. Prim Care Respir J 2007; 
16(2):71-81. 
223. O’Callaghan C, Nerbrink O, Vidgren MT. The history of inhaled drug therapy. In: 
Bisgaard H, O’Callaghan C, Smaldone GC, editors. Drug delivery to the lung. Lung 
biology in health and disease. Marcel Dekker; 2002. p. 1-20. 
224. Rau JL. The inhalation of drugs: advantages and problems. Respir Care 2005; 
50(3):367-82. 
225. Dessanges JF. A history of nebulization. J Aerosol Med 2001; 14(1):65-71. 
226. Knott FA, Southwell N. Aerosol Penicillin in the Oxygen Tent. Arch Dis Child 1946; 
21(105):16-8. 
227. Humphrey J, Joules H. Penicillin inhalation in pulmonary disease. Lancet 1946; 
2(6416):221-5. 
228. Southwell N. Inhaled penicillin in bronchial infections. Lancet 1946; 2(6416):225-7. 
229. Hurst A. Penicillin nebulization in bronchopulmonary disease: a preliminary report. 
Rocky Mt Med J 1946; 43:219-21. 
230. O’Riordan T. Inhaled antimicrobial therapy: from cystic fibrosis to the flu. Respir 
Care 2000; 45(7):836–45. 
231. McAllen MK, Kochanowski SJ, Shaw KM. Steroid aerosols in asthma: an 
assessment of betamethasone valerate and a 12-month study of patients on maintenance 
treatment. Br Med J 1974; 1(5900):171-5. 
232. Muttil P, Wang C, Hickey AJ. Inhaled drug delivery for tuberculosis therapy. Pharm 
Res 2009; 26(11):2401-16. 
233. Geller DE, Flume PA, Staab D, Fischer R, Loutit JS, Conrad DJ, et al. Levofloxacin 
inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. 
Am J Respir Crit Care Med 2011; 183(11):1510-6. 
References 
________________________________________________________________________________ 
169 
 
234. Bernstein DI, Reuman PD, Sherwood JR, Young EC, Schiff GM. Ribavirin small-
particle-aerosol treatment of influenza B virus infection. Antimicrob Agents Chemother 
1988; 32(5):761-4. 
235. Mohammad RA, Klein KC. Inhaled amphotericin B for prophylaxis against invasive 
Aspergillus infections. Ann Pharmacother 2006; 40(12):2148-54. 
236. Aitken M, Burke W, McDonald G, Shak S, Montgomery A, Smith A. Recombinant 
human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 
study. JAMA 1992; 267(14):1947-51. 
237. Jones LH, Baldock H, Bunnage ME, Burrows J, Clarke N, Coghlan M, et al. 
Inhalation by design: dual pharmacology β-2 agonists/M3 antagonists for the treatment of 
COPD. Bioorg Med Chem Lett 2011; 21(9):2759-63. 
238. de Galan B, Simsek S, Tack C, Heine R. Efficacy and safety of inhaled insulin in 
the treatment of diabetes mellitus. Neth J Med 2006; 64(9):319-25. 
239. Huland E, Burger A, Fleischer J, Fornara P, Hatzmann E, Heidenreich A, et al. 
Efficacy and safety of inhaled recombinant interleukin-2 in high-risk renal cell cancer 
patients compared with systemic interleukin-2: an outcome study. Folia Biologica 2003; 
49(5):183-90. 
240. Videira M, Almeida AJ, Fabra A. Preclinical evaluation of a pulmonary delivered 
paclitaxel-loaded lipid nanocarrier antitumor effect. Nanomedicine 2011; 8(7):1208-15. 
241. Hokey DA, Misra A. Aerosol vaccines for tuberculosis: a fine line between 
protection and pathology. Tuberculosis (Edinb) 2011; 91(1):82-5. 
242. Lu D, Garcia-Contreras L, Muttil P, Padilla D, Xu D, Liu J, et al. Pulmonary 
immunization using antigen 85-B polymeric microparticles to boost tuberculosis immunity. 
AAPS J 2010; 12(3):338-47. 
243. Todoroff J, Ucakar B, Inglese M, Vandermarliere S, Fillee C, Renauld JC, et al. 
Targeting the deep lungs, Poloxamer 407 and a CpG oligonucleotide optimize immune 
responses to Mycobacterium tuberculosis antigen 85A following pulmonary delivery. Eur J 
Pharm Biopharm 2013; 84(1):40-8. 
244. Cryan S, Sivadas N, Garcia-Contreras L. In vivo animal models for drug delivery 
across the lung mucosal barrier. Adv Drug Deliv Rev 2007; 59(11):1133-51. 
245. Stocks J, Hislop AA. Structure and function of the respiratory system- 
developmental aspects and their relevance to aerosol therapy. In: Bisgaard H, 
O’Callaghan C, Smaldone GC, editors. Drug delivery to the lung. Lung biology in 
health and disease. New York: Marcel Dekker; 2001. p. 47-104. 
246. Widmaier E, Raff H, Strang K, editors. Vander's Human Physiology - The 
Mechanisms of Body Function. 10th ed: McGraw-Hill Higher Education; 2006. 
247. Groneberg D, Fischer A, Chung K, Daniel H. Molecular mechanisms of pulmonary 
peptidomimetic drug and peptide transport. Am J Respir Cell Mol Biol 2004; 30(3):251-60. 
248. Kim K, Malik A. Protein transport across the lung epithelial barrier. Am J Physiol 
Lung Cell Mol Physiol 2003; 284(2):L247-59. 
249. Vlahovic G, Russell ML, Mercer RR, Crapo JD. Cellular and connective tissue 
changes in alveolar septal walls in emphysema. Am J Respir Crit Care Med 1999; 
160(6):2086-92. 
250. Yang W, Peters J, Williams Rr. Inhaled nanoparticles - a current review. Int J 
Pharm 2008; 356(1-2):239-47. 
251. Rytting E, Nguyen J, Wang X, Kissel T. Biodegradable polymeric nanocarriers for 
pulmonary drug delivery. Expert Opin Drug Deliv 2008; 5(6):629-39. 
Self-assembled polymeric micelles as powders for pulmonary administration of insulin 
_______________________________________________________________________ 
170 
 
252. Tomoda K, Ohkoshi T, Nakajima T, Makino K. Preparation and properties of 
inhalable nanocomposite particles: effects of the size, weight ratio of the primary 
nanoparticles in nanocomposite particles and temperature at a spray-dryer inlet upon 
properties of nanocomposite particles. Colloids Surf B 2008; 64(1):70-6. 
253. Scheuch G, Kohlhaeufl MJ, Brand P, Siekmeier R. Clinical perspectives on 
pulmonary systemic and macromolecular delivery. Adv Drug Deliv Rev 2006; 58(9-
10):996-1008. 
254. Hastings R, Folkesson H, Matthay M. Mechanisms of alveolar protein clearance in 
the intact lung. Am J Physiol Lung Cell Mol Physiol 2004; 286(4):L679-89. 
255. Berthiaume Y, Albertine K, Grady M, Fick G, Matthay M. Protein clearance from 
the air spaces and lungs of unanesthetized sheep over 144 h. J Appl Physiol 1989; 
67(5):1887-97. 
256. Patton JS, Fishburn CS, Weers JG. The lungs as a portal of entry for systemic 
drug delivery. Proc Am Thorac Soc 2004; 1(4):338-44. 
257. Folkesson H, Weström B, Karlsson B. Permeability of the respiratory tract to 
different-sized macromolecules after intratracheal instillation in young and adult rats. Acta 
Physiol Scand 1990; 139(2):347-54. 
258. Conhaim R, Watson K, Lai-Fook S, Harms B. Transport properties of alveolar 
epithelium measured by molecular hetastarch absorption in isolated rat lungs. J Appl 
Physiol 2001; 91(4):1730-40. 
259. Holter J, Weiland J, Pacht E, Gadek J, Davis W. Protein permeability in the adult 
respiratory distress syndrome. Loss of size selectivity of the alveolar epithelium. J Clin 
Invest 1986; 78(6):1513-22. 
260. Siekmeier R, Scheuch G. Systemic treatment by inhalation of macromolecules-
principles, problems, and examples. J Physiol Pharmacol 2008; 59 Suppl 6:53-79. 
261. Bitonti AJ, Dumont JA. Pulmonary administration of therapeutic proteins using an 
immunoglobulin transport pathway. Adv Drug Deliv Rev 2006; 58(9-10):1106-18. 
262. Bitonti A, Dumont J, Low S, Peters R, Kropp K, Palombella V, et al. Pulmonary 
delivery of an erythropoietin Fc fusion protein in non-human primates through an 
immunoglobulin transport pathway. PNAS 2004; 101(26):9763-8. 
263. Morris CJ, Smith MW, Griffiths PC, McKeown NB, Gumbleton M. Enhanced 
pulmonary absorption of a macromolecule through coupling to a sequence-specific phage 
display-derived peptide. J Control Release 2011; 151(1):83-94. 
264. Jeong SH. Analytical methods and formulation factors to enhance protein stability 
in solution. Arch Pharm Res 2012; 35(11):1871-86. 
265. Frokjaer S, Otzen DE. Protein drug stability: a formulation challenge. Nat Rev Drug 
Discov 2005; 4(4):298-306. 
266. de Boer AH, Gjaltema D, Hagedoorn P, Frijlink HW. Characterization of inhalation 
aerosols: a critical evaluation of cascade impactor analysis and laser diffraction technique. 
Int J Pharm 2002; 249(1-2):219-31. 
267. Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug 
delivery. Int J Pharm 2010; 392(1-2):1-19. 
268. Heyder J. Deposition of inhaled particles in the human respiratory tract and 
consequences for regional targeting in respiratory drug delivery. Proc Am Thorac Soc 
2004; 1(4):315-20. 
269. Crowder T, Rosati J, Schroeter J, Hickey A, Martonen T. Fundamental effects of 
particle morphology on lung delivery: predictions of Stokes' law and the particular 
References 
________________________________________________________________________________ 
171 
 
relevance to dry powder inhaler formulation and development. Pharm Res 2002; 
19(3):239-45. 
270. Champion JA, Walker A, Mitragotri S. Role of particle size in phagocytosis of 
polymeric microspheres. Pharm Res 2008; 25(8):1815-21. 
271. Chono S, Tanino T, Seki T, Morimoto K. Uptake characteristics of liposomes by rat 
alveolar macrophages: influence of particle size and surface mannose modification. J 
Pharm Pharmacol 2007; 59(1):75-80. 
272. Al-Qadi S, Grenha A, Carrión-Recio D, Seijo B, Remuñán-López C. 
Microencapsulated chitosan nanoparticles for pulmonary protein delivery: in vivo 
evaluation of insulin-loaded formulations. J Control Release 2012; 157(3):383-90. 
273. Yu SS, Lau CM, Thomas SN, Jerome WG, Maron DJ, Dickerson JH, et al. Size- 
and charge-dependent non-specific uptake of PEGylated nanoparticles by macrophages. 
Int J Nanomedicine 2012; 7:799-813. 
274. Yue H, Wei W, Yue Z, Lv P, Wang L, Ma G, et al. Particle size affects the cellular 
response in macrophages. Eur J Pharm Sci 2010; 41(5):650-7. 
275. Telko MJ, Hickey AJ. Dry powder inhaler formulation. Respir Care 2005; 
50(9):1209-27. 
276. Dolovich MB, Dhand R. Aerosol drug delivery: developments in device design and 
clinical use. Lancet 2011; 377(9770):1032-45. 
277. Islam N, Gladki E. Dry powder inhalers (DPIs)-a review of device reliability and 
innovation. Int J Pharm 2008; 360(1-2):1-11. 
278. Muralidharan P, Malapit M, Mallory E, Hayes D, Mansour HM. Inhalable 
nanoparticulate powders for respiratory delivery. Invited review. Nanomedicine 2015; in 
press. 
279. Shoyele SA, Cawthorne S. Particle engineering techniques for inhaled 
biopharmaceuticals. Adv Drug Deliv Rev 2006; 58(9-10):1009-29. 
280. Donovan MJ, Kim SH, Raman V, Smyth HD. Dry powder inhaler device influence 
on carrier particle performance. J Pharm Sci 2012; 101(3):1097-107. 
281. Pitchayajittipong C, Price R, Shur J, Kaerger JS, Edge S. Characterisation and 
functionality of inhalation anhydrous lactose. Int J Pharm 2010; 390(2):134-41. 
282. Kaialy W, Ticehurst M, Nokhodchi A. Dry powder inhalers: mechanistic evaluation 
of lactose formulations containing salbutamol sulphate. Int J Pharm 2012; 423(2):184-94. 
283. Kaialy W, Alhalaweh A, Velaga SP, Nokhodchi A. Influence of lactose carrier 
particle size on the aerosol performance of budesonide from a dry powder inhaler. Powder 
Technol 2012; 227:74–85. 
284. Young PM, Cocconi D, Colombo P, Bettini R, Price R, Steele DF, et al. 
Characterization of a surface modified dry powder inhalation carrier prepared by "particle 
smoothing". J Pharm Pharmacol 2002; 54(10):1339-44. 
285. Schiavone H, Palakodaty S, Clark A, York P, Tzannis ST. Evaluation of SCF-
engineered particle-based lactose blends in passive dry powder inhalers. Int J Pharm 
2004; 281(1-2):55-66. 
286. Le VN, Hoang Thi TH, Robins E, Flament MP. Dry powder inhalers: study of the 
parameters influencing adhesion and dispersion of fluticasone propionate. AAPS 
PharmSciTech 2012; 13(2):477-84. 
287. Le VN, Hoang Thi TH, Robins E, Flament MP. In vitro evaluation of powders for 
inhalation: the effect of drug concentration on particle detachment. Int J Pharm 2012; 
424(1-2):44-9. 
Self-assembled polymeric micelles as powders for pulmonary administration of insulin 
_______________________________________________________________________ 
172 
 
288. Dickhoff BH, de Boer AH, Lambregts D, Frijlink HW. The effect of carrier surface 
and bulk properties on drug particle detachment from crystalline lactose carrier particles 
during inhalation, as function of carrier payload and mixing time. Eur J Pharm Biopharm 
2003; 56(2):291-302. 
289. Dickhoff BH, de Boer AH, Lambregts D, Frijlink HW. The effect of carrier surface 
treatment on drug particle detachment from crystalline carriers in adhesive mixtures for 
inhalation. Int J Pharm 2006; 327(1-2):17-25. 
290. U.S. Department of Health and Human Services Food and Drug 
Administration, Guidance for Industry: Nonclinical Studies for the Safety Evaluation of 
Pharmaceutical Excipients. 2005. 
291. ICH M3 (R2), Non-Clinical Safety Studies for the Conduct of Human Clinical Trials 
and Marketing Authorization for Pharmaceuticals. CPMP/ICH/286/95. 2009. 
292. ICH S3A, Note for Guidance on Toxicokinetics: The Assessment of Systemic 
Exposure in Toxicity Studies. CPMP/ICH/384/95. 1994. 
293. Zaru M, Mourtas S, Klepetsanis P, Fadda AM, Antimisiaris SG. Liposomes for drug 
delivery to the lungs by nebulization. Eur J Pharm Biopharm 2007; 67(3):655-66. 
294. FDA. GRAS Notice Inventory. 
http://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/NoticeInventory [Accessed 
on March 2015]. 
295. de Jesús Valle MJ, Dinis-Oliveira RJ, Carvalho F, Bastos ML, Sánchez Navarro A. 
Toxicological evaluation of lactose and chitosan delivered by inhalation. J Biomater Sci 
Polym Ed 2008; 19(3):387-97. 
296. Grenha A, Grainger C, Dailey L, Seijo B, Martin G, Remuñán-López C, et al. 
Chitosan nanoparticles are compatible with respiratory epithelial cells in vitro. Eur J Pharm 
Sci 2007; 31(2):73-84. 
297. Mura S, Hillaireau H, Nicolas J, Le Droumaguet B, Gueutin C, Zanna S, et al. 
Influence of surface charge on the potential toxicity of PLGA nanoparticles towards Calu-3 
cells. Int J Nanomedicine 2011; 6:2591-605. 
298. Davis ME, Brewster ME. Cyclodextrin-based pharmaceutics: past, present and 
future. Nat Rev Drug Discov 2004; 3(12):1023-35. 
299. Bailey MM, Gorman EM, Munson EJ, Berkland C. Pure insulin nanoparticle 
agglomerates for pulmonary delivery. Langmuir 2008; 24(23):13614-20. 
300. Pilcer G, Vanderbist F, Amighi K. Spray-dried carrier-free dry powder tobramycin 
formulations with improved dispersion properties. J Pharm Sci 2009; 98(4):1463-75. 
301. Garcia-Contreras L, Fiegel J, Telko MJ, Elbert K, Hawi A, Thomas M, et al. Inhaled 
large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. 
Antimicrob Agents Chemother 2007; 51(8):2830-6. 
302. Mueannoom W, Srisongphan A, Taylor KM, Hauschild S, Gaisford S. Thermal ink-
jet spray freeze-drying for preparation of excipient-free salbutamol sulphate for inhalation. 
Eur J Pharm Biopharm 2012; 80(1):149-55. 
303. Sharma G, Mueannoom W, Buanz AB, Taylor KM, Gaisford S. In vitro 
characterisation of terbutaline sulphate particles prepared by thermal ink-jet spray freeze 
drying. Int J Pharm 2013; 447(1-2):165-70. 
304. DeHaan WH, Finlay WH. In vitro monodisperse aerosol deposition in a mouth and 
throat with six different inhalation devices. J Aerosol Med 2001; 14(3):361-7. 
References 
________________________________________________________________________________ 
173 
 
305. Coates MS, Fletcher DF, Chan HK, Raper JA. Effect of design on the performance 
of a dry powder inhaler using computational fluid dynamics. Part 1: Grid structure and 
mouthpiece length. J Pharm Sci 2004; 93(11):2863-76. 
306. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part II: the role of inhalant 
delivery devices and drug formulations in therapeutic effectiveness of aerosolized 
medications. Br J Clin Pharmacol 2003; 56(6):600-12. 
307. Alexander BD, Winkler TP, Shi S, Dodds Ashley ES, Hickey AJ. In vitro 
characterization of nebulizer delivery of liposomal amphotericin B aerosols. Pharm Dev 
Technol 2011; 16(6):577-82. 
308. Heinemann L. The failure of exubera: are we beating a dead horse? J Diabetes Sci 
Technol 2008; 2(3):518-29. 
309. Kriksunov LB, Gumaste AV, inventors; Microdose Technologies, Inc assignee. 
US20080202514 A1. Inhaler 2008. 
310. Crowder TM. Highly reproducible powder aerosolisation for lung delivery using 
powder-specific electromechanical vibration. Expert Opin Drug Deliv 2005; 2(3):579-85. 
311. Wakefield K, Genova PA, inventors; IEP Pharmaceutical Devices Inc., assignee. 
WO2001085245 A1. Pneumatic breath actuated inhaler 2001. 
312. Brunton L, Lazo J, Parker K, editors. Goodman & Gilman's the pharmacological 
basis of therapeutics. 11th ed. McGraw-Hill Professional; 2006. 
313. Katzung B, editor. Basic & clinical pharmacology. 8th ed. Lange Medical 
Books/McGraw-Hill; 2001. 
314. Agu R, Ugwoke M, Armand M, Kinget R, Verbeke N. The lung as a route for 
systemic delivery of therapeutic proteins and peptides. Respir Res 2001; 2(4):198-209. 
315. Cheng K, Mahato R. Biopharmaceutical challenges: pulmonary delivery of proteins 
and peptides. In: Meibohm B, editor. Pharmacokinetics and pharmacodynamics of biotech 
drugs - principles and case studies in drug development. 1st ed. Weinheim: WILEY-VCH 
Verlag GmbH & Co. KGaA; 2006. p. 209-42. 
316. Fineberg SE, Kawabata T, Finco-Kent D, Liu C, Krasner A. Antibody response to 
inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and 
III inhaled insulin (Exubera) trials and a two-year extension trial. J Clin Endocrinol Metab 
2005; 90(6):3287-94. 
317. Wolzt M, de la Peña A, Berclaz P, Tibaldi F, Gates J, Muchmore D. AIR inhaled 
insulin versus subcutaneous insulin: pharmacokinetics, glucodynamics, and pulmonary 
function in asthma. Diabetes Care 2008; 31(4):735-40. 
318. Skyler J, Cefalu W, Kourides I, Landschulz W, Balagtas C, Cheng S, et al. Efficacy 
of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. 
Lancet 2001; 357(9253):331-5. 
319. Rosenstock J, Cefalu W, Hollander P, Belanger A, Eliaschewitz F, Gross J, et al. 
Two-year pulmonary safety and efficacy of inhaled human insulin (Exubera) in adult 
patients with type 2 diabetes. Diabetes Care 2008; 31(9):1723-8. 
320. Soares S, Costa A, Sarmento B. Novel non-invasive methods of insulin delivery. 
Expert Opin Drug Deliv 2012; 9(12):1539-58. 
321. Karathanasis E, Bhavane R, Annapragada A. Glucose-sensing pulmonary delivery 
of human insulin to the systemic circulation of rats. Int J Nanomedicine 2007; 2(3):501-13. 
322. Nyambura B, Kellaway I, Taylor K. Insulin nanoparticles: stability and 
aerosolization from pressurized metered dose inhalers. Int J Pharm 2009; 375(1-2):114-
22. 
Self-assembled polymeric micelles as powders for pulmonary administration of insulin 
_______________________________________________________________________ 
174 
 
323. Opar A. Another blow for inhaled protein therapeutics. Nat Rev Drug Discov 2008; 
7:189-90. 
324. Angelo R, Rousseau K, Grant M, Leone-Bay A, Richardson P. Technosphere 
insulin: defining the role of Technosphere particles at the cellular level. J Diabetes Sci 
Technol 2009; 3(3):545-54. 
325. Pfützner A, Mann A, Steiner S. Technosphere/Insulin-a new approach for effective 
delivery of human insulin via the pulmonary route. Diabetes Technol Ther 2002; 4(5):589-
94. 
326. Zisser H, Jovanovic L, Markova K, Petrucci R, Boss A, Richardson P, et al. 
Technosphere insulin effectively controls postprandial glycemia in patients with type 2 
diabetes mellitus. Diabetes Technol Ther 2012; 14(11):997-1001. 
327. Potocka E, Amin N, Cassidy J, Schwartz SL, Gray M, Richardson PC, et al. Insulin 
pharmacokinetics following dosing with Technosphere insulin in subjects with chronic 
obstructive pulmonary disease. Curr Med Res Opin 2010; 26(10):2347-53. 
328. Raskin P, Heller S, Honka M, Chang PC, Boss AH, Richardson PC, et al. 
Pulmonary function over 2 years in diabetic patients treated with prandial inhaled 
Technosphere Insulin or usual antidiabetes treatment: a randomized trial. Diabetes Obes 
Metab 2012; 14(2):163-73. 
329. Liu J, Gong T, Fu H, Wang C, Wang X, Chen Q, et al. Solid lipid nanoparticles for 
pulmonary delivery of insulin. Int J Pharm 2008; 356(1-2):333-44. 
330. Huang X, Du Y, Yuan H, Hu F. Preparation and pharmacodynamics of low-
molecular-weight chitosan nanoparticles containing insulin. Carbohydr Polym 2009; 
76(3):368–73. 
331. Yamamoto H, Hoshina W, Kurashima H, Takeuchi H, Kawashima Y, Yokoyama T, 
et al. Engineering of poly(DL-lactic-co-glycolic acid) nanocomposite particles for dry 
powder inhalation dosage forms of insulin with the spray-fluidized bed granulating system. 
Adv Powder Technol 2007; 18(2):215-28. 
332. Kawashima Y, Yamamoto H, Takeuchi H, Fujioka S, Hino T. Pulmonary delivery of 
insulin with nebulized DL-lactide/glycolide copolymer (PLGA) nanospheres to prolong 
hypoglycemic effect. J Control Release 1999; 62(1-2):279-87. 
333. Grenha A, Seijo B, Remuñán-López C. Microencapsulated chitosan nanoparticles 
for lung protein delivery. Eur J Pharm Sci 2005; 25(4-5):427-37. 
334. Zhang Q, Shen Z, Nagai T. Prolonged hypoglycemic effect of insulin-loaded 
polybutylcyanoacrylate nanoparticles after pulmonary administration to normal rats. Int J 
Pharm 2001; 218(1-2):75-80. 
335. Huang Y, Wang C. Pulmonary delivery of insulin by liposomal carriers. J Control 
Release 2006; 113(1):9-14. 
336. Bi R, Shao W, Wang Q, Zhang N. Spray-freeze-dried dry powder inhalation of 
insulin-loaded liposomes for enhanced pulmonary delivery. J Drug Target 2008; 
16(9):639-48. 
337. Chono S, Fukuchi R, Seki T, Morimoto K. Aerosolized liposomes with dipalmitoyl 
phosphatidylcholine enhance pulmonary insulin delivery. J Control Release 2009; 
137(2):104-9. 
338. Marino MT, Costello D, Baughman R, Boss A, Cassidy J, Damico C, et al. 
Pharmacokinetics and pharmacodynamics of inhaled GLP-1 (MKC253): proof-of-concept 
studies in healthy normal volunteers and in patients with type 2 diabetes. Clin Pharmacol 
Ther 2010; 88(2):243-50. 
References 
________________________________________________________________________________ 
175 
 
339. Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M. Effect of an interleukin-4 
variant on late phase asthmatic response to allergen challenge in asthmatic patients: 
results of two phase 2a studies. Lancet 2007; 370(9596):1422-31. 
340. Getz EB, Fisher DM, Fuller R. Human pharmacokinetics/pharmacodynamics of an 
interleukin-4 and interleukin-13 dual antagonist in asthma. J Clin Pharmacol 2009; 
49(9):1025-36. 
341. Bridges RJ, Newton BB, Pilewski JM, Devor DC, Poll CT, Hall RL. Na+ transport in 
normal and CF human bronchial epithelial cells is inhibited by BAY 39-9437. Am J Physiol 
Lung Cell Mol Physiol 2001; 281(1):L16-23. 
342. Moss RB, Hansen C, Sanders RL, Hawley S, Li T, Steigbigel RT. A phase II study 
of DAS181, a novel host directed antiviral for the treatment of influenza infection. J Infect 
Dis 2012; 206(12):1844-51. 
343. Chan RW, Chan MC, Wong AC, Karamanska R, Dell A, Haslam SM, et al. 
DAS181 inhibits H5N1 influenza virus infection of human lung tissues. Antimicrob Agents 
Chemother 2009; 53(9):3935-41. 
344. Drozd DR, Limaye AP, Moss RB, Sanders RL, Hansen C, Edelman JD, et al. 
DAS181 treatment of severe parainfluenza type 3 pneumonia in a lung transplant 
recipient. Transpl Infect Dis 2013; 15(1):E28-32. 
345. Aerovance. A phase I/II study to investigate the efficacy and safety of AER 002 in 
cystic fibrosis given at 3 mg, 10 mg, and 30 mg doses in single then multiple ascending 
doses and to determine efficacy of the highest tolerable dose in a 4-Week proof of 
concept study. 2005-000313-35: https://www.clinicaltrialsregister.eu [accessed on 
December 2014]. 
346. APTPharmaceuticals. CIS001 extension study of cyclosporine inhalation solution 
(CIS002). NCT00938236: http://clinicaltrials.gov [accessed on December 2014]. 
347. University Medical Centre Groningen. Pilot study of cyclosporine A dry powder 
inhalation in lung transplant patients with bronchiolitis obliterans syndrome. 
NCT00378677: https://clinicaltrials.gov [accessed on December 2014]. 
348. Moss RB, Mayer-Hamblett N, Wagener J, Daines C, Hale K, Ahrens R, et al. 
Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized 
interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease. Pediatr 
Pulmonol 2005; 39(3):209-18. 
349. Hallstrand TS, Ochs HD, Zhu Q, Liles WC. Inhaled IFN-gamma for persistent 
nontuberculous mycobacterial pulmonary disease due to functional IFN-gamma 
deficiency. Eur Respir J 2004; 24(3):367-70. 
350. Kim D, Mudaliar S, Chinnapongse S, Chu N, Boies SM, Davis T, et al. Dose-
response relationships of inhaled insulin delivered via the Aerodose insulin inhaler and 
subcutaneously injected insulin in patients with type 2 diabetes. Diabetes Care 2003; 
26(10):2842-7. 
351. DancePharmaceuticals. A phase 1/2 trial investigating the pharmacokinetics, 
pharmacodynamics and safety of inhaled insulin in subjects with type 1 diabetes. 2012-
002071-34: https://www.clinicaltrialsregister.eu [accessed on December 2014]. 
352. Rave KM, Nosek L, de la Peña A, Seger M, Ernest CS, Heinemann L, et al. Dose 
response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin 
lispro. Diabetes Care 2005; 28(10):2400-5. 
353.  QDose. Investigating the pharmacokinetics and pharmacodynamics of 
recombinant human insulin administered by dry powder inhaler. NCT00426920: 
http://clinicaltrials.gov [accessed on December 2014]. 
Self-assembled polymeric micelles as powders for pulmonary administration of insulin 
_______________________________________________________________________ 
176 
 
354. Garcia-Contreras L, Morçöl T, Bell SJ, Hickey AJ. Evaluation of novel particles as 
pulmonary delivery systems for insulin in rats. AAPS PharmSci 2003; 5(2):E9. 
355. Heise T, Brugger A, Cook C, Eckers U, Hutchcraft A, Nosek L, et al. PROMAXX 
inhaled insulin: safe and efficacious administration with a commercially available dry 
powder inhaler. Diabetes Obes Metab 2009; 11(5):455-9. 
356. Eichelberg C, Andreas A, Heuer R, Huland H, Heinzer H, Huland E. Long-term 
tumor control with inhalational interleukin 2 therapy in cardiac high risk patients with 
metastatic renal carcinoma. J Urol 2008; 179(4):167. 
357. Tazawa R, Nakata K, Inoue Y, Nukiwa T. Granulocyte-macrophage colony-
stimulating factor inhalation therapy for patients with idiopathic pulmonary alveolar 
proteinosis: a pilot study; and long-term treatment with aerosolized granulocyte-
macrophage colony-stimulating factor: a case report. Respirology 2006; 11 Suppl:S61-4. 
358. CSLBehring. Safety and tolerability study of liquid alpha1 proteinase inhibitor (API) 
in subjects with cystic fibrosis. NCT01347190: http://clinicaltrials.gov [accessed on 
October 2014]. 
359. Kobayashi S, Kondo S, Juni K. Pulmonary delivery of salmon calcitonin dry 
powders containing absorption enhancers in rats. Pharm Res 1996; 13(1):80-3. 
360. Yamamoto A, Okumura S, Fukuda Y, Fukui M, Takahashi K, Muranishi S. 
Improvement of the pulmonary absorption of (Asu1,7)-eel calcitonin by various absorption 
enhancers and their pulmonary toxicity in rats. J Pharm Sci 1997; 86(10):1144-7. 
361. Yang M, Velaga S, Yamamoto H, Takeuchi H, Kawashima Y, Hovgaard L, et al. 
Characterisation of salmon calcitonin in spray-dried powder for inhalation. Effect of 
chitosan. Int J Pharm 2007; 331(2):176-81. 
362. Shoyele SA, Sivadas N, Cryan SA. The effects of excipients and particle 
engineering on the biophysical stability and aerosol performance of parathyroid hormone 
(1-34) prepared as a dry powder for inhalation. AAPS PharmSciTech 2011; 12(1):304-11. 
363. Schreier H, McNicol K, Bennett D, Teitelbaum Z, Derendorf H. Pharmacokinetics 
of detirelix following intratracheal instillation and aerosol inhalation in the unanesthetized 
awake sheep. Pharm Res 1994; 11(7):1056-9. 
364. Bennett D, Tyson E, Nerenberg C, Mah S, de Groot J, Teitelbaum Z. Pulmonary 
delivery of detirelix by intratracheal instillation and aerosol inhalation in the briefly 
anesthetized dog. Pharm Res 1994; 11(7):1048-55. 
365. van Zandwijk N, Jassem E, Dubbelmann R, Braat M, Rumke P. Aerosol 
application of interferon-alpha in the treatment of bronchioloalveolar carcinoma. Eur J 
Cancer 1990; 26(6):738-40. 
366. Low S, Nunes S, Bitonti A, Dumont J. Oral and pulmonary delivery of FSH-Fc 
fusion proteins via neonatal Fc receptor-mediated transcytosis. Hum Reprod 2005; 
20(7):1805-13. 
367. Onoue S, Yamamoto K, Kawabata Y, Hirose M, Mizumoto T, Yamada S. Novel dry 
powder inhaler formulation of glucagon with addition of citric acid for enhanced pulmonary 
delivery. Int J Pharm 2009; 382(1-2):144-50. 
368. Roy I, Vij N. Nanodelivery in airway diseases: challenges and therapeutic 
applications. Nanomedicine 2010; 6(2):237-44. 
369. Alpar HO, Somavarapu S, Atuah KN, Bramwell VW. Biodegradable mucoadhesive 
particulates for nasal and pulmonary antigen and DNA delivery. Adv Drug Deliv Rev 2005; 
57(3):411-30. 
References 
________________________________________________________________________________ 
177 
 
370. Lai S, Wang Y, Hanes J. Mucus-penetrating nanoparticles for drug and gene 
delivery to mucosal tissues. Adv Drug Deliv Rev 2009; 61(2):158-71. 
371. Tang BC, Dawson M, Lai SK, Wang YY, Suk JS, Yang M, et al. Biodegradable 
polymer nanoparticles that rapidly penetrate the human mucus barrier. PNAS 2009; 
106(46):19268-73. 
372. Suk JS, Boylan NJ, Trehan K, Tang BC, Schneider CS, Lin JM, et al. N-
acetylcysteine enhances cystic fibrosis sputum penetration and airway gene transfer by 
highly compacted DNA nanoparticles. Mol Ther 2011; 19(11):1981-9. 
373. Suk JS, Lai SK, Wang YY, Ensign LM, Zeitlin PL, Boyle MP, et al. The penetration 
of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive 
polymer nanoparticles. Biomaterials 2009; 30(13):2591-7. 
374. Shahiwala A, Misra A. A preliminary pharmacokinetic study of liposomal leuprolide 
dry powder inhaler: a technical note. AAPS PharmSciTech 2005; 6(3):E482-6. 
375. Letsou G, Safi H, Reardon M, Ergenoglu M, Li Z, Klonaris C, et al. 
Pharmacokinetics of liposomal aerosolized cyclosporine A for pulmonary 
immunosuppression. Ann Thorac Surg 1999; 68(6):2044-8. 
376. Waldrep J, Arppe J, Jansa K, Vidgren M. Experimental pulmonary delivery of 
cyclosporin A by liposome aerosol. Int J Pharm 1998; 160(2):239-49. 
377. Gilbert B, Knight C, Alvarez F, Waldrep C, Rodarte J, Knight V, et al. Tolerance of 
volunteers to cyclosporine A-dilauroylphosphatidylcholine liposome aerosol. Am J Respir 
Crit Care Med 1997; 156(6):1789-93. 
378. Khanna C, Hasz D, Klausner J, Anderson P. Aerosol delivery of interleukin 2 
liposomes is nontoxic and biologically effective: canine studies. Clin Cancer Res 1996; 
2(4):721-34. 
379. Khanna C, Anderson P, Hasz D, Katsanis E, Neville M, Klausner J. Interleukin-2 
liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary 
metastases. Cancer 1997; 79(7):1409-21. 
380. Skubitz K, Anderson P. Inhalational interleukin-2 liposomes for pulmonary 
metastases: a phase I clinical trial. Anticancer Drugs 2000; 11(7):555-63. 
381. Ten R, Anderson P, Zein N, Temesgen Z, Clawson M, Weiss W. Interleukin-2 
liposomes for primary immune deficiency using the aerosol route. Int Immunopharmacol 
2002; 2(2-3):333-44. 
382. Kaipel M, Wagner A, Wassermann E, Vorauer-Uhl K, Kellner R, Redl H, et al. 
Increased biological half-life of aerosolized liposomal recombinant human Cu/Zn 
superoxide dismutase in pigs. J Aerosol Med Pulm Drug Deliv 2008; 21(3):281-90. 
383. Lange C, Hancock R, Samuel J, Finlay W. In vitro aerosol delivery and regional 
airway surface liquid concentration of a liposomal cationic peptide. J Pharm Sci 2001; 
90(10):1647-57. 
384. Menon JU, Ravikumar P, Pise A, Gyawali D, Hsia CC, Nguyen KT. Polymeric 
nanoparticles for pulmonary protein and DNA delivery. Acta Biomater 2014; 10(6):2643-
52. 
385. Kunda NK, Alfagih IM, Dennison SR, Tawfeek HM, Somavarapu S, Hutcheon GA, 
et al. Bovine serum albumin adsorbed PGA-co-PDL nanocarriers for vaccine delivery via 
dry powder inhalation. Pharm Res 2015; 32(4):1341-53. 
386. Tawfeek HM, Evans AR, Iftikhar A, Mohammed AR, Shabir A, Somavarapu S, et 
al. Dry powder inhalation of macromolecules using novel PEG-co-polyester microparticle 
carriers. Int J Pharm 2013; 441(1-2):611-9. 
Self-assembled polymeric micelles as powders for pulmonary administration of insulin 
_______________________________________________________________________ 
178 
 
387. Grenha A. Microencapsulación de nanopartículas de quitosano para la 
administración pulmonar de macromoléculas terapéuticas. Santiago de Compostela: 
Universidad de Santiago de Compostela, Facultad de Farmacia; 2006. 
388. Yamamoto H, Kuno Y, Sugimoto S, Takeuchi H, Kawashima Y. Surface-modified 
PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by 
mucoadhesion and opening of the intercellular tight junctions. J Control Release 2005; 
102(2):373-81. 
389. Yang M, Yamamoto H, Kurashima H, Takeuchi H, Yokoyama T, Tsujimoto H, et al. 
Design and evaluation of poly(DL-lactic-co-glycolic acid) nanocomposite particles 
containing salmon calcitonin for inhalation. Eur J Pharm Sci 2012; 46(5):374-80. 
390. Yang M, Yamamoto H, Kurashima H, Takeuchi H, Yokoyama T, Tsujimoto H, et al. 
Design and evaluation of inhalable chitosan-modified poly (DL-lactic-co-glycolic acid) 
nanocomposite particles. Eur J Pharm Sci 2012; 47(1):235-43. 
391. Sinsuebpol C, Chatchawalsaisin J, Kulvanich P. Preparation and in vivo absorption 
evaluation of spray dried powders containing salmon calcitonin loaded chitosan 
nanoparticles for pulmonary delivery. Drug Des Devel Ther 2013; 7:861-73. 
392. Klingler C, Müller B, Steckel H. Insulin-micro- and nanoparticles for pulmonary 
delivery. Int J Pharm 2009; 377(1-2):173-9. 
393. Cipolla D, Gonda I, Chan HK. Liposomal formulations for inhalation. Ther Deliv 
2013; 4(8):1047-72. 
394. Willis L, Hayes D, Mansour HM. Therapeutic liposomal dry powder inhalation 
aerosols for targeted lung delivery. Lung 2012; 190(3):251-62. 
395. Insmed Incorporated. Phase 1b/2a multidose safety and tolerability study of 
liposomal amikacin for inhalation (Arikace™) in cystic fibrosis patient with chronic 
infections due to Pseudomonas aeruginosa. NCT00558844: https://clinicaltrials.gov 
[accessed on February 2015]. 
396. Aradigm Corporation. A multicenter, randomized, double-blind, placebo-controlled 
study to evaluate the safety and efficacy of Pulmaquin® in the management of chronic 
lung infections with Pseudomonas aeruginosa in patients with non-cystic fibrosis 
bronchiectasis, including 28 day open-label extension. NCT02104245: 
https://clinicaltrials.gov [accessed on January 2015]. 
397. Chen CH, Cuong NV, Chen YT, So RC, Liau I, Hsieh MF. Overcoming multidrug 
resistance of breast cancer cells by the micellar doxorubicin nanoparticles of mPEG-PCL-
graft-cellulose. J Nanosci Nanotechnol 2011; 11(1):53-60. 
398. Rijnders BJ, Cornelissen JJ, Slobbe L, Becker MJ, Doorduijn JK, Hop WC, et al. 
Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary 
aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin 
Infect Dis 2008; 46(9):1401-8. 
399. Barwicz J, Christian S, Gruda I. Effects of the aggregation state of amphotericin B 
on its toxicity to mice. Antimicrob Agents Chemother 1992; 36(10):2310-5. 
400. Moazeni E, Gilani K, Najafabadi AR, Reza Rouini M, Mohajel N, Amini M, et al. 
Preparation and evaluation of inhalable itraconazole chitosan based polymeric micelles. 
Daru 2012; 20(1):85. 
401. Vadakkan MV, Annapoorna K, Sivakumar KC, Mundayoor S, Kumar GS. Dry 
powder cationic lipopolymeric nanomicelle inhalation for targeted delivery of antitubercular 
drug to alveolar macrophage. Int J Nanomedicine 2013; 8:2871-85. 
References 
________________________________________________________________________________ 
179 
 
402. Gill KK, Nazzal S, Kaddoumi A. Paclitaxel loaded PEG(5000)-DSPE micelles as 
pulmonary delivery platform: formulation characterization, tissue distribution, plasma 
pharmacokinetics, and toxicological evaluation. Eur J Pharm Biopharm 2011; 79(2):276-
84. 
403. Garbuzenko OB, Mainelis G, Taratula O, Minko T. Inhalation treatment of lung 
cancer: the influence of composition, size and shape of nanocarriers on their lung 
accumulation and retention. Cancer Biol Med 2014; 11(1):44-55. 
404. Gaber N, Darwis Y, Peh K, Tan Y. Characterization of polymeric micelles for 
pulmonary delivery of beclomethasone dipropionate. J Nanosci Nanotechnol 2006; 6(9-
10):3095-101. 
405. Sahib MN, Abdulameer SA, Darwis Y, Peh KK, Tan YT. Solubilization of 
beclomethasone dipropionate in sterically stabilized phospholipid nanomicelles (SSMs): 
physicochemical and in vitro evaluations. Drug Des Devel Ther 2012; 6:29-42. 
406. Sahib MN, Darwis Y, Peh KK, Abdulameer SA, Tan YT. Rehydrated sterically 
stabilized phospholipid nanomicelles of budesonide for nebulization: physicochemical 
characterization and in vitro, in vivo evaluations. Int J Nanomedicine 2011; 6:2351-66. 
407. Craparo EF, Teresi G, Bondi' ML, Licciardi M, Cavallaro G. Phospholipid-
polyaspartamide micelles for pulmonary delivery of corticosteroids. Int J Pharm 2011; 
406(1-2):135-44. 
408. Hu FQ, Zhao MD, Yuan H, You J, Du YZ, Zeng S. A novel chitosan 
oligosaccharide-stearic acid micelles for gene delivery: properties and in vitro transfection 
studies. Int J Pharm 2006; 315(1-2):158-66. 
409. Hu FQ, Wu XL, Du YZ, You J, Yuan H. Cellular uptake and cytotoxicity of shell 
crosslinked stearic acid-grafted chitosan oligosaccharide micelles encapsulating 
doxorubicin. Eur J Pharm Biopharm 2008; 69(1):117-25. 
410. Laouini A, Andrieu V, Vecellio L, Fessi H, Charcosset C. Characterization of 
different vitamin E carriers intended for pulmonary drug delivery. Int J Pharm 2014; 471(1-
2):385-90. 
411. Laouini A, Koutroumanis KP, Charcosset C, Georgiadou S, Fessi H, Holdich RG, 
et al. pH-sensitive micelles for targeted drug delivery prepared using a novel membrane 
contactor method. ACS Appl Mater Interfaces 2013; 5(18):8939-47. 
412. Wu Y, Li M, Gao H. Polymeric micelle composed of PLA and chitosan as a drug 
carrier. J Polym Res 2009; 16(1):11-8. 
413. Chen L, Xie Z, Hu J, Chen X, Jing X. Enantiomeric PLA-PEG block copolymers 
and their stereocomplex micelles used as rifampin delivery. J Nanopart Res 2007; 
9(5):777-85. 
414. Silva M, Lara A, Leite C, Ferreira E. Potential tuberculostatic agents: Micelle-
forming copolymer poly(ethylene glycol)-poly(aspartic acid) prodrug with isoniazid. Arch 
Pharm 2001; 334(6):189-93. 
415. McConville JT, Overhoff KA, Sinswat P, Vaughn JM, Frei BL, Burgess DS, et al. 
Targeted high lung concentrations of itraconazole using nebulized dispersions in a murine 
model. Pharm Res 2006; 23(5):901-11. 
416. Vaughn JM, McConville JT, Burgess D, Peters JI, Johnston KP, Talbert RL, et al. 
Single dose and multiple dose studies of itraconazole nanoparticles. Eur J Pharm 
Biopharm 2006; 63(2):95-102. 
Self-assembled polymeric micelles as powders for pulmonary administration of insulin 
_______________________________________________________________________ 
180 
 
417. Alvarez CA, Wiederhold NP, McConville JT, Peters JI, Najvar LK, Graybill JR, et 
al. Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary 
aspergillosis. J Infect 2007; 55(1):68-74. 
418. Hoeben BJ, Burgess DS, McConville JT, Najvar LK, Talbert RL, Peters JI, et al. In 
vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of 
invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2006; 50(4):1552-4. 
419. Vaughn JM, Wiederhold NP, McConville JT, Coalson JJ, Talbert RL, Burgess DS, 
et al. Murine airway histology and intracellular uptake of inhaled amorphous itraconazole. 
Int J Pharm 2007; 338(1-2):219-24. 
420. Liu D, Hsieh J, Fan X, Yang J, Chung T. Synthesis, characterization and drug 
delivery behaviors of new PCP polymeric micelles. Carbohydr Polym 2007; 68(3):544-54. 
421. Kontoyianni C, Sideratou Z, Theodossiou T, Tziveleka LA, Tsiourvas D, Paleos 
CM. A novel micellar PEGylated hyperbranched polyester as a prospective drug delivery 
system for paclitaxel. Macromol Biosci 2008; 8(9):871-81. 
422. Yang Y, Chen C, Yang J, Tsai T. Spray-dried microparticles containing polymeric 
micelles encapsulating hematoporphyrin. AAPS J 2010; 12(2):138-46. 
423. Roesler S, Koch FP, Schmehl T, Weissmann N, Seeger W, Gessler T, et al. 
Amphiphilic, low molecular weight poly(ethylene imine) derivatives with enhanced stability 
for efficient pulmonary gene delivery. J Gene Med 2011; 13(2):123-33. 
424. Chao Y, Chang S, Lu S, Hwang T, Hsieh W, Liaw J. Ethanol enhanced in vivo 
gene delivery with non-ionic polymeric micelles inhalation. J Control Relesease 2007; 
118(1):105-17. 
425. Umashankar M, Sachdeva R, Gulati M. Aquasomes: a promising carrier for 
peptides and protein delivery. Nanomedicine 2010; 6(3):419-26. 
426. Liechty WB, Kryscio DR, Slaughter BV, Peppas NA. Polymers for drug delivery 
systems. Annu Rev Chem Biomol Eng 2010; 1:149-73. 
427. Wang Y, Li Y, Zhang L, Fang X. Pharmacokinetics and biodistribution of paclitaxel-
loaded pluronic P105 polymeric micelles. Arch Pharm Res 2008; 31(4):530-8. 
428. Sundar S, Kundu J, Kundu S. Biopolymeric nanoparticles. Sci Technol Adv Mater 
2010; 11(1):1-13. 
429. Sung J, Pulliam B, Edwards D. Nanoparticles for drug delivery to the lungs. Trends 
Biotechnol 2007; 25(12):563-70. 
430. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene 
delivery to cells and tissue. Adv Drug Deliv Rev 2003; 55(3):329-47. 
431. Gaucher G, Dufresne MH, Sant VP, Kang N, Maysinger D, Leroux JC. Block 
copolymer micelles: preparation, characterization and application in drug delivery. J 
Control Release 2005; 109(1-3):169-88. 
432. Sarmento B, Ribeiro A, Veiga F, Ferreira D. Development and validation of a rapid 
reversed-phase HPLC method for the determination of insulin from nanoparticulate 
systems. Biomed Chromatogr 2006; 20(9):898-903. 
433. Cambre JN, Sumerlin BS. Biomedical applications of boronic acid polymers. 
Polymer 2011; 52(21):4631-43. 
434. Yang T, Ji R, Deng XX, Du FS, Li ZC. Glucose-responsive hydrogels based on 
dynamic covalent chemistry and inclusion complexation. Soft Matter 2014; 10(15):2671-8. 
435. Yang H, Zhang C, Li C, Liu Y, An Y, Ma R, et al. Glucose-responsive polymer 
vesicles templated by α-CD/PEG inclusion complex. Biomacromolecules 2015; 
16(4):1372–1381. 
References 
________________________________________________________________________________ 
181 
 
436. Yao Y, Shen H, Zhang G, Yang J, Jin X. Synthesis of poly(N-isopropylacrylamide)-
co-poly(phenylboronate ester) acrylate and study on their glucose-responsive behavior. J 
Colloid Interface Sci 2014; 431:216-22. 
437. Samad A, Sultana Y, Aqil M. Liposomal drug delivery systems: an update review. 
Curr Drug Deliv 2007; 4(4):297-305. 
438. ICH. Impurities: Guideline for Residual Solvents Q3C (R5). 2011. 
439. Tsui H-W, Wang J-H, Hsu Y-H, Chen L-J. Study of heat of micellization and phase 
separation for Pluronic aqueous solutions by using a high sensitivity differential scanning 
calorimetry. Colloid Polym Sci 2010; 288:1687-96. 
440. Lin Y, Alexandridis P. Temperature-dependent adsorption of Pluronic F127 block 
copolymers onto carbon black particles dispersed in aqueous media. J Phys Chem B 
2002; 106:10834-44. 
441. Desai PR, Jain NJ, Sharma RK, Bahadur P. Effect of additives on the micellization 
of PEO/PPO/PEO block copolymer F127 in aqueous solution. Colloids Surf A 2001; 
178(1-3):57-69. 
442. Wu Y, Sprik R, Poon W, Eiser E. Effect of salt on the phase behaviour of F68 
triblock PEO/PPO/PEO copolymer. J Phys: Condens Matter 2006; 18(19):4461–70. 
443. Batrakova EV, Kabanov AV. Pluronic block copolymers: evolution of drug delivery 
concept from inert nanocarriers to biological response modifiers. J Control Release 2008; 
130(2):98-106. 
444. Alexandridis P, Hatton TA. Poly(ethylene oxide)-poly(propylene oxide)-poly 
(ethylene oxide) block copolymer surfactants in aqueous solutions and at interfaces: 
thermodynamics, structure, dynamics, and modeling. Colloids Surf A 1995; 96(1-2):1-46. 
445. Jokerst JV, Lobovkina T, Zare RN, Gambhir SS. Nanoparticle PEGylation for 
imaging and therapy. Nanomedicine (Lond) 2011; 6(4):715-28. 
446. Ibricevic A, Guntsen SP, Zhang K, Shrestha R, Liu Y, Sun JY, et al. PEGylation of 
cationic, shell-crosslinked-knedel-like nanoparticles modulates inflammation and 
enhances cellular uptake in the lung. Nanomedicine 2013; 9(7):912-22. 
447. Wood GC. Aerosolized antibiotics for treating hospital-acquired and ventilator-
associated pneumonia. Expert Rev Anti Infect Ther 2011; 9(11):993-1000. 
448. Rubin BK, Williams RW. Emerging aerosol drug delivery strategies: from bench to 
clinic. Adv Drug Deliv Rev 2014; 75:141-8.  
449. Yang MY, Chan JG, Chan HK. Pulmonary drug delivery by powder aerosols. J 
Control Release 2014; 193:228-240. 
450. Carvalho TC, Peters JI, Williams RO. Influence of particle size on regional lung 
deposition-what evidence is there? Int J Pharm 2011; 406(1-2):1-10. 
451. Newman SP, Chan HK. In vitro/in vivo comparisons in pulmonary drug delivery. J 
Aerosol Med Pulm Drug Deliv 2008; 21(1):77-84. 
452. Dong A, Huang P, Caughey WS. Protein secondary structures in water from 
second-derivative amide I infrared spectra. Biochemistry 1990; 29(13):3303-8. 
453. Soares S, Fonte P, Costa A, Andrade J, Seabra V, Ferreira D, et al. Effect of 
freeze-drying, cryoprotectants and storage conditions on the stability of secondary 
structure of insulin-loaded solid lipid nanoparticles. Int J Pharm 2013; 456(2):370-81. 
454. Kelly SM, Jess TJ, Price NC. How to study proteins by circular dichroism. Biochim 
Biophys Acta 2005; 1751(2):119-39. 
455. European Pharmacopoeia 8th edition. Strasbourg: EDQM, Council of Europe; 
2014. 
Self-assembled polymeric micelles as powders for pulmonary administration of insulin 
_______________________________________________________________________ 
182 
 
456. Holt J. MMADcalculator. http://www.mmadcalculator.com [accessed on February 
2015]. 
457. Moore JW, Flanner HH. Mathematical comparison of dissolution profiles. Pharm 
Tech 1996; 20:64-74. 
458. Rave K, Potocka E, Heinemann L, Heise T, Boss AH, Marino M, et al. 
Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous 
injection of regular human insulin. Diabetes Obes Metab 2009; 11(7):715-20. 
459. Lebhardt T, Roesler S, Uusitalo HP, Kissel T. Surfactant-free redispersible 
nanoparticles in fast-dissolving composite microcarriers for dry-powder inhalation. Eur J 
Pharm Biopharm 2011; 78(1):90-6. 
460. Makino K, Yamamoto N, Higuchi K, Harada N, Ohshima H, Terada H. Phagocytic 
uptake of polystyrene microspheres by alveolar macrophages: effects of the size and 
surface properties of the microspheres. Colloids Surf B 2003; 27(1):33–9. 
461. Liu Z, Liu D, Wang L, Zhang J, Zhang N. Docetaxel-loaded pluronic P123 
polymeric micelles: in vitro and in vivo evaluation. Int J Mol Sci 2011; 12(3):1684-96. 
462. Hirsjärvi S, Peltonen L, Hirvonen J. Effect of sugars, surfactant, and tangential flow 
filtration on the freeze-drying of poly(lactic acid) nanoparticles. AAPS PharmSciTech 
2009; 10(2):488-94. 
463. Djuris J, Nikolakakis I, Ibric S, Djuric Z, Kachrimanis K. Preparation of 
carbamazepine-Soluplus solid dispersions by hot-melt extrusion, and prediction of drug-
polymer miscibility by thermodynamic model fitting. Eur J Pharm Biopharm 2013; 
84(1):228-37. 
464. Thakral NK, Ray AR, Bar-Shalom D, Eriksson AH, Majumdar DK. Soluplus-
solubilized citrated camptothecin-a potential drug delivery strategy in colon cancer. AAPS 
PharmSciTech 2012; 13(1):59-66. 
465. Albertini B, Passerini N, Di Sabatino M, Monti D, Burgalassi S, Chetoni P, et al. 
Poloxamer 407 microspheres for orotransmucosal drug delivery. Part I: formulation, 
manufacturing and characterization. Int J Pharm 2010; 399(1-2):71-9. 
466. Gill P, Moghadam TT, Ranjbar B. Differential scanning calorimetry techniques: 
applications in biology and nanoscience. J Biomol Tech 2010; 21(4):167-93. 
467. Guo C, Liu H, Wang J, Chen J. Conformational structure of triblock copolymers by 
FT-Raman and FTIR spectroscopy. J Colloid Interface Sci 1999; 209(2):368-73. 
468. Piergies N, Proniewicz E, Ozaki Y, Kim Y, Proniewicz LM. Influence of substituent 
type and position on the adsorption mechanism of phenylboronic acids: infrared, Raman, 
and surface-enhanced Raman spectroscopy studies. J Phys Chem A 2013; 117(27):5693-
705. 
469. Vanea E, Simon V. XPS and Raman study of zinc containing silica microparticles 
loaded with insulin. Appl Surf Sci 2013; 280:144–50. 
470. Griebenow K, Klibanov A. On protein denaturation in aqueous−organic mixtures 
but not in pure organic solvents. J Am Chem Soc 1996; 118(47):11695-700. 
471. Mi Y, Wood G, Thoma L. Cryoprotection mechanisms of polyethylene glycols on 
lactate dehydrogenase during freeze-thawing. AAPS J 2004; 6(3):e22. 
472. Sarmento B, Ferreira D, Jorgensen L, van de Weert M. Probing insulin's secondary 
structure after entrapment into alginate/chitosan nanoparticles. Eur J Pharm Biopharm 
2007; 65(1):10-7. 
473. Martin SR, Schilstra MJ. Circular dichroism and its application to the study of 
biomolecules. Methods Cell Biol 2008; 84:263-93. 
References 
________________________________________________________________________________ 
183 
 
474. Lu X, Gao H, Li C, Yang YW, Wang Y, Fan Y, et al. Polyelectrolyte complex 
nanoparticles of amino poly(glycerol methacrylate)s and insulin. Int J Pharm 2012; 
423(2):195-201. 
475. Fang JY, Hsu SH, Leu YL, Hu JW. Delivery of cisplatin from Pluronic co-polymer 
systems: liposome inclusion and alginate coupling. J Biomater Sci Polym Ed 2009; 20(7-
8):1031-47. 
476. Shamma RN, Basha M. Soluplus®: a novel polymeric solubilizer for optimization of 
carvedilol solid dispersions: formulation design and effect of method of preparation. 
Powder Technol 2013; 237:406–14. 
477. Hassan MS, Lau RW. Effect of particle shape on dry particle inhalation: study of 
flowability, aerosolization, and deposition properties. AAPS PharmSciTech 2009; 
10(4):1252-62. 
478. Kaialy W, Martin GP, Ticehurst MD, Royall P, Mohammad MA, Murphy J, et al. 
Characterisation and deposition studies of recrystallised lactose from binary mixtures of 
ethanol/butanol for improved drug delivery from dry powder inhalers. AAPS J 2011; 
13(1):30-43. 
479. Kumar TM, Misra A. Formulation and evaluation of insulin dry powder for 
inhalation. Drug Dev Ind Pharm 2006; 32(6):677-86. 
480. Shen ZG, Chen WH, Jugade N, Gao LY, Glover W, Shen JY, et al. Fabrication of 
inhalable spore like pharmaceutical particles for deep lung deposition. Int J Pharm 2012; 
430(1-2):98-103. 
481. White S, Bennett DB, Cheu S, Conley PW, Guzek DB, Gray S, et al. EXUBERA: 
pharmaceutical development of a novel product for pulmonary delivery of insulin. Diabetes 
Technol Ther 2005; 7(6):896-906. 
482. Johal B, Howald M, Fischer M, Marshall J, Venthoye G. Fine particle profile of 
fluticasone propionate/formoterol fumarate versus other combination products: the 
DIFFUSE study. Comb Prod Ther 2013; 3:39-51. 
483. Shi S, Ashley ES, Alexander BD, Hickey AJ. Initial characterization of micafungin 
pulmonary delivery via two different nebulizers and multivariate data analysis of aerosol 
mass distribution profiles. AAPS PharmSciTech 2009; 10(1):129-37. 
484. Kisich KO, Higgins MP, Park I, Cape SP, Lindsay L, Bennett DJ, et al. Dry powder 
measles vaccine: particle deposition, virus replication, and immune response in cotton 
rats following inhalation. Vaccine 2011; 29(5):905-12. 
485. Telko MJ, Hickey AJ. Aerodynamic and electrostatic properties of model dry 
powder aerosols: a comprehensive study of formulation factors. AAPS PharmSciTech 
2014; 15(6):1378-97. 
486. Baker EH, Clark N, Brennan AL, Fisher DA, Gyi KM, Hodson ME, et al. 
Hyperglycemia and cystic fibrosis alter respiratory fluid glucose concentrations estimated 
by breath condensate analysis. J Appl Physiol (1985) 2007; 102(5):1969-75. 
487. Amancha KP, Balkundi S, Lvov Y, Hussain A. Pulmonary sustained release of 
insulin from microparticles composed of polyelectrolyte layer-by-layer assembly. Int J 
Pharm 2014; 466(1-2):96-108. 
488. Chou DH, Webber MJ, Tang BC, Lin AB, Thapa LS, Deng D, et al. Glucose-
responsive insulin activity by covalent modification with aliphatic phenylboronic acid 
conjugates. PNAS 2015; 112(8):2401-6. 
Self-assembled polymeric micelles as powders for pulmonary administration of insulin 
_______________________________________________________________________ 
184 
 
489. Lee TH, Lin SY. Pluronic F68 enhanced the conformational stability of salmon 
calcitonin in both aqueous solution and lyophilized solid form. Biopolymers 2011; 
95(11):785-91. 
490. Akash MS, Rehman K, Sun H, Chen S. Assessment of release kinetics, stability 
and polymer interaction of poloxamer 407-based thermosensitive gel of interleukin-1 
receptor antagonist. Pharm Dev Technol 2014; 19(3):278-84. 
491. Pikal MJ, Rigsbee DR. The stability of insulin in crystalline and amorphous solids: 
observation of greater stability for the amorphous form. Pharm Res 1997; 14(10):1379-87. 
492. McElroy MC, Kirton C, Gliddon D, Wolff RK. Inhaled biopharmaceutical drug 
development: nonclinical considerations and case studies. Inhal Toxicol 2013; 25(4):219-
32. 
493. Sarmento B, Martins S, Ferreira D, Souto EB. Oral insulin delivery by means of 
solid lipid nanoparticles. Int J Nanomedicine 2007; 2(4):743-9. 
494. Fonte P, Nogueira T, Gehm C, Ferreira D, Sarmento B. Chitosan-coated solid lipid 
nanoparticles enhance the oral absorption of insulin. Drug Deliv and Transl Res 2011; 
1(4):299–308. 
495. Hamishehkar H, Emami J, Najafabadi AR, Gilani K, Minaiyan M, Hassanzadeh K, 
et al. Pharmacokinetics and pharmacodynamics of controlled release insulin loaded PLGA 
microcapsules using dry powder inhaler in diabetic rats. Biopharm Drug Dispos 2010; 
31(2-3):189-201. 
496. Kaur G, Narang RK, Rath G, Goyal AK. Advances in pulmonary delivery of 
nanoparticles. Artif Cells Blood Substit Immobil Biotechnol 2012; 40(1-2):75-96. 
497. Ahmed F, Alexandridis P, Neelamegham S. Synthesis and application of 
fluorescein-labeled pluronic block copolymers to the study of polymer−surface 
interactions. Langmuir 2001; 17(2):537–46. 
498. Jung HH, Park K, Han DK. Preparation of TGF-β1-conjugated biodegradable 
pluronic F127 hydrogel and its application with adipose-derived stem cells. J Control 
Release 2010; 147(1):84-91. 
499. Lippens E, Swennen I, Gironès J, Declercq H, Vertenten G, Vlaminck L, et al. Cell 
survival and proliferation after encapsulation in a chemically modified Pluronic F127 
hydrogel. J Biomater Appl 2013; 27(7):828-39. 
500. Batrakova EV, Li S, Vinogradov SV, Alakhov VY, Miller DW, Kabanov AV. 
Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: 
contributions of energy depletion and membrane fluidization. J Pharmacol Exp Ther 2001; 
299(2):483-93. 
501. Demina T, Grozdova I, Krylova O, Zhirnov A, Istratov V, Frey H, et al. Relationship 
between the structure of amphiphilic copolymers and their ability to disturb lipid bilayers. 
Biochemistry 2005; 44(10):4042-54. 
502. Widdicombe JG. Airway liquid: a barrier to drug diffusion? Eur Respir J 1997; 
10(10):2194-7. 
503. Rennard SI, Basset G, Lecossier D, O'Donnell KM, Pinkston P, Martin PG, et al. 
Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of 
dilution. J Appl Physiol (1985) 1986; 60(2):532-8. 
504. Herbst KL, Hirsch IB. Insulin strategies for primary care providers. Clin Diabetes 
2002; 20(1):11-7. 
505. Foster KA, Avery ML, Yazdanian M, Audus KL. Characterization of the Calu-3 cell 
line as a tool to screen pulmonary drug delivery. Int J Pharm 2000; 208(1-2):1-11. 
References 
________________________________________________________________________________ 
185 
 
506. Wang Z, Zhang Q. Transport of proteins and peptides across human cultured 
alveolar A549 cell monolayer. Int J Pharm 2004; 269(2):451-6. 
507. Antunes F, Andrade F, Araújo F, Ferreira D, Sarmento B. Establishment of a triple 
co-culture in vitro cell models to study intestinal absorption of peptide drugs. Eur J Pharm 
Biopharm 2013; 83(3):427-35. 
508. Mathia NR, Timoszyk J, Stetsko PI, Megill JR, Smith RL, Wall DA. Permeability 
characteristics of Calu-3 human bronchial epithelial cells: in vitro-in vivo correlation to 
predict lung absorption in rats. J Drug Target 2002; 10(1):31-40. 
509. Sarmento B, Andrade F, Silva SB, Rodrigues F, das Neves J, Ferreira D. Cell-
based in vitro models for predicting drug permeability. Expert Opin Drug Metab Toxicol 
2012; 8(5):607-21. 
510. Zheng J, Zheng Y, Chen J, Fang F, He J, Li N, et al. Enhanced pulmonary 
absorption of recombinant human insulin by pulmonary surfactant and phospholipid 
hexadecanol tyloxapol through Calu-3 monolayers. Pharmazie 2012; 67(5):448-51. 
511. Rave K, Bott S, Heinemann L, Sha S, Becker R, Willavize S, et al. Time-action 
profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and 
regular human insulin. Diabetes Care 2005; 28(5):1077-82. 
512. Hussain A, Ahsan F. Indication of transcytotic movement of insulin across human 
bronchial epithelial cells. J Drug Target 2006; 14(4):181-90. 
513. Pezron I, Mitra R, Pal D, Mitra A. Insulin aggregation and asymmetric transport 
across human bronchial epithelial cell monolayers (Calu-3). J Pharm Sci 2002; 
91(4):1135-46. 
514. Shubber S, Vllasaliu D, Rauch C, Jordan F, Illum L, Stolnik S. Mechanism of 
mucosal permeability enhancement of CriticalSorb® (Solutol® HS15) investigated In vitro 
in cell cultures. Pharm Res 2015; 32(2):516-27. 
515. Illum L, Jordan F, Lewis AL. CriticalSorb: a novel efficient nasal delivery system for 
human growth hormone based on Solutol HS15. J Control Release 2012; 162(1):194-200. 
516. Caroni P. New EMBO members' review: actin cytoskeleton regulation through 
modulation of PI(4,5)P(2) rafts. EMBO J 2001; 20(16):4332-6. 
517. Vllasaliu D, Exposito-Harris R, Heras A, Casettari L, Garnett M, Illum L, et al. Tight 
junction modulation by chitosan nanoparticles: comparison with chitosan solution. Int J 
Pharm 2010; 400(1-2):183-93. 
518. Fanning AS, Ma TY, Anderson JM. Isolation and functional characterization of the 
actin binding region in the tight junction protein ZO-1. FASEB J 2002; 16(13):1835-7. 
519. Xiao K, Li Y, Luo J, Lee JS, Xiao W, Gonik AM, et al. The effect of surface charge 
on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. 
Biomaterials 2011; 32(13):3435-46. 
520. Shan X, Liu C, Yuan Y, Xu F, Tao X, Sheng Y, et al. In vitro macrophage uptake 
and in vivo biodistribution of long-circulation nanoparticles with poly(ethylene-glycol)-
modified PLA (BAB type) triblock copolymer. Colloids Surf B 2009; 72(2):303-11. 
521. Besheer A, Vogel J, Glanz D, Kressler J, Groth T, Mäder K. Characterization of 
PLGA nanospheres stabilized with amphiphilic polymers: hydrophobically modified 
hydroxyethyl starch vs pluronics. Mol Pharm 2009; 6(2):407-15. 
522. Jain TK, Foy SP, Erokwu B, Dimitrijevic S, Flask CA, Labhasetwar V. Magnetic 
resonance imaging of multifunctional pluronic stabilized iron-oxide nanoparticles in tumor-
bearing mice. Biomaterials 2009; 30(35):6748-56. 
Self-assembled polymeric micelles as powders for pulmonary administration of insulin 
_______________________________________________________________________ 
186 
 
523. Geiser M. Update on macrophage clearance of inhaled micro- and nanoparticles. J 
Aerosol Med Pulm Drug Deliv 2010; 23(4):207-17. 
524. Lunov O, Syrovets T, Loos C, Beil J, Delacher M, Tron K, et al. Differential uptake 
of functionalized polystyrene nanoparticles by human macrophages and a monocytic cell 
line. ACS Nano 2011; 5(3):1657-69. 
525. Patel B, Gupta N, Ahsan F. Particle engineering to enhance or lessen uptake by 
alveolar macrophages and to influence therapeutic outcomes. Eur J Pharm Biopharm 
2014; 89:163-74. 
526. McCormack FX, Whitsett JA. The pulmonary collectins, SP-A and SP-D, 
orchestrate innate immunity in the lung. J Clin Invest 2002; 109(6):707-12. 
527. Heale JP, Pollard AJ, Stokes RW, Simpson D, Tsang A, Massing B, et al. Two 
distinct receptors mediate nonopsonic phagocytosis of different strains of Pseudomonas 
aeruginosa. J Infect Dis 2001; 183(8):1214-20. 
528. Seaton BA, Crouch EC, McCormack FX, Head JF, Hartshorn KL, Mendelsohn R. 
Review: structural determinants of pattern recognition by lung collectins. Innate Immun 
2010; 16(3):143-50. 
529. Patel B, Gupta V, Ahsan F. PEG-PLGA based large porous particles for pulmonary 
delivery of a highly soluble drug, low molecular weight heparin. J Control Release 2012; 
162(2):310-20. 
530. Sakagami M. In vivo, in vitro and ex vivo models to assess pulmonary absorption 
and disposition of inhaled therapeutics for systemic delivery. Adv Drug Deliv Rev 2006; 
58(9-10):1030-60. 
531. Schanker LS. Drug absorption from the lung. Biochem Pharmacol 1978; 27(4):381-
5. 
532. Brown RA, Schanker LS. Absorption of aerosolized drugs from the rat lung. Drug 
Metab Dispos 1983; 11(4):355-60. 
533. Schanker LS, Mitchell EW, Brown RA. Species comparison of drug absorption 
from the lung after aerosol inhalation or intratracheal injection. Drug Metab Dispos 1986; 
14(1):79-88. 
534. Codrons V, Vanderbist F, Ucakar B, Préat V, Vanbever R. Impact of formulation 
and methods of pulmonary delivery on absorption of parathyroid hormone (1-34) from rat 
lungs. J Pharm Sci 2004; 93(5):1241-52. 
535. Suarez S, O'Hara P, Kazantseva M, Newcomer CE, Hopfer R, McMurray DN, et al. 
Airways delivery of rifampicin microparticles for the treatment of tuberculosis. J Antimicrob 
Chemother 2001; 48(3):431-4. 
536. Herber-Jonat S, Mittal R, Gsinn S, Bohnenkamp H, Guenzi E, Schulze A. 
Comparison of lung accumulation of cationic liposomes in normal rats and LPS-treated 
rats. Inflamm Res 2010; 60(3):245-53. 
537. Pauluhn J. Acute nose-only inhalation exposure of rats to di- and triphosgene 
relative to phosgene. Inhal Toxicol 2011; 23(2):65-73. 
538. Phalen RF, Oldham MJ, Wolff RK. The relevance of animal models for aerosol 
studies. J Aerosol Med Pulm Drug Deliv 2008; 21(1):113-24. 
539. Driscoll KE, Costa DL, Hatch G, Henderson R, Oberdorster G, Salem H, et al. 
Intratracheal instillation as an exposure technique for the evaluation of respiratory tract 
toxicity: uses and limitations. Toxicol Sci 2000; 55(1):24-35. 
540. Lizio R, Westhof A, Lehr CM, Klenner T. Oral endotracheal intubation of rats for 
intratracheal instillation and aerosol drug delivery. Lab Anim 2001; 35(3):257-60. 
References 
________________________________________________________________________________ 
187 
 
541. Wu KK, Huan Y. Streptozotocin-induced diabetic models in mice and rats. Curr 
Protoc Pharmacol 2008; 40:5.47.1-5.47.14. 
542. Sarmento B, Ribeiro A, Veiga F, Sampaio P, Neufeld R, Ferreira D. 
Alginate/chitosan nanoparticles are effective for oral insulin delivery. Pharm Res 2007; 
24(12):2198-206. 
543. Sajeesh S, Bouchemal K, Marsaud V, Vauthier C, Sharma CP. Cyclodextrin 
complexed insulin encapsulated hydrogel microparticles: an oral delivery system for 
insulin. J Control Release 2010; 147(3):377-84. 
544. Cu Y, Saltzman WM. Drug delivery: stealth particles give mucus the slip. Nat Mater 
2009; 8(1):11-3. 
545. Wang YY, Lai SK, Suk JS, Pace A, Cone R, Hanes J. Addressing the PEG 
mucoadhesivity paradox to engineer nanoparticles that "slip" through the human mucus 
barrier. Angew Chem Int Ed Engl 2008; 47(50):9726-9. 
546. Oda K, Yumoto R, Nagai J, Katayama H, Takano M. Mechanism underlying insulin 
uptake in alveolar epithelial cell line RLE-6TN. Eur J Pharmacol 2011; 672(1-3):62-9. 
547. Hindlycke M, Jansson L. Glucose tolerance and pancreatic islet blood flow in rats 
after intraperitoneal administration of different anesthetic drugs. Ups J Med Sci 1992; 
97(1):27-35. 
548. Wellington D, Mikaelian I, Singer L. Comparison of ketamine-xylazine and 
ketamine-dexmedetomidine anesthesia and intraperitoneal tolerance in rats. J Am Assoc 
Lab Anim Sci 2013; 52(4):481-7. 
549. Venâncio C, Félix L, Almeida V, Coutinho J, Antunes L, Peixoto F, et al. Acute 
ketamine impairs mitochondrial function and promotes superoxide dismutase activity in 
the rat brain. Anesth Analg 2015; 120(2):320-8. 
550. Stoever JA, Palmer JP. Inhaled insulin and insulin antibodies: a new twist to an old 
debate. Diabetes Technol Ther 2002; 4(2):157-61. 
551. Heise T, Bott S, Tusek C, Stephan JA, Kawabata T, Finco-Kent D, et al. The effect 
of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin: a 
prospective randomized pharmacodynamic study. Diabetes Care 2005; 28(9):2161-9. 
552. Sarmiento EG. Inhaled insulin and its effects on the lungs. Arch Bronconeumol 
2007; 43(12):643-5. 
 
